0001585364-19-000056.txt : 20190509 0001585364-19-000056.hdr.sgml : 20190509 20190509170137 ACCESSION NUMBER: 0001585364-19-000056 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20190330 FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PERRIGO Co plc CENTRAL INDEX KEY: 0001585364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36353 FILM NUMBER: 19811536 BUSINESS ADDRESS: STREET 1: THE SHARP BUILDING STREET 2: HOGAN PLACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 TY74 BUSINESS PHONE: 269-673-8451 MAIL ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 FORMER COMPANY: FORMER CONFORMED NAME: PERRIGO Co Ltd DATE OF NAME CHANGE: 20130828 10-Q 1 cy19q110q.htm 10-Q Document
false--12-31Q120192019-03-300001585364falseLarge Accelerated FilerPERRIGO Co plcfalse00640000068000000.190.190.0010.0011000000000010000000000868400000000.00010.000110000000100000000 0001585364 2019-01-01 2019-03-30 0001585364 2019-05-03 0001585364 2018-01-01 2018-03-31 0001585364 2019-03-30 0001585364 2018-12-31 0001585364 us-gaap:NewAccountingPronouncementMember 2017-12-31 0001585364 us-gaap:CommonStockMember 2018-03-31 0001585364 us-gaap:CommonStockMember 2017-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001585364 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001585364 us-gaap:RetainedEarningsMember 2018-03-31 0001585364 us-gaap:NewAccountingPronouncementMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001585364 2018-03-31 0001585364 us-gaap:RetainedEarningsMember 2017-12-31 0001585364 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2017-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001585364 2017-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001585364 us-gaap:CommonStockMember 2018-12-31 0001585364 us-gaap:CommonStockMember 2019-03-30 0001585364 us-gaap:CommonStockMember 2019-01-01 2019-03-30 0001585364 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2018-12-31 0001585364 us-gaap:NewAccountingPronouncementMember 2018-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-30 0001585364 us-gaap:RetainedEarningsMember 2018-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-30 0001585364 us-gaap:RetainedEarningsMember 2019-03-30 0001585364 prgo:OtherGeographicalAreasMember 2018-01-01 2018-03-31 0001585364 country:US 2018-01-01 2018-03-31 0001585364 srt:EuropeMember 2018-01-01 2018-03-31 0001585364 srt:EuropeMember 2019-01-01 2019-03-30 0001585364 country:US 2019-01-01 2019-03-30 0001585364 prgo:OtherGeographicalAreasMember 2019-01-01 2019-03-30 0001585364 prgo:AntiParasiteMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:OtherCHCIMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:GastrointestinalMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:CoughColdAllergyandSinusMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:InfantNutritionalsMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:AnimalHealthMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:OtherCHCAMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:RXPharmaceuticalsMember 2019-01-01 2019-03-30 0001585364 prgo:CoughColdandAllergyMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:OtherCHCAMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:AnalgesicsMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:CoughColdAllergyandSinusMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:SmokingCessationMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:PersonalCareandDermaTherapeuticsMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:VitaminsMineralsAndDietarySupplementsMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:RXPharmaceuticalsMember 2018-01-01 2018-03-31 0001585364 prgo:NaturalHealthandVMSMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:InfantNutritionalsMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:NaturalHealthandVMSMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:AnimalHealthMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:OtherCHCIMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:LifestyleMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:SmokingCessationMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:VitaminsMineralsAndDietarySupplementsMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:GastrointestinalMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:LifestyleMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:PersonalCareandDermaTherapeuticsMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:AntiParasiteMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:CoughColdandAllergyMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:AnalgesicsMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 country:IE 2018-01-01 2018-03-31 0001585364 country:IE 2019-01-01 2019-03-30 0001585364 prgo:ContractManufacturingMember 2019-01-01 2019-03-30 0001585364 prgo:ContractManufacturingMember 2018-01-01 2018-03-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2019-03-30 0001585364 prgo:ConsumerSelfCareAmericasMember 2018-03-31 0001585364 prgo:ConsumerSelfCareAmericasMember 2019-03-30 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-03-30 0001585364 us-gaap:LicensingAgreementsMember 2018-12-31 0001585364 us-gaap:TrademarksAndTradeNamesMember 2018-12-31 0001585364 us-gaap:LicensingAgreementsMember 2019-03-30 0001585364 prgo:TrademarksTradeNamesandBrandsMember 2019-03-30 0001585364 us-gaap:TrademarksAndTradeNamesMember 2019-03-30 0001585364 us-gaap:CustomerRelationshipsMember 2018-12-31 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2019-03-30 0001585364 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001585364 us-gaap:NoncompeteAgreementsMember 2019-03-30 0001585364 prgo:TrademarksTradeNamesandBrandsMember 2018-12-31 0001585364 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001585364 us-gaap:DevelopedTechnologyRightsMember 2019-03-30 0001585364 us-gaap:CustomerRelationshipsMember 2019-03-30 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001585364 prgo:ConsumerSelfCareAmericasMember 2018-12-31 0001585364 prgo:RXPharmaceuticalsMember 2019-03-30 0001585364 prgo:RXPharmaceuticalsMember 2018-12-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2018-12-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2018-03-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-03-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-30 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-30 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member 2019-03-30 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member 2019-03-30 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-03-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-03-30 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-12-31 0001585364 prgo:MeasurementInputTaxRateMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-12-31 0001585364 us-gaap:ScenarioForecastMember 2020-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:MeasurementInputDiscountRateMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:ScenarioForecastMember 2020-01-01 2020-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:ScenarioForecastMember 2020-12-31 0001585364 us-gaap:FairValueMeasurementsNonrecurringMember prgo:ConsumerSelfCareAmericasMember 2018-12-31 0001585364 prgo:RoyaltyPharmaMember 2018-01-01 2018-03-31 0001585364 prgo:RoyaltyPharmaMember us-gaap:MeasurementInputPriceVolatilityMember 2018-03-31 0001585364 prgo:RoyaltyPharmaMember 2019-01-01 2019-03-30 0001585364 prgo:RoyaltyPharmaMember us-gaap:MeasurementInputPriceVolatilityMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-30 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-03-30 0001585364 us-gaap:OtherNoncurrentAssetsMember 2018-12-31 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0001585364 us-gaap:OtherNoncurrentAssetsMember 2019-03-30 0001585364 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 0001585364 prgo:OtherExpenseIncomeNetMember 2019-01-01 2019-03-30 0001585364 prgo:OtherExpenseIncomeNetMember 2018-01-01 2018-03-31 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-03-30 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-30 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-30 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-03-30 0001585364 us-gaap:CostOfSalesMember 2019-01-01 2019-03-30 0001585364 us-gaap:InterestExpenseMember 2019-01-01 2019-03-30 0001585364 us-gaap:SalesRevenueNetMember 2019-01-01 2019-03-30 0001585364 us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesRevenueGoodsNetMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember 2018-01-01 2018-03-31 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember 2019-01-01 2019-03-30 0001585364 currency:GBP us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:EUR us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:CAD us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:XXX us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:MXN us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:GBP us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:NOK us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:CNY us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:PLN us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:CNY us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:PLN us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:USD us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:RON us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:RON us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:XXX us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:NOK us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:ILS us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:MXN us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:USD us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:ILS us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:SEK us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:EUR us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:CAD us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:DKK us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:SEK us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:DKK us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:NondesignatedMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:NondesignatedMember 2019-01-01 2019-03-30 0001585364 prgo:OperatingLeasesMember 2019-03-30 0001585364 us-gaap:MaterialReconcilingItemsMember 2019-03-30 0001585364 prgo:LongtermDebtLessCurrentPortionMember 2019-03-30 0001585364 us-gaap:AccruedLiabilitiesMember 2019-03-30 0001585364 us-gaap:OtherNoncurrentLiabilitiesMember 2019-03-30 0001585364 prgo:CurrentIndebtednessMember 2019-03-30 0001585364 2019-01-01 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2018-03-08 0001585364 2014-12-05 2014-12-05 0001585364 prgo:A2018RevolverMember 2018-03-08 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2014-12-05 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2018-03-08 0001585364 prgo:A2018RevolverMember 2019-03-30 0001585364 prgo:A4.375seniornotedueMarch152026Member 2019-03-30 0001585364 prgo:A4.9SeniorLoandue2044Member 2018-12-31 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Member 2019-03-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2019-03-30 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Member 2018-12-31 0001585364 prgo:A4.375seniornotedueMarch152026Member 2019-01-01 2019-03-30 0001585364 prgo:A3.9seniornotedue2024Member 2018-12-31 0001585364 prgo:A4.375seniornotedueMarch152026Member 2018-12-31 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Member 2018-12-31 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Member 2019-03-30 0001585364 prgo:A5.105SeniornotedueJuly192023Member 2019-01-01 2019-03-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2018-12-31 0001585364 prgo:A4.9SeniorLoandue2044Member 2019-03-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2019-01-01 2019-03-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2019-03-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2019-01-01 2019-03-30 0001585364 prgo:A5.105SeniornotedueJuly192023Member 2018-12-31 0001585364 prgo:A3.9seniornotedue2024Member 2019-01-01 2019-03-30 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2019-03-30 0001585364 prgo:A3.9seniornotedue2024Member 2019-03-30 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Member 2019-01-01 2019-03-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2019-03-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2019-01-01 2019-03-30 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Member 2019-01-01 2019-03-30 0001585364 prgo:A5.105SeniornotedueJuly192023Member 2019-03-30 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2018-12-31 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2018-12-31 0001585364 prgo:A4.9SeniorLoandue2044Member 2019-01-01 2019-03-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2018-12-31 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2019-01-01 2019-03-30 0001585364 prgo:A2018RevolverMember 2018-12-31 0001585364 2018-10-31 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-30 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-30 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-30 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-30 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-30 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-30 0001585364 us-gaap:RevenueCommissionersIrelandMember 2018-11-29 0001585364 2017-08-15 2017-08-15 0001585364 2012-01-01 2012-12-31 0001585364 2009-01-01 2009-12-31 0001585364 2018-01-01 2018-12-31 0001585364 2011-01-01 2011-12-31 0001585364 2010-01-01 2010-12-31 0001585364 prgo:AberdeenCanadaFundsGlobalEquityFundetal.v.PerrigoCompanyplcetal.Member 2019-02-22 0001585364 prgo:ManningNapierAdvisorsLLCv.PerrigoCompanyplcetal.Member 2018-01-16 0001585364 prgo:CasesFiledinIsraelMember 2018-01-01 2018-12-31 0001585364 2011-12-31 0001585364 2018-01-26 0001585364 prgo:OZMasterFundLtd.etal.v.PerrigoCompanyplcetal.Member 2019-02-06 0001585364 prgo:NationwideMutualFundsetal.v.PerrigoCompanyplcetal.Member 2018-10-29 0001585364 prgo:FirstManhattanCo.v.PerrigoCompanyplcetal.Member 2018-02-16 0001585364 prgo:PriceFixingLawsuitSupermarketChainsMember 2013-12-28 0001585364 prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member 2017-06-28 0001585364 prgo:HarelInsuranceCompanyLTD.etal.v.PerrigoCompanyplcetal.Member 2018-02-13 0001585364 prgo:WCMAlternativeEventDriveFundetal.v.PerrigoCo.plcetal.Member 2018-11-15 0001585364 prgo:SchwabCapitalTrustetal.v.PerrigoCompanyplcetal.Member 2019-01-31 0001585364 prgo:HudsonBayMasterFundLtd.etal.v.PerrigoCo.plcetal.Member 2018-11-15 0001585364 prgo:TIAACREFInvestmentManagementLLC.etal.v.PerrigoCompanyplcetal.Member 2018-04-20 0001585364 2017-06-21 0001585364 prgo:CarmignacGestionS.A.v.PerrigoCompanyplcetal.Member 2017-11-01 0001585364 prgo:PricefixingLawsuitManagedCareOrganizationMember 2018-08-03 0001585364 prgo:EltroxinClassActionMember 2018-11-21 2018-11-21 0001585364 prgo:PricefixingLawsuitHealthInsuranceCarrierMember 2019-01-16 2019-01-16 0001585364 prgo:PricefixingLawsuitHealthInsuranceCarrierMember 2019-01-16 0001585364 prgo:EltroxinClassActionMember 2011-10-01 2011-11-30 0001585364 prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member 2017-06-28 2017-06-28 0001585364 prgo:HighfieldsCapitalILPetal.v.PerrigoCompanyplcetal.Member 2019-02-14 0001585364 prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member 2019-03-30 0001585364 prgo:CasesFiledinIsraelMember 2017-12-31 0001585364 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-30 0001585364 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-03-31 0001585364 prgo:RanirGlobalHoldingsLLCMember us-gaap:SubsequentEventMember 2019-05-08 2019-05-08 0001585364 us-gaap:SubsequentEventMember 2019-05-08 2019-05-08 0001585364 us-gaap:SubsequentEventMember 2019-04-26 xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR xbrli:shares iso4217:USD iso4217:EUR prgo:product iso4217:ILS prgo:supermarket prgo:manufacturer prgo:application prgo:individual prgo:complaint prgo:plaintiff prgo:case iso4217:USD iso4217:ILS prgo:dozens prgo:defendant
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________
 FORM 10-Q
_______________________________________________
[X]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 30, 2019
OR
[  ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission file number 001-36353
_______________________________________________
Perrigo Company plc
(Exact name of registrant as specified in its charter)
_______________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Ireland
 
Not Applicable
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
The Sharp Building, Hogan Place, Dublin 2, Ireland
 
-
(Address of principal executive offices)
 
(Zip Code)
+353 1 7094000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
_______________________________________ 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report), and (2) has been subject to such filing requirements for the past 90 days.    YES [X]    NO  [ ]
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    YES  [X]   NO [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
[X]
 
Accelerated filer
[ ]
 
Non-accelerated filer
[ ]
 
Smaller reporting company
[ ]
Emerging growth company
[ ]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   [ ]  YES  [X] NO
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares
PRGO
New York Stock Exchange
As of May 3, 2019, there were 135,991,315 ordinary shares outstanding.


PERRIGO COMPANY PLC
FORM 10-Q
INDEX
 
PAGE
NUMBER
 
 
PART I. FINANCIAL INFORMATION
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 
 
 
2
 
 
 
3
 
 
 
4
 
 
 
5
 
 
 
6
 
 
 
7
 
 
 
8
 
 
 
9
 
 
 
10
 
 
 
11
 
 
 
12
 
 
 
13
 
 
 
14
 
 
 
15
 
 
 
16
 
 
 
 
 
 
 
 
 
 
 
 
PART II. OTHER INFORMATION
 
 
 
 
 
 
 
 
 
 
 
 
 


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this report are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” "forecast," “predict,” “potential” or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment ("NoA") issued by the Irish Office of the Revenue Commissioners (“Irish Revenue”) and the Notice of Proposed Adjustment ("NOPA") issued by the U.S. Internal Revenue Service and the impact that an adverse result in such proceedings would have on operating results, cash flows and liquidity; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NoA and the NOPA; potential impacts of ongoing or future government investigations and regulatory initiatives; the impact of tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts, and strategic and other initiatives. Statements regarding the separation of the RX business, including the expected benefits, anticipated timing, form of any such separation and whether the separation ultimately occurs, are all subject to various risks and uncertainties, including future financial and operating results, our ability to separate the business, the effect of existing interdependencies with our manufacturing and shared service operations, and the tax consequences of the planned separation to us or our shareholders. Furthermore, we may incur additional tax liabilities in respect of 2016 and prior years or be found to have breached certain provisions of Irish company law in connection with our restatement of our previously-filed financial statements, which may result in additional expenses and penalties. These and other important factors, including those discussed in our form 10-K for the year-ended December 31, 2018, this report under “Risk Factors” and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This report contains trademarks, trade names and service marks that are the property of Perrigo Company plc, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the ®, ™ and SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.


1
Perrigo Company plc - Item 1

PART I.     FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS (UNAUDITED)

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
(unaudited)
 
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Net sales
$
1,174.5

 
$
1,217.0

Cost of sales
725.7

 
724.3

Gross profit
448.8

 
492.7

 
 
 
 
Operating expenses
 
 
 
Distribution
23.3

 
24.7

Research and development
40.2

 
38.4

Selling
148.6

 
161.3

Administration
125.1

 
107.6

Impairment charges
4.1

 
—

Restructuring
9.3

 
1.5

Other operating expense (income)
(4.1
)
 
2.9

Total operating expenses
346.5

 
336.4

 
 
 
 
Operating income
102.3

 
156.3

 
 
 
 
Change in financial assets
(10.4
)
 
9.6

Interest expense, net
28.6

 
31.4

Other (income) expense, net
3.2

 
4.3

Loss on extinguishment of debt
—

 
0.5

Income before income taxes
80.9

 
110.5

Income tax expense
17.0

 
29.7

Net income
$
63.9

 
$
80.8

 
 
 
 
Earnings per share
 
 
 
Basic
$
0.47

 
$
0.57

Diluted
$
0.47

 
$
0.57

 
 
 
 
Weighted-average shares outstanding
 
 
 
Basic
135.9

 
140.8

Diluted
136.2

 
141.4



See accompanying Notes to the Condensed Consolidated Financial Statements.

2
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in millions)
(unaudited)
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Net income
$
63.9

 
$
80.8

Other comprehensive income (loss):
 
 
 
Foreign currency translation adjustments
(16.8
)
 
73.0

Change in fair value of derivative financial instruments, net of tax
1.7

 
(0.6
)
Change in post-retirement and pension liability, net of tax
(0.5
)
 
(0.2
)
Other comprehensive income (loss), net of tax
(15.6
)
 
72.2

Comprehensive income
$
48.3

 
$
153.0

See accompanying Notes to the Condensed Consolidated Financial Statements.


3
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except per share amounts)
(unaudited)
 
March 30,
2019
 
December 31,
2018
Assets
 
 
 
Cash and cash equivalents
$
837.9

 
$
551.1

Accounts receivable, net of allowance for doubtful accounts of $6.8 and $6.4, respectively
1,118.7

 
1,073.1

Inventories
912.9

 
878.0

Prepaid expenses and other current assets
139.8

 
400.0

Total current assets
3,009.3

 
2,902.2

Property, plant and equipment, net
821.1

 
829.1

Operating lease assets
146.8

 
—

Goodwill and indefinite-lived intangible assets
3,999.0

 
4,029.1

Definite-lived intangible assets, net
2,757.9

 
2,858.9

Deferred income taxes
2.7

 
1.2

Other non-current assets
382.7

 
362.9

Total non-current assets
8,110.2

 
8,081.2

Total assets
$
11,119.5

 
$
10,983.4

Liabilities and Shareholders’ Equity
 
 
 
Accounts payable
$
549.2

 
$
474.9

Payroll and related taxes
117.3

 
132.1

Accrued customer programs
379.6

 
442.4

Accrued liabilities
232.0

 
201.3

Accrued income taxes
85.9

 
96.5

Current indebtedness
467.9

 
190.2

Total current liabilities
1,831.9

 
1,537.4

Long-term debt, less current portion
2,749.9

 
3,052.2

Deferred income taxes
282.4

 
282.3

Other non-current liabilities
554.5

 
443.4

Total non-current liabilities
3,586.8

 
3,777.9

Total liabilities
5,418.7

 
5,315.3

Commitments and contingencies - Refer to Note 13

 

Shareholders’ equity
 
 
 
Controlling interests:
 
 
 
Preferred shares, $0.0001 par value per share, 10 shares authorized
—

 
—

Ordinary shares, €0.001 par value per share, 10,000 shares authorized
7,409.4

 
7,421.7

Accumulated other comprehensive income
69.0

 
84.6

Retained earnings (accumulated deficit)
(1,777.8
)
 
(1,838.3
)
Total controlling interest
5,700.6

 
5,668.0

Noncontrolling interest
0.2

 
0.1

Total shareholders’ equity
5,700.8

 
5,668.1

Total liabilities and shareholders' equity
$
11,119.5

 
$
10,983.4

 
 
 
 
Supplemental Disclosures of Balance Sheet Information
 
 
 
Ordinary shares, issued and outstanding
136.0

 
135.9


See accompanying Notes to the Condensed Consolidated Financial Statements.

4
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in millions, except per share amounts)
(unaudited)
 
Ordinary Shares
Issued
 
Accumulated
Other
Comprehensive
Income
 
Retained
Earnings
(Accumulated Deficit)
 
Total
 
Shares
 
Amount
Balance at December 31, 2017
140.8

 
$
7,892.9

 
$
253.1

 
$
(1,975.5
)
 
$
6,170.5

Adoption of new accounting standards
—

 
—

 
(1.0
)
 
6.3

 
5.3

Net income
—

 
—

 
—

 
80.8

 
80.8

Other comprehensive income
—

 
—

 
72.2

 
—

 
72.2

Stock options exercised
—

 
0.2

 
—

 
—

 
0.2

Restricted stock plan
0.2

 
—

 
—

 
—

 
—

Compensation for stock options
—

 
2.7

 
—

 
—

 
2.7

Compensation for restricted stock
—

 
10.0

 
—

 
—

 
10.0

Cash dividends, $0.19 per share
—

 
(26.7
)
 
—

 
—

 
(26.7
)
Shares withheld for payment of employees' withholding tax liability
—

 
(1.5
)
 
—

 
—

 
(1.5
)
Repurchases of ordinary shares
(1.3
)
 
(108.1
)
 
—

 
—

 
(108.1
)
Balance at March 31, 2018
139.7

 
$
7,769.5

 
$
324.3

 
$
(1,888.4
)
 
$
6,205.4

 
Ordinary Shares
Issued
 
Accumulated
Other
Comprehensive
Income
 
Retained
Earnings
(Accumulated Deficit)
 
Total
 
Shares
 
Amount
Balance at December 31, 2018
135.9

 
$
7,421.7

 
$
84.6

 
$
(1,838.3
)
 
$
5,668.0

Adoption of new accounting standards
—

 
—

 
—

 
(3.4
)
 
(3.4
)
Net income
—

 
—

 
—

 
63.9

 
63.9

Other comprehensive loss
—

 
—

 
(15.6
)
 
—

 
(15.6
)
Restricted stock plan
0.2

 
—

 
—

 
—

 
—

Compensation for stock options
—

 
1.8

 
—

 
—

 
1.8

Compensation for restricted stock
—

 
14.2

 
—

 
—

 
14.2

Cash dividends, $0.19 per share
—

 
(25.9
)
 
—

 
—

 
(25.9
)
Shares withheld for payment of employees' withholding tax liability
(0.1
)
 
(2.4
)
 
—

 
—

 
(2.4
)
Balance at March 30, 2019
136.0

 
$
7,409.4

 
$
69.0

 
$
(1,777.8
)
 
$
5,700.6


See accompanying Notes to the Condensed Consolidated Financial Statements.

5
Perrigo Company plc - Item 1

PERRIGO COMPANY PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Cash Flows From (For) Operating Activities
 
 
 
Net income
$
63.9

 
$
80.8

Adjustments to derive cash flows:
 
 
 
Depreciation and amortization
96.6

 
109.5

Share-based compensation
12.4

 
12.7

Impairment charges
4.1

 
—

Change in financial assets
(10.4
)
 
9.6

Loss on extinguishment of debt
—

 
0.5

Restructuring charges
9.3

 
1.5

Deferred income taxes
3.9

 
(7.2
)
Amortization of debt premium
(1.9
)
 
(2.1
)
Other non-cash adjustments, net
13.4

 
12.1

Subtotal
191.3

 
217.4

Increase (decrease) in cash due to:
 
 
 
Accounts receivable
(48.5
)
 
2.6

Inventories
(37.5
)
 
(43.7
)
Accounts payable
75.4

 
57.5

Payroll and related taxes
(19.9
)
 
(38.9
)
Accrued customer programs
(61.7
)
 
17.3

Accrued liabilities
(3.8
)
 
(24.0
)
Accrued income taxes
(10.0
)
 
6.4

Other, net
9.2

 
(22.2
)
Subtotal
(96.8
)
 
(45.0
)
Net cash from (for) operating activities
94.5

 
172.4

Cash Flows From (For) Investing Activities
 
 
 
Proceeds from royalty rights
1.2

 
10.0

Royalty Pharma contingent milestone payment
250.0

 
—

Additions to property, plant and equipment
(21.1
)
 
(13.4
)
Net proceeds from sale of business and other assets
—

 
1.3

Net cash from (for) investing activities
230.1

 
(2.1
)
Cash Flows From (For) Financing Activities
 
 
 
Issuances of long-term debt
—

 
431.0

Payments on long-term debt
(12.3
)
 
(444.5
)
Borrowings (repayments) of revolving credit agreements and other financing, net
(0.3
)
 
(6.2
)
Deferred financing fees
—

 
(2.4
)
Repurchase of ordinary shares
—

 
(108.1
)
Cash dividends
(25.9
)
 
(26.7
)
Other financing, net
(3.1
)
 
(5.7
)
Net cash from (for) financing activities
(41.6
)
 
(162.6
)
Effect of exchange rate changes on cash and cash equivalents
3.8

 
0.9

Net increase (decrease) in cash and cash equivalents
286.8

 
8.6

Cash and cash equivalents, beginning of period
551.1

 
678.7

Cash and cash equivalents, end of period
$
837.9

 
$
687.3


See accompanying Notes to the Condensed Consolidated Financial Statements.

6
Perrigo Company plc - Item 1
Note 1



NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are dedicated to making lives better by bringing “Quality, Affordable Self-Care Products™” that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Segment Reporting Change

               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the Consumer Self-Care International segment to the Prescription Pharmaceuticals segment and we made certain adjustments to our allocations between segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Note 2 and Note 15.

Our new reporting and operating segments are as follows:

•
Consumer Self-Care Americas ("CSCA"), formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada.
•
Consumer Self-Care International ("CSCI"), formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.
•
Prescription Pharmaceuticals ("RX"), comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.


7
Perrigo Company plc - Item 1
Note 1


Recent Accounting Standard Pronouncements
    
Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract
 
This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement
 
This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.
 
January 1, 2020
 
We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606
 
This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans
 
This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.
 
December 31, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.


NOTE 2 – REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.


8
Perrigo Company plc - Item 1
Note 2


Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
U.S.
$
768.8

 
$
786.4

Europe(2)
340.9

 
361.9

All other countries(3)
64.8

 
68.7

 
$
1,174.5

 
$
1,217.0


(1) Derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $5.2 million and $5.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively.
(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
CSCA(1)
 
 
 
Cough/cold/allergy/sinus
$
132.6

 
$
141.5

Gastrointestinal
100.3

 
92.2

Infant nutritionals
96.0

 
103.4

Analgesics
88.8

 
93.7

Smoking cessation
66.8

 
65.9

Animal health
19.6

 
26.3

Vitamins, minerals and dietary supplements
3.4

 
3.0

Other CSCA(2)
74.3

 
75.6

Total CSCA
581.8

 
601.6

CSCI
 
 
 
Cough/cold/allergy/sinus
95.7

 
98.7

Lifestyle
81.5

 
89.7

Personal care and derma-therapeutics
66.0

 
75.6

Natural health and vitamins, minerals and dietary supplements
29.8

 
33.2

Anti-parasites
26.7

 
28.1

Other CSCI(3)
51.1

 
52.5

Total CSCI
350.8

 
377.8

Total RX
241.9

 
237.6

Total net sales
$
1,174.5

 
$
1,217.0


(1)    Includes net sales from our OTC contract manufacturing business.
(2)
Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3)
Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.


9
Perrigo Company plc - Item 1
Note 2


While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $67.3 million and $69.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Short-term contract assets
Prepaid expenses and other current assets
 
$
18.1

 
$
25.5



NOTE 3 – GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
 
 
December 31,
2018
 
Currency Translation Adjustments
 
March 30,
2019
CSCA(1)
 
$
1,713.7

 
$
1.2

 
$
1,714.9

CSCI(2)
 
1,151.3

 
(17.7
)
 
1,133.6

RX
 
1,114.8

 
2.9

 
1,117.7

Total goodwill
 
$
3,979.8

 
$
(13.6
)
 
$
3,966.2



(1)
We had accumulated impairments of $24.5 million and $161.2 million for the three months ended March 31, 2018 and March 30, 2019, respectively.
(2)
We had accumulated impairments of $868.4 million for the three months ended March 31, 2018 and March 30, 2019.


10
Perrigo Company plc - Item 1
Note 3


Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):
 
March 30, 2019
 
December 31, 2018
 
Gross
 
Accumulated
Amortization
 
Gross
 
Accumulated
Amortization
Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
18.5

 
$
—

 
$
18.1

 
$
—

In-process research and development
14.3

 
—

 
31.2

 
—

Total indefinite-lived intangibles
$
32.8

 
$
—

 
$
49.3

 
$
—

Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements and supply agreements
$
180.4

 
$
101.9

 
$
178.6

 
$
99.0

Developed product technology, formulations, and product rights
1,333.1

 
686.0

 
1,318.8

 
654.6

Customer relationships and distribution networks
1,562.5

 
587.6

 
1,586.6

 
566.5

Trademarks, trade names, and brands
1,257.8

 
201.3

 
1,282.4

 
188.5

Non-compete agreements
12.6

 
11.7

 
12.9

 
11.8

Total definite-lived intangibles
$
4,346.4

 
$
1,588.5

 
$
4,379.3

 
$
1,520.4

Total intangible assets
$
4,379.2

 
$
1,588.5

 
$
4,428.6

 
$
1,520.4



We recorded amortization expense of $75.4 million and $87.2 million for the three months ended March 30, 2019 and March 31, 2018, respectively.     

We recorded an impairment charge of $4.1 million on a certain IPR&D asset during the three months ended March 30, 2019 due to changes in projected development and regulatory timelines.

NOTE 4 – INVENTORIES

Major components of inventory were as follows (in millions):
 
 
March 30,
2019
 
December 31,
2018
Finished goods
$
474.0

 
$
444.9

Work in process
199.3

 
197.5

Raw materials
239.6

 
235.6

Total inventories
$
912.9

 
$
878.0




11
Perrigo Company plc - Item 1
Note 5


NOTE 5 – FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
 
 
March 30, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
Measured at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Investment securities
 
$
3.7

 
$
—

 
$
—

 
$
9.4

 
$
—

 
$
—

Foreign currency forward contracts
 
—

 
3.2

 
—

 
—

 
3.8

 
—

Funds associated with Israeli severance liability
 
—

 
13.4

 
—

 
—

 
13.0

 
—

Royalty Pharma contingent milestone payments
 
—

 
—

 
83.6

 
—

 
—

 
323.2

Total assets
 
$
3.7

 
$
16.6

 
$
83.6

 
$
9.4

 
$
16.8

 
$
323.2

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
Foreign currency forward contracts
 
$
—

 
$
5.8

 
$
—

 
$
—

 
$
9.2

 
$
—

Contingent consideration
 
—

 
—

 
12.4

 
—

 
—

 
15.3

Total liabilities
 
$
—

 
$
5.8

 
$
12.4

 
$
—

 
$
9.2

 
$
15.3

 
 
 
 
 
 
 
 
 
 
 
 
 
Measured at fair value on a non-recurring basis:
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill(1)
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
42.2

Indefinite-lived intangible assets(2)
 
—

 
—

 
—

 
—

 
—

 
10.5

Definite-lived intangible assets(3)
 
—

 
—

 
—

 
—

 
—

 
22.4

Total assets
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
75.1



(1)
As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.
(2)
As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.
(3)
As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.

There were no transfers among Level 1, 2, and 3 during the three months ended March 30, 2019 or the year ended December 31, 2018.

Royalty Pharma Contingent Milestone Payments

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
323.2

 
$
134.5

Payments received
(250.0
)
 
—

Change in fair value
10.4

 
(9.6
)
Ending balance
$
83.6

 
$
124.9




12
Perrigo Company plc - Item 1
Note 5


We value our contingent milestone payments from Royalty Pharma using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma until the contingent milestones are resolved. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Volatility
30.0
%
 
30.0
%
Rate of return
8.02
%
 
8.08
%

During the three months ended March 30, 2019, the fair value of the Royalty Pharma contingent milestone payments increased $10.4 million driven by higher projected global net sales of Tysabri® and the estimated probability of achieving the earn-out. During the three months ended March 31, 2018, the fair value of the Royalty Pharma contingent milestone payments decreased $9.6 million due primarily to projected global net sales of Tysabri® temporarily falling below the threshold required for payment of the $250.0 million milestone payment for 2018.

In order for us to receive the 2020 milestone payment of $400.0 million, Royalty Pharma contingent payments for Tysabri® sales in 2020 must exceed $351.0 million. If Royalty Pharma contingent payments for Tysabri® sales do not meet the prescribed threshold in 2020, we will write off the $83.6 million asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to $400.0 million and recognize income of $316.4 million in Change in financial assets on the Condensed Consolidated Statements of Operations.

Contingent Consideration

The table below summarizes the change in fair value of contingent consideration (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
15.3

 
$
22.0

Changes in value
1.2

 
0.4

Currency translation adjustments
—

 
0.1

Settlements and other adjustments
(4.1
)
 
(4.4
)
Ending balance
$
12.4

 
$
18.1



Goodwill and Intangible Assets

Animal Health

When determining the fair value of our animal health reporting unit for the year ended December 31, 2018, we utilized a combination of comparable company market and discounted cash flow techniques. In our comparable company market approach, we considered observable market information and transactions for companies that we deemed to be of a comparable nature, scope, and size of animal health (Level 2 inputs). Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products, plus gross margin, advertising and promotion, and other operating expenses based on the growth plans (Level 3 inputs). In our discounted cash flow analysis, we utilized projected sales growth rate and discount rate assumptions of 2.5% and 9.8%, respectively. The discount rate correlates with the required investment return and risk that we believe market participants would apply to the projected growth rate. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows and applied the jurisdictional tax rate of 22.8%. We weighted indications of fair value resulting from the market approach and present value techniques, considering the

13
Perrigo Company plc - Item 1
Note 5


reasonableness of the range of measurements and the point within the range that we determined was most representative of fair market conditions.

When assessing our animal health indefinite-lived intangible asset for the year ended December 31, 2018, we utilized a multi-period excess earnings method ("MPEEM") to determine the fair value of the intangible asset. Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products. We utilized long-term growth rate and discount rate assumptions of (0.3)% and 9.8%, respectively, and we applied a jurisdictional tax rate of 22.8%.

When assessing our animal health definite-lived assets for impairment for the year ended December 31, 2018, we utilized a combination of MPEEM and relief from royalty methods to determine the fair values of definite-lived assets within the asset group. The projected financial information, inputs, and assumptions utilized were consistent with those utilized in the goodwill discounted cash flow analysis described above.

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):
 
March 30,
2019
 
December 31,
2018
 
Level 1
 
Level 2
 
Level 1
 
Level 2
Public Bonds
 
 
 
 
 
 
 
Carrying Value (excluding discount)
$
2,600.0

 
 
 
$
2,600.0

 
 
Fair value
$
2,472.0

 
 
 
$
2,316.6

 
 
 
 
 
 
 
 
 
 
Retail bond and private placement note
 
 
 
 
 
 
 
Carrying value (excluding premium)
 
 
$
286.1

 
 
 
$
292.5

Fair value
 
 
$
301.9

 
 
 
$
307.9



The fair values of our public bonds for all periods were based on quoted market prices. The fair values of our retail bond and private placement note for all periods were based on interest rates offered for borrowings of a similar nature and remaining maturities.

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.

NOTE 6 – INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):
Measurement Category
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Fair value method
 
Prepaid expenses and other current assets
 
$
3.7

 
$
9.4

Fair value method(1)
 
Other non-current assets
 
$
3.7

 
$
4.4

Equity method
 
Other non-current assets
 
$
15.8

 
$
15.1


(1)
Measured at fair value using the Net Asset Value practical expedient.


14
Perrigo Company plc - Item 1
Note 6


The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):
 
 
 
 
Three Months Ended
Measurement Category
 
Income Statement Location
 
March 30,
2019
 
March 31,
2018
Fair value method
 
Other (income) expense, net
 
$
6.1

 
$
4.4

Equity method
 
Other (income) expense, net
 
$
(0.7
)
 
$
0.2



On January 1, 2018, as a result of the adoption of ASU 2016-01 Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities ("ASU 2016-01"), we made a $1.0 million cumulative-effect adjustment to Retained earnings (accumulated deficit) net of tax that consisted of net unrealized losses on previously classified as available for sale securities from Other comprehensive income ("OCI").

NOTE 7 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2018 and the year ended December 31, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.

Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in Other (income) expense, net on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of:

•
Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and

•
Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.

Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We recognized all changes in fair value of the excluded components in Other (income) expense, net, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and Retained earnings (accumulated deficit) from applying this policy on existing hedges at the date of adoption was immaterial.

We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to Note 5). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.


15
Perrigo Company plc - Item 1
Note 7


Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of March 30, 2019 and December 31, 2018.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is 18 months.

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.
    
All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

Interest Rate Swaps

Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. There were no active designated or non-designated interest rate swaps as of March 30, 2019 and December 31, 2018.


16
Perrigo Company plc - Item 1
Note 7


Foreign Currency Derivatives

Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):
 
 
Notional Amount
 
 
March 30,
2019
 
December 31,
2018
Israeli Shekel (ILS)
 
$
290.1

 
$
232.6

British Pound (GBP)
 
107.1

 
90.2

European Euro (EUR)
 
103.1

 
134.2

Swedish (SEK)
 
76.4

 
38.7

Danish Krone (DKK)
 
52.8

 
56.5

United States Dollar (USD)
 
42.0

 
39.3

Canadian Dollar (CAD)
 
35.4

 
31.7

Polish Zloty (PLZ)
 
28.7

 
18.2

Chinese Yuan (CNY)
 
16.8

 
—

Norwegian Krone (NOK)
 
14.9

 
6.2

Romanian New Leu (RON)
 
4.7

 
4.4

Mexican Peso (MPX)
 
2.6

 
25.9

Other
 
8.7

 
8.7

Total
 
$
783.3

 
$
686.6



Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):
 
 
 
Asset Derivatives
 
 
 
Fair Value
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Prepaid expenses and other current assets
 
$
0.6

 
$
2.0

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Prepaid expenses and other current assets
 
$
2.6

 
$
1.8

 
 
 
Liability Derivatives
 
 
 
Fair Value
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
4.2

 
$
6.4

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
1.6

 
$
2.8



17
Perrigo Company plc - Item 1
Note 7



The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):
 
 
Three months ended
 
 
March 30, 2019
Instrument
 
Amount of Gain/(Loss) Recorded in OCI(1)
 
Classification of Gain/(Loss) Reclassified from AOCI into Earnings
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
 
Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing
 
Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements
 
 
 
Interest expense, net
 
$
(0.4
)
 
Interest expense, net
 
$
—

Foreign currency forward contracts
 
$
(1.0
)
 
Net sales
 
0.2

 
Net sales
 
(0.1
)
 
 
 
 
Cost of sales
 
(1.3
)
 
Cost of sales
 
(1.1
)
 
 
 
 
 
 
$
(1.5
)
 
 
 
$
(1.2
)

(1) Net loss of $2.7 million is expected to be reclassified out of AOCI into earnings during the next 12 months.
 
 
Three months ended
 
 
March 31, 2018
 
 
Effective Portion
Instrument
 
Amount of Gain/(Loss) Recorded in OCI
 
Classification of Gain/(Loss) Reclassified from AOCI into Earnings
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements
 
 
 
Interest expense, net
 
$
(0.4
)
Foreign currency forward contracts
 
$
(0.2
)
 
Net sales
 
(0.1
)
 
 
 
 
Cost of sales
 
2.3

 
 
 
 
Interest expense, net
 
(1.0
)
 
 
 
 
Other (income) expense, net
 
(0.4
)
 
 
 
 
 
 
$
0.4



The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):
 
 
 
 
Three months ended
Non-Designated Derivatives
 
Income Statement
Location
 
March 30,
2019
 
March 31,
2018
Foreign currency forward contracts
 
Other (income) expense, net
 
$
(8.8
)
 
$
3.5

 
 
Interest expense, net
 
0.4

 
(0.9
)
Total
 
 
 
$
(8.4
)
 
$
2.6



The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Condensed Consolidated Statements of Operations in Other (income) expense, net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar-translated amounts of each Income Statement account in current and/or future periods.


18
Perrigo Company plc - Item 1
Note 7


The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):
 
 
Three months ended
 
 
March 30, 2019
 
 
Net Sales
 
Cost of Sales
 
Interest Expense, net
 
Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded
 
$
1,174.5

 
$
725.7

 
$
28.6

 
$
3.2

 
 
 
 
 
 
 
 
 
The effects of cash flow hedging:
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedging relationships
 
 
 
 
 
 
 
 
Foreign currency forward contracts
 
 
 
 
 
 
 
 
Amount of gain or (loss) reclassified from AOCI into earnings
 
$
0.2

 
$
(1.3
)
 
$
—

 
$
—

Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach
 
$
(0.1
)
 
$
(1.1
)
 
$
—

 
$
—

Interest rate swap agreements
 
 
 
 
 
 
 
 
Amount of gain or (loss) reclassified from AOCI into earnings
 
$
—

 
$
—

 
$
(0.4
)
 
$
—



NOTE 8 – LEASES

We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.
 
We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider

19
Perrigo Company plc - Item 1
Note 8


renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The balance sheet location of our lease assets and liabilities were as follows (in millions):
Assets
 
Balance Sheet Location
 
March 30,
2019
Operating
 
Operating lease assets
 
$
146.8

Finance
 
Other non-current assets
 
9.9

Total
 
 
 
$
156.7

Liabilities
 
Balance Sheet Location
 
March 30,
2019
Current
 
 
 
 
Operating
 
Accrued liabilities
 
$
34.8

Finance
 
Current indebtedness
 
1.9

Non-Current
 
 
 
 
Operating
 
Other non-current liabilities
 
116.4

Finance
 
Long-term debt, less current portion
 
4.7

Total
 
 
 
$
157.8

    
The below table shows our lease assets and liabilities by reporting segment (in millions):
 
 
Assets
 
Liabilities
 
 
Operating
 
Financing
 
Operating
 
Financing
 
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
CSCA
 
$
30.1

 
$
1.9

 
$
30.2

 
$
1.4

CSCI
 
43.5

 
6.1

 
44.4

 
3.3

RX
 
38.6

 
0.1

 
40.1

 
0.1

Unallocated
 
34.6

 
1.8

 
36.5

 
1.8

Total
 
$
146.8

 
$
9.9

 
$
151.2

 
$
6.6



Lease expense was as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Operating leases(a)
 
$
12.0

 
 
 
Finance leases
 
 
Amortization
 
$
0.7

Interest
 
0.1

Total
 
$
0.8


(a) Includes short-term leases and variable lease costs, which are immaterial.
    

20
Perrigo Company plc - Item 1
Note 8


Total operating lease expense for the three months ended March 31, 2018 was $11.9 million.

The annual future maturities of our leases as of March 30, 2019 are as follows (in millions):
 
 
Operating Leases
 
Finance Leases
 
Total
2019
 
$
31.0

 
$
1.7

 
$
32.7

2020
 
33.1

 
1.6

 
34.7

2021
 
24.0

 
2.9

 
26.9

2022
 
18.1

 
0.5

 
18.6

2023
 
15.0

 
0.3

 
15.3

After 2023
 
53.4

 
—

 
53.4

Total lease payments
 
174.6

 
7.0

 
181.6

Less: Interest
 
23.4

 
0.4

 
23.8

Present value of lease liabilities
 
$
151.2

 
$
6.6

 
$
157.8



Our weighted average lease terms and discount rates are as follows:
 
 
Three Months Ended
 
 
March 30,
2019
Weighted-average remaining lease term (in years)
 
 
Operating leases
 
6.81

Finance leases
 
2.59

Weighted-average discount rate
 
 
Operating leases
 
4.20
%
Finance leases
 
4.17
%


Our lease cash flow classifications are as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Cash paid for amounts included in the measurement of lease liabilities
 
 
Operating cash flows for operating leases
 
$
11.7

Operating cash flows for finance leases
 
$
0.1

Financing cash flows for finance leases
 
$
0.7

Leased assets obtained in exchange for new operating lease liabilities
 
$
4.7




21
Perrigo Company plc - Item 1
Note 9



NOTE 9 – INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):
 
 
 
 
 
March 30,
2019
 
December 31,
2018
Term loans
 
 
 
 
 
 
2018 Term loan due March 8, 2020(1)
 
 
$
331.3

 
$
351.3

Notes and Bonds
 
 
 
 
 
 
Coupon
Due
 
 
 
 
 
 
5.000%
May 23, 2019(1)
 
 
134.6

 
137.6

 
3.500%
March 15, 2021
 
 
280.4

 
280.4

 
3.500%
December 15, 2021
 
 
309.6

 
309.6

 
5.105%
July 19, 2023(1)
 
 
151.5

 
154.9

 
4.000%
November 15, 2023
 
 
215.6

 
215.6

 
3.900%
December 15, 2024
 
 
700.0

 
700.0

 
4.375%
March 15, 2026
 
 
700.0

 
700.0

 
5.300%
November 15, 2043
 
 
90.5

 
90.5

 
4.900%
December 15, 2044
 
 
303.9

 
303.9

 
Total notes and bonds
 
 
2,886.1

 
2,892.5

Other financing
6.2

 
2.8

Unamortized premium (discount), net
9.8

 
12.2

Deferred financing fees
(15.6
)
 
(16.4
)
Total borrowings outstanding
3,217.8

 
3,242.4

 
Current indebtedness
(467.9
)
 
(190.2
)
Total long-term debt less current portion
$
2,749.9

 
$
3,052.2



(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
    
We are in compliance with all covenants under our debt agreements as of March 30, 2019.

Revolving Credit Agreements

On March 8, 2018, we terminated the revolving credit agreement entered into on December 5, 2014 and entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2014 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of March 30, 2019 or December 31, 2018.

Term Loans

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, maturing December 5, 2019. On March 8, 2018, we refinanced the €350.0 million outstanding under the term loan with the proceeds of a new €350.0 million ($431.0 million) term loan, maturing March 8, 2020 (the "2018 Term Loan"). In addition, as a result of the refinancing during the three months ended March 31, 2018, we recorded a loss of $0.5 million, consisting of the write-off of deferred financing fees in Loss on extinguishment of debt on the Condensed Consolidated Statements of Operations. During the three months ended March 30, 2019, we made $12.3 million in scheduled principal payments on the 2018 Term Loan.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no borrowings outstanding at March 30, 2019 or December 31, 2018.

We have financing leases that are reported in the above table under "Other financing" (refer to Note 8).


22
Perrigo Company plc - Item 1
Note 10


NOTE 10 – EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Numerator:
 
 
 
Net income
$
63.9

 
$
80.8

 
 
 
 
Denominator:
 
 
 
Weighted average shares outstanding for basic EPS
135.9

 
140.8

Dilutive effect of share-based awards
0.3

 
0.6

Weighted average shares outstanding for diluted EPS
136.2

 
141.4

 
 
 
 
Anti-dilutive share-based awards excluded from computation of diluted EPS
2.1

 
0.7



Shareholders' Equity

Share Repurchases

Following the expiration of our 2015 share repurchase plan authorization, in October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. We did not repurchase any shares during the three months ended March 30, 2019. During the three months ended March 31, 2018, we repurchased 1.3 million ordinary shares at an average repurchase price of $81.92 per share, for a total of $108.1 million.

NOTE 11 – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):
 
Fair Value of Derivative Financial Instruments, net of tax
 
Foreign Currency Translation Adjustments
 
Post-Retirement and Pension Liability Adjustments, net of tax
 
Total AOCI
Balance at December 31, 2018
$
(15.5
)
 
$
104.5

 
$
(4.4
)
 
$
84.6

OCI before reclassifications
(1.2
)
 
(16.8
)
 
(0.5
)
 
(18.5
)
Amounts reclassified from AOCI
2.9

 
—

 
—

 
2.9

Other comprehensive loss
$
1.7

 
$
(16.8
)
 
$
(0.5
)
 
$
(15.6
)
Balance at March 30, 2019
$
(13.8
)
 
$
87.7

 
$
(4.9
)
 
$
69.0


    

23
Perrigo Company plc - Item 1
Note 12


NOTE 12 – INCOME TAXES

The effective tax rates were as follows:
Three Months Ended
March 30,
2019
 
March 31,
2018
21.1
%
 
26.9
%


The effective tax rate for the three months ended March 30, 2019 decreased compared to the prior year period due primarily to additional valuation allowances recorded against deferred tax assets in the prior year.

Our tax rate is subject to adjustment over the balance of the calendar year due to, among other things, the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, Internal Revenue Service ("IRS") proposed regulations related to tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.

We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the United States, Israel, Belgium, France, and the United Kingdom.

On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the IRS, plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017. The cumulative deferred charge as recorded on the balance sheet is $29.7 million lower than the amounts reflected above due to overpayments credited to succeeding years, such that the actual refund the company is seeking to receive will be reduced by that amount. In addition, we recently conceded a royalty due to Perrigo U.S. on all omeprazole sales that equates to a 24% of our refund claims and any omeprazole adjustments that may be asserted by the IRS for future years.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December

24
Perrigo Company plc - Item 1
Note 12


31, 2013. Athena was the originator of the patents associated with Tysabri® prior to the acquisition of Athena by Elan in 1996. In response to the draft notice of proposed adjustment, we provided the IRS with substantial additional documentation supporting our position. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it. For subsequent developments refer to Note 16.

On October 31, 2018, we received an audit finding letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the years ended December 31, 2012 and December 31, 2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri® intellectual property and other assets related to Tysabri® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Amended Assessment (“NoA”) on November 29, 2018 which assesses an Irish corporation tax liability against Elan Pharma in the amount of €1,636 million, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA by Irish Revenue. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. If we are ultimately successful in the judicial review proceedings the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made, which could take up to, or more than, a year.

We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Ireland and other jurisdictions in Europe. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015 (which covers the period of the Elan transaction). The Israel Tax Authority's audit of our fiscal years ended June 29, 2013 and June 28, 2014 concluded with no material impact to the financial statements and the Israel Tax Authority is now auditing our fiscal years ended June 27, 2015, December 31, 2015, December 31, 2016 and December 31, 2017.

Tax Law Changes

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (“U.S. Tax Act”). The U.S. Tax Act includes a number of significant changes to existing U.S. tax laws that impact us. These changes include a corporate income tax rate reduction from 35% to 21% and the elimination or reduction of certain U.S. deductions and credits including limitations on the U.S. deductibility of interest expense and executive compensation. The U.S. Tax Act also transitions the U.S. taxation of international earnings from a worldwide system to a modified territorial system. These changes were effective beginning in 2018. The U.S. Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated U.S. owned foreign corporations’ previously untaxed foreign earnings (“Transition Toll Tax”). We paid our full Transition Toll Tax liability as of December 31, 2018.

On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of the U.S. GAAP ASC 740 income tax accounting for tax law changes enacted in the U.S. during 2017, in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the U.S. Tax Act. In accordance with SAB 118, for the year ended December 31, 2017, we recorded an income tax benefit of $2.4 million in connection with the remeasurement of certain deferred tax assets and liabilities and also recorded a $17.5 million increase of current tax expense in connection with the Transition Toll Tax on cumulative U.S. owned foreign earnings of $1.2 billion. For the year ended December 31, 2018, we completed the accounting for the income tax effects of the U.S. Tax Act. Based on additional guidance issued by the IRS and updates to our calculations we recorded a benefit of $6.3 million related to the Transition Toll Tax. There were no other material changes to the amounts recorded at December 31, 2017. We also finalized the provisional estimate related to our assertion on unremitted earnings of foreign subsidiaries recording an additional deferred tax liability of $8.3 million for the state income tax impacts of repatriating undistributed foreign earnings.


25
Perrigo Company plc - Item 1
Note 12


The U.S. Tax Act subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We have elected an accounting policy to provide for the tax expense related to GILTI in the year the tax is incurred ("period cost method"). At December 31, 2018, we made a reasonable estimate of the tax effect of a GILTI inclusion for 2018 and recorded additional tax expense of $9.4 million, net of U.S. foreign tax credits. In 2018, we had no tax expense resulting from the base erosion anti-avoidance tax ("BEAT") in 2018 and recorded an immaterial tax benefit for deductions related to foreign-derived intangible income ("FDII").

On January 1, 2019, we adopted ASU 2018-02 Income Statement - Reporting Comprehensive Income. Upon adoption, we did not elect to reclassify the income tax effects of the U.S. Tax Cuts and Jobs Act from AOCI to Retained earnings (accumulated deficit).

NOTE 13 – CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of March 30, 2019, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to, individually or in the aggregate, have a material adverse effect on our financial condition, results of operations, or cash flows. 

Price-Fixing Lawsuits

We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs and/or allocate customers starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The same class plaintiffs have filed complaints naming us as a co-defendant, along with 27 other manufacturers, alleging an overarching conspiracy to fix or raise the prices of 15 generic prescription pharmaceutical products starting in 2011. Perrigo manufactures only two of the products at issue, Nystatin cream and Nystatin ointment.

We have also been named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. The only allegations specific to us relate to Clobetasol, Desonide, Econazole, and Nystatin.

On August 3, 2018, a large managed care organization filed a complaint against us alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to us concern Clobetasol, Desonide, Econazole, and Nystatin cream/ointment.

Most recently, on January 16, 2019, a similar suit was brought by a health insurance carrier in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to us concern Clobetasol, Desonide, Econazole, and Nystatin cream/ointment.

Certain complaints listed above were amended in December 2017, January 2018, and April 2019. All of the above complaints have been consolidated for pretrial proceedings, along with complaints filed against other companies alleging price fixing with respect to more than two dozen other drugs, as part of a case captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 in the U.S. District Court for the Eastern District of Pennsylvania.

26
Perrigo Company plc - Item 1
Note 13



Pursuant to the court’s schedule staging various cases in phases, we moved to dismiss the complaints relating to Clobetasol and Econazole. The court issued a decision denying the motions in part in October 2018 and issued a second decision in February 2019 dismissing various state law claims, but allowing other state law claims to proceed. We filed answers to the Clobetasol complaints on December 31, 2018. We filed answers to the Desonide and Econazole complaints on March 15, 2019.

Motions to dismiss certain other complaints listed above were filed on February 21, 2019. Plaintiffs’ oppositions are due on May 2, 2019. Deposition discovery is currently stayed for all cases, but documentary discovery is proceeding. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.

Securities Litigation
 
In the United States (cases related to events in 2015-2017)

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders - shareholders who purchased shares during the period April 21, 2015 through May 3, 2017 on the U.S. exchanges; shareholders who purchased shares during the same period on the Tel Aviv exchange; and shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares.The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition and the alleged price fixing activities

27
Perrigo Company plc - Item 1
Note 13


with respect to six generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation has begun. We intend to defend the lawsuit vigorously.

On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Carmignac Gestion, S.A. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On January 16, 2018, Manning & Napier Advisors, LLC filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Manning & Napier Advisors, LLC v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5) and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On January 26, 2018, two different plaintiff groups (the Mason Capital group and the Pentwater group) each filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). The same law firm represents these two plaintiff groups, and the two complaints are substantially similar. These two cases are not securities class actions. One case is styled Mason Capital L.P., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The other case is styled Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al., and also was filed in the U.S. District Court for the District of New Jersey. Both cases are assigned to the same federal judge that is hearing the class action case and the other individual cases described above (Carmignac and Manning & Napier). Each complaint asserts claims under Securities Exchange Act sections 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the factual

28
Perrigo Company plc - Item 1
Note 13


allegations in these two cases overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the Carmignac case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to these cases conferred about how these cases should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in these cases. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuits vigorously.

On February 13, 2018, a group of plaintiff investors affiliated with Harel Insurance Investments & Financial Services, Ltd. filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). This lawsuit is not a securities class action. The new complaint is substantially similar to the amended complaint in the Roofers' Pension Fund case. The relevant period in the new complaint stretches from February 2014 to May 2, 2017. The complaint adds as defendants two individuals who served on our Board prior to 2016. The case is styled Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action cases and the four other individual cases described above (Carmignac, Manning & Napier, Mason Capital, and Pentwater). The Harel Insurance Company complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule 10b‑5) and section 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. The complaint also asserts claims based on Israeli securities laws. In general, the plaintiffs' allegations describe events during the period from February 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset from February 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the four opt out cases also described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On February 16, 2018, First Manhattan Company filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled First Manhattan Co. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the five other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. This lawsuit was filed by the same law firm that filed the Manning & Napier Advisors case and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier Advisors case. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. On April 20, 2018, the plaintiff filed an amended complaint that did not materially change the factual allegations of the original complaint. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.


29
Perrigo Company plc - Item 1
Note 13


On April 20, 2018, a group of plaintiff investors affiliated with TIAA-CREF filed a lawsuit against us and the same individuals who are the defendants in the Harel Insurance case complaint. This lawsuit is not a securities class action. The law firm representing the plaintiffs in the Harel Insurance case also represents the TIAA-CREF plaintiff entities in this case, and the new complaint is substantially similar to the Harel Insurance complaint. The relevant period in the new complaint is August 14, 2014 to May 2, 2017 inclusive. The case is styled TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action case and the six other individual cases described above (Carmignac, Manning & Napier, Mason Capital, Pentwater, Harel Insurance, and First Manhattan). The TIAA-CREF Investment Management complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule l0b-5), section 14(e) (related to tender offer disclosures) against all defendants as well as section 20(a) control person liability against the individual defendants. In general, plaintiffs' allegations describe events during the period from August 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset from August 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On October 29, 2018, Nationwide Mutual Funds and Nationwide Variable Insurance Trust (both on behalf of several fund series) filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the seven other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the First Manhattan case, the Manning & Napier Advisors case, and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. The defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Westchester Capital Funds filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P. case and the Pentwater Equity Opportunities Master Fund Ltd. case (described above) represents the affiliates of the Westchester Funds in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital and in the Pentwater cases described above. The case is styled WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The WCM case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the eight other individual cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5) and 14(e) against all defendants as well as 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 as well us up through May 3, 2017. Plaintiffs identify disclosures concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing

30
Perrigo Company plc - Item 1
Note 13


activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Hudson Bay Capital Management LP filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P., the Pentwater Equity Opportunities Master Fund Ltd., and the WCM cases (described above) represents the affiliates of Hudson Bay Capital Management in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital, in the Pentwater, and in the WCM cases described above. The case is styled Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The Hudson Bay Fund case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the nine other individual cases described above. The complaint asserts claims under Securities Exchange Act section 14(e) against all defendants and section 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On January 31, 2019, Schwab Capital Trust and a variety of other Schwab entities filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Schwab Capital Trust, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the ten other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, and the Nationwide Mutual Funds case described above and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending in the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual cases described above. We intend to defend the lawsuit vigorously.

On February 6, 2019, OZ Master Fund, Ltd. and a related entity filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the eleven other opt out cases described above. The complaint asserts claims under Securities Exchange Act

31
Perrigo Company plc - Item 1
Note 13


sections 10(b) (and SEC Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties have submitted an agreed stipulation to the court regarding a proposed schedule and are awaiting the court’s approval. We intend to defend the lawsuit vigorously.

On February 14, 2019, Highfields Capital I LP and related entities filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Highfields Capital I LP, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of Massachusetts. The complaint asserts claims under Securities Exchange Act sections 14(e) and 18 against all defendants, as well as 20(a) control person liability against the individual defendants. The complaint also asserts Massachusetts state law claims under Massachusetts Unfair Business Methods Law (chapter 93A § 11), and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged improper accounting for the Tysabri® asset. Some of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above and with allegations in one or more of the opt out cases described above. Plaintiffs do not provide a clear calculation of how they estimated damages and seek treble damages, punitive damages, and attorney's fees. On May 7, 2019, defendants filed a motion to transfer this case to the U.S. District Court for the District of New Jersey so that the proceedings in this case can be coordinated with the other cases (discussed above) pending in that court. We intend to defend the lawsuit vigorously.

On February 22, 2019, Aberdeen Canada Funds -- Global Equity Funds (and 30 other entities, some unrelated to Aberdeen) filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the twelve other opt-out cases pending in that Court. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5) against all defendants and 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged undisclosed pricing pressure for generic prescription pharmaceuticals, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, the Nationwide Mutual Funds case, and the Schwab Capital Trust case described above, and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual Funds cases described above. The plaintiff does not provide an estimate of damages. We intend to defend the lawsuit vigorously.


32
Perrigo Company plc - Item 1
Note 13


In Israel (cases related to events in 2015-2017)

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. Three cases were filed; one was voluntarily dismissed in each of 2017 and 2018 and one was stayed in 2018. We are consulting Israeli counsel about our response to these allegations and we intend to defend this case vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst & Young LLP ("EY") (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = 0.28 cents). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the Roofers’ Pension Fund case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.

In the United States (cases related to Irish Tax events)

On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (Masih v. Perrigo Company, et al.). Plaintiff purports to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contend that the Company, in its Form 10‑Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff does not provide an estimate of class damages. The Court has selected lead plaintiffs and changed the name of the case to In re Perrigo Company plc Sec. Litig. The lead plaintiffs filed an amended complaint on April 12, 2019, which names the same defendants, asserts the same class period, and invokes the same Exchange Act sections. The amended complaint generally repeats the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. We intend to defend the lawsuit vigorously.

In Israel (cases related to Irish Tax events)

On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our CFO Ronald Winowiecki in Tel Aviv District Court (Baton v. Perrigo Company plc, et. al.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the In re Perrigo Company plc Sec. Litig case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. We filed a request for a stay, the plaintiff agreed in part, and the court approved a stay and required the parties to update the court about the U.S. proceedings by September 1, 2019. We intend to defend the lawsuit vigorously.


33
Perrigo Company plc - Item 1
Note 13


Eltroxin

During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by our subsidiary, Perrigo Israel Agencies Ltd. The respondents included our subsidiaries, Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel.

One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.

Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd.

On June 16, 2015, we submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. We have filed our statement of defense to the underlying proceedings. The underlying proceedings have been stayed pending the outcome of the mediation process and, if necessary, a decision on the motion to appeal.

On November 14, 2017 the parties submitted an agreed settlement agreement to the approval of the Supreme Court, which referred the approval back to the District Court. During three hearings that took place on November 29, 2017, December 13, 2017 and January 11, 2018, the District Court opined that it would approve the settlement agreement subject to certain amendments to be proposed by the court (which would not impact the monetary settlement reached) and set a hearing for January 30, 2018 to discuss and finalize the proposed changes. Meanwhile, the Court ordered the settlement to be (1) provided to the Attorney General ("AG") for review (standard procedure); and (2) published in the written media (newspapers), to enable the class members to submit any objections or “opt-out” to  the proposed settlement by February 15, 2018.

On February 21, 2018, the District Court held a hearing to, among other things, review objections received from class members who had notified the District Court of their desire to opt out of the settlement. In addition, a representative of the AG's office notified the District Court that, based upon their preliminary examination of the settlement, they intend to object to the settlement in its current form. The District Court recommended that the parties continue to discuss and minimize objections to the settlement and scheduled another hearing for May 13, 2018.
    
The District Court Justice was appointed as a Supreme Court Justice and ordered to move the case to a different panel. In an effort to reach a decision before the appointment, an additional hearing was held on March 12, 2018 in which the court urged the parties to try and exhaust their negotiations to the fullest and provide an update by May 13, 2018. In addition, the Court ordered the AG to submit its opinion to the settlement agreement by May 30, 2018, which was extended until July 23, 2018.

On August 2, 2018, the AG submitted its objection to the settlement, noting, among other things, that it did not provide compensation for harm to autonomy. On August 12, 2018, we submitted our response to the Attorney General's objection together with an amended settlement which incorporated the court's comments.  Following the submission of the amended settlement agreement on August 23, 2018, the District Court rendered a decision that it will be willing to approve the amended settlement agreement providing that a few additional amendments will be made. Both parties agreed to carry out the requested amendments. On September 13, 2018, the AG filed a request to file a response to the amended settlement agreement and asked for an extension to file a response until

34
Perrigo Company plc - Item 1
Note 13


November 11, 2018, which was granted by the court. On November 11, 2018 the AG asked and was granted another ten days extension to file a response. On November 21, 2018 the AG filed its response in which he mainly repeated his previous objection to the settlement claiming that the settlement amount does not provide a suitable compensation for harm to the autonomy and that the mechanism payment is complex and will deter patients from receiving appropriate compensation for pain and suffering. The AG repeated his opinion that each member of the group should be compensated for harm to the autonomy while claiming a minimum amount of 250 NIS should be provided for each patient. In addition, the AG detailed an alternative mechanism and list of categories that he asserts would be a better and less complex solution to provide the compensation amount.

On November 29, 2018, the court approved the Eltroxin settlement agreement. In a lengthy decision, the court detailed the various aspects of the settlement as well as the objections submitted to the settlement, including the main objection submitted by the AG. The court added a number of comments ordering the parties to make minor changes to the agreement, mainly concerning the operation of the mechanism, however none of the agreement foundations are affected by these changes. The court found that the settlement is "worthwhile, reasonable and fair" and ordered its publication and approval.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV ("Holdco") (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo has recently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issue recently disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have a further basis for its counterclaim against Perrigo. The proposed additional counterclaim theory does not appear to increase any damages sought. The Tribunal has not decided whether to grant Alychlo permission to introduce the additional counterclaim. There can be no assurance that our Claim will be successful, and the Sellers deny liability for the Claim. We deny that Alychlo is entitled to any relief (including monetary relief) under either the existing counterclaim or the proposed additional counterclaim theory.
 The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.

Other Matters

Our Board of Directors received a shareholder demand letter dated October 30, 2018 relating to the allegations in the securities cases and price fixing lawsuits described above. The letter demands that the Board of Directors initiate an action against certain current and former executives and Board members to recover damages allegedly caused to the Company. In response, the Company reminded the shareholder that any derivative claim can only proceed in accordance with Irish law, the law that governs the Company’s internal affairs. The shareholder has responded that he intends to file a lawsuit asserting derivative claims but has not yet filed a lawsuit.


35
Perrigo Company plc - Item 1
Note 15


NOTE 14 – RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and asset impairments. The following reflects our restructuring activity (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
24.0

 
$
21.4

Additional charges
5.9

 
1.5

Payments
(9.0
)
 
(10.8
)
Non-cash adjustments
(0.4
)
 
0.3

Ending balance
$
20.5

 
$
12.4



The charges incurred during the three months ended March 30, 2019 were primarily associated with the reorganization of our executive management team. There were no other material restructuring programs that significantly impacted any individual segment for the three months ended March 30, 2019 or March 31, 2018. All charges are recorded in Restructuring expense on the Condensed Consolidated Financial Statements. The remaining $20.5 million liability for employee severance benefits and lease exit costs is expected to be paid within the next year.

NOTE 15 – SEGMENT INFORMATION
    
Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company.

The below tables show select financial measures by reporting segment (in millions):
 
 
Total Assets
 
 
March 30,
2019
 
December 31,
2018
CSCA
 
$
3,704.6

 
$
3,571.7

CSCI
 
4,597.8

 
4,613.0

RX
 
2,817.1

 
2,798.7

Total
 
$
11,119.5

 
$
10,983.4

 
Three Months Ended
 
March 30, 2019
 
March 31, 2018
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CSCA
$
581.8

 
$
94.2

 
$
10.1

 
$
601.6

 
$
118.6

 
$
15.2

CSCI
350.8

 
8.1

 
44.1

 
377.8

 
12.3

 
51.1

RX
241.9

 
60.6

 
21.2

 
237.6

 
61.2

 
20.9

Unallocated
—

 
(60.6
)
 
—

 
—

 
(35.8
)
 
—

Total
$
1,174.5

 
$
102.3

 
$
75.4

 
$
1,217.0

 
$
156.3

 
$
87.2



NOTE 16 – SUBSEQUENT EVENTS

Notice of Proposed Adjustment

On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of

36
Perrigo Company plc - Item 1
Note 15


Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on Perrigo’s liquidity and capital resources (refer to Note 12).

Animal Health Divestiture

On May 8, 2019, we signed a definitive agreement for the sale of our animal health business to PetIQ for $185.0 million in cash, plus a working capital adjustment. We expect to finalize the sale within the next six months. The divestiture of this business is not expected to have a material impact on our operations or financial results.

Ranir Global Holdings, LLC

On May 8, 2019, we reached a definitive agreement to purchase privately-held Ranir Global Holdings, LLC (“Ranir”) in a transaction valued at $750.0 million on a cash-free, debt-free basis. We intend to fund the transaction with approximately $450.0 million of cash on hand and the balance through short-term debt. Headquartered in Grand Rapids, Michigan, Ranir is a leading global supplier of private label and branded oral care products. The transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. The proposed transaction, which has been unanimously approved by both our and Ranier's boards of directors, is subject to the satisfaction of closing conditions, including customary regulatory approvals. The transaction is expected to close during the third quarter of calendar year 2019.

ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXECUTIVE OVERVIEW

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements included in this Form 10-Q and our Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”). These historical financial statements may not be indicative of our future performance. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under “Risk Factors” in Item 1A of our 2018 Form 10-K and Part II. Item 1A of this Form 10-Q.

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are dedicated to making lives better by bringing “Quality, Affordable Self-Care Products™” that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.


37
Perrigo Company plc - Item 2
Executive Overview



Segment Reporting Change

               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the Consumer Self-Care International segment to the Prescription Pharmaceuticals segment and we made certain adjustments to our allocations between segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Item 1. Note 2 and Note 15. For results by segment, see "Segment Results" below.

Our new reporting and operating segments are as follows:

•
Consumer Self-Care Americas ("CSCA"), formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada.
•
Consumer Self-Care International ("CSCI"), formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.
•
Prescription Pharmaceuticals ("RX"), comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.

Highlights

•
On August 9, 2018, we announced a plan to separate our RX business, which, when completed, will enable us to focus on expanding our consumer-facing businesses. We have begun the preparations for the separation, which may include a possible sale, spin-off, merger or other form of separation. While we are currently targeting to complete the separation by the end of 2019, the form of separation may delay its completion beyond this date and into 2020. In connection with the proposed separation, we anticipate incurring significant preparation costs, excluding restructuring expenses and transaction costs, in the range of $45.0 million to $80.0 million depending on the final structure of a transaction, with a spin-off resulting in costs at the higher end of this range.

•
On May 8, 2019, we reached a definitive agreement to purchase privately-held Ranir Global Holdings, LLC (“Ranir”) in a transaction valued at $750.0 million on a cash-free, debt-free basis. We intend to fund the transaction with approximately $450 million of cash on hand and the balance through short-term debt. Headquartered in Grand Rapids, Michigan, Ranir is a leading global supplier of private label and branded oral care products. The transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. The proposed transaction, which has been unanimously approved by both our and Ranir's board of directors, is subject to the satisfaction of closing conditions, including customary regulatory approvals. The transaction is expected to close during the third quarter of calendar year 2019.

RESULTS OF OPERATIONS

CONSOLIDATED

Recent Developments

Notice of Proposed Adjustment

On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40% penalty. This amount excludes consideration of offsetting tax attributes and potentially

38
Perrigo Company plc - Item 2
Consolidated


material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on Perrigo’s liquidity and capital resources (refer to Item 1. Note 12).

Consolidated Results

Three Month Comparison
 
Three Months Ended
(in millions)
March 30,
2019
 
March 31,
2018
Net sales
$
1,174.5

 
$
1,217.0

Gross profit
$
448.8

 
$
492.7

Gross profit %
38.2
%
 
40.5
%
Operating income
$
102.3

 
$
156.3

Operating income %
8.7
%
 
12.8
%
chart-5095151ccba65a95916.jpg
 
chart-ee2c5fc1da03539bb7f.jpg
* Total net sales by geography is derived from the location of the entity that sells to a third party.

Net sales decreased $42.5 million, or 4%, over the prior year period due to:

•
$38.4 million decrease in net sales of existing products due primarily to pricing pressure;
•
$35.7 million decrease due primarily to unfavorable European Euro and Israeli Shekel foreign currency translation; and
•
$23.1 million decrease due to discontinued products; partially offset by
•
$54.7 million increase due to new product sales.

Operating income decreased $54.0 million, or 35%, over the prior year period due to:

•
$43.9 million decrease in gross profit, or a 230 basis points decrease in gross profit as a percentage of net sales, due primarily to pricing pressure, unfavorable product mix, and increased costs for certain products.

•
$10.1 million increase in operating expenses due primarily to:
•
$7.8 million increase in restructuring expense; and
•
$2.0 million increase in selling expense due primarily to the timing of animal health promotions.


39
Perrigo Company plc - Item 2
CSCA


CONSUMER SELF-CARE AMERICAS

Recent Developments

•
On May 8, 2019, we signed a definitive agreement for the sale of our animal health business to PetIQ for $185.0 million in cash, plus a working capital adjustment. We expect to finalize the sale within the next six months. The divestiture of this business is not expected to have a material impact on our operations or financial results.

•
As discussed above, on May 8, 2019, we reached a definitive agreement to purchase Ranir in a transaction valued at $750.0 million on a cash-free, debt-free basis. The transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. The transaction is expected to close during the third quarter of calendar year 2019.

Segment Results

Three Month Comparison
 
Three Months Ended
(in millions)
March 30,
2019
 
March 31,
2018
Net sales
$
581.8

 
$
601.6

Gross profit
$
184.0

 
$
205.9

Gross profit %
31.6
%
 
34.2
%
Operating income
$
94.2

 
$
118.6

Operating income %
16.2
%
 
19.7
%

Three Months Ended March 30, 2019 vs. Three Months Ended March 31, 2018

Net sales decreased $19.8 million, or 3%, over the prior year period primarily due to:

•
$15.3 million decrease in net sales of existing products due primarily to:
•
Pricing pressure across all categories; and
•
Lower sales volumes in our cough/cold/allergy/sinus, analgesics, infant nutritionals and animal health categories; partially offset by
•
Higher sales volumes in our gastrointestinal category; and
•
$10.7 million decrease due to discontinued products; partially offset by
•
$7.0 million increase due primarily to the launches of various new antacids and cough/cold/allergy products.

Operating income decreased $24.4 million, or 21%, over the prior year period due to:

•
$21.9 million decrease in gross profit, or 260 basis points decrease in gross profit as a percentage of net sales, due primarily to pricing pressure and increased commodity costs related to certain products in the cough/cold/allergy/sinus categories and operating inefficiencies related to infant formula production.

•
$2.5 million increase in operating expenses due primarily to:
•
$4.1 million In-Process R&D impairment charge; and
•
$1.2 million increase in selling expense due to the timing of animal health promotions; partially offset by
•
$4.1 million contingent consideration gain.


40
Perrigo Company plc - Item 2
CSCI


CONSUMER SELF-CARE INTERNATIONAL

Recent Trends and Developments

•
Management continues to implement its previously disclosed strategy for brand prioritization, sales force restructuring, and manufacturing insourcing, which is expected to reduce selling costs, improve operating margins and focus on higher value OTC products. As part of this strategy, we are making progress on the previously reported CSCI restructuring plan that we expect to improve our cost structure.

Segment Results

Three Month Comparison
 
Three Months Ended
(in millions)
March 30,
2019
 
March 31,
2018
Net sales
$
350.8

 
$
377.8

Gross profit
$
168.4

 
$
185.9

Gross profit %
48.0
%
 
49.2
%
Operating income
$
8.1

 
$
12.3

Operating income %
2.3
%
 
3.3
%

Three Months Ended March 30, 2019 vs. Three Months Ended March 31, 2018

Net sales decreased $27.0 million, or 7%, over the prior year period due to:

•
$33.6 million decrease due to unfavorable European Euro foreign currency translation;
•
$17.4 million decrease in net sales of existing products due primarily to lower volume in the personal care and derma-therapeutics and lifestyle categories; and
•
$2.0 million decrease due to discontinued products; partially offset by
•
$26.0 million increase due primarily to the launches of various new lifestyle, cough/cold/allergy, and personal care and derma-therapeutics products.

Operating income decreased $4.2 million, or 35%, over the prior year period due to:

•
$17.5 million decrease in gross profit, or 120 basis point decrease in gross profit as a percentage of net sales, due primarily to less favorable product mix and increased external cost for certain products in the personal care and derma-therapeutics category.

•
$13.3 million decrease in operating expenses due primarily to the effect of European Euro favorable foreign currency translation.


41
Perrigo Company plc - Item 2
RX


PRESCRIPTION PHARMACEUTICALS

Recent Trends and Developments

•
We continue to experience a substantial year-over-year reduction in pricing in our RX segment due to competitive pressures. This softness in pricing is attributable to various factors, including increased focus from customers to capture competition in specific products, supply chain productivity savings, and consolidation of certain customers. While in the first quarter of 2019 we experienced a year-over-year decrease in pricing pressure, we expect softness in pricing to continue to impact the segment for the foreseeable future.

Segment Results

Three Month Comparison
 
Three Months Ended
(in millions)
March 30,
2019
 
March 31,
2018
Net sales
$
241.9

 
$
237.6

Gross profit
$
96.4

 
$
100.9

Gross profit %
39.9
%
 
42.5
%
Operating income
$
60.6

 
$
61.2

Operating income %
25.1
%
 
25.8
%

Three Months Ended March 30, 2019 vs. Three Months Ended March 31, 2018

Net sales increased $4.3 million, or 2%, over the prior year period due primarily to:

•
$21.7 million increase in new product sales due primarily to Testosterone Gel 1.62% gel pumps (generic equivalent to Androgel®) and Acyclovir 5% Cream (generic equivalent to Zovirax®); partially offset by
•
$10.4 million decrease due to discontinued products; and
•
$5.7 million decrease in net sales of existing products due primarily to pricing pressure and decreased sales volumes of certain products.

Operating income decreased $0.6 million, or 1%, over the prior year period due to:

•
$4.5 million decrease in gross profit, or 260 basis points decrease of gross profit as a percentage of net sales, due primarily to less favorable product mix.

•
$3.9 million decrease in operating expenses due primarily to the absence of $4.1 million of acquisition charges and certain adjustments to contingent consideration.

Unallocated Expenses

Unallocated expenses are comprised of certain corporate services not allocated to our reporting segments and are recorded in Operating income on the Condensed Consolidated Statements of Operations. Unallocated expenses were as follows (in millions):
Three Months Ended
March 30,
2019
 
March 31,
2018
$
60.6

 
$
35.8


The increase of $24.8 million in unallocated expenses during the three months ended March 30, 2019 compared to the prior year period was due to an increase of $17.9 million of Administration expense due primarily to increased legal and consulting fees and an increase of $7.7 million in Restructuring expense related primarily to the reorganization of our executive management team.

42
Perrigo Company plc - Item 2
Unallocated, Interest, Other, and Taxes



Change in Financial Assets, Interest expense, net, and Other (income) expense, net (Consolidated)
 
Three Months Ended
(in millions)
March 30,
2019
 
March 31,
2018
Change in financial assets
$
(10.4
)
 
$
9.6

Interest expense, net
$
28.6

 
$
31.4

Other (income) expense, net
$
3.2

 
$
4.3


Change in Financial Assets

During the three months ended March 30, 2019, the fair value of the Royalty Pharma contingent milestone payments increased $10.4 million driven by higher projected global net sales of Tysabri® and the estimated probability of achieving the earn-out. During the three months ended March 31, 2018, the fair value of the Royalty Pharma contingent milestone payments decreased $9.6 million due primarily to projected global net sales of Tysabri® temporarily falling below the threshold required for payment of the $250.0 million milestone payment for 2018.

In order for us to receive the 2020 milestone payment of $400.0 million, Royalty Pharma contingent payments for Tysabri® sales in 2020 must exceed $351.0 million. If Royalty Pharma contingent payments for Tysabri® sales do not meet the prescribed threshold in 2020, we will write off the $83.6 million asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to $400.0 million and recognize income of $316.4 million in Change in financial assets on the Condensed Consolidated Statements of Operations (refer to Item 1. Note 5).

Interest Expense, Net

Interest expense, net was $28.6 million during the three months ended March 30, 2019 compared to $31.4 million for the three months ended March 31, 2018. The $2.8 million decrease was due primarily to changes in our underlying hedge exposure (refer to Item 1. Note 7).

Other Expense, Net

Other (income) expense, net was $3.2 million expense for the three months ended March 30, 2019 compared to $4.3 million expense for the three months ended March 31, 2018. The $1.1 million decrease was due primarily to $1.0 million of favorable changes in revaluation of monetary assets and liabilities held in foreign currencies.

Income Taxes (Consolidated)

The effective tax rates were as follows:
Three Months Ended
March 30,
2019
 
March 31,
2018
21.1
%
 
26.9
%

The effective tax rate for the three months ended March 30, 2019 decreased compared to the prior year period due primarily to additional valuation allowances recorded against deferred tax assets in the prior year (refer to Item 1. Note 12 for more information on income taxes).

FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES

We finance our operations with internally generated funds, supplemented by credit arrangements with third parties and capital market financing. We routinely monitor current and expected operational requirements and financial market conditions to evaluate other available financing sources including revolving bank credit and

43
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


securities offerings. In determining our future capital requirements we regularly consider, among other factors, known trends and uncertainties, such as the Notice of Assessment ("NoA") and the Notice of Proposed Adjustment ("NOPA") and other contingencies. We note that no payment of the additional amounts assessed by Irish Revenue pursuant to the NoA or proposed by the IRS in the NOPA is currently required, and no such payment is expected to be required, unless and until a final determination of the matter is reached that is adverse to us, which could take several years in either case. Based on the foregoing, management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements, as described below. However, we continue to evaluate the impact of the above factors on liquidity and may determine that modifications to our capital structure are appropriate if market conditions deteriorate, favorable capital market opportunities become available, or any change in conditions relating to the NoA, the NOPA or other contingencies has a material impact on our capital requirements.

Cash and Cash Equivalents

chart-f715b0ee48225a40866.jpg
* Working capital represents current assets less current liabilities, excluding cash and cash equivalents, and current indebtedness.

Cash, cash equivalents, cash flows from operations, and borrowings available under our credit facilities are expected to be sufficient to finance our liquidity and capital expenditures in both the short and long term. Although our lenders have made commitments to make funds available to us in a timely fashion under our revolving credit agreements and overdraft facilities, if economic conditions worsen or new information becomes publicly available impacting the institutions’ credit rating or capital ratios, these lenders may be unable or unwilling to lend money pursuant to our existing credit facilities. Should our outlook on liquidity requirements change substantially from current projections, we may seek additional sources of liquidity in the future.

Cash Generated by Operating Activities
chart-6741377481db3b5310c.jpg

44
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


The $77.9 million decrease in operating cash inflow was due primarily to:

•
Decreased net earnings after adjustments for items such as deferred income taxes, impairment charges, restructuring charges, changes in our financial assets, share-based compensation, amortization of debt premium, and depreciation and amortization;

•
Changes in accrued customer programs due primarily to pricing dynamics in our RX segment, as well as timing of rebate and chargeback payments; and

•
Changes in accounts receivable due primarily to timing of shipments and receipt of payments in our CSCI, CSCA and RX segments; partially offset by

•
Changes in accrued liabilities due primarily to the change in royalty and profit sharing accruals as well as changes in legal and litigation accruals, partially offset by deferred revenue associated with BCH-Belgium distribution contracts; and

•
Changes in accounts payable due primarily to the timing of payments, and mix of payment terms.

Cash Generated by (Used in) Investing Activities
chart-6681394ba8e6b7b6c0b.jpg

The $232.2 million increase in investing cash inflow was due primarily to:

•
$250.0 million increase from the receipt of the Royalty Pharma contingent milestone payment; partially offset by
•
$8.8 million decrease in proceeds from royalty rights; and
•
$7.7 million increase in capital spending due primarily to increased tablet and infant formula capacity and quality/regulation projects.


45
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


Cash (Used in) Financing Activities

chart-c40ee33d0dfb9db21d0.jpg
The $121.0 million decrease in financing cash outflow was due primarily to:

•
$108.1 million decrease in share repurchases;
•
$5.9 million decrease in borrowings (repayments) of revolving credit agreements and other financing; and
•
$2.4 million decrease in deferred financing fees.

The declaration and payment of dividends, if any, is subject to the discretion of our Board of Directors and will depend on our earnings, financial condition, availability of distributable reserves, capital and surplus requirements, and other factors our Board of Directors may consider relevant.

In October 2018, the Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date.

Borrowings and Capital Resources
chart-039cc1c102fc583384a.jpg
 
chart-263b0786b3f7a1559bc.jpg
Revolving Credit Agreements

On March 8, 2018, we terminated the revolving credit agreement entered into in December 2014 and entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of March 30, 2019 or December 31, 2018.


46
Perrigo Company plc - Item 2
Financial Condition, Liquidity and Capital Resources


Term Loans and Notes

We had $2.9 billion outstanding under our notes and bonds as of both March 30, 2019 and December 31, 2018. We had $331.3 million and $351.3 million outstanding under our term loan as of March 30, 2019 and December 31, 2018, respectively.

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, maturing December 5, 2019. On March 8, 2018, we refinanced the €350.0 million outstanding under the term loan with the proceeds of a new €350.0 million ($431.0 million) term loan, maturing March 8, 2020 (the "2018 Term Loan"). During the three months ended March 30, 2019, we made $12.3 million in scheduled principal payments on the 2018 Term Loan.

Overdraft Facilities

We have overdraft facilities available that we use to support our cash management operations. There were no borrowings outstanding at March 30, 2019 or December 31, 2018.

Leases

We had $157.8 million of lease liabilities and $156.7 million of lease assets as of March 30, 2019, respectively.

Accounts Receivable Factoring

The total amount factored on a non-recourse basis and excluded from accounts receivable was $23.3 million and $24.3 million at March 30, 2019 and December 31, 2018, respectively.

We are in compliance with all covenants under our debt agreements as of March 30, 2019 (refer to Item 1. Note 8 and Note 9 for more information on all of the above lease activity and debt facilities, respectively).

Credit Ratings
    
Our credit ratings on March 30, 2019 were Baa3 (stable) and BBB- (stable) by Moody's Investors Service and Standard and Poor's Rating Services, respectively.

Credit rating agencies review their ratings periodically and, therefore, the credit rating assigned to us by each agency may be subject to revision at any time. Accordingly, we are not able to predict whether current credit ratings will remain as disclosed above. Factors that can affect our credit ratings include changes in operating performance, the economic environment, our financial position, and changes in business strategy. If changes in our credit ratings were to occur, they could impact, among other things, future borrowing costs, access to capital markets, and vendor financing terms.

Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, net sales or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into R&D arrangements with third parties that often require milestone payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required upon the successful achievement of an important point in the development life cycle of the product. Because of the contingent nature of these payments, they are not included in the table of contractual obligations included in our 2018 Form 10-K and referred to below.
Contractual Obligations and Commitments

There were no material changes in contractual obligations as of March 30, 2019 from those provided in our 2018 Form 10-K.


47
Perrigo Company plc - Item 2
Unallocated, Interest, Other, and Taxes


Critical Accounting Policies

The determination of certain amounts in our financial statements requires the use of estimates. These estimates are based upon our historical experiences combined with management’s understanding of current facts and circumstances. Although the estimates are considered reasonable based on the currently available information, actual results could differ from the estimates we have used. There have been no material changes to the critical accounting policies disclosed in our 2018 Form 10-K other than the hedging policies that we updated upon adoption of ASU 2017-12 (refer to Item 1. Note 7) and our leasing polices that we updated upon adoption of ASU 2016-02 (refer to Item 1. Note 8).

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our quantitative or qualitative disclosures found in Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," of our 2018 Form 10-K.

ITEM 4.        CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act) as of March 30, 2019. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective in ensuring that all material information relating to us and our consolidated subsidiaries required to be included in our periodic SEC filings would be made known to them by others within those entities in a timely manner and that no changes are required at this time.

Evaluation of the Effectiveness of Internal Control over Financial Reporting

Our management assessed the effectiveness of our internal control over financial reporting as of March 30, 2019. The framework used in carrying out our evaluation was the 2013 Internal Control - Integrated Framework published by the Committee of Sponsoring Organizations ("COSO") of the Treadway Commission. In evaluating our information technology controls, we also used components of the framework contained in the Control Objectives for Information and related Technology, which was developed by the Information Systems Audit and Control Association’s IT Governance Institute, as a complement to the COSO internal control framework. Management has concluded that our internal control over financial reporting was effective as of March 30, 2019. The results of management’s assessment have been reviewed with our Audit Committee.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended March 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.     OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

Refer to Part I, Item 1. Note 13 of the Notes to the Condensed Consolidated Financial Statements.


48
Perrigo Company plc - Item 1A
Risk Factors




ITEM 1A.    RISK FACTORS

Our Annual Report on Form 10-K for the year ended December 31, 2018 includes a detailed discussion of our risk factors. At the time of this filing, there have been no material changes to the risk factors that were included in the Form 10-K, other than as described below.

Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business.

Over the last several years, we have experienced a number of changes in our executive leadership. Most recently, on March 20, 2019, we announced the appointment of Raymond P. Silcock as Chief Financial Officer and principal accounting officer. Mr. Silcock’s appointment followed the resignation of Ronald L. Winowiecki, who had held those roles since his appointment in February 2017. Changes in executive management create uncertainty. Moreover, changes in our company as a result of management transition could have a disruptive impact on our ability to implement, or result in changes to, our strategy and could negatively impact our business, financial condition and results of operations.

The resolution of uncertain tax positions could be unfavorable, which could have an adverse effect on our business.

Although we believe that our tax estimates are reasonable and that our tax filings are prepared in accordance with all applicable tax laws, the final determination with respect to any tax audit or any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results or cash flows in the periods for which that determination is made and in future periods after the determination. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties or interest assessments.

We are currently involved in several audits and adjustments related disputes, including litigation, with the IRS. These include litigation regarding our 2009, 2010, 2011, and 2012 tax years, as well as proposed audit adjustments related to litigation costs related to Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the 2011, 2012 and 2013 tax years.

In addition, on October 31, 2018, we received an audit finding letter from Irish Revenue for the years under audit 2012-2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri® intellectual property and other assets related to Tysabri® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Assessment ("NoA") on November 29, 2018, which assesses an Irish corporation tax liability against Elan Pharma in the amount of €1,636.0 million, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. If Perrigo is ultimately successful in the judicial review proceedings, the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made, which could take up to, or more than, a year. No payment of any amount related to this assessment is required to be made, if at all, until all applicable proceedings have been completed, which could take a number of years. However, while we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is ultimately resolved unfavorably it would have a material adverse impact on us, including on liquidity and capital resources.

On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation

49
Perrigo Company plc - Item 1A
Risk Factors




prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on our liquidity and capital resources.

In addition, going forward, uncertainty regarding the future outcome of the NoA or NOPA may have an adverse impact on our financial condition and strategy, including our plan to separate our RX business.

At this time, we cannot predict the outcome of any audit or related litigation. Unfavorable developments in or resolutions of matters such as those discussed above could, individually or in the aggregate, have a material impact on our Condensed Consolidated Financial Statements in future periods (refer to Item 1, Note 12 for further information related to uncertain tax positions and ongoing tax audits and Item 1. Note 13 for further information related to legal proceedings).


50
Perrigo Company plc - Item 6
Exhibits


ITEM 6.    EXHIBITS

Exhibit
Number
 
Description
 
 
 
3.1
 
 
 
 
3.2
 
 
 
 
10.1
 
 
 
 
10.2
 
 
 
 
10.3
 
 
 
 
10.4
 
 
 
 
10.5
 
 
 
 
10.6
 
 
 
 
10.7
 
 
 
 
10.8
 
 
 
 
10.9
 
 
 
 
31.1
 
 
 
 
31.2
 
 
 
 
32
 
 
 
 
101
 
The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter year ended March 30, 2019, formatted in Extensible Business Reporting Language, (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) the Notes to the Condensed Consolidated Financial Statements.


51

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
PERRIGO COMPANY PLC
 
 
 
(Registrant)
 
 
 
 
Date:
May 9, 2019
 
/s/ Murray S. Kessler
 
 
 
Murray S. Kessler
 
 
 
Chief Executive Officer and President
 
 
 
(Principal Executive Officer)
 
 
 
 
Date:
May 9, 2019
 
/s/ Raymond P. Silcock
 
 
 
Raymond P. Silcock
 
 
 
Chief Financial Officer
 
 
 
(Principal Accounting and Financial Officer)


52
 EX-10.7 2 cy19q110qex107.htm EXHIBIT 10.7 Exhibit

Exhibit 10.7

AMENDMENT NO. 1
TO
EMPLOYMENT AGREEMENT

The Employment Agreement made and entered into effective October 8, 2018 by and between Perrigo Management Company (the “Company”) and Murray Kessler (“Executive”), is hereby Amended by this Amendment No. 1, effective as of February 13, 2019 (this “Amendment”).
WHEREAS, the Company and the Executive desire to amend the Agreement in order to avoid the unintended forfeiture of equity compensation upon Executive’s expected retirement date.
NOW, THEREFORE for good and valuable consideration, the receipt of which is acknowledged, Executive and the Company agree as follows:
1.
Paragraph 3(c) of the Agreement (Long-Term Incentive Awards) is amended and restated in its entirety as follows:
“Long-Term Incentive Awards. Beginning in the calendar year 2019, Executive will be eligible to participate in Parent’s 2013 Long-Term Incentive Plan (or successor plan), as amended (the “2013 LTIP”), on terms and conditions as determined in the sole and absolute discretion of the Committee; provided, that annual grants shall (i) be on the same terms and conditions (including the form and mix of grant types) as, and granted to Executive at the same time as such awards are granted to, other members of the Company’s executive committee, and (ii) have a grant date fair value of not less than $7,750,000; provided, further, that, the term “Retirement” as used in the applicable annual grant award agreement shall mean the Executive attaining age 62 and not as defined in the 2013 LTIP. During the Employment Period, Executive shall also be eligible to participate in other long-term cash and equity incentive plans, practices, policies, and programs applicable generally to other senior executives of the Company, as determined by the Committee in its sole and absolute discretion.”
2.
This Amendment may be executed in counterparts and each counterpart will be deemed an original.

3.
Except as expressly provided herein, the rest of the Agreement shall remain unaltered and in full force and effect.



[Signature Page Follows]
    




IN WITNESS WHEREOF, this Amendment has been duly executed by the Parties as of the date written above.

EXECUTIVE

/s/ Murray S. Kessler
Name: Murray S. Kessler
Title: President and Chief Executive Officer
 
 


PERRIGO MANAGEMENT COMPANY
 
 
By:
/s/ Todd W. Kingma
Name:  
Todd W. Kingma
Title:
Executive Vice President, General Counsel, and
Secretary






 EX-10.9 3 cy19q110qex109.htm EXHIBIT 10.9 Exhibit
Exhibit 10.9

winowieckiperrigoagre_image1.jpg

April 16, 2019
PERSONAL AND CONFIDENTIAL

Mr. Ronald Winowiecki

RE:
Employment Separation and Severance
Perrigo Company Confidential Wavier and Release Agreement 1
Dear Ron:
As a result of a decision by Perrigo to make a change in the Chief Financial Officer (“CFO”) role, your employment with Perrigo Company plc will end June 30, 2019 (“Executive’s Severance Date”); you will have no continued employment opportunity with Perrigo. This Waiver and Release Agreement 1 (“the Agreement” or “Agreement 1”) is entered into by and between Perrigo Company plc (“Perrigo” or “the Company”), and Ronald Winowiecki (“you” or “Employee” or “Executive”). As of March 25, 2019, you will step down from your CFO position and as compensation for doing so, you remain employed through June 30, 2019 (the “Severance Date”) to assist with the transition of duties; your compensation, including but not limited to your base salary at the rate of $643,150 per annum, will remain unchanged through the Executive’s Severance Date.
It is expected that, during the period from the date hereof through the Executive’s Severance Date you will perform the job responsibilities described in this paragraph in a satisfactory manner, using your best efforts to perform those responsibilities.  Your job responsibilities shall be to assist with any knowledge transfer needed, including training of others within the organization. It is understood that you will no longer be responsible to perform the job responsibilities of a CFO on or after March 25, 2019. Additionally, you must conduct yourself in accordance with the standards set forth by Perrigo’s policies and procedures, including policies set forth in Perrigo’s employee handbook.
Perrigo will extend to Employee the Perrigo Company plc Executive Committee Severance Policy As Amended and Restated Effective February 13, 2019 (the “Policy”). To be eligible to receive any benefits under the Policy, (i) Executive shall have executed and delivered this Agreement to Company within the time period described in Section 28(d) below, (ii) Executive shall not have timely revoked this Agreement in the manner described in Section 28(e) below, (iii) Executive shall have executed and delivered the agreement described in Section 29 below as “Agreement 2” to Company within the time period described in Section 29(b), and (iv) Executive shall not have timely revoked this Agreement in the manner described in Section 29(c) below, in which event the severance pay described in Section 1 below will be paid in a lump-sum within 20 days following the end of the seven (7) day revocation period described in Section 29(c) below. Benefits available to Executive in exchange for Executive’s execution of both (A) this Agreement 1, and (B) the Supplemental Waiver and Release Agreement described in Section 29 below as “Agreement 2” which has been presented to Executive along with this Agreement 1, are summarized as follows:
1.Severance pay (the “Severance Pay”) in an amount equal to the sum of (i) 150% of Executive’s ending base salary as of Executive’s Severance Date and (ii) 150% of Executive’s Target Bonus, totaling the gross amount of $1,738,125.00. The Company will withhold all required country, federal, state, and local taxes and FICA from these amounts.

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 2



2.    An incentive payment pro-rated based on the portion of the year that Executive was employed through the Severance Date (i.e., fifty percent) and based on the 2019 actual incentive payout approved by the Board of Directors of the Company pursuant to the Perrigo Company plc Annual Incentive Plan, assuming that Executive’s individual performance level was 100%, to be paid in a lump sum payment at the regularly scheduled annual incentive payment date of February/March of the calendar year following Executive’s Severance Date, provided, however, that the Company will pay such amount to the Executive no later than March 15, 2020, unless a determination of the performance measures has not been approved by the Board of Directors due to unforeseeable circumstances, within the meaning of Treasury Regulation 1.409A-1(b)(4)(ii). The Company will withhold all required federal, state, and local taxes and FICA from this amount. For avoidance of doubt, in the event that 100% of the 2019 incentive targets were achieved, the amount of the 2019 incentive payout to Executive would be $257,500.
3.    If Executive is enrolled in the Perrigo Company Employee Welfare Benefits Plan at the Executive’s Severance Date, Executive and/or covered family members are eligible for Company-paid group health continuation coverage under COBRA for eighteen (18) months (notwithstanding that severance will be paid in a lump sum). Please refer to the Policy for further detail. Executive understands that Executive can exercise Executive’s rights to elect COBRA coverage without signing this Agreement; however, the Company will not pay for any such coverage if the Agreement is not signed and not timely revoked. See the attached Benefits At-A-Glance for contact information to begin this process. If Executive elects COBRA coverage, the Company will pay the premiums directly to the insurance company in a timely fashion so as to assure continuation of coverage.
4.    Career transition assistance of up to $25,000 if begun within 120 days following Executive’s Severance Date. You will be provided with a Right Management document for contact information to begin this process. The Company will pay the cost of such assistance directly to Right Management in a timely fashion so as to assure continuation of such assistance.
5.    Your unvested equity awards outstanding under the Company’s Long-Term Incentive Plan will continue to vest per their original vesting schedules and will remain outstanding for their original terms, and performance-based restricted stock units will vest based on actual performance at the end of their original performance periods, in each case in accordance with and subject to the terms of the plan as in effect on Executive’s Severance Date.
6.    The Company will reimburse Executive for Executive Tax and Financial Planning Services for calendar year 2018 and calendar year 2019, at the rate of $7,500 per year, and shall deliver that $15,000 amount to Executive at the same time as it pays the Severance Pay to him. The Company will withhold all required country, federal, state, and local taxes and FICA from this amount.
7.    The Company shall reimburse Executive for reasonable legal fees incurred in connection with the separation and the drafting of the applicable documentation related thereto, but in no event shall the amount of such reimbursement exceed $7,500. Kohrman Jackson & Krantz PLL, 1375 East 9th Street 29th Floor, Cleveland, OH 44114, shall provide an invoice to Perrigo directly for such legal fees and Perrigo will pay an amount no greater than $7,500, within 60 days of receipt of the invoice. As legally required, the Company shall report all fees to tax authorities on appropriate forms.
8.    General Release by Executive. In full consideration of Employee meeting the Conditions of Eligibility of the Policy and for the Severance Pay and Severance Benefits to be provided to Employee under the Policy, Employee voluntarily and knowingly releases and discharges the Company, its parents, subsidiaries and Affiliates, and their respective officers, directors, shareholders, employees, subsidiaries, divisions, parent companies, employee benefit plans and fiduciaries, both past and present (the “Released Parties”), from any and all claims, debts, suits or causes of action, known or unknown, based upon any fact, circumstance, or event occurring or existing at or prior to the Eligible Employee’s execution of this Waiver and Release Agreement, including, but not limited to, any claims or actions arising out of or during the Eligible Employee’s employment with the Company and/or separation of

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 3



employment, including any claim under the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., as amended Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., as amended, the Americans with Disabilities Act, 42 U.S.C. § 12101 et seq., the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 301 et seq., as amended, the Older Workers Benefit Protection Act, 29 U.S.C. § 621 et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Civil Rights Act and any and all other federal, state or local laws, and any contract, tort, or common law claims now or hereafter recognized, including, without limitation, any claim of breach of contract, promissory estoppel, detrimental reliance, wrongful discharge, false imprisonment, assault, battery, intentional infliction of emotional distress, defamation, slander, libel, fraud, invasion of privacy, breach of the covenant of good faith and fair dealing, breach of fiduciary duty, conversion, and tortious interference with any type of third-party relationship, as well as any and all damages that may arise out of any such claims, including, without limitation, claims for economic loss, lost profits, loss of capital, lost wages, lost earning capacity, emotional distress, mental anguish, personal injuries, punitive damages, or any future damages, and claims of retaliation of any nature, including, but not limited to, the anti-retaliatory provisions of the statutes identified in this Section 8. “Affiliate” means any member of the group of corporations, trades or businesses or other organizations compromising the “controlled group” with the Company.
9.    General Release by the Company. In consideration of the agreements of Executive set forth in this Agreement, the Company, on behalf of itself and its Affiliates, voluntarily and knowingly releases and discharges Executive, his heirs, executors and parties in interest with him, from any and all claims, debts, suits or causes of action, known or unknown, based upon any fact, circumstance, or event occurring or existing at or prior to the Company’s execution of this Waiver and Release Agreement.
10.    Noncompetition and Nonsolicitation. In exchange for the severance pay and benefits described in Sections 1 -7 above, and consistent with Article VI of the Policy, Executive agrees to execute the Noncompetition and Nonsolicitation Agreement in the form of Exhibit A to this Agreement.
11.    Resignation of Officer Positions. Effective as of April 1, 2019, the Executive hereby resigns from his position on the Executive Committee of the Company. Effective on April 1, 2019, the Executive hereby resigns his position as Chief Financial Officer of the Company, and from any other position he holds with any of the Company's affiliates. While the Parties agree that such resignations are intended to be self-effectuating, the Executive further agrees to execute any documentation the Company determines necessary or appropriate to facilitate such resignation.
12.    Exclusions from General Release. Excluded from the General Release above are any claims or rights which cannot be waived by law, including Employee’s right, if any, to workers’ compensation benefits (although Employee represents that Employee has reported all work-related injuries or illnesses, if any, that Employee suffered or sustained during employment with the Company), unemployment insurance benefits, or vested rights under any retirement plan. Employee understands that also excluded from the General Release is the right to file an administrative charge of discrimination (or similar charge) or to participate in any other type of state or federal investigation. However, by signing this Agreement Employee agrees that Employee is waiving any right to monetary or injunctive relief, recovery or reinstatement in connection with any such charge or investigation.
13.    Confidential Information, Intellectual Property, and Company Property. Employee agrees to continue to abide by the terms and conditions of the Confidentiality Agreement entered into by Employee with the Company that is incorporated in its entirety into this Agreement by reference as well as the Confidential Information covenants in Article X of the Policy.
14.    Return of Corporate Property and Records. Employee agrees to return to the Company, before commencement of payment of the severance, all of the Company’s property in Employee’s possession or control including Company credit cards and checks, Company provided computer and cell phone equipment, flash drives, keys, Company car, and all books, records, files, notes, pricing information, customer lists and other data and information pertaining to the business of the Company in any format, delivered to or obtained by Employee or otherwise developed

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 4



by Employee in connection with the performance of duties as an employee of the Company and Employee further agrees to retain no copies of any such materials in Employee’s possession or control.
15.    Ownership of Claims. Employee represents that Employee has not transferred or assigned, or purported to transfer or assign, to any person or entity, any claim described in this Agreement. Employee further agrees to indemnify and hold harmless the Company against any and all claims based upon, arising out of, or in any way connected with any such actual or purported transfer or assignment.
16.    Employee Acknowledgements. Employee acknowledges that that Employee is not aware of any job injury or illness for which Employee has not already filed a claim. Employee represents that Employee has not filed any action, claim, charge, or complaint against the Company with any local, state, federal, or Irish agency or court. Employee acknowledges that he has at all times been an “exempt” employee (as defined under the Fair Labor Standards Act and any similar state and local statutes and ordinances and, as a result, has reported hours worked. Employee further acknowledges that he has been paid for all hours worked, including overtime; (if applicable).
17.    Complete Defense. Employee understands and agrees that this Agreement may be pled as a complete defense to and provides the basis for summary dismissal of any claim or entitlement released and waived by this Agreement which may be asserted in any suit or claim by the Employee against the Company, or those persons or entities released in this Agreement.
18.    Post Transition Assistance. In consideration of the payments and benefits set forth in this Agreement, the Executive agrees that he shall remain available to the Company and its affiliates (whether or not on the Severance Date), at times reasonably agreeable to Executive, to provide assistance in the transitioning his duties, manage the handoff of relationships and provide such other advice, expertise or knowledge with respect to his duties to the Company and Affiliates as may reasonably be requested by or through the CEO or CFO from time to time, through December 31, 2019.
19.    Cooperation. Executive agrees to be truthful in any and all investigations or statements regarding the Company and provide reasonable assistance to the Company and its advisors, at times reasonably agreeable to Executive, with any audit, investigation or any regulatory or judicial proceeding, litigation or administrative proceedings relating to events occurring during Executive’s employment with the Company, as to which he has knowledge, including, but not limited to, any matters upon which Executive was working at the time of Executive’s separation. Executive shall also be available, at times reasonably agreeable to Executive, to the Company for any meetings or conferences the Company deems necessary in preparation for the defense or prosecution of any such proceedings, including, but not limited to, interviews and factual investigations, affidavits, and appearing at the reasonable request of the Company to give testimony without the required services of a subpoena or any other legal process. The Company shall reimburse Executive for reasonable out-of-pocket costs and expenses (including travel, lodging and meals) incurred by Executive while Executive’s services are being utilized by the Company pursuant to this Section, subject to reasonable documentation and compliance with the standard expense reimbursement policy of the Company. The Company shall pay any such reimbursements in accordance with the requirements set forth in Section 22(b) below.
20.    Indemnification. The Company and its Affiliates shall indemnify Executive and hold Executive harmless to the fullest extent permitted by the laws the State of Michigan, against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses, losses, and damages resulting from Executive’s good faith performance of Executive’s duties and obligations with the Company and its Affiliates. The Company and its Affiliates shall cover Executive under directors’ and officers’ liability insurance both during and, while potential liability exists, after employment or non-employment service as a director or officer, as applicable, in the same amount and to the same extent as the Company and its Affiliates cover their other officers and directors. These obligations shall survive the termination of Executive’s employment with the Company and its Affiliates. If any proceeding is brought or threatened against Executive in respect of which indemnity may be sought against the Company or its Affiliates pursuant to the foregoing, Executive shall notify the Company promptly in writing of the institution of such proceeding and the

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 5



Company or its Affiliates shall assume the defense thereof and the employment of counsel and payment of all fees and expenses; provided, however, that if a conflict of interest exists between the Company or its applicable Affiliate and Executive such that it is not legally practicable for the Company or its applicable Affiliate to assume Executive’s defense, Executive shall be entitled to retain separate counsel reasonably acceptable to the Company or its applicable Affiliate and the Company or its applicable Affiliate shall assume the obligation for, and shall make direct payment of all reasonable fees and expenses to, such counsel. It is acknowledged and agreed that the indemnification described in this Section applies, among other things, to claims arising out of or related to any of the litigation described in the Form 10-K, Annual Report for the year ended December 31, 2018, filed by the Company with the United States Securities and Exchange Commission.
21.    Nondisparagement. Employee shall not, directly or indirectly or through an agent, in any manner, publicly or privately (including through social media), disparage or impugn the reputation or character of the Company, including its management, products, services, and/or the Employee’s treatment by the Company. Employee will be responsible for any breach of this section caused by Employee, Employee’s attorneys, family members, representatives and agents. Employee will be in breach of this section if Employee, Employee’s family members, attorneys, representatives and/or agents disclose any non-public information concerning the payment made to Employee as a result of this Agreement (other than such disclosure to Employee’s spouse, attorneys, accountants or financial advisors), or engage in disparagement or violate this section. This covenant shall not be construed to interfere with Employee’s enforcement of this Agreement, pursuit of legal rights or claims not covered by the General Release in this Agreement, or ability to testify truthfully under oath pursuant to a subpoena, other legal process, or government investigation. The Company also agrees that the Operating Committee (formerly known as the Executive Committee) of the Company shall not, directly or indirectly or through an agent, in any manner, publicly or privately (including through social media), disparage or impugn the reputation or character of the Employee in any way, and that the Company will be responsible for any breach of this section by any member of the Operating Committee/Executive Committee, such member’s attorneys, family members, representatives and agents.
22.    Section 409A.
(a)    General. To the extent required by applicable law, this Agreement shall be interpreted in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the Department of Treasury regulations and other interpretive guidance issued thereunder, each as in effect from time to time (collectively, “Section 409A”). It is intended that payments and benefits made or provided under this Agreement shall not result in penalty taxes or accelerated taxation pursuant to Section 409A. To the maximum extent permitted by applicable law, the amounts payable to Executive under this Agreement shall be made in reliance upon Treasury Regulation Section 1.409A-1(b)(9) (with respect to separation pay plans) or Treasury Regulation Section 1.409A-1(b)(4) (with respect to short-term deferrals). For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation for purposes of applying the exclusion under Section 409A for short-term deferral amounts, the separation pay exception or any other exception or exclusion under Section 409A. All payments to be made upon a termination of employment under this Agreement may only be made upon a "separation from service" under Section 409A to the extent necessary in order to avoid the imposition of penalty taxes on the Executive pursuant to Section 409A. In no event may the Executive, directly or indirectly, designate the calendar year of any payment under this Agreement, and to the extent required by Section 409A of the Code, any payment that may be paid in more than one taxable year (depending on the time that the Executive executes the Release) shall be paid in the later taxable year.
(b)    Reimbursements and In-Kind Benefits. Notwithstanding anything to the contrary in this Agreement, all reimbursements and in-kind benefits provided under this Agreement shall be made in accordance with the requirements of Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive's lifetime (or during a shorter period of time specified in this Agreement); (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (iii) the reimbursement of

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 6



an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.
(c)    Delay of Payments. Notwithstanding any other provision of this Agreement to the contrary, if (i) the Executive is considered a “specified employee” for purposes of Section 409A (as determined in accordance with the methodology established by the Company and its affiliates as in effect on Executive’s Severance Date) and (ii) the deferral of the commencement of any payments or benefits otherwise payable hereunder or pursuant to any other agreement with the Company as a result of such termination of employment is necessary in order to prevent any prohibited distribution under Section 409A(a)(2)(B)(i) of the Code,  then any payment that constitutes nonqualified deferred compensation within the meaning of Section 409A that is otherwise due to the Executive under this Agreement during the six-month period immediately following the Executive's separation from service (as determined in accordance with Section 409A) on account of the Executive's separation from service shall be accumulated and paid to the Executive on the first business day of the seventh month following his separation from service (the “Delayed Payment Date”). If the Executive dies during the postponement period, the amounts and entitlements delayed on account of Section 409A shall be paid to the personal representative of his estate on the first to occur of the Delayed Payment Date or 30 calendar days after the date of the Executive's death. For purposes of clarity, the six (6) month delay shall not apply in the case of severance pay contemplated by Treasury Regulation Section 1.409A(b)(9)(iii) to the extent set forth in this provision.
(d)    The payments to Executive under this Agreement are intended to be exempt from the requirements of Section 409A, and shall be interpreted and administered in a manner consistent with those intentions.
23.    User IDs and Passwords. Immediately upon Company’s request, Employee agrees to provide all User IDs and Passwords used by Employee, and of any other party of which Employee is aware, to access Company ESI on Company computers, electronic devices, and software.
24.    Re-employment. Employee agrees that Employee will disclose the existence of this Agreement in writing to the Company or its parent, subsidiaries and affiliates, should Employee ever seek employment with the Company or its parent, any subsidiary or affiliate in the future. Employee also agrees that this Agreement constitutes a legitimate, nondiscriminatory reason to decline to hire Employee, or to terminate Employee’s employment should Employee fail to disclose this Agreement as required above; provided, however, that this paragraph shall not apply in the event that the Company acquires, merges with or becomes affiliated with an entity at which Executive is then employed or to which Executive is providing services.
25.    Miscellaneous.
(a)    In the event of Employee’s death, this Agreement is personal to and non-assignable by Employee but is binding upon Employee’s heirs and estate and the Employee’s estate shall be entitled to the continued payment of any severance benefits remaining under Article V of the Policy;
(b)    This Agreement is assignable by and is binding upon the Company’s successors and assigns but such assignment shall not relieve the Company of its obligations hereunder;
(c)    This Agreement is the entire agreement between the parties regarding Employee’s separation of employment with the Company and supersedes all prior agreements and understandings between the parties with respect to the subject matter of this Agreement, except as specifically noted in this Agreement;
(d)    No modification of this Agreement shall be valid unless it is in writing and signed by both parties;

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 7



(e)    This Agreement in no way shall be construed as an admission by the Company that it acted wrongfully toward Employee or that Employee has any rights against the Company for any wrongful action;
(f)    By executing this Agreement, Employee acknowledges that Employee’s employment has been at-will and that no one has made Employee promises relating to the length of Employee’s employment with the Company and that no one has promised Employee any future employment with the Company or any of its affiliates;
(g)    If any part of this Agreement is found to be unenforceable, the other provisions shall remain fully valid and enforceable.
26.    Default. In addition to the legal right of both parties to enforce the terms of this Agreement, in the event of a breach of any payment obligation to Employee under this Agreement; or the breach by Employee of numbered paragraphs 11, 14, or 22; or, a breach resulting from either party beginning litigation contrary to the prohibitions in this Agreement, except for a claim by Employee under the Age Discrimination in Employment Act, despite that any such claim is released by the Agreement, the breaching party shall be liable to the non-breaching party in the amount of $25,000.00; provided, however, that if the breach involves a breach of any payment obligation to Employee under this Agreement, said $25,000 amount shall be in addition to, and shall not reduce in any way, the amount of the payments due to Employee form the Company pursuant to this Agreement; in addition, the prevailing party in any litigation to remedy said breach shall be entitled to be awarded its reasonable attorneys’ fees and costs.
27.    Governing Law. This Agreement shall in all respects be interpreted, enforced and governed under applicable federal law and in the event reference shall be made to state law, the internal laws of the State of Michigan shall apply, without regard to choice of law principles.
28.    Acknowledgements.    In signing this Agreement, Employee acknowledges that:
(a)    The Company has not provided Employee with any tax advice, and Employee is solely responsible for the tax consequences of compensation provided under this Agreement or under any Company benefit plan;
(b)    Employee has signed this Agreement voluntarily and knowingly in exchange for the consideration described in this Agreement and the Policy, which Employee acknowledges as adequate and satisfactory and beyond that to which Employee is otherwise entitled;
(c)    Employee is advised by the Company to consult with an attorney before signing this Agreement;
(d)    Employee has at least forty-five (45) days in which to consider the Agreement and that Employee has signed on the date indicated below after concluding that this Agreement is satisfactory;
(e)    Employee is advised by the Company that this Agreement shall not become effective or enforceable until seven (7) days after Employee’s execution of this Agreement, provided that the Agreement is not timely revoked in accordance with this paragraph. Employee also understands that Employee may revoke this Agreement during the seven (7) day period. To be effective, Employee’s revocation must be in writing and delivered to Bryan Rojek, Vice President, Global Total Rewards, Human Resources Department, 515 Eastern Ave., Allegan, Michigan 49010 within the seven (7) day revocation period. Employee understands that seven (7) days after Employee’s execution of this Agreement, this Agreement will become effective and enforceable without any further affirmative action by either Employee or the Company;
(f)    that neither the Company nor any of its agents, representatives, employees, or attorneys, have made any representations to Employee concerning the terms or effects of this Agreement other than those contained in this Agreement; and

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 8



(g)    Executive has received a copy of the Perrigo Company plc Executive Committee Severance Policy As Amended and Restated February 13, 2019.
29.    Execution and Delivery of Agreement 2.    Employee acknowledges that:
(a)    Employee will execute and deliver to the Company the Supplemental Waiver and Release Agreement which has been presented to Executive along with this Agreement 1 (“Agreement 2”) no earlier than July 1, 2019 and no later than August 16, 2019.;
(b)    Employee agrees that this provides him at least forty-five (45) days after the Executive’s Severance Date in which to consider, and to execute and deliver to the Company, Agreement 2;
(c)    Employee is advised by the Company to consult with a lawyer before executing Agreement 2 and that Agreement 2 shall not become effective or enforceable until seven (7) days after Employee’s execution of Agreement 2, provided that Agreement 2 is not timely revoked in accordance with this paragraph. Employee also understands that Employee may revoke Agreement 2 during the seven (7) day period. To be effective, Employee’s revocation must be in writing and delivered to Bryan Rojek, Vice President, Global Total Rewards, Human Resources Department, 515 Eastern Ave., Allegan, Michigan 49010 within the seven (7) day revocation period. Employee understands that seven (7) days after Employee’s execution of Agreement 2, Agreement 2 will become effective and enforceable without any further affirmative action by either Employee or the Company.
Please contact Todd Kingma, EVP, General Counsel at 269-686-1941 if you have any questions. On behalf of Perrigo, I thank you for your service and wish you the best in your future endeavors.

Sincerely,
PERRIGO COMPANY, PLC
 
 
By:

/s/ Bryan J. Rojek
 
      Bryan J. Rojek
Its:
Vice President, Global Total Rewards
 
 


I have read this Perrigo Company Confidential Waiver and Release Agreement and I understand all of its terms. I enter into and sign this Perrigo Company Confidential Waiver and Release Agreement knowingly and voluntarily with full knowledge of what it means.


Date:
4/17/19
 
/s/ Ronald Winowiecki
 
 
 
Ronald Winowiecki
 
 
 
 
 
 
 
 
 
 
 
PLEASE RETURN TO:

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 9



 
 
 





Bryan Rojek
Vice President of Global Total Rewards
Human Resources Department
Perrigo Company plc
515 Eastern Avenue
Allegan, MI 49010

Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 10




Exhibit A Noncompetition and Nonsolitication Agreement
This Noncompetition and Nonsolicitation Agreement (“Agreement”) is entered into by and between Perrigo Management Company, a Michigan corporation, and its parents, subsidiaries, affiliates, (the “Company”) and Ronald Winowiecki (“Executive”). This Agreement was entered into in exchange for agreed upon consideration.
1.Noncompetition. For nine (9) months following July 1, 2019, Executive shall not (i) directly or indirectly, without the prior written consent of the Company, engage in or invest as an owner, partner, stockholder, licensor, director, officer, agent or consultant for any Person that conducts a business that is in competition with a business conducted by the Company or any of its Affiliates anywhere in the world; or (ii) accept employment or an engagement for the provision of services in any capacity, including as an employee, director, consultant or advisor, directly or indirectly, with any Person that conducts a business that is in competition with a business conducted by the Company or any of its Affiliates anywhere in the world. For purposes hereof, conducting a business that is in competition with a business conducted by the Company or any of its Affiliates shall include the sale, manufacture, distribution or research and development of any product or service that is similar to a product or service sold, distributed, marketed or being researched or developed (including through a joint venture or investment in another entity) by the Company or any of its Affiliates, including store brand and value brand OTC drug or nutritional products, extended topical generic prescription pharmaceutical products, infant nutrition products and any other product or products that the Company or an Affiliate is marketing or actively planning to market during Executive’s employment with the Company and, during the nine month period following July 1, 2019. If there is a completed sale, transfer or other disposition of the Perrigo Prescription Pharmaceutical business within the nine (9) month period following July 1, 2019, Paragraph 1 of this Agreement will not apply only as it pertains to the Perrigo Prescription Pharmaceutical business. Notwithstanding the foregoing, nothing in this provision shall prevent Executive from passively owning two percent (2%) or less of the outstanding securities of any class of any company listed on a national securities exchange or quoted on an automated quotation system. Executive may make a written request in writing to the CHRO of Perrigo for an exception to this Paragraph 1 and such exception will not be unreasonably withheld.
2.    Nonsolicitation of Service Providers. For twelve (12) months following July 1, 2019, Executive shall not, directly or indirectly, without the prior written consent of the Company, (i) actively solicit, recruit or hire any Person who is at such time, or who at any time during the 12­month period prior to such solicitation or hiring had been, an employee or consultant of the Company or any of its Affiliates, (ii) solicit or encourage any employee of the Company or any of its Affiliates to leave the employment of the Company or any of its Affiliates or (iii) interfere with the relationship of the Company or any of its Affiliates with any Person or entity who or that is employed by or otherwise engaged to perform services for the Company or any of its Affiliates.


Initials /s/ RW
Personal & Confidential
Mr. Ronald Winowiecki
April 16, 2019
Page 11



/s/ Ronald Winowiecki
 
Perrigo Management Company
Ronald Winowiecki
 
 
 
 
/s/ Todd Kingma
 
 
 
By: Todd Kingma
 
 
 
Its: EVP & Secretay
 
 
 
 
 
 


Initials /s/ RW
 EX-31.1 4 cy19q110qex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Murray S. Kessler, certify that:
1.
I have reviewed this report on Form 10-Q of Perrigo Company plc;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2019
/s/ Murray S. Kessler
Murray S. Kessler
Chief Executive Officer
 



 EX-31.2 5 cy19q110qex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Raymond P. Silcock, certify that:
1.
I have reviewed this report on Form 10-Q of Perrigo Company plc;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2019
/s/ Raymond P. Silcock
Raymond P. Silcock
Chief Financial Officer
 



 EX-32 6 cy19q110qex32.htm EXHIBIT 32 Exhibit


Exhibit 32
The following statement is being made to the Securities and Exchange Commission solely for the purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.
Securities and Exchange Commission
450 Fifth Street NW
Washington, D.C. 20549
 
Re:
Perrigo Company plc

Ladies and Gentlemen:
In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), each of the undersigned hereby certifies that:
(i)
this Quarterly Report on Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(ii)
the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Perrigo Company plc.


 
 
 
 
Date:
May 9, 2019
 
/s/ Murray S. Kessler
 
 
 
Murray S. Kessler
 
 
 
Chief Executive Officer and President
 
 
 
 
 
 
 
 
Date:
May 9, 2019
 
/s/ Raymond P. Silcock
 
 
 
Raymond P. Silcock
 
 
 
Chief Financial Officer
 
 
 





 EX-101.SCH 7 prgo-20190330.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Shareholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Earnings Per Share and Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Earnings Per Share and Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Earnings Per Share and Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Fair Value Measurements - Financial Instruments at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Goodwill and Intangible Assets - Intangible categories (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Income Taxes Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Indebtedness - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Indebtedness - Schedule of Borrowings Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Indebtedness - Schedule of Borrowings Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Leases - Annual Future Maturities of Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Leases - Annual Future Maturities of Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Leases - Annual Future Maturities of Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Leases - Balance Sheet Location of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2411407 - Disclosure - Leases - Lease Cash Flow Classifications (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Leases - Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Leases - Weighted Average Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Revenue Recognition - Schedule of Revenue by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Revenue Recognition - Schedule of Revenue by Product (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2420401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 prgo-20190330_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 prgo-20190330_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 prgo-20190330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Reported Value Measurement Reported Value Measurement [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Public bonds Public Bonds and Private Placement [Member] Public Bonds and Private Placement Retail Bonds Retail Bonds [Member] Retail Bonds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Public bonds Senior Notes Retail bond and private placement note Long-term Debt Statement of Stockholders' Equity [Abstract] Dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Declared Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Ordinary Shares Issued Common Stock [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Numerator: Numerator [Abstract] Numerator: [Abstract] Net income Net Income (Loss) Attributable to Parent Denominator: Denominator [Abstract] Denominator [Abstract] Weighted average shares outstanding for basic EPS Weighted Average Number of Shares Outstanding, Basic Dilutive effect of share-based awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average shares outstanding for diluted EPS Weighted Average Number of Shares Outstanding, Diluted Anti-dilutive share-based awards excluded from computation of diluted EPS (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Stock Repurchased During Period, Shares Stock Repurchased During Period, Shares Share price (in dollars per share) Accelerated Share Repurchases, Final Price Paid Per Share Repurchase of equity amount Proceeds from (Repurchase of) Equity Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated other comprehensive income (loss) Comprehensive Income (Loss) Note [Text Block] Leases [Abstract] Leases Lessee, Operating Leases [Text Block] Leases Lessee, Finance Leases [Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] 2014 Term loan due December 5, 2019 2014 Euro-Denominated Term Loan due December 5, 2019 [Member] 2014 Euro-Denominated Term Loan due December 5, 2019 [Member] 2018 Euro-Denominated Term Loan due March 8, 2020 2018 Euro-Denominated Term Loan due March 8, 2020 [Member] 2018 Euro-Denominated Term Loan due March 8, 2020 [Member] 2018 Revolver 2018 Revolver [Member] 2018 Revolver [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt instrument, issuance date Debt Instrument, Issuance Date Face amount of debt Debt Instrument, Face Amount Borrowings outstanding Long-term Line of Credit Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Repayments of debt Repayments of Debt Outstanding balance Line of Credit Facility, Fair Value of Amount Outstanding Earnings per share and shareholders' equity Earnings Per Share [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net of allowance for doubtful accounts of $6.8 and $6.4, respectively Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Operating lease assets Operating Lease, Right-of-Use Asset Goodwill and indefinite-lived intangible assets Goodwill And Indefinite Lived Intangibles Aggregate carrying amount, as of the balance sheet date, of goodwill and other indefinite-lived intangible assets. Goodwill represents the carrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of ASC Topic 350 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Indefinite-lived intangible assets represent the carrying amount of intangible assets which have a projected indefinite period of benefit (hence are not amortized), allocated to the reportable segment. These assets, acquired either individually or as part of a group of assets, in either an asset acquisition or business combination, are assessed at least annually for impairment. Examples may include trade secrets, contractual rights, trade names, and licensing agreements. Definite-lived intangible assets, net Finite-Lived Intangible Assets, Net Deferred income taxes Deferred Income Tax Assets, Net Other non-current assets Other Assets, Noncurrent Total non-current assets Assets, Noncurrent Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Payroll and related taxes Employee-related Liabilities, Current Accrued customer programs Accrued Customer Programs Carrying value as of the balance sheet date of customer programs, which include customer chargebacks and rebates payable. Accrued liabilities Accrued Liabilities, Current Accrued income taxes Accrued Income Taxes, Current Current indebtedness Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Long-term debt, less current portion Long-term Debt, Excluding Current Maturities Deferred income taxes Deferred Income Tax Liabilities, Net Other non-current liabilities Other Liabilities, Noncurrent Total non-current liabilities Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies - Refer to Note 13 Commitments and Contingencies Shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Controlling interests: Controlling Interest [Abstract] Controlling Interest [Abstract] Preferred shares, $0.0001 par value per share, 10 shares authorized Preferred Stock, Value, Issued Ordinary shares, €0.001 par value per share, 10,000 shares authorized Common Stock, Value, Issued Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Total controlling interest Stockholders' Equity Attributable to Parent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders' equity Liabilities and Equity Supplemental Disclosures of Balance Sheet Information Balance Sheet Related Disclosures [Abstract] Ordinary shares, issued and outstanding (in shares) Common Stock, Shares, Issued Derivative Instruments and Hedging Activities Disclosure [Abstract] Reclassification out of Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated derivatives: Designated as Hedging Instrument [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Interest expense, net Interest Expense [Member] Net sales Sales Revenue, Goods, Net [Member] Cost of sales Cost of Sales [Member] Other (income) expense, net Other Nonoperating Income (Expense) [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap Interest Rate Swap [Member] Foreign currency forward contracts Foreign Exchange Forward [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Amount of Gain/(Loss) Recorded in OCI (Effective Portion) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Schedule of accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Contract with Customer Balances Contract with Customer, Asset and Liability [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] CSCA Consumer Self-Care Americas [Member] Consumer Self-Care Americas [Member] CSCI Consumer Self-Care International [Member] Consumer Self-Care International [Member] RX RX Pharmaceuticals [Member] RX Pharmaceuticals [Member] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] December 31, 2018 Goodwill Currency Translation Adjustments Goodwill, Foreign Currency Translation Gain (Loss) March 30, 2019 Accumulated impairments Goodwill, Impaired, Accumulated Impairment Loss Schedule of Debt Instruments [Table] Schedule of Debt Instruments [Table] Schedule of Debt Instruments [Table] 5.000% Unsecured Senior notes due May 23, 2019 5.000% Unsecured Senior notes due May 23, 2019 [Member] 5.000% Unsecured Senior notes due May 23, 2019 [Member] 3.500% Unsecured Senior notes due March 15, 2021 3.500% Unsecured Senior notes due March 15, 2021 [Member] 3.500% Unsecured Senior notes due March 15, 2021 [Member] 3.5% Senior note due December 15, 2021 3.5% Senior note due December 15, 2021 [Member] 3.5% Senior note due 2021 [Member] 5.105% Senior note due July 19, 2023 5.105% Senior note due July 19, 2023 [Member] 5.105% Senior note due July 19, 2023 [Member] 4.00% unsecured senior notes due November 15, 2023 4.00% Unsecured Senior Notes due November 15, 2023 [Member] 4.00% Unsecured Senior Notes due November 15, 2023 [Member] 3.9% senior note due December 15, 2024 3.9% senior note due 2024 [Member] 3.9% senior note due 2024 [Member] 4.375% senior note due March 15, 2026 4.375% senior note due March 15, 2026 [Member] 4.375% senior note due March 15, 2026 [Member] 5.30% unsecured senior notes due November 15, 2043 5.30% Unsecured Senior Notes due November 15, 2043 [Member] 5.30% Unsecured Senior Notes due November 15, 2043 [Member] 4.9% senior notes due December 15, 2044 4.9% Senior Loan due 2044 [Member] 4.9% Senior Loan due 2044 [Member] Series Debt Instrument, Description Term loans Loans Payable Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Senior notes Other financing Other Long-term Debt Unamortized premium (discount), net Debt Instrument, Unamortized Discount (Premium), Net Deferred financing fees Debt Instrument, Fee Amount Total borrowings outstanding Debt, Long-term and Short-term, Combined Amount Current indebtedness Debt, Current Derivative instruments and hedging activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Measured at fair value on a recurring basis Fair Value, Measurements, Recurring [Member] Measured at fair value on a non-recurring basis Fair Value, Measurements, Nonrecurring [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Measured at fair value on a recurring basis: Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Assets: Assets, Fair Value Disclosure [Abstract] Investment securities Investments, Fair Value Disclosure Foreign currency forward contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Funds associated with Israeli severance liability Funds Associated With Israeli Post Employment Benefits Fair Value Disclosure Funds Associated With Israeli Post Employment Benefits Fair Value Disclosure Royalty Pharma contingent milestone payments Potential Contingent Milestone Payments Potential Contingent Milestone Payments Total assets Assets, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Foreign currency forward contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Contingent consideration Business Combination, Contingent Consideration, Liability Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Measured at fair value on a non-recurring basis: Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Unobservable Input Reconciliation [Abstract] Goodwill Goodwill, Fair Value Disclosure Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Definite-lived intangible assets Finite-lived Intangible Assets, Fair Value Disclosure Goodwill carrying amount Indefinite-lived intangible assets carrying value Indefinite-lived Intangible Assets (Excluding Goodwill) Definite-lived intangible assets carrying value Accounting Policies [Abstract] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Derivatives instruments and hedging Derivatives, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Unallocated Segment Reconciling Items [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Operating lease assets Operating Leases [Member] Operating Leases [Member] Other non-current assets Other Noncurrent Assets [Member] Accrued liabilities Accrued Liabilities [Member] Current indebtedness Current Indebtedness [Member] Current Indebtedness [Member] Other noncurrent liabilities Other Noncurrent Liabilities [Member] Long-term debt, less current portion Long-term Debt, Less Current Portion [Member] Long-term Debt, Less Current Portion [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Finance leases Finance Lease, Right-of-Use Asset Right-of-Use Asset Right-of-Use Asset Right-of-Use Asset Operating lease liability, current Operating Lease, Liability, Current Finance lease liability, current Finance Lease, Liability, Current Operating lease liability, noncurrent Operating Lease, Liability, Noncurrent Finance lease liability, noncurrent Finance Lease, Liability, Noncurrent Present value of lease liabilities Lease Liabilities Lease Liabilities Total operating lease liabilities Operating Lease, Liability Total finance lease liabilities Finance Lease, Liability Summary of significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Restructuring Charges [Abstract] Restructuring charges Restructuring and Related Activities Disclosure [Text Block] Segment Reporting [Abstract] Segment information Segment Reporting Disclosure [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity registrant name Entity Registrant Name Entity central index key Entity Central Index Key Current calendar year end date Current Fiscal Year End Date Entity filer category Entity Filer Category Document type Document Type Document period end date Document Period End Date Document calendar year focus Document Fiscal Year Focus Document calendar period focus Document Fiscal Period Focus Amendment flag Amendment Flag Entity common stock, shares outstanding Entity Common Stock, Shares Outstanding Entity emerging growth company Entity Emerging Growth Company Entity small business Entity Small Business Operating cash flows for operating leases Operating Lease, Payments Operating cash flows for finance leases Finance Lease, Interest Payment on Liability Financing cash flows for finance leases Finance Lease, Principal Payments Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Measurement Input, Long-term Revenue Growth Rate Measurement Input, Long-term Revenue Growth Rate [Member] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Measurement Input, Tax Rate Measurement Input, Tax Rate [Member] Measurement Input, Tax Rate [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Royalty Pharma Royalty Pharma [Member] Royalty Pharma [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Royalty Pharma Contingent Milestone Payments Royalty Pharma Contingent Milestone Payments [Member] Royalty Pharma Contingent Milestone Payments [Member] Measured on a recurring basis Reporting Unit, Discounted Cash Flow, Measurement Input Reporting Unit, Discounted Cash Flow, Measurement Input Reporting Unit, Discounted Cash Flow, Measurement Input Transfers among level 1, 2, and 3 Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount Potential contingent milestone payments Volatility rate assumed Business Combination, Contingent Consideration, Liability, Measurement Input Rate of return Fair Value Assumptions, Rate of Return Fair Value Assumptions, Rate of Return Increase (decrease) in fair value of milestone payment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Fair value adjustment Assets, Fair Value Adjustment Net sales threshold to trigger milestone payment Net Sales Threshold For Milestone Payment Net Sales Threshold For Milestone Payment Write-off of contingent milestone payment if sales threshold is not met Write-off of Contingent Milestone Payment if Sales Threshold Not Met, Amount Write-off of Contingent Milestone Payment if Sales Threshold Not Met, Amount Adjusted asset balance is prescribed threshold is exceeded Asset, Adjusted Fair Value if Sales Threshold Met Asset, Adjusted Fair Value if Sales Threshold Met Estimated fair valued contingent milestone payment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input Income recognized from change is asset Fair Value, Option, Changes in Fair Value, Gain (Loss) Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Change in fair value of derivative financial instruments, net of tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent Change in post-retirement and pension liability, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Foreign Currency Forward Contracts Schedule of Foreign Currency Forward Contracts [Table Text Block] Schedule of Foreign Currency Forward Contracts [Table Text Block] Schedule of derivative instruments in statement of financial position, fair value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Amount of Gain/(Loss) Recognized against Earnings Derivatives Not Designated as Hedging Instruments [Table Text Block] Classification of Gain (Loss) Recognized in Earnings on Fair Value and Cash Flow Hedging Relationships Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Short-term contract assets Contract with Customer, Asset, Gross, Current Inventory Disclosure [Abstract] Schedule of inventory, current Schedule of Inventory, Current [Table Text Block] Indebtedness Debt Disclosure [Text Block] Weighted-average remaining lease term - Operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average lease term - Finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average discount rate - Operating lease (percent) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - Finance lease (percent) Finance Lease, Weighted Average Discount Rate, Percent Operating Lease Liabilities, Payments Due [Abstract] Operating Lease Liabilities, Payments Due [Abstract] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five After 2023 Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease Liabilities, Payments, Due [Abstract] Finance Lease Liabilities, Payments, Due [Abstract] 2019 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2020 Finance Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Five After 2023 Finance Lease, Liability, Payments, Due after Year Five Total lease payments Finance Lease, Liability, Payments, Due Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Lease Liabilities, Payments, Due [Abstract] Lease Liabilities, Payments, Due [Abstract] Lease Liabilities, Payments, Due [Abstract] 2019 Lease, Liability, Payments, Remainder of Fiscal Year Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lease, Liability, Payments, Due Year Two Lease, Liability, Payments, Due Year Two 2021 Lease, Liability, Payments, Due Year Three Lease, Liability, Payments, Due Year Three 2022 Lease, Liability, Payments, Due Year Four Lease, Liability, Payments, Due Year Four 2023 Lease, Liability, Payments, Due Year Five Lease, Liability, Payments, Due Year Five After 2023 Lease, Liability, Payments, Due after Year Five Lease, Liability, Payments, Due after Year Five Total lease payments Lease, Liability, Payments, Due Lease, Liability, Payments, Due Less: Interest Lease, Liability, Undiscounted Excess Amount Lease, Liability, Undiscounted Excess Amount Fair value of derivative financial instruments, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Post-Retirement and Pension Liability Adjustments, net of tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income [Roll Forward] Accumulated Other Comprehensive Income [Roll Forward] Accumulated Other Comprehensive Income [Roll Forward] Balance, beginning OCI before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Amounts reclassified from AOCI Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Balance, ending Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Revenue Commissioners, Ireland Revenue Commissioners, Ireland [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Income tax examination, penalties and interest expense Income Tax Examination, Penalties and Interest Expense Income tax overpayments applied to succeeding years Income Tax Overpayments Applied to Succeeding Years Income Tax Overpayments Applied to Succeeding Years Royalty conceded on all omeprazole sales as a percent of refund claims (percent) Concession of Royalty Due on Sales as Percent of Refund Claims, Percent Concession of Royalty Due on Sales as Percent of Refund Claims, Percent Unsettled audit assessment from income tax examination Income Tax Examination, Unsettled Assessed Audit Liability Income Tax Examination, Unsettled Assessed Audit Liability Income tax benefit Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense (Benefit) Tax expense in connection with Transition Toll Tax Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit) Foreign earnings Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings of Foreign Subsidiary Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings of Foreign Subsidiary Tax Cuts and Jobs Act of 2017, change in tax rate, provisional income tax expense (benefit) Tax Cuts and Jobs Act of 2017, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit) Global intangible low-taxed income, income tax expense (benefit) Global Intangible Low-taxed Income, Income Tax Expense (Benefit) Global Intangible Low-taxed Income, Income Tax Expense (Benefit) Schedule of New Accounting Pronouncements Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Revenue recognition Revenue from Contract with Customer [Text Block] Income Statement [Abstract] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Cost of sales Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses Operating Expenses [Abstract] Distribution Production and Distribution Costs Research and development Research and Development Expense Selling Selling and Marketing Expense Administration General and Administrative Expense Impairment charges Asset Impairment Charges Restructuring charges Restructuring Charges Other operating expense (income) Other Operating Income (Loss) Other Operating Income (Loss) Total operating expenses Operating Expenses Operating income Operating Income (Loss) Change in financial assets Interest expense, net Interest Income (Expense), Net Other (income) expense, net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Domestic Income tax expense Income Tax Expense (Benefit) Net income Earnings per share Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Diluted (in shares) Investments [Abstract] Investments Cost and Equity Method Investments Disclosure [Text Block] Balance Sheet Location of Lease Assets and Liabilities Assets and Liabilities, Lessee [Table Text Block] Assets and Liabilities, Lessee [Table Text Block] Finance Lease Maturity Finance Lease, Liability, Maturity [Table Text Block] Operating Lease Liability Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Lease Expense Lease, Cost [Table Text Block] Weighted Average Lease Terms and Discount Rates Lessee, Weighted Average Lease Terms and Discount Rates [Table Text Block] Lessee, Weighted Average Lease Terms and Discount Rates [Table Text Block] Leease Cash Flow Classifications Lessee, Cash Flow Classifications [Table Text Block] Lessee, Cash Flow Classifications [Table Text Block] Fair Value, Assets Measured on Recurring and Nonrecurring Basis Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Reconciliation of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Statement of Cash Flows [Abstract] Cash Flows From (For) Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to derive cash flows: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Share-based compensation Share-based Compensation Impairment charges Change in financial assets Loss on extinguishment of debt Deferred income taxes Deferred Income Tax Expense (Benefit) Amortization of debt premium Amortization of Debt Discount (Premium) Other non-cash adjustments, net Other Operating Activities, Cash Flow Statement Subtotal Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Increase (decrease) in cash due to: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Accounts payable Increase (Decrease) in Accounts Payable Payroll and related taxes Increase (Decrease) in Employee Related Liabilities Accrued customer programs Increase Decrease In Accrued Customer Programs The net change during the reporting period in the aggregate amount of accrued customer programs including chargebacks and rebate payables. Accrued liabilities Increase (Decrease) in Accrued Liabilities Accrued income taxes Increase (Decrease) in Income Taxes Payable Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Subtotal Increase (Decrease) in Operating Capital Net cash from (for) operating activities Net Cash Provided by (Used in) Operating Activities Cash Flows From (For) Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Proceeds from royalty rights Proceeds from Royalties Received Royalty Pharma contingent milestone payment Proceeds from Contingent Milestone Payment Proceeds from Contingent Milestone Payment Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Net proceeds from sale of business and other assets Proceeds from Divestiture of Businesses Net cash from (for) investing activities Net Cash Provided by (Used in) Investing Activities Cash Flows From (For) Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of long-term debt Proceeds from Issuance of Long-term Debt Payments on long-term debt Repayments of Long-term Debt Borrowings (repayments) of revolving credit agreements and other financing, net Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less Deferred financing fees Payments of Financing Costs Repurchase of ordinary shares Payments for Repurchase of Common Stock Cash dividends Payments of Dividends Other financing, net Proceeds from (Payments for) Other Financing Activities Net cash from (for) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Inventories Inventory Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Price-Fixing Lawsuit, Supermarket Chains Price-Fixing Lawsuit, Supermarket Chains [Member] Price-Fixing Lawsuit, Supermarket Chains [Member] Price-fixing Lawsuit, Managed Care Organization Price-fixing Lawsuit, Managed Care Organization [Member] Price-fixing Lawsuit, Managed Care Organization [Member] Price-fixing Lawsuit, Health Insurance Carrier Price-fixing Lawsuit, Health Insurance Carrier [Member] Price-fixing Lawsuit, Health Insurance Carrier [Member] Carmignac Gestion, S.A. v. Perrigo Company plc, et al. Carmignac Gestion, S.A. v. Perrigo Company plc, et al. [Member] Carmignac Gestion, S.A. v. Perrigo Company plc, et al. [Member] Manning & Napier Advisors, LLC v. Perrigo Company plc, et al. Manning & Napier Advisors, LLC v. Perrigo Company plc, et al. [Member] Manning & Napier Advisors, LLC v. Perrigo Company plc, et al. [Member] Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al. Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al. [Member] Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al. [Member] First Manhattan Co. v. Perrigo Company plc, et al. First Manhattan Co. v. Perrigo Company plc, et al. [Member] First Manhattan Co. v. Perrigo Company plc, et al. [Member] TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al. TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al. [Member] TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al. [Member] Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al. Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al. [Member] Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al. [Member] WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al. WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al. [Member] WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al. [Member] Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al. Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al. [Member] Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al. [Member] Schwab Capital Trust, et al. v. Perrigo Company plc, et al. Schwab Capital Trust, et al. v. Perrigo Company plc, et al. [Member] Schwab Capital Trust, et al. v. Perrigo Company plc, et al. [Member] OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al. OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al. [Member] OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al. [Member] Highfields Capital I LP, et al. v. Perrigo Company plc, et al. Highfields Capital I LP, et al. v. Perrigo Company plc, et al. [Member] Highfields Capital I LP, et al. v. Perrigo Company plc, et al. [Member] Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al. Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al. [Member] Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al. [Member] Cases Filed in Israel Cases Filed in Israel [Member] Cases Filed in Israel [Member] Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al. Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al. [Member] Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al. [Member] Eltroxin Class Action Eltroxin Class Action [Member] Eltroxin Class Action [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of manufacturers Loss Contingency, Number Of Manufacturers Loss Contingency, Number Of Manufacturers Number of supermarket chains Loss Contingency, Number Of Supermarket Chains Loss Contingency, Number Of Supermarket Chains Number of generic prescription pharmaceuticals Loss Contingency, Number Of Generic Prescription Pharmaceuticals Loss Contingency, Number Of Generic Prescription Pharmaceuticals Number of products manufactured by the Company Loss Contingency, Number Of Prescription Pharmaceuticals Loss Contingency, Number Of Prescription Pharmaceuticals Number of defendants Loss Contingency, Number of Defendants Number of dozens of other drugs Loss Contingency, Number Of Dozens Of Other Drugs Loss Contingency, Number Of Dozens Of Other Drugs Number of individuals Loss Contingency, Number Of Individuals Loss Contingency, Number Of Individuals Number of co-defendants Loss Contingency, Number of Co-defendants Loss Contingency, Number of Co-defendants Number of additional plaintiffs Number of Additional Plaintiffs Number of Additional Plaintiffs Number of opt out cases Loss Contingency, Number Of Opt Out Cases Loss Contingency, Number Of Opt Out Cases Number of plaintiff groups Loss Contingency, Number Of Plaintiff Groups Loss Contingency, Number Of Plaintiff Groups Number of complaints Loss Contingency, Number Of Complaints Loss Contingency, Number Of Complaints Number of cases Loss Contingency, Number Of Cases Loss Contingency, Number Of Cases Number of overlapped cases Loss Contingency, Number Of Overlapped Cases Loss Contingency, Number Of Overlapped Cases Number of cases dismissed Loss Contingency, Claims Dismissed, Number Number of cases stayed Loss Contingency, Number Of Cases Stayed Loss Contingency, Number Of Cases Stayed Number of current or former directors and officers Loss Contingency, Number of Current Or Former Directors And Officers Loss Contingency, Number of Current Or Former Directors And Officers Damages sought by plaintiff Loss Contingency, Damages Sought, Value Foreign currency exchange rate, remeasurement Foreign Currency Exchange Rate, Remeasurement Number of applications filed Loss Contingency, Number Of Applications Filed Loss Contingency, Number Of Applications Filed Number of applications dismissed Loss Contingency, Number Of Applications Dismissed Loss Contingency, Number Of Applications Dismissed Number of applications consolidated Loss Contingency, Number Of Applications Consolidated Loss Contingency, Number Of Applications Consolidated Damages sought, value per patient Loss Contingency, Damages Sought, Value per Patient Loss Contingency, Damages Sought, Value per Patient Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] U.S. UNITED STATES Europe Europe [Member] All other countries Other Geographical Areas [Member] Other Geographical Areas [Member] Ireland IRELAND Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Operating leases Operating Lease, Cost Finance leases Finance Lease, Cost [Abstract] Amortization Finance Lease, Right-of-Use Asset, Amortization Interest Finance Lease, Interest Expense Total Finance Lease, Cost Finance Lease, Cost Operating lease expense Operating Lease, Expense Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Net Sales Sales Revenue, Net [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Amount of Gain/(Loss) Recorded in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Amount of Gain/(Loss) Reclassified from AOCI into Earnings Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach Gain (Loss) on Components Excluded from Assessment of Foreign Currency Cash Flow Hedge Effectiveness Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net Net gain expected to be reclassified out of AOCI into earnings in the next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Contract manufacturing Contract Manufacturing [Member] Contract Manufacturing [Member] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Foreign Currency Fair Value Hedge Derivative [Table] Foreign Currency Fair Value Hedge Derivative [Table] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Israeli Shekel (ILS) Israel, New Shekels British Pound (GBP) United Kingdom, Pounds European Euro (EUR) Euro Member Countries, Euro Swedish (SEK) Sweden, Kronor Danish Krone (DKK) Denmark, Kroner United States Dollar (USD) United States of America, Dollars Canadian Dollar (CAD) Canada, Dollars Polish Zloty (PLZ) Poland, Zlotych Chinese Yuan (CNY) China, Yuan Renminbi Norwegian Krone (NOK) Norway, Krone Romanian New Leu (RON) Romania, New Lei Mexican Peso (MPX) Mexico, Pesos Other No currency Foreign Currency Fair Value Hedge Derivative [Line Items] Foreign Currency Fair Value Hedge Derivative [Line Items] Notional amount of derivatives Derivative, Notional Amount Subsequent Event [Table] Subsequent Event [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Ranir Global Holdings, LLC Ranir Global Holdings, LLC [Member] Ranir Global Holdings, LLC [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] IRS notice of proposed adjustment amount from 2011,2012 and 2013 audit of Athena, including penalty IRS Notice of Proposed Audit Adjustment Amount, Including Penalty IRS Notice of Proposed Audit Adjustment Amount, Including Penalty IRS notice of proposed adjustment, penalty (percent) IRS Notice of Proposed Adjustment, Penalty, Percent IRS Notice of Proposed Adjustment, Penalty, Percent Definitive agreement for sale of animal health business, amount Sale Price of Divestiture Sale Price of Divestiture Definitive purchase agreement amount Business Combination, Consideration Transferred Cash on hand used to fund acquisition Payments to Acquire Businesses, Gross Statement [Table] Statement [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adoption of new accounting standards Adjustments for New Accounting Pronouncement [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (shares) Shares, Outstanding Adoption of new accounting standards Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income (loss) Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Restricted stock plan (shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Compensation for stock options Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Compensation for restricted stock Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition Cash dividends, $0.19 per share Dividends, Common Stock, Cash Shares withheld for payment of employees' withholding tax liability (shares) Shares Paid for Tax Withholding for Share Based Compensation Shares withheld for payment of employees' withholding tax liability Adjustments Related to Tax Withholding for Share-based Compensation Repurchases of ordinary shares (shares) Repurchases of ordinary shares Stock Repurchased During Period, Value Ending balance (shares) Cough/Cold/Allergy/Sinus Cough, Cold, Allergy and Sinus [Member] Cough, Cold, Allergy and Sinus [Member] Gastrointestinal Gastrointestinal [Member] Gastrointestinal [Member] Infant nutritionals Infant Nutritionals [Member] Infant Nutritionals [Member] Analgesics Analgesics [Member] Analgesics [Member] Smoking cessation Smoking Cessation [Member] Smoking Cessation [Member] Animal health Animal Health [Member] Animal Health [Member] Vitamins, Minerals and Dietary Supplements Vitamins, Minerals, and Dietary Supplements [Member] Vitamins, Minerals, and Dietary Supplements [Member] Other CHCA Other CHCA [Member] Other CHC [Member] Cough, Cold, and Allergy Cough, Cold, and Allergy [Member] Cough, Cold, and Allergy [Member] Lifestyle Lifestyle [Member] Lifestyle [Member] Personal care and derma-therapeutics Personal Care and Derma-Therapeutics [Member] Personal Care and Derma-Therapeutics [Member] Natural Health and Vitamins, Minerals and Dietary Supplements Natural Health and VMS [Member] Natural Health and VMS [Member] Anti-Parasite Anti-Parasite [Member] Anti-Parasite [Member] Other CHCI Other CHCI [Member] Other CHCI [Member] Schedule Of Finite And Indefinite Lived Assets By Major Class [Table] Schedule Of Finite And Indefinite Lived Assets By Major Class [Table] Schedule Of Finite And Indefinite Lived Assets By Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Distribution and license agreements and supply agreements Licensing Agreements [Member] Developed product technology, formulations, and product rights Developed Technology Rights [Member] Customer relationships and distribution networks Customer Relationships [Member] Trademarks and Trade Names [Member] Trademarks and Trade Names [Member] Non-compete agreements Noncompete Agreements [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trademarks, trade names, and brands Trademarks, Trade Names, and Brands [Member] Trademarks, Trade Names, and Brands [Member] In-process research and development In Process Research and Development [Member] Finite And Indefinite Lived Assets By Major Class [Line Items] Finite And Indefinite Lived Assets By Major Class [Line Items] Finite and Indefinite-Lived Assets By Major Class [Line Items] Indefinite-lived intangibles: Gross Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Intangible assets amortization expense Amortization of Intangible Assets Impairment of indefinite lived intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Equity securities Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] Equity security expense (income) Equity Method Investments [Table Text Block] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Finished goods Inventory, Finished Goods, Gross Work in process Inventory, Work in Process, Gross Raw materials Inventory, Raw Materials, Gross Total inventories Income taxes Income Tax Disclosure [Text Block] Fair value measurements Fair Value Disclosures [Text Block] Schedule of segment reporting information, by segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning balance Restructuring Reserve Additional charges Restructuring, Additional Charges Restructuring, Additional Charges Payments Payments for Restructuring Non-cash adjustments Restructuring Reserve, Settled without Cash Ending balance Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Other (income) expense, net Other Expense (Income), Net [Member] Other Expense (Income), Net [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Interest expense, net The effects of cash flow hedging: Effect of Cash Flow Hedges on Results of Operations [Abstract] Foreign currency forward contracts Foreign Currency Cash Flow Hedges [Abstract] Amount of gain or (loss) reclassified from AOCI into earnings Interest rate swap agreements Interest Rate Cash Flow Hedges [Abstract] Amount of gain or (loss) reclassified from AOCI into earnings Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Contingent consideration Contingent Consideration Classified as Equity [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Royalty Pharma Contingent Milestone Payments Beginning balance Payments received Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Change in fair value Ending balance Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Changes in value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Foreign currency effect Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Effect Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Effect Settlements and other adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Ending balance Restructuring and related costs Restructuring and Related Costs [Table Text Block] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Stockholders' Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred shares, authorized Preferred Stock, Shares Authorized Ordinary shares, par value (in EUR per share) Common Stock, Par or Stated Value Per Share Ordinary shares, authorized Common Stock, Shares Authorized Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] ASU 2016-01 Accounting Standards Update 2016-01 [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity securities, fair value method Equity Securities, FV-NI Equity securities, equity method, other non-current assets Equity Method Investments Equity securities, fair value method, other expense (income) Equity Securities, FV-NI, Gain (Loss) Equity securities, equity method, other expense (income) Income (Loss) from Equity Method Investments Reclassification to retained earnings Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Non-designated derivatives: Not Designated as Hedging Instrument [Member] Prepaid expenses and other current assets Accrued liabilities Other Liabilities [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Asset Derivatives Derivative Asset, Fair Value, Amount Not Offset Against Collateral Liability Derivatives Derivative Liability, Fair Value, Amount Not Offset Against Collateral Amount of Gain/(Loss) Recognized against Earnings Derivative, Gain (Loss) on Derivative, Net Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Lease liabilities Lease assets Schedule of debt Schedule of Debt [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total Assets Operating Income (Loss) Intangible Asset Amortization Schedule of goodwill Schedule of Goodwill [Table Text Block] Schedule of finite and indefinite-lived intangible assets Schedule Of Finite And Indefinite Lived Intangible Assets [Table Text Block] Schedule of Finite and Indefinite-Lived Intangible Assets [Table Text Block] EX-101.PRE 11 prgo-20190330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 chart-039cc1c102fc583384a.jpg begin 644 chart-039cc1c102fc583384a.jpg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end GRAPHIC 13 chart-263b0786b3f7a1559bc.jpg begin 644 chart-263b0786b3f7a1559bc.jpg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end GRAPHIC 14 chart-5095151ccba65a95916.jpg begin 644 chart-5095151ccba65a95916.jpg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chart-6681394ba8e6b7b6c0b.jpg begin 644 chart-6681394ba8e6b7b6c0b.jpg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chart-6741377481db3b5310c.jpg begin 644 chart-6741377481db3b5310c.jpg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end GRAPHIC 17 chart-c40ee33d0dfb9db21d0.jpg begin 644 chart-c40ee33d0dfb9db21d0.jpg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chart-ee2c5fc1da03539bb7f.jpg begin 644 chart-ee2c5fc1da03539bb7f.jpg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ⅅ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end GRAPHIC 19 chart-f715b0ee48225a40866.jpg begin 644 chart-f715b0ee48225a40866.jpg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end GRAPHIC 20 winowieckiperrigoagre_image1.jpg begin 644 winowieckiperrigoagre_image1.jpg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end XML 21 cy19q110q_htm.xml IDEA: XBRL DOCUMENT 0001585364 2019-01-01 2019-03-30 0001585364 2019-05-03 0001585364 2018-01-01 2018-03-31 0001585364 2019-03-30 0001585364 2018-12-31 0001585364 us-gaap:NewAccountingPronouncementMember 2017-12-31 0001585364 us-gaap:CommonStockMember 2018-03-31 0001585364 us-gaap:CommonStockMember 2017-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001585364 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001585364 us-gaap:RetainedEarningsMember 2018-03-31 0001585364 us-gaap:NewAccountingPronouncementMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001585364 2018-03-31 0001585364 us-gaap:RetainedEarningsMember 2017-12-31 0001585364 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2017-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001585364 2017-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001585364 us-gaap:CommonStockMember 2018-12-31 0001585364 us-gaap:CommonStockMember 2019-03-30 0001585364 us-gaap:CommonStockMember 2019-01-01 2019-03-30 0001585364 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2018-12-31 0001585364 us-gaap:NewAccountingPronouncementMember 2018-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-30 0001585364 us-gaap:RetainedEarningsMember 2018-12-31 0001585364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-30 0001585364 us-gaap:RetainedEarningsMember 2019-03-30 0001585364 prgo:OtherGeographicalAreasMember 2018-01-01 2018-03-31 0001585364 country:US 2018-01-01 2018-03-31 0001585364 srt:EuropeMember 2018-01-01 2018-03-31 0001585364 srt:EuropeMember 2019-01-01 2019-03-30 0001585364 country:US 2019-01-01 2019-03-30 0001585364 prgo:OtherGeographicalAreasMember 2019-01-01 2019-03-30 0001585364 prgo:AntiParasiteMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:OtherCHCIMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:GastrointestinalMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:CoughColdAllergyandSinusMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:InfantNutritionalsMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:AnimalHealthMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:OtherCHCAMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:RXPharmaceuticalsMember 2019-01-01 2019-03-30 0001585364 prgo:CoughColdandAllergyMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:OtherCHCAMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:AnalgesicsMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:CoughColdAllergyandSinusMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:SmokingCessationMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:PersonalCareandDermaTherapeuticsMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:VitaminsMineralsAndDietarySupplementsMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:RXPharmaceuticalsMember 2018-01-01 2018-03-31 0001585364 prgo:NaturalHealthandVMSMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:InfantNutritionalsMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:NaturalHealthandVMSMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:AnimalHealthMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:OtherCHCIMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:LifestyleMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:SmokingCessationMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:VitaminsMineralsAndDietarySupplementsMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-03-31 0001585364 prgo:GastrointestinalMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 prgo:LifestyleMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:PersonalCareandDermaTherapeuticsMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:AntiParasiteMember prgo:ConsumerSelfCareInternationalMember 2019-01-01 2019-03-30 0001585364 prgo:CoughColdandAllergyMember prgo:ConsumerSelfCareInternationalMember 2018-01-01 2018-03-31 0001585364 prgo:AnalgesicsMember prgo:ConsumerSelfCareAmericasMember 2019-01-01 2019-03-30 0001585364 country:IE 2018-01-01 2018-03-31 0001585364 country:IE 2019-01-01 2019-03-30 0001585364 prgo:ContractManufacturingMember 2019-01-01 2019-03-30 0001585364 prgo:ContractManufacturingMember 2018-01-01 2018-03-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2019-03-30 0001585364 prgo:ConsumerSelfCareAmericasMember 2018-03-31 0001585364 prgo:ConsumerSelfCareAmericasMember 2019-03-30 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-03-30 0001585364 us-gaap:LicensingAgreementsMember 2018-12-31 0001585364 us-gaap:TrademarksAndTradeNamesMember 2018-12-31 0001585364 us-gaap:LicensingAgreementsMember 2019-03-30 0001585364 prgo:TrademarksTradeNamesandBrandsMember 2019-03-30 0001585364 us-gaap:TrademarksAndTradeNamesMember 2019-03-30 0001585364 us-gaap:CustomerRelationshipsMember 2018-12-31 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2019-03-30 0001585364 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001585364 us-gaap:NoncompeteAgreementsMember 2019-03-30 0001585364 prgo:TrademarksTradeNamesandBrandsMember 2018-12-31 0001585364 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001585364 us-gaap:DevelopedTechnologyRightsMember 2019-03-30 0001585364 us-gaap:CustomerRelationshipsMember 2019-03-30 0001585364 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001585364 prgo:ConsumerSelfCareAmericasMember 2018-12-31 0001585364 prgo:RXPharmaceuticalsMember 2019-03-30 0001585364 prgo:RXPharmaceuticalsMember 2018-12-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2018-12-31 0001585364 prgo:ConsumerSelfCareInternationalMember 2018-03-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-03-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationClassifiedAsEquityMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-30 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-30 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member 2019-03-30 0001585364 prgo:RetailBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member 2019-03-30 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001585364 prgo:PublicBondsandPrivatePlacementMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-03-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-03-30 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-12-31 0001585364 prgo:MeasurementInputTaxRateMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-12-31 0001585364 us-gaap:ScenarioForecastMember 2020-12-31 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:MeasurementInputDiscountRateMember prgo:ConsumerSelfCareAmericasMember 2018-01-01 2018-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:ScenarioForecastMember 2020-01-01 2020-12-31 0001585364 prgo:RoyaltyPharmaContingentMilestonePaymentsMember us-gaap:ScenarioForecastMember 2020-12-31 0001585364 us-gaap:FairValueMeasurementsNonrecurringMember prgo:ConsumerSelfCareAmericasMember 2018-12-31 0001585364 prgo:RoyaltyPharmaMember 2018-01-01 2018-03-31 0001585364 prgo:RoyaltyPharmaMember us-gaap:MeasurementInputPriceVolatilityMember 2018-03-31 0001585364 prgo:RoyaltyPharmaMember 2019-01-01 2019-03-30 0001585364 prgo:RoyaltyPharmaMember us-gaap:MeasurementInputPriceVolatilityMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-30 0001585364 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-30 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-03-30 0001585364 us-gaap:OtherNoncurrentAssetsMember 2018-12-31 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0001585364 us-gaap:OtherNoncurrentAssetsMember 2019-03-30 0001585364 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 0001585364 prgo:OtherExpenseIncomeNetMember 2019-01-01 2019-03-30 0001585364 prgo:OtherExpenseIncomeNetMember 2018-01-01 2018-03-31 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-03-30 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-30 0001585364 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-30 0001585364 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-03-30 0001585364 us-gaap:CostOfSalesMember 2019-01-01 2019-03-30 0001585364 us-gaap:InterestExpenseMember 2019-01-01 2019-03-30 0001585364 us-gaap:SalesRevenueNetMember 2019-01-01 2019-03-30 0001585364 us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesRevenueGoodsNetMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember 2018-01-01 2018-03-31 0001585364 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember 2019-01-01 2019-03-30 0001585364 currency:GBP us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:EUR us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:CAD us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:XXX us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:MXN us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:GBP us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:NOK us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:CNY us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:PLN us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:CNY us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:PLN us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:USD us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:RON us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:RON us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:XXX us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:NOK us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:ILS us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:MXN us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:USD us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:ILS us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:SEK us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:EUR us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:CAD us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:DKK us-gaap:ForeignExchangeForwardMember 2019-03-30 0001585364 currency:SEK us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 currency:DKK us-gaap:ForeignExchangeForwardMember 2018-12-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:NondesignatedMember 2018-01-01 2018-03-31 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-30 0001585364 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001585364 us-gaap:NondesignatedMember 2019-01-01 2019-03-30 0001585364 prgo:OperatingLeasesMember 2019-03-30 0001585364 us-gaap:MaterialReconcilingItemsMember 2019-03-30 0001585364 prgo:LongtermDebtLessCurrentPortionMember 2019-03-30 0001585364 us-gaap:AccruedLiabilitiesMember 2019-03-30 0001585364 us-gaap:OtherNoncurrentLiabilitiesMember 2019-03-30 0001585364 prgo:CurrentIndebtednessMember 2019-03-30 0001585364 2019-01-01 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2018-03-08 0001585364 2014-12-05 2014-12-05 0001585364 prgo:A2018RevolverMember 2018-03-08 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2014-12-05 0001585364 prgo:A2014EuroDenominatedTermLoandueDecember52019Member 2018-03-08 0001585364 prgo:A2018RevolverMember 2019-03-30 0001585364 prgo:A4.375seniornotedueMarch152026Member 2019-03-30 0001585364 prgo:A4.9SeniorLoandue2044Member 2018-12-31 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Member 2019-03-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2019-03-30 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Member 2018-12-31 0001585364 prgo:A4.375seniornotedueMarch152026Member 2019-01-01 2019-03-30 0001585364 prgo:A3.9seniornotedue2024Member 2018-12-31 0001585364 prgo:A4.375seniornotedueMarch152026Member 2018-12-31 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Member 2018-12-31 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Member 2019-03-30 0001585364 prgo:A5.105SeniornotedueJuly192023Member 2019-01-01 2019-03-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2018-12-31 0001585364 prgo:A4.9SeniorLoandue2044Member 2019-03-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2019-01-01 2019-03-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2019-03-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2019-01-01 2019-03-30 0001585364 prgo:A5.105SeniornotedueJuly192023Member 2018-12-31 0001585364 prgo:A3.9seniornotedue2024Member 2019-01-01 2019-03-30 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2019-03-30 0001585364 prgo:A3.9seniornotedue2024Member 2019-03-30 0001585364 prgo:A5.000UnsecuredSeniornotesdueMay232019Member 2019-01-01 2019-03-30 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2019-03-30 0001585364 prgo:A3.5SeniornotedueDecember152021Member 2019-01-01 2019-03-30 0001585364 prgo:A3.500UnsecuredSeniornotesdueMarch152021Member 2019-01-01 2019-03-30 0001585364 prgo:A5.105SeniornotedueJuly192023Member 2019-03-30 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2018-12-31 0001585364 prgo:A5.30UnsecuredSeniorNotesdueNovember152043Member 2018-12-31 0001585364 prgo:A4.9SeniorLoandue2044Member 2019-01-01 2019-03-30 0001585364 prgo:A4.00UnsecuredSeniorNotesdueNovember152023Member 2018-12-31 0001585364 prgo:A2018EuroDenominatedTermLoandueMarch82020Member 2019-01-01 2019-03-30 0001585364 prgo:A2018RevolverMember 2018-12-31 0001585364 2018-10-31 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-30 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-30 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-30 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-30 0001585364 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001585364 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-30 0001585364 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-30 0001585364 us-gaap:RevenueCommissionersIrelandMember 2018-11-29 0001585364 2017-08-15 2017-08-15 0001585364 2012-01-01 2012-12-31 0001585364 2009-01-01 2009-12-31 0001585364 2018-01-01 2018-12-31 0001585364 2011-01-01 2011-12-31 0001585364 2010-01-01 2010-12-31 0001585364 prgo:AberdeenCanadaFundsGlobalEquityFundetal.v.PerrigoCompanyplcetal.Member 2019-02-22 0001585364 prgo:ManningNapierAdvisorsLLCv.PerrigoCompanyplcetal.Member 2018-01-16 0001585364 prgo:CasesFiledinIsraelMember 2018-01-01 2018-12-31 0001585364 2011-12-31 0001585364 2018-01-26 0001585364 prgo:OZMasterFundLtd.etal.v.PerrigoCompanyplcetal.Member 2019-02-06 0001585364 prgo:NationwideMutualFundsetal.v.PerrigoCompanyplcetal.Member 2018-10-29 0001585364 prgo:FirstManhattanCo.v.PerrigoCompanyplcetal.Member 2018-02-16 0001585364 prgo:PriceFixingLawsuitSupermarketChainsMember 2013-12-28 0001585364 prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member 2017-06-28 0001585364 prgo:HarelInsuranceCompanyLTD.etal.v.PerrigoCompanyplcetal.Member 2018-02-13 0001585364 prgo:WCMAlternativeEventDriveFundetal.v.PerrigoCo.plcetal.Member 2018-11-15 0001585364 prgo:SchwabCapitalTrustetal.v.PerrigoCompanyplcetal.Member 2019-01-31 0001585364 prgo:HudsonBayMasterFundLtd.etal.v.PerrigoCo.plcetal.Member 2018-11-15 0001585364 prgo:TIAACREFInvestmentManagementLLC.etal.v.PerrigoCompanyplcetal.Member 2018-04-20 0001585364 2017-06-21 0001585364 prgo:CarmignacGestionS.A.v.PerrigoCompanyplcetal.Member 2017-11-01 0001585364 prgo:PricefixingLawsuitManagedCareOrganizationMember 2018-08-03 0001585364 prgo:EltroxinClassActionMember 2018-11-21 2018-11-21 0001585364 prgo:PricefixingLawsuitHealthInsuranceCarrierMember 2019-01-16 2019-01-16 0001585364 prgo:PricefixingLawsuitHealthInsuranceCarrierMember 2019-01-16 0001585364 prgo:EltroxinClassActionMember 2011-10-01 2011-11-30 0001585364 prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member 2017-06-28 2017-06-28 0001585364 prgo:HighfieldsCapitalILPetal.v.PerrigoCompanyplcetal.Member 2019-02-14 0001585364 prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member 2019-03-30 0001585364 prgo:CasesFiledinIsraelMember 2017-12-31 0001585364 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-30 0001585364 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-03-31 0001585364 prgo:RanirGlobalHoldingsLLCMember us-gaap:SubsequentEventMember 2019-05-08 2019-05-08 0001585364 us-gaap:SubsequentEventMember 2019-05-08 2019-05-08 0001585364 us-gaap:SubsequentEventMember 2019-04-26 shares iso4217:USD shares pure iso4217:EUR shares iso4217:USD iso4217:EUR prgo:product iso4217:ILS prgo:supermarket prgo:manufacturer prgo:application prgo:individual prgo:complaint prgo:plaintiff prgo:case iso4217:USD iso4217:ILS prgo:dozens prgo:defendant false --12-31 Q1 2019 2019-03-30 0001585364 false Large Accelerated Filer PERRIGO Co plc false 0 0 6400000 6800000 0.19 0.19 0.001 0.001 10000000000 10000000000 868400000 0 0 0.0001 0.0001 10000000 10000000 0 10-Q 135991315 1174500000 1217000000.0 725700000 724300000 448800000 492700000 23300000 24700000 40200000 38400000 148600000 161300000 125100000 107600000 4100000 0 9300000 1500000 4100000 -2900000 346500000 336400000 102300000 156300000 10400000 -9600000 -28600000 -31400000 -3200000 -4300000 0 -500000 80900000 110500000 17000000.0 29700000 63900000 80800000 0.47 0.57 0.47 0.57 135900000 140800000 136200000 141400000 63900000 80800000 -16800000 73000000.0 1700000 -600000 500000 200000 -15600000 72200000 48300000 153000000.0 837900000 551100000 1118700000 1073100000 912900000 878000000.0 139800000 400000000.0 3009300000 2902200000 821100000 829100000 146800000 0 3999000000.0 4029100000 2757900000 2858900000 2700000 1200000 382700000 362900000 8110200000 8081200000 11119500000 10983400000 549200000 474900000 117300000 132100000 379600000 442400000 232000000.0 201300000 85900000 96500000 467900000 190200000 1831900000 1537400000 2749900000 3052200000 282400000 282300000 554500000 443400000 3586800000 3777900000 5418700000 5315300000 0 0 7409400000 7421700000 69000000.0 84600000 -1777800000 -1838300000 5700600000 5668000000.0 200000 100000 5700800000 5668100000 11119500000 10983400000 136000000.0 135900000 140800000 7892900000 253100000 -1975500000 6170500000 -1000000.0 6300000 5300000 80800000 80800000 72200000 72200000 200000 200000 200000 2700000 2700000 10000000.0 10000000.0 26700000 26700000 1500000 1500000 1300000 108100000 108100000 139700000 7769500000 324300000 -1888400000 6205400000 135900000 7421700000 84600000 -1838300000 5668000000.0 -3400000 -3400000 63900000 63900000 -15600000 -15600000 200000 1800000 1800000 14200000 14200000 25900000 25900000 100000 2400000 2400000 136000000.0 7409400000 69000000.0 -1777800000 5700600000 63900000 80800000 96600000 109500000 12400000 12700000 4100000 0 10400000 -9600000 0 -500000 9300000 1500000 3900000 -7200000 -1900000 -2100000 13400000 12100000 191300000 217400000 48500000 -2600000 37500000 43700000 75400000 57500000 -19900000 -38900000 -61700000 17300000 -3800000 -24000000.0 -10000000.0 6400000 -9200000 22200000 96800000 45000000.0 94500000 172400000 1200000 10000000.0 250000000.0 0 21100000 13400000 0 1300000 230100000 -2100000 0 431000000.0 12300000 444500000 -300000 -6200000 0 2400000 0 108100000 25900000 26700000 -3100000 -5700000 -41600000 -162600000 3800000 900000 286800000 8600000 551100000 678700000 837900000 687300000 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">The Company</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are dedicated to making lives better by bringing “</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Quality, Affordable Self-Care Products™”</span><span style="font-family:Arial;font-size:10pt;"> that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Basis of Presentation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Segment Reporting Change</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the </span><span style="font-family:Arial;">Consumer Self-Care International</span><span style="font-family:Arial;font-size:10pt;"> segment to the </span><span style="font-family:Arial;">Prescription Pharmaceuticals</span><span style="font-family:Arial;font-size:10pt;"> segment and we made certain adjustments to our allocations between segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in </span><a href="#sF0E9C8F572F558B58D0559DEC6276732" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 2</span></a><span style="font-family:Arial;font-size:10pt;"> and </span><a href="#s8AE8C7EC97B35E94B63785774409C15D" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 15</span></a><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our new reporting and operating segments are as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-weight:bold;">Consumer Self-Care Americas</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> ("</span><span style="font-family:Arial;font-weight:bold;">CSCA</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;">")</span><span style="font-family:Arial;font-size:10pt;">, formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-weight:bold;">Consumer Self-Care International</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> ("</span><span style="font-family:Arial;font-weight:bold;">CSCI</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;">")</span><span style="font-family:Arial;font-size:10pt;">,</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:10pt;">formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-weight:bold;">Prescription Pharmaceuticals</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> ("</span><span style="font-family:Arial;font-weight:bold;">RX</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;">"), </span><span style="font-family:Arial;font-size:10pt;">comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standard Pronouncements</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:42%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit. </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr></table></div> Basis of Presentation<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span>. all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Recent Accounting Standard Pronouncements<div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:42%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit. </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr></table></div> As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:42%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit. </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are currently evaluating the implications of adoption on our Consolidated Financial Statements.</span></div></td></tr></table></div> <span style="font-family:Arial;font-weight:bold;">REVENUE RECOGNITION</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We generated net sales in the following geographic locations</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:Arial;font-size:10pt;">(in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:328px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:134px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>768.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>786.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Europe</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>361.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">All other countries</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:96px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"/></span><span style="font-family:Arial;font-size:8pt;">(1) Derived from the location of the entity that sells to a third party.</span></div><div style="line-height:120%;text-align:left;padding-left:90px;text-indent:72px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2) Includes Ireland net sales of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$5.4 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the </span><span style="font-family:Arial;font-size:8pt;">three months ended</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">March 30, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">March 31, 2018</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:96px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following is a summary of our net sales by category (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:587px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:400px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:77px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cough/cold/allergy/sinus</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gastrointestinal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Infant nutritionals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>96.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Analgesics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>88.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Smoking cessation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Animal health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vitamins, minerals and dietary supplements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other CSCA</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total CSCA</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cough/cold/allergy/sinus</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>98.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lifestyle</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Personal care and derma-therapeutics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Natural health and vitamins, minerals and dietary supplements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Anti-parasites</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other CSCI</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total CSCI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>377.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total RX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1)    Includes net sales from our OTC contract manufacturing business.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was </span><span style="font-family:Arial;font-size:10pt;"><span>$67.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$69.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Contract Balances</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides information about contract assets from contracts with customers (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:26%;"/><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Short-term contract assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> We generated net sales in the following geographic locations<span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) </sup></span><span style="font-family:Arial;font-size:10pt;">(in millions):</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:328px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:134px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>768.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>786.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Europe</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>361.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">All other countries</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:96px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"/></span><span style="font-family:Arial;font-size:8pt;">(1) Derived from the location of the entity that sells to a third party.</span></div><div style="line-height:120%;text-align:left;padding-left:90px;text-indent:72px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2) Includes Ireland net sales of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$5.4 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the </span><span style="font-family:Arial;font-size:8pt;">three months ended</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">March 30, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">March 31, 2018</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:96px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following is a summary of our net sales by category (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:587px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:400px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:77px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cough/cold/allergy/sinus</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gastrointestinal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Infant nutritionals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>96.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Analgesics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>88.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Smoking cessation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Animal health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vitamins, minerals and dietary supplements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other CSCA</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total CSCA</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cough/cold/allergy/sinus</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>98.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lifestyle</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Personal care and derma-therapeutics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Natural health and vitamins, minerals and dietary supplements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Anti-parasites</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other CSCI</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total CSCI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>377.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total RX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1)    Includes net sales from our OTC contract manufacturing business.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(3)</span></div>Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales. 768800000 786400000 340900000 361900000 64800000 68700000 1174500000 1217000000.0 5200000 5400000 132600000 141500000 100300000 92200000 96000000.0 103400000 88800000 93700000 66800000 65900000 19600000 26300000 3400000 3000000.0 74300000 75600000 581800000 601600000 95700000 98700000 81500000 89700000 66000000.0 75600000 29800000 33200000 26700000 28100000 51100000 52500000 350800000 377800000 241900000 237600000 1174500000 1217000000.0 67300000 69400000 The following table provides information about contract assets from contracts with customers (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:26%;"/><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Short-term contract assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 18100000 25500000 <span style="font-family:Arial;font-weight:bold;">GOODWILL AND INTANGIBLE ASSETS</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:67.50524109014675%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,713.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,714.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,151.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(17.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,133.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,114.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,117.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,979.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,966.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We had accumulated impairments of </span><span style="font-family:Arial;font-size:8pt;"><span>$24.5 million</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$161.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the three months ended </span><span style="font-family:Arial;font-size:8pt;">March 31, 2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">March 30, 2019</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We had accumulated impairments of </span><span style="font-family:Arial;font-size:8pt;"><span>$868.4 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the three months ended </span><span style="font-family:Arial;font-size:8pt;">March 31, 2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">March 30, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:-18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets and related accumulated amortization consisted of the following (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.85534591194968%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortization</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:none;">Indefinite-lived intangibles</span><span style="font-family:Arial;font-size:9pt;text-decoration:none;">:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total indefinite-lived intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:none;">Definite-lived intangibles</span><span style="font-family:Arial;font-size:9pt;text-decoration:none;">:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Distribution and license agreements and supply agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>180.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>101.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Developed product technology, formulations, and product rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,333.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>686.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,318.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>654.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer relationships and distribution networks</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,562.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>587.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,586.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>566.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,257.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,282.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>188.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-compete agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total definite-lived intangibles</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,346.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,588.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,379.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,520.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,379.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,588.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,428.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,520.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recorded amortization expense of </span><span style="font-family:Arial;font-size:10pt;"><span>$75.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$87.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively.     </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">We recorded an impairment charge of </span><span style="font-family:Arial;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> on a certain IPR&amp;D asset during the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span> due to changes in projected development and regulatory timelines. Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:67.50524109014675%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,713.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,714.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,151.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(17.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,133.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,114.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,117.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,979.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,966.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We had accumulated impairments of </span><span style="font-family:Arial;font-size:8pt;"><span>$24.5 million</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$161.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the three months ended </span><span style="font-family:Arial;font-size:8pt;">March 31, 2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">March 30, 2019</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(2) </span></div><span style="font-family:Arial;font-size:8pt;">We had accumulated impairments of </span><span style="font-family:Arial;font-size:8pt;"><span>$868.4 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the three months ended </span><span style="font-family:Arial;font-size:8pt;">March 31, 2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">March 30, 2019</span>. 1713700000 1200000 1714900000 1151300000 -17700000 1133600000 1114800000 2900000 1117700000 3979800000 -13600000 3966200000 24500000 161200000 868400000 Intangible assets and related accumulated amortization consisted of the following (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.85534591194968%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortization</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:none;">Indefinite-lived intangibles</span><span style="font-family:Arial;font-size:9pt;text-decoration:none;">:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total indefinite-lived intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:none;">Definite-lived intangibles</span><span style="font-family:Arial;font-size:9pt;text-decoration:none;">:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Distribution and license agreements and supply agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>180.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>101.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Developed product technology, formulations, and product rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,333.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>686.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,318.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>654.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer relationships and distribution networks</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,562.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>587.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,586.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>566.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Trademarks, trade names, and brands</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,257.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,282.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>188.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-compete agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total definite-lived intangibles</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,346.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,588.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,379.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,520.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,379.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,588.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,428.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,520.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 18500000 18100000 14300000 31200000 32800000 49300000 180400000 101900000 178600000 99000000.0 1333100000 686000000.0 1318800000 654600000 1562500000 587600000 1586600000 566500000 1257800000 201300000 1282400000 188500000 12600000 11700000 12900000 11800000 4346400000 1588500000 4379300000 1520400000 4379200000 1588500000 4428600000 1520400000 75400000 87200000 4100000 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">INVENTORIES</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Major components of inventory were as follows (in millions):</span></div><span style="font-family:Arial;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.538784067085956%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>474.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>444.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>197.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>912.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>878.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Major components of inventory were as follows (in millions):<span style="font-family:Arial;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.538784067085956%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>474.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>444.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>197.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>912.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>878.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 474000000.0 444900000 199300000 197500000 239600000 235600000 912900000 878000000.0 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investment securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Funds associated with Israeli severance liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Royalty Pharma contingent milestone payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Measured at fair value on a non-recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indefinite-lived intangible assets</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Definite-lived intangible assets</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, goodwill with a carrying amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$178.9 million</span></span><span style="font-family:Arial;font-size:8pt;"> was written down to a fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$42.2 million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$46.9 million</span></span><span style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$10.5 million</span></span><span style="font-family:Arial;font-size:8pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, definite-lived intangible assets with a carrying amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$72.0 million</span></span><span style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$22.4 million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There were no transfers among Level 1, 2, and 3 during the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> or the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Pharma Contingent Milestone Payments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:478px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:285px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Payments received</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(250.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We value our contingent milestone payments from Royalty Pharma using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> that are received by Royalty Pharma until the contingent milestones are resolved. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:306px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:113px;"/><td style="width:82px;"/><td style="width:10px;"/><td style="width:5px;"/><td style="width:82px;"/><td style="width:10px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rate of return</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;">, the fair value of the Royalty Pharma contingent milestone payments increased </span><span style="font-family:Arial;font-size:10pt;"><span>$10.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> driven by higher projected global net sales of Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> and the estimated probability of achieving the earn-out. During the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the fair value of the Royalty Pharma contingent milestone payments decreased </span><span style="font-family:Arial;font-size:10pt;"><span>$9.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> due primarily to projected global net sales of Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> temporarily falling below the threshold required for payment of the </span><span style="font-family:Arial;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> milestone payment for 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In order for us to receive the 2020 milestone payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, Royalty Pharma contingent payments for Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> sales in 2020 must exceed </span><span style="font-family:Arial;font-size:10pt;"><span>$351.0 million</span></span><span style="font-family:Arial;font-size:10pt;">. If Royalty Pharma contingent payments for Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> sales do not meet the prescribed threshold in 2020, we will write off the </span><span style="font-family:Arial;font-size:10pt;"><span>$83.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to </span><span style="font-family:Arial;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and recognize income of </span><span style="font-family:Arial;font-size:10pt;"><span>$316.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> in </span><span style="font-family:Arial;font-size:10pt;">Change in financial assets</span><span style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes the change in fair value of contingent consideration (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:396px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:202px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Changes in value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settlements and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Animal Health</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When determining the fair value of our animal health reporting unit for the year ended December 31, 2018, we utilized a combination of comparable company market and discounted cash flow techniques. In our comparable company market approach, we considered observable market information and transactions for companies that we deemed to be of a comparable nature, scope, and size of animal health (Level 2 inputs). Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products, plus gross margin, advertising and promotion, and other operating expenses based on the growth plans (Level 3 inputs). In our discounted cash flow analysis, we utilized projected sales growth rate and discount rate assumptions of </span><span style="font-family:Arial;font-size:10pt;"><span>2.5%</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>9.8%</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. The discount rate correlates with the required investment return and risk that we believe market participants would apply to the projected growth rate. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows and applied the jurisdictional tax rate of </span><span style="font-family:Arial;font-size:10pt;"><span>22.8%</span></span><span style="font-family:Arial;font-size:10pt;">. We weighted indications of fair value resulting from the market approach and present value techniques, considering the </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">reasonableness of the range of measurements and the point within the range that we determined was most representative of fair market conditions.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When assessing our animal health indefinite-lived intangible asset for the year ended December 31, 2018, we utilized a multi-period excess earnings method ("MPEEM") to determine the fair value of the intangible asset. Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products. We utilized long-term growth rate and discount rate assumptions of </span><span style="font-family:Arial;font-size:10pt;"><span>(0.3)%</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>9.8%</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and we applied a jurisdictional tax rate of </span><span style="font-family:Arial;font-size:10pt;"><span>22.8%</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When assessing our animal health definite-lived assets for impairment for the year ended December 31, 2018, we utilized a combination of MPEEM and relief from royalty methods to determine the fair values of definite-lived assets within the asset group. The projected financial information, inputs, and assumptions utilized were consistent with those utilized in the goodwill discounted cash flow analysis described above.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fixed Rate Long-term Debt</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">    </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our fixed rate long-term debt consisted of the following (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:233px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Public Bonds</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Carrying Value (excluding discount)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,600.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,600.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,472.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,316.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Retail bond and private placement note</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Carrying value (excluding premium)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>286.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>301.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>307.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair values of our public bonds for all periods were based on quoted market prices. The fair values of our retail bond and private placement note for all periods were based on interest rates offered for borrowings of a similar nature and remaining maturities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div>The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value. The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investment securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Funds associated with Israeli severance liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Royalty Pharma contingent milestone payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Measured at fair value on a non-recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indefinite-lived intangible assets</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Definite-lived intangible assets</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, goodwill with a carrying amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$178.9 million</span></span><span style="font-family:Arial;font-size:8pt;"> was written down to a fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$42.2 million</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$46.9 million</span></span><span style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$10.5 million</span></span><span style="font-family:Arial;font-size:8pt;">. </span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(3)</span></div><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, definite-lived intangible assets with a carrying amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$72.0 million</span></span><span style="font-family:Arial;font-size:8pt;"> were written down to a fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$22.4 million</span></span>. 3700000 0 0 9400000 0 0 0 3200000 0 0 3800000 0 0 13400000 0 0 13000000.0 0 0 0 83600000 0 0 323200000 3700000 16600000 83600000 9400000 16800000 323200000 0 5800000 0 0 9200000 0 0 0 12400000 0 0 15300000 0 5800000 12400000 0 9200000 15300000 0 0 0 0 0 42200000 0 0 0 0 0 10500000 0 0 0 0 0 22400000 0 0 0 0 0 75100000 178900000 42200000 46900000 10500000 72000000.0 22400000 The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:478px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:285px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Payments received</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(250.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>124.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 323200000 134500000 250000000.0 0 10400000 -9600000 83600000 124900000 0.300 0.300 0.0802 0.0808 10400000 -9600000 250000000.0 400000000.0 351000000.0 83600000 400000000.0 316400000 The table below summarizes the change in fair value of contingent consideration (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:396px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:202px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Changes in value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settlements and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 15300000 22000000.0 -1200000 -400000 0 100000 4100000 4400000 12400000 18100000 0.025 0.098 0.228 -0.003 0.098 0.228 Our fixed rate long-term debt consisted of the following (in millions): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:233px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:56px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Public Bonds</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Carrying Value (excluding discount)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,600.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,600.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,472.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,316.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Retail bond and private placement note</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Carrying value (excluding premium)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>286.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>301.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>307.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2600000000.0 2600000000.0 2472000000.0 2316600000 286100000 292500000 301900000 307900000 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">INVESTMENTS</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.79643231899266%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Measurement Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value method</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value method</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Equity method</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Measured at fair value using the Net Asset Value practical expedient.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.56243441762854%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Measurement Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value method</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Equity method</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">On January 1, 2018, as a result of the adoption of ASU 2016-01 Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities ("ASU 2016-01"), we made a </span><span style="font-family:Arial;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> cumulative-effect adjustment to </span><span style="font-family:Arial;font-size:10pt;">Retained earnings (accumulated deficit)</span> net of tax that consisted of net unrealized losses on previously classified as available for sale securities from Other comprehensive income ("OCI"). The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions): <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.79643231899266%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Measurement Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value method</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value method</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Equity method</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Measured at fair value using the Net Asset Value practical expedient.</span></div></td></tr></table><br/> 3700000 9400000 3700000 4400000 15800000 15100000 The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.56243441762854%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Measurement Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fair value method</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Equity method</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -6100000 -4400000 700000 -200000 1000000.0 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2018 and the year ended December 31, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in </span><span style="font-family:Arial;font-size:10pt;">Other (income) expense, net</span><span style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We recognized all changes in fair value of the excluded components in </span><span style="font-family:Arial;font-size:10pt;">Other (income) expense, net</span><span style="font-family:Arial;font-size:10pt;">, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and </span><span style="font-family:Arial;font-size:10pt;">Retained earnings (accumulated deficit)</span><span style="font-family:Arial;font-size:10pt;"> from applying this policy on existing hedges at the date of adoption was immaterial. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to </span><a href="#s9569CD88A1A45D0AAF9335C1B7BEC5D5" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 5</span></a><span style="font-family:Arial;font-size:10pt;">). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:10pt;">All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"/><span style="font-family:Arial;font-size:10pt;">We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is </span><span style="font-family:Arial;font-size:10pt;">18</span><span style="font-family:Arial;font-size:10pt;"> months.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Interest rate risk management - </span><span style="font-family:Arial;font-size:10pt;">We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign currency exchange risk management - </span><span style="font-family:Arial;font-size:10pt;">We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Swaps </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"/><span style="font-family:Arial;font-size:10pt;">Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. There were no active designated or non-designated interest rate swaps as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Derivatives</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"/><span style="font-family:Arial;font-size:10pt;">Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:44%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Israeli Shekel (ILS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>290.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>232.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">British Pound (GBP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">European Euro (EUR)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Swedish (SEK)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Danish Krone (DKK)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States Dollar (USD)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Canadian Dollar (CAD)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Polish Zloty (PLZ)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chinese Yuan (CNY)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Norwegian Krone (NOK)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Romanian New Leu (RON)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mexican Peso (MPX)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>783.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>686.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Effects of Derivatives on the Financial Statements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:218px;"/><td style="width:237px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:218px;"/><td style="width:237px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:803px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:200px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:132px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:132px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:109px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recorded in OCI</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1) Net </span><span style="font-family:Arial;font-size:8pt;">loss</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;"><span>$2.7 million</span></span><span style="font-family:Arial;font-size:8pt;"> is expected to be reclassified out of AOCI into earnings during the next 12 months.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:200px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:108px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:166px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:109px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Effective Portion</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recorded in OCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:570px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:200px;"/><td style="width:5px;"/><td style="width:166px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-Designated Derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Condensed Consolidated Statements of Operations in </span><span style="font-family:Arial;font-size:10pt;">Other (income) expense, net</span><span style="font-family:Arial;font-size:10pt;"> for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar-translated amounts of each Income Statement account in current and/or future periods. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:741px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:373px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost of Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Interest Expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other (Income) Expense, net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>725.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The effects of cash flow hedging:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain (loss) on cash flow hedging relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of gain or (loss) reclassified from AOCI into earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of gain or (loss) reclassified from AOCI into earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2018 and the year ended December 31, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in </span><span style="font-family:Arial;font-size:10pt;">Other (income) expense, net</span><span style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We recognized all changes in fair value of the excluded components in </span><span style="font-family:Arial;font-size:10pt;">Other (income) expense, net</span><span style="font-family:Arial;font-size:10pt;">, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and </span><span style="font-family:Arial;font-size:10pt;">Retained earnings (accumulated deficit)</span><span style="font-family:Arial;font-size:10pt;"> from applying this policy on existing hedges at the date of adoption was immaterial. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to </span><a href="#s9569CD88A1A45D0AAF9335C1B7BEC5D5" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 5</span></a><span style="font-family:Arial;font-size:10pt;">). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:10pt;">All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;"/><span style="font-family:Arial;font-size:10pt;">We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is </span><span style="font-family:Arial;font-size:10pt;">18</span><span style="font-family:Arial;font-size:10pt;"> months.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Interest rate risk management - </span><span style="font-family:Arial;font-size:10pt;">We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign currency exchange risk management - </span><span style="font-family:Arial;font-size:10pt;">We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div>All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes. Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:44%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Israeli Shekel (ILS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>290.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>232.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">British Pound (GBP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">European Euro (EUR)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Swedish (SEK)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Danish Krone (DKK)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States Dollar (USD)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Canadian Dollar (CAD)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Polish Zloty (PLZ)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chinese Yuan (CNY)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Norwegian Krone (NOK)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Romanian New Leu (RON)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mexican Peso (MPX)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>783.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>686.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 290100000 232600000 107100000 90200000 103100000 134200000 76400000 38700000 52800000 56500000 42000000.0 39300000 35400000 31700000 28700000 18200000 16800000 0 14900000 6200000 4700000 4400000 2600000 25900000 8700000 8700000 783300000 686600000 The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:218px;"/><td style="width:237px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:218px;"/><td style="width:237px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-designated derivatives:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 600000 2000000.0 2600000 1800000 4200000 6400000 1600000 2800000 The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:803px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:200px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:132px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:132px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:109px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recorded in OCI</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:8pt;">(1) Net </span><span style="font-family:Arial;font-size:8pt;">loss</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;"><span>$2.7 million</span></span> is expected to be reclassified out of AOCI into earnings during the next 12 months. -400000 0 -1000000.0 200000 -100000 -1300000 -1100000 -1500000 -1200000 -2700000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:200px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:108px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:166px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:109px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Effective Portion</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Recorded in OCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount of Gain/(Loss) Reclassified from AOCI into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -400000 -200000 -100000 2300000 -1000000.0 -400000 400000 The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:570px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:200px;"/><td style="width:5px;"/><td style="width:166px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-Designated Derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Income Statement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -8800000 3500000 400000 -900000 -8400000 2600000 The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:741px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:373px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost of Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Interest Expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other (Income) Expense, net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>725.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The effects of cash flow hedging:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain (loss) on cash flow hedging relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of gain or (loss) reclassified from AOCI into earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swap agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of gain or (loss) reclassified from AOCI into earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1174500000 725700000 -28600000 -3200000 200000 -1300000 0 0 -100000 -1100000 0 0 0 0 -400000 0 <span style="font-family:Arial;font-weight:bold;">LEASES</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$166.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$164.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;"> months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The balance sheet location of our lease assets and liabilities were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:571px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:160px;"/><td style="width:5px;"/><td style="width:306px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:571px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:160px;"/><td style="width:5px;"/><td style="width:306px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current indebtedness</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Long-term debt, less current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The below table shows our lease assets and liabilities by reporting segment (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:469px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:73px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease expense was as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:279px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:180px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:144px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"/><span style="font-family:Arial;font-size:8pt;"/><span style="font-family:Arial;font-size:8pt;">(a) Includes short-term leases and variable lease costs, which are immaterial</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-left:24px;text-indent:48px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">    </span></div><div style="line-height:120%;padding-left:24px;text-indent:96px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total operating lease expense for the three months ended </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$11.9 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The annual future maturities of our leases as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:468px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:192px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">After 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our weighted average lease terms and discount rates are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:541px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:436px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:10px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Weighted-average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our lease cash flow classifications are as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:490px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:385px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:89px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows for finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing cash flows for finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Leased assets obtained in exchange for new operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> <span style="font-family:Arial;font-weight:bold;">LEASES</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$166.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$164.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;"> months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The balance sheet location of our lease assets and liabilities were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:571px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:160px;"/><td style="width:5px;"/><td style="width:306px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:571px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:160px;"/><td style="width:5px;"/><td style="width:306px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current indebtedness</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Long-term debt, less current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The below table shows our lease assets and liabilities by reporting segment (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:469px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:73px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease expense was as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:279px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:180px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:144px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"/><span style="font-family:Arial;font-size:8pt;"/><span style="font-family:Arial;font-size:8pt;">(a) Includes short-term leases and variable lease costs, which are immaterial</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-left:24px;text-indent:48px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">    </span></div><div style="line-height:120%;padding-left:24px;text-indent:96px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total operating lease expense for the three months ended </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$11.9 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The annual future maturities of our leases as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:468px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:192px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">After 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our weighted average lease terms and discount rates are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:541px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:436px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:10px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Weighted-average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our lease cash flow classifications are as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:490px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:385px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:89px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows for finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing cash flows for finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Leased assets obtained in exchange for new operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$166.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$164.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;"> months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div>Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. 166500000 164000000.0 The balance sheet location of our lease assets and liabilities were as follows (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:571px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:160px;"/><td style="width:5px;"/><td style="width:306px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:571px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:160px;"/><td style="width:5px;"/><td style="width:306px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current indebtedness</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Long-term debt, less current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The below table shows our lease assets and liabilities by reporting segment (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:469px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:73px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 146800000 9900000 156700000 34800000 1900000 116400000 4700000 157800000 30100000 1900000 30200000 1400000 43500000 6100000 44400000 3300000 38600000 100000 40100000 100000 34600000 1800000 36500000 1800000 146800000 9900000 151200000 6600000 Lease expense was as follows (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:279px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:180px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:82px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;"/><span style="font-family:Arial;font-size:8pt;"/><span style="font-family:Arial;font-size:8pt;">(a) Includes short-term leases and variable lease costs, which are immaterial</span>. 12000000.0 700000 100000 800000 11900000 The annual future maturities of our leases as of <span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in millions):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:468px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:192px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">After 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The annual future maturities of our leases as of <span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> are as follows (in millions):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:468px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:192px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">After 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 31000000.0 1700000 32700000 33100000 1600000 34700000 24000000.0 2900000 26900000 18100000 500000 18600000 15000000.0 300000 15300000 53400000 0 53400000 174600000 7000000.0 181600000 23400000 400000 23800000 151200000 6600000 157800000 Our weighted average lease terms and discount rates are as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:541px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:436px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:10px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Weighted-average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;background-color:#cceeff;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div> P6Y9M21D P2Y7M2D 0.0420 0.0417 Our lease cash flow classifications are as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:490px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:385px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:89px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows for finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing cash flows for finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Leased assets obtained in exchange for new operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11700000 100000 700000 4700000 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">INDEBTEDNESS</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total borrowings outstanding are summarized as follows (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.48427672955975%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:2%;"/><td style="width:13%;"/><td style="width:27%;"/><td style="width:5%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term loans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2018 Term loan due March 8, 2020</span></span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>331.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>351.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Coupon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Due</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.000%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>May 23, 2019</span></span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.500%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">March 15, 2021</span></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.500%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">December 15, 2021</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>309.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>309.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.105%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>July 19, 2023</span></span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.000%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">November 15, 2023</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>215.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>215.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.900%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">December 15, 2024</span></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.375%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">March 15, 2026</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.300%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">November 15, 2043</span></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.900%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">December 15, 2044</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>303.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>303.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total notes and bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,886.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,892.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Other financing</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized premium (discount), net</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Deferred financing fees</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15.6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.4</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total borrowings outstanding</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,217.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,242.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current indebtedness</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(467.9</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(190.2</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total long-term debt less current portion</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,749.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,052.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:72px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are in compliance with all covenants under our debt agreements as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Credit Agreements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On March 8, 2018, we terminated the revolving credit agreement entered into on December 5, 2014 and entered into a </span><span style="font-family:Arial;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> revolving credit agreement maturing on March 8, 2023 (the "2014 Revolver"). There were </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> borrowings outstanding under the 2018 Revolver as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> or </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Term Loans</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On </span><span style="font-family:Arial;font-size:10pt;"><span><span style="white-space:nowrap">December 5, 2014</span></span></span><span style="font-family:Arial;font-size:10pt;">, Perrigo Finance entered into a term loan agreement consisting of a </span><span style="font-family:Arial;font-size:10pt;"><span>€500.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> (</span><span style="font-family:Arial;font-size:10pt;"><span>$614.3 million</span></span><span style="font-family:Arial;font-size:10pt;">) tranche, maturing December 5, 2019. On March 8, 2018, we refinanced the </span><span style="font-family:Arial;font-size:10pt;"><span>€350.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> outstanding under the term loan with the proceeds of a new </span><span style="font-family:Arial;font-size:10pt;"><span>€350.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> (</span><span style="font-family:Arial;font-size:10pt;"><span>$431.0 million</span></span><span style="font-family:Arial;font-size:10pt;">) term loan, maturing March 8, 2020 (the "2018 Term Loan"). In addition, as a result of the refinancing during the three months ended March 31, 2018, we recorded a loss of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, consisting of the write-off of deferred financing fees in </span><span style="font-family:Arial;font-size:10pt;">Loss on extinguishment of debt</span><span style="font-family:Arial;font-size:10pt;"> on the Condensed Consolidated Statements of Operations. During the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;">, we made </span><span style="font-family:Arial;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> in scheduled principal payments on the 2018 Term Loan.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Financing</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> borrowings outstanding at </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> or </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">We have financing leases that are reported in the above table under "Other financing" (refer to </span><a href="#sc858b5bb95434d11b169853b5a7fccb3" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 8</span></a>). Total borrowings outstanding are summarized as follows (in millions): <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.48427672955975%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:2%;"/><td style="width:13%;"/><td style="width:27%;"/><td style="width:5%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term loans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2018 Term loan due March 8, 2020</span></span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>331.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>351.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Coupon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Due</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.000%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>May 23, 2019</span></span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.500%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">March 15, 2021</span></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.500%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">December 15, 2021</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>309.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>309.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.105%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>July 19, 2023</span></span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.000%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">November 15, 2023</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>215.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>215.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.900%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">December 15, 2024</span></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.375%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">March 15, 2026</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.300%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">November 15, 2043</span></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.900%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">December 15, 2044</span></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>303.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>303.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total notes and bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,886.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,892.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:normal;">Other financing</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized premium (discount), net</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Deferred financing fees</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15.6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.4</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total borrowings outstanding</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,217.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,242.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current indebtedness</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(467.9</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(190.2</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total long-term debt less current portion</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,749.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,052.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div>(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate. 2018 Term loan due March 8, 2020 331300000 351300000 0.05000 May 23, 2019 134600000 137600000 0.03500 2021-03-15 280400000 280400000 0.03500 2021-12-15 309600000 309600000 0.05105 July 19, 2023 151500000 154900000 0.04000 2023-11-15 215600000 215600000 0.03900 2024-12-15 700000000.0 700000000.0 0.04375 2026-03-15 700000000.0 700000000.0 0.05300 2043-11-15 90500000 90500000 0.04900 2044-12-15 303900000 303900000 2886100000 2892500000 6200000 2800000 -9800000 -12200000 15600000 16400000 3217800000 3242400000 467900000 190200000 2749900000 3052200000 1000000000.0 0 2014-12-05 500000000.0 614300000 350000000.0 350000000.0 431000000.0 -500000 12300000 0 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Earnings per Share</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.71278825995807%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>80.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for basic EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>135.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>140.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>136.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Anti-dilutive share-based awards excluded from computation of diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Shareholders' Equity</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Share Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">Following the expiration of our 2015 share repurchase plan authorization, in October 2018, our Board of Directors authorized up to </span><span style="font-family:Arial;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. We did not repurchase any shares during the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;">. During the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, we repurchased </span><span style="font-family:Arial;font-size:10pt;"><span>1.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> ordinary shares at an average repurchase price of </span><span style="font-family:Arial;font-size:10pt;"><span>$81.92</span></span><span style="font-family:Arial;font-size:10pt;"> per share, for a total of </span><span style="font-family:Arial;font-size:10pt;"><span>$108.1 million</span></span>. A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.71278825995807%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>80.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for basic EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>135.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>140.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average shares outstanding for diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>136.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Anti-dilutive share-based awards excluded from computation of diluted EPS</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 63900000 80800000 135900000 140800000 300000 600000 136200000 141400000 2100000 700000 1000000000.0 1300000 81.92 -108100000 <span style="font-family:Arial;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Changes in our AOCI balances, net of tax were as follows (in millions): </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value of Derivative Financial Instruments, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Post-Retirement and Pension Liability Adjustments, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total AOCI</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>104.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>84.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">OCI before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(18.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance at March 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Changes in our AOCI balances, net of tax were as follows (in millions): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value of Derivative Financial Instruments, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Post-Retirement and Pension Liability Adjustments, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total AOCI</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>104.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>84.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">OCI before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(18.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance at March 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -15500000 104500000 -4400000 84600000 -1200000 -16800000 -500000 -18500000 -2900000 0 0 -2900000 1700000 -16800000 -500000 -15600000 -13800000 87700000 -4900000 69000000.0 <span style="font-family:Arial;font-weight:bold;">INCOME TAXES</span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The effective tax rates were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:191px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:81px;"/><td style="width:11px;"/><td style="width:5px;"/><td style="width:81px;"/><td style="width:11px;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"/><span style="font-family:Arial;font-size:10pt;">The effective tax rate for the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">decreased compared to the prior year period due primarily to additional valuation allowances recorded against deferred tax assets in the prior year</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our tax rate is subject to adjustment over the balance of the calendar year due to, among other things, the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, Internal Revenue Service ("IRS") proposed regulations related to tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the United States, Israel, Belgium, France, and the United Kingdom.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover </span><span style="font-family:Arial;font-size:10pt;"><span>$163.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> of Federal income tax, penalties, and interest assessed and collected by the IRS, plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of </span><span style="font-family:Arial;font-size:10pt;"><span>$37.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the 2009 tax year, </span><span style="font-family:Arial;font-size:10pt;"><span>$61.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the 2010 tax year, </span><span style="font-family:Arial;font-size:10pt;"><span>$40.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the 2011 tax year, and </span><span style="font-family:Arial;font-size:10pt;"><span>$24.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017. The cumulative deferred charge as recorded on the balance sheet is </span><span style="font-family:Arial;font-size:10pt;"><span>$29.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> lower than the amounts reflected above due to overpayments credited to succeeding years, such that the actual refund the company is seeking to receive will be reduced by that amount. In addition, we recently conceded a royalty due to Perrigo U.S. on all omeprazole sales that equates to a </span><span style="font-family:Arial;font-size:10pt;"><span>24%</span></span><span style="font-family:Arial;font-size:10pt;"> of our refund claims and any omeprazole adjustments that may be asserted by the IRS for future years.</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">31, 2013. Athena was the originator of the patents associated with Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> prior to the acquisition of Athena by Elan in 1996. In response to the draft notice of proposed adjustment, we provided the IRS with substantial additional documentation supporting our position. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it. For subsequent developments refer to </span><a href="#s02a325c755b045e283fbc985cb98a912" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 16</span></a><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On October 31, 2018, we received an audit finding letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the years ended December 31, 2012 and December 31, 2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri® intellectual property and other assets related to Tysabri® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Amended Assessment (“NoA”) on November 29, 2018 which assesses an Irish corporation tax liability against Elan Pharma in the amount of </span><span style="font-family:Arial;font-size:10pt;"><span>€1,636 million</span></span><span style="font-family:Arial;font-size:10pt;">, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA by Irish Revenue. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. If we are ultimately successful in the judicial review proceedings the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made, which could take up to, or more than, a year.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Ireland and other jurisdictions in Europe. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015 (which covers the period of the Elan transaction). The Israel Tax Authority's audit of our fiscal years ended June 29, 2013 and June 28, 2014 concluded with no material impact to the financial statements and the Israel Tax Authority is now auditing our fiscal years ended June 27, 2015, December 31, 2015, December 31, 2016 and December 31, 2017.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Tax Law Changes</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (“U.S. Tax Act”). The U.S. Tax Act includes a number of significant changes to existing U.S. tax laws that impact us. These changes include a corporate income tax rate reduction from </span><span style="font-family:Arial;font-size:10pt;">35%</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;">21%</span><span style="font-family:Arial;font-size:10pt;"> and the elimination or reduction of certain U.S. deductions and credits including limitations on the U.S. deductibility of interest expense and executive compensation. The U.S. Tax Act also transitions the U.S. taxation of international earnings from a worldwide system to a modified territorial system. These changes were effective beginning in 2018. The U.S. Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated U.S. owned foreign corporations’ previously untaxed foreign earnings (“Transition Toll Tax”). We paid our full Transition Toll Tax liability as of December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of the U.S. GAAP ASC 740 income tax accounting for tax law changes enacted in the U.S. during 2017, in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the U.S. Tax Act. In accordance with SAB 118, for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;">, we recorded an income tax benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> in connection with the remeasurement of certain deferred tax assets and liabilities and also recorded a </span><span style="font-family:Arial;font-size:10pt;"><span>$17.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> increase of current tax expense in connection with the Transition Toll Tax on cumulative U.S. owned foreign earnings of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:Arial;font-size:10pt;">. For the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, we completed the accounting for the income tax effects of the U.S. Tax Act. Based on additional guidance issued by the IRS and updates to our calculations we recorded a benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> related to the Transition Toll Tax. There were no other material changes to the amounts recorded at December 31, 2017. We also finalized the provisional estimate related to our assertion on unremitted earnings of foreign subsidiaries recording an additional deferred tax liability of </span><span style="font-family:Arial;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the state income tax impacts of repatriating undistributed foreign earnings.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The U.S. Tax Act subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We have elected an accounting policy to provide for the tax expense related to GILTI in the year the tax is incurred ("period cost method"). At December 31, 2018, we made a reasonable estimate of the tax effect of a GILTI inclusion for 2018 and recorded additional tax expense of </span><span style="font-family:Arial;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, net of U.S. foreign tax credits. In 2018, we had no tax expense resulting from the base erosion anti-avoidance tax ("BEAT") in 2018 and recorded an immaterial tax benefit for deductions related to foreign-derived intangible income ("FDII").</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div>On January 1, 2019, we adopted ASU 2018-02 Income Statement - Reporting Comprehensive Income. Upon adoption, we did not elect to reclassify the income tax effects of the U.S. Tax Cuts and Jobs Act from AOCI to Retained earnings (accumulated deficit). The effective tax rates were as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:191px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:81px;"/><td style="width:11px;"/><td style="width:5px;"/><td style="width:81px;"/><td style="width:11px;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div> 0.211 0.269 163600000 37200000 61500000 40200000 24700000 29700000 0.24 1636000000 -2400000 17500000 1200000000 6300000 8300000 9400000 <span style="font-family:Arial;font-weight:bold;">CONTINGENCIES</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;">, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to, individually or in the aggregate, have a material adverse effect on our financial condition, results of operations, or cash flows. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Price-Fixing Lawsuits</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs and/or allocate customers starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The same class plaintiffs have filed complaints naming us as a co-defendant, along with </span><span style="font-family:Arial;font-size:10pt;"><span>27</span></span><span style="font-family:Arial;font-size:10pt;"> other manufacturers, alleging an overarching conspiracy to fix or raise the prices of </span><span style="font-family:Arial;font-size:10pt;"><span>15</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceutical products starting in 2011. Perrigo manufactures only </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> of the products at issue, Nystatin cream and Nystatin ointment. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have also been named a co-defendant along with </span><span style="font-family:Arial;font-size:10pt;"><span>35</span></span><span style="font-family:Arial;font-size:10pt;"> other manufacturers in a complaint filed by </span><span style="font-family:Arial;font-size:10pt;"><span>three</span></span><span style="font-family:Arial;font-size:10pt;"> supermarket chains alleging that defendants conspired to fix prices of </span><span style="font-family:Arial;font-size:10pt;"><span>31</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceutical products starting in 2013. The only allegations specific to us relate to Clobetasol, Desonide, Econazole, and Nystatin. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 3, 2018, a large managed care organization filed a complaint against us alleging price-fixing and customer allocation concerning </span><span style="font-family:Arial;font-size:10pt;"><span>17</span></span><span style="font-family:Arial;font-size:10pt;"> different products among </span><span style="font-family:Arial;font-size:10pt;"><span>27</span></span><span style="font-family:Arial;font-size:10pt;"> manufacturers including Perrigo. The only allegations specific to us concern Clobetasol, Desonide, Econazole, and Nystatin cream/ointment. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Most recently, on January 16, 2019, a similar suit was brought by a health insurance carrier in the U.S. District Court for the District of Minnesota alleging a</span><span style="font-family:Arial;font-size:10pt;color:#ff0000;"> </span><span style="font-family:Arial;font-size:10pt;">conspiracy to fix prices of </span><span style="font-family:Arial;font-size:10pt;"><span>30</span></span><span style="font-family:Arial;font-size:10pt;"> products among </span><span style="font-family:Arial;font-size:10pt;"><span>30</span></span><span style="font-family:Arial;font-size:10pt;"> defendants. The only allegations specific to us concern Clobetasol, Desonide, Econazole, and Nystatin cream/ointment. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain complaints listed above were amended in December 2017, January 2018, and April 2019. All of the above complaints have been consolidated for pretrial proceedings, along with complaints filed against other companies alleging price fixing with respect to more than </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> dozen other drugs, as part of a case captioned </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">In re Generic Pharmaceuticals Pricing Antitrust Litigation,</span><span style="font-family:Arial;font-size:10pt;"> MDL No. 2724 in the U.S. District Court for the Eastern District of Pennsylvania. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> Pursuant to the court’s schedule staging various cases in phases, we moved to dismiss the complaints relating to Clobetasol and Econazole. The court issued a decision denying the motions in part in October 2018 and issued a second decision in February 2019 dismissing various state law claims, but allowing other state law claims to proceed. We filed answers to the Clobetasol complaints on December 31, 2018. We filed answers to the Desonide and Econazole complaints on March 15, 2019.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Motions to dismiss certain other complaints listed above were filed on February 21, 2019. Plaintiffs’ oppositions are due on May 2, 2019. Deposition discovery is currently stayed for all cases, but documentary discovery is proceeding. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Securities Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">In the United States (cases related to events in 2015-2017)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund v. Papa, et al.)</span><span style="font-family:Arial;font-size:10pt;">. The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Wilson v. Papa, et al</span><span style="font-family:Arial;font-size:10pt;">.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. On December 8, 2016, the court consolidated the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Wilson</span><span style="font-family:Arial;font-size:10pt;"> case under the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Roofers’ Pension Fund </span><span style="font-family:Arial;font-size:10pt;">case and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Wilson</span><span style="font-family:Arial;font-size:10pt;"> case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders - shareholders who purchased shares during the period April 21, 2015 through May 3, 2017 on the U.S. exchanges; shareholders who purchased shares during the same period on the Tel Aviv exchange; and shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares.The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition and the alleged price fixing activities </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation has begun. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and </span><span style="font-family:Arial;font-size:10pt;"><span>three</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac Gestion, S.A. v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case, the parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On January 16, 2018, Manning &amp; Napier Advisors, LLC filed a securities lawsuit against us and </span><span style="font-family:Arial;font-size:10pt;"><span>three</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier Advisors, LLC v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5) and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">® </sup></span><span style="font-family:Arial;font-size:10pt;">asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case, the parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On January 26, 2018, </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> different plaintiff groups (the Mason Capital group and the Pentwater group) each filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case). The same law firm represents these two plaintiff groups, and the </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> complaints are substantially similar. These </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> cases are not securities class actions. One case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Mason Capital L.P., et al. v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The other case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and also was filed in the U.S. District Court for the District of New Jersey. Both cases are assigned to the same federal judge that is hearing the class action case and the other individual cases described above (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac </span><span style="font-family:Arial;font-size:10pt;">and </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier</span><span style="font-family:Arial;font-size:10pt;">). Each complaint asserts claims under Securities Exchange Act sections 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset. Many of the factual </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">allegations in these </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> cases overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above and the allegations in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above), the parties to these cases conferred about how these cases should proceed. The parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in these cases. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuits vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On February 13, 2018, a group of plaintiff investors affiliated with Harel Insurance Investments &amp; Financial Services, Ltd. filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case). This lawsuit is not a securities class action. The new complaint is substantially similar to the amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case. The relevant period in the new complaint stretches from February 2014 to May 2, 2017. The complaint adds as defendants </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> individuals who served on our Board prior to 2016. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action cases and the </span><span style="font-family:Arial;font-size:10pt;"><span>four</span></span><span style="font-family:Arial;font-size:10pt;"> other individual cases described above (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Mason Capital</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Pentwater</span><span style="font-family:Arial;font-size:10pt;">). The </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Harel Insurance Company</span><span style="font-family:Arial;font-size:10pt;"> complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule 10b‑5) and section 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. The complaint also asserts claims based on Israeli securities laws. In general, the plaintiffs' allegations describe events during the period from February 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset from February 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above and the allegations in the </span><span style="font-family:Arial;font-size:10pt;"><span>four</span></span><span style="font-family:Arial;font-size:10pt;"> opt out cases also described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On February 16, 2018, First Manhattan Company filed a securities lawsuit against us and </span><span style="font-family:Arial;font-size:10pt;"><span>three</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">First Manhattan Co. v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>five</span></span><span style="font-family:Arial;font-size:10pt;"> other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset. This lawsuit was filed by the same law firm that filed the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier Advisors</span><span style="font-family:Arial;font-size:10pt;"> case and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac</span><span style="font-family:Arial;font-size:10pt;"> case described above and generally makes the same factual assertions as in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier Advisors</span><span style="font-family:Arial;font-size:10pt;"> case. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. On April 20, 2018, the plaintiff filed an amended complaint that did not materially change the factual allegations of the original complaint. After the court issued its July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above), the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case, the parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in this case and the remaining defendants filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On April 20, 2018, a group of plaintiff investors affiliated with TIAA-CREF filed a lawsuit against us and the same individuals who are the defendants in the Harel Insurance case complaint. This lawsuit is not a securities class action. The law firm representing the plaintiffs in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Harel Insurance</span><span style="font-family:Arial;font-size:10pt;"> case also represents the TIAA-CREF plaintiff entities in this case, and the new complaint is substantially similar to the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Harel Insurance</span><span style="font-family:Arial;font-size:10pt;"> complaint. The relevant period in the new complaint is August 14, 2014 to May 2, 2017 inclusive. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">TIAA-CREF</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Investment Management, LLC., et al. v. Perrigo Company plc, et al</span><span style="font-family:Arial;font-size:10pt;">., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> other individual cases described above (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac, Manning &amp; Napier, Mason Capital, Pentwater, Harel Insurance, </span><span style="font-family:Arial;font-size:10pt;">and</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> First Manhattan</span><span style="font-family:Arial;font-size:10pt;">). The </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">TIAA-CREF</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Investment Management</span><span style="font-family:Arial;font-size:10pt;"> complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule l0b-5), section 14(e) (related to tender offer disclosures) against all defendants as well as section 20(a) control person liability against the individual defendants. In general, plaintiffs' allegations describe events during the period from August 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset from August 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case also overlap with the allegations of the June 2017 amended complaint in the</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above) the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On October 29, 2018, Nationwide Mutual Funds and Nationwide Variable Insurance Trust (both on behalf of several fund series) filed a securities lawsuit against us and </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>seven</span></span><span style="font-family:Arial;font-size:10pt;"> other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">First Manhattan </span><span style="font-family:Arial;font-size:10pt;">case, the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier Advisors</span><span style="font-family:Arial;font-size:10pt;"> case, and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac</span><span style="font-family:Arial;font-size:10pt;"> case described above and generally makes the same factual assertions as in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier</span><span style="font-family:Arial;font-size:10pt;"> case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofer’s Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers' Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. The defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On November 15, 2018, a group of plaintiff investors affiliated with Westchester Capital Funds filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Mason Capital L.P.</span><span style="font-family:Arial;font-size:10pt;"> case and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Pentwater Equity Opportunities Master Fund Ltd.</span><span style="font-family:Arial;font-size:10pt;"> case (described above) represents the affiliates of the Westchester Funds in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Mason Capital </span><span style="font-family:Arial;font-size:10pt;">and in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Pentwater</span><span style="font-family:Arial;font-size:10pt;"> cases described above. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and is filed in the U.S. District Court for the District of New Jersey. The </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">WCM</span><span style="font-family:Arial;font-size:10pt;"> case is assigned to the same federal judge that is hearing the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofer’s Fund</span><span style="font-family:Arial;font-size:10pt;"> class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>eight</span></span><span style="font-family:Arial;font-size:10pt;"> other individual cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5) and 14(e) against all defendants as well as 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 as well us up through May 3, 2017. Plaintiffs identify disclosures concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On November 15, 2018, a group of plaintiff investors affiliated with Hudson Bay Capital Management LP filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Mason Capital L.P.</span><span style="font-family:Arial;font-size:10pt;">, the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Pentwater Equity Opportunities Master Fund Ltd.</span><span style="font-family:Arial;font-size:10pt;">, and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">WCM</span><span style="font-family:Arial;font-size:10pt;"> cases (described above) represents the affiliates of Hudson Bay Capital Management in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Mason Capital</span><span style="font-family:Arial;font-size:10pt;">, in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Pentwater</span><span style="font-family:Arial;font-size:10pt;">, and in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">WCM</span><span style="font-family:Arial;font-size:10pt;"> cases described above. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and is filed in the U.S. District Court for the District of New Jersey. The </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Hudson Bay Fund </span><span style="font-family:Arial;font-size:10pt;">case is assigned to the same federal judge that is hearing the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofer’s Fund</span><span style="font-family:Arial;font-size:10pt;"> class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>nine</span></span><span style="font-family:Arial;font-size:10pt;"> other individual cases described above. The complaint asserts claims under Securities Exchange Act section 14(e) against all defendants and section 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On January 31, 2019, Schwab Capital Trust and a variety of other Schwab entities filed a securities lawsuit against us and </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Schwab Capital Trust, et al. v. Perrigo Company plc, et a</span><span style="font-family:Arial;font-size:10pt;">l., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>ten</span></span><span style="font-family:Arial;font-size:10pt;"> other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac</span><span style="font-family:Arial;font-size:10pt;"> case, the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier</span><span style="font-family:Arial;font-size:10pt;"> case, the</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> First Manhattan</span><span style="font-family:Arial;font-size:10pt;"> case, and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutual Funds</span><span style="font-family:Arial;font-size:10pt;"> case described above and generally makes the same factual assertions as in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutual Funds</span><span style="font-family:Arial;font-size:10pt;"> case. The complaint does not include factual allegations that the court dismissed in the July 2018 ruling in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofer’s Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofer’s Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac, Manning &amp; Napier, First Manhattan</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutua</span><span style="font-family:Arial;font-size:10pt;">l cases described above. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"/><span style="font-family:Arial;font-size:10pt;">On February 6, 2019, OZ Master Fund, Ltd. and a related entity filed a securities lawsuit against us and </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al</span><span style="font-family:Arial;font-size:10pt;">., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>eleven</span></span><span style="font-family:Arial;font-size:10pt;"> other opt out cases described above. The complaint asserts claims under Securities Exchange Act </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">sections 10(b) (and SEC Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofer’s Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above. The plaintiff does not provide an estimate of damages. The parties have submitted an agreed stipulation to the court regarding a proposed schedule and are awaiting the court’s approval. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On February 14, 2019, Highfields Capital I LP and related entities filed a securities lawsuit against the Company and </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Highfields Capital I LP, et al. v. Perrigo Company plc, et al</span><span style="font-family:Arial;font-size:10pt;">., and was filed in the U.S. District Court for the District of Massachusetts. The complaint asserts claims under Securities Exchange Act sections 14(e) and 18 against all defendants, as well as 20(a) control person liability against the individual defendants. The complaint also asserts Massachusetts state law claims under Massachusetts Unfair Business Methods Law (chapter 93A § 11), and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> asset. Some of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Roofer’s Pension Fund</span><span style="font-family:Arial;font-size:10pt;"> case described above and with allegations in one or more of the opt out cases described above. Plaintiffs do not provide a clear calculation of how they estimated damages and seek treble damages, punitive damages, and attorney's fees. On May 7, 2019, defendants filed a motion to transfer this case to the U.S. District Court for the District of New Jersey so that the proceedings in this case can be coordinated with the other cases (discussed above) pending in that court. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On February 22, 2019, Aberdeen Canada Funds -- Global Equity Funds (and </span><span style="font-family:Arial;font-size:10pt;"><span>30</span></span><span style="font-family:Arial;font-size:10pt;"> other entities, some unrelated to Aberdeen) filed a securities lawsuit against the Company and </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al.</span><span style="font-family:Arial;font-size:10pt;">, and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the </span><span style="font-family:Arial;font-size:10pt;"><span>twelve</span></span><span style="font-family:Arial;font-size:10pt;"> other opt-out cases pending in that Court. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5) against all defendants and 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged undisclosed pricing pressure for generic prescription pharmaceuticals, and alleged price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac</span><span style="font-family:Arial;font-size:10pt;"> case, the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Manning &amp; Napier</span><span style="font-family:Arial;font-size:10pt;"> case, the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">First Manhattan</span><span style="font-family:Arial;font-size:10pt;"> case, the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutual Funds</span><span style="font-family:Arial;font-size:10pt;"> case, and the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Schwab Capital Trust</span><span style="font-family:Arial;font-size:10pt;"> case described above, and generally makes the same factual assertions as in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutual Funds</span><span style="font-family:Arial;font-size:10pt;"> case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Carmignac, Manning &amp; Napier, First Manhattan,</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Nationwide Mutual Funds</span><span style="font-family:Arial;font-size:10pt;"> cases described above. The plaintiff does not provide an estimate of damages. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">In Israel (cases related to events in 2015-2017)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. </span><span style="font-family:Arial;font-size:10pt;"><span>Three</span></span><span style="font-family:Arial;font-size:10pt;"> cases were filed; </span><span style="font-family:Arial;font-size:10pt;"><span>one</span></span><span style="font-family:Arial;font-size:10pt;"> was voluntarily dismissed in each of 2017 and 2018 and </span><span style="font-family:Arial;font-size:10pt;"><span>one</span></span><span style="font-family:Arial;font-size:10pt;"> was stayed in 2018. We are consulting Israeli counsel about our response to these allegations and we intend to defend this case vigorously.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. </span><span style="font-family:Arial;font-size:10pt;">The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst &amp; Young LLP ("EY") (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>six</span></span><span style="font-family:Arial;font-size:10pt;"> generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of </span><span style="font-family:Arial;font-size:10pt;"><span>2.7 billion</span></span><span style="font-family:Arial;font-size:10pt;"> NIS (approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$760.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> at 1 NIS = </span><span style="font-family:Arial;font-size:10pt;"><span>0.28 cents</span></span><span style="font-family:Arial;font-size:10pt;">). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Roofers’ Pension Fund </span><span style="font-family:Arial;font-size:10pt;">case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">In the United States (cases related to Irish Tax events)</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Masih v. Perrigo Company, et al</span><span style="font-family:Arial;font-size:10pt;">.). Plaintiff purports to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contend that the Company, in its Form 10‑Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff does not provide an estimate of class damages. The Court has selected lead plaintiffs and changed the name of the case to </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">In re Perrigo Company plc Sec</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Litig</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:10pt;"> The lead plaintiffs filed an amended complaint on April 12, 2019, which names the same defendants, asserts the same class period, and invokes the same Exchange Act sections. The amended complaint generally repeats the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. We intend to defend the lawsuit vigorously. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">In Israel (cases related to Irish Tax events)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our CFO Ronald Winowiecki in Tel Aviv District Court (</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Baton v. Perrigo Company plc, et. al</span><span style="font-family:Arial;font-size:10pt;">.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">In re Perrigo Company plc Sec. Litig </span><span style="font-family:Arial;font-size:10pt;">case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. We filed a request for a stay, the plaintiff agreed in part, and the court approved a stay and required the parties to update the court about the U.S. proceedings by September 1, 2019. We intend to defend the lawsuit vigorously.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Eltroxin</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During October and November 2011, </span><span style="font-family:Arial;font-size:10pt;"><span>nine</span></span><span style="font-family:Arial;font-size:10pt;"> applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by our subsidiary, Perrigo Israel Agencies Ltd. The respondents included our subsidiaries, Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"/><span style="font-family:Arial;font-size:10pt;"><span>One</span></span><span style="font-family:Arial;font-size:10pt;"> of the applications was dismissed and the remaining </span><span style="font-family:Arial;font-size:10pt;"><span>eight</span></span><span style="font-family:Arial;font-size:10pt;"> applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On June 16, 2015, we submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. We have filed our statement of defense to the underlying proceedings. The underlying proceedings have been stayed pending the outcome of the mediation process and, if necessary, a decision on the motion to appeal.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On November 14, 2017 the parties submitted an agreed settlement agreement to the approval of the Supreme Court, which referred the approval back to the District Court. During three hearings that took place on November 29, 2017, December 13, 2017 and January 11, 2018, the District Court opined that it would approve the settlement agreement subject to certain amendments to be proposed by the court (which would not impact the monetary settlement reached) and set a hearing for January 30, 2018 to discuss and finalize the proposed changes. Meanwhile, the Court ordered the settlement to be (1) provided to the Attorney General ("AG") for review (standard procedure); and (2) published in the written media (newspapers), to enable the class members to submit any objections or “opt-out” to  the proposed settlement by February 15, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On February 21, 2018, the District Court held a hearing to, among other things, review objections received from class members who had notified the District Court of their desire to opt out of the settlement. In addition, a representative of the AG's office notified the District Court that, based upon their preliminary examination of the settlement, they intend to object to the settlement in its current form. The District Court recommended that the parties continue to discuss and minimize objections to the settlement and scheduled another hearing for May 13, 2018.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The District Court Justice was appointed as a Supreme Court Justice and ordered to move the case to a different panel. In an effort to reach a decision before the appointment,</span><span style="font-family:Arial;font-size:10pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:10pt;">an additional hearing was held on March 12, 2018 in which</span><span style="font-family:Arial;font-size:10pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:10pt;">the court urged the parties to try and exhaust their negotiations to the fullest and provide an update by May 13, 2018. In addition, the Court ordered the AG to submit its opinion to the settlement agreement by May 30, 2018, which was extended until July 23, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 2, 2018, the AG submitted its objection to the settlement, noting, among other things, that it did not provide compensation for harm to autonomy. On August 12, 2018, we submitted our response to the Attorney General's objection together with an amended settlement which incorporated the court's comments.  Following the submission of the amended settlement agreement on August 23, 2018, the District Court rendered a decision that it will be willing to approve the amended settlement agreement providing that a few additional amendments will be made. Both parties agreed to carry out the requested amendments. On September 13, 2018, the AG filed a request to file a response to the amended settlement agreement and asked for an extension to file a response until </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 11, 2018, which was granted by the court.</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:10pt;">On November 11, 2018 the AG asked and was granted another ten days extension to file a response. On November 21, 2018 the AG filed its response in which he mainly repeated his previous objection to the settlement claiming that the settlement amount does not provide a suitable compensation for harm to the autonomy and that the mechanism payment is complex and will deter patients from receiving appropriate compensation for pain and suffering. The AG repeated his opinion that each member of the group should be compensated for harm to the autonomy while claiming a minimum amount of </span><span style="font-family:Arial;font-size:10pt;"><span>250</span></span><span style="font-family:Arial;font-size:10pt;"> NIS should be provided for each patient. In addition, the AG detailed an alternative mechanism and list of categories that he asserts would be a better and less complex solution to provide the compensation amount.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On November 29, 2018, the court approved the Eltroxin settlement agreement. In a lengthy decision, the court detailed the various aspects of the settlement as well as the objections submitted to the settlement, including the main objection submitted by the AG. The court added a number of comments ordering the parties to make minor changes to the agreement, mainly concerning the operation of the mechanism, however none of the agreement foundations are affected by these changes. The court found that the settlement is "worthwhile, reasonable and fair" and ordered its publication and approval.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Claim Arising from the Omega Acquisition </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV ("Holdco") (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo has recently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issue recently disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have a further basis for its counterclaim against Perrigo. The proposed additional counterclaim theory does not appear to increase any damages sought. The Tribunal has not decided whether to grant Alychlo permission to introduce the additional counterclaim. There can be no assurance that our Claim will be successful, and the Sellers deny liability for the Claim. We deny that Alychlo is entitled to any relief (including monetary relief) under either the existing counterclaim or the proposed additional counterclaim theory.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Matters </span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div>Our Board of Directors received a shareholder demand letter dated October 30, 2018 relating to the allegations in the securities cases and price fixing lawsuits described above. The letter demands that the Board of Directors initiate an action against certain current and former executives and Board members to recover damages allegedly caused to the Company. In response, the Company reminded the shareholder that any derivative claim can only proceed in accordance with Irish law, the law that governs the Company’s internal affairs. The shareholder has responded that he intends to file a lawsuit asserting derivative claims but has not yet filed a lawsuit. 27 15 2 35 3 31 17 27 30 30 2 11 6 3 3 6 2 2 2 6 2 2 4 6 4 3 5 6 6 6 2 7 6 8 6 9 6 2 10 6 2 11 6 2 30 2 12 6 3 1 1 11 6 2700000000 760000000.0 0.28 9 1 8 250 <span style="font-family:Arial;font-weight:bold;">RESTRUCTURING CHARGES</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and asset impairments. The following reflects our restructuring activity (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:385px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:184px;"/><td style="width:6px;"/><td style="width:86px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:86px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Additional charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-cash adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">The charges incurred during the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> were primarily associated with the reorganization of our executive management team. There were no other material restructuring programs that significantly impacted any individual segment for the </span><span style="font-family:Arial;font-size:10pt;">three months ended</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">March 30, 2019</span><span style="font-family:Arial;font-size:10pt;"> or </span><span style="font-family:Arial;font-size:10pt;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. All charges are recorded in </span><span style="font-family:Arial;font-size:10pt;">Restructuring</span><span style="font-family:Arial;font-size:10pt;"> expense on the Condensed Consolidated Financial Statements. The remaining </span><span style="font-family:Arial;font-size:10pt;"><span>$20.5 million</span></span> liability for employee severance benefits and lease exit costs is expected to be paid within the next year. The following reflects our restructuring activity (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:385px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:184px;"/><td style="width:6px;"/><td style="width:86px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:86px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Additional charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-cash adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 24000000.0 21400000 5900000 1500000 9000000.0 10800000 -400000 300000 20500000 12400000 20500000 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">SEGMENT INFORMATION</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The below tables show select financial measures by reporting segment (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:49.10807974816369%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:38%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Assets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,704.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,571.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,597.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,613.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,817.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,798.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,119.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,983.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>118.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>377.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unallocated</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(60.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(35.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>102.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The below tables show select financial measures by reporting segment (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:49.10807974816369%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:38%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Assets</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,704.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,571.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,597.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,613.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,817.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,798.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,119.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,983.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Intangible Asset Amortization</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>118.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">CSCI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>377.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RX</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unallocated</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(60.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(35.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>102.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 3704600000 3571700000 4597800000 4613000000.0 2817100000 2798700000 11119500000 10983400000 581800000 94200000 10100000 601600000 118600000 15200000 350800000 8100000 44100000 377800000 12300000 51100000 241900000 60600000 21200000 237600000 61200000 20900000 0 -60600000 0 0 -35800000 0 1174500000 102300000 75400000 1217000000.0 156300000 87200000 <span style="font-family:Arial;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</span><span style="font-family:inherit;font-size:10pt;"> </span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Notice of Proposed Adjustment </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Athena’s in-process R&amp;D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$843.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which represents additional tax and a </span><span style="font-family:Arial;font-size:10pt;"><span>40%</span></span><span style="font-family:Arial;font-size:10pt;"> penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on Perrigo’s liquidity and capital resources (refer to </span><a href="#s87721785D4335BF785077F621E579AEB" style="font-family:Arial;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Note 12</span></a><span style="font-family:Arial;font-size:10pt;">).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Animal Health Divestiture</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On May 8, 2019, we signed a definitive agreement for the sale of our animal health business to PetIQ for </span><span style="font-family:Arial;font-size:10pt;"><span>$185.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in cash, plus a working capital adjustment. We expect to finalize the sale within the next six months. The divestiture of this business is not expected to have a material impact on our operations or financial results.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Ranir Global Holdings, LLC</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:10pt;">On </span><span style="font-family:Arial;">May 8, 2019</span><span style="font-family:Arial;font-size:10pt;">, we reached a definitive agreement to purchase privately-held Ranir Global Holdings, LLC (“Ranir”) in a transaction valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$750.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> on a cash-free, debt-free basis. We intend to fund the transaction with approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$450.0 million</span></span> of cash on hand and the balance through short-term debt. Headquartered in Grand Rapids, Michigan, Ranir is a leading global supplier of private label and branded oral care products. The transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. The proposed transaction, which has been unanimously approved by both our and Ranier's boards of directors, is subject to the satisfaction of closing conditions, including customary regulatory approvals. The transaction is expected to close during the third quarter of calendar year 2019. 843000000.0 0.40 185000000.0 750000000.0 450000000.0 Derived from the location of the entity that sells to a third party. Includes net sales from our OTC contract manufacturing business. Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate. Includes net sales generated primarily in Israel, Mexico, Australia and Canada. Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales. (2)As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million. (a) Includes short-term leases and variable lease costs, which are immaterial. (1) Measured at fair value using the Net Asset Value practical expedient. Includes Ireland net sales of $5.2 million and $5.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively. (3)As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million. Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales. (1)As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million. XML 22 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document and Entity Information - shares
 3 Months Ended
Mar. 30, 2019
May 03, 2019
Document and Entity Information [Abstract]    
Entity registrant name PERRIGO Co plc  
Entity central index key 0001585364  
Current calendar year end date --12-31  
Entity filer category Large Accelerated Filer  
Document type 10-Q  
Document period end date Mar. 30, 2019  
Document calendar year focus 2019  
Document calendar period focus Q1  
Amendment flag false  
Entity common stock, shares outstanding   135,991,315
Entity emerging growth company false  
Entity small business false  
XML 23 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Income Statement [Abstract]    
Net sales [1] $ 1,174.5 $ 1,217.0
Cost of sales 725.7 724.3
Gross profit 448.8 492.7
Operating expenses    
Distribution 23.3 24.7
Research and development 40.2 38.4
Selling 148.6 161.3
Administration 125.1 107.6
Impairment charges 4.1 0.0
Restructuring charges 9.3 1.5
Other operating expense (income) (4.1) 2.9
Total operating expenses 346.5 336.4
Operating income 102.3 156.3
Change in financial assets (10.4) 9.6
Interest expense, net 28.6 31.4
Other (income) expense, net 3.2 4.3
Loss on extinguishment of debt 0.0 0.5
Income before income taxes 80.9 110.5
Income tax expense 17.0 29.7
Net income $ 63.9 $ 80.8
Earnings per share    
Basic (in dollars per share) $ 0.47 $ 0.57
Diluted (in dollars per share) $ 0.47 $ 0.57
Weighted-average shares outstanding    
Basic (in shares) 135.9 140.8
Diluted (in shares) 136.2 141.4
[1] Derived from the location of the entity that sells to a third party.
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Statement of Comprehensive Income [Abstract]    
Net income $ 63.9 $ 80.8
Other comprehensive income (loss):    
Foreign currency translation adjustments (16.8) 73.0
Change in fair value of derivative financial instruments, net of tax 1.7 (0.6)
Change in post-retirement and pension liability, net of tax (0.5) (0.2)
Other comprehensive income (loss), net of tax (15.6) 72.2
Comprehensive income $ 48.3 $ 153.0
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
shares in Millions, $ in Millions
Mar. 30, 2019
Dec. 31, 2018
Assets    
Cash and cash equivalents $ 837.9 $ 551.1
Accounts receivable, net of allowance for doubtful accounts of $6.8 and $6.4, respectively 1,118.7 1,073.1
Inventories 912.9 878.0
Prepaid expenses and other current assets 139.8 400.0
Total current assets 3,009.3 2,902.2
Property, plant and equipment, net 821.1 829.1
Operating lease assets 146.8 0.0
Goodwill and indefinite-lived intangible assets 3,999.0 4,029.1
Definite-lived intangible assets, net 2,757.9 2,858.9
Deferred income taxes 2.7 1.2
Other non-current assets 382.7 362.9
Total non-current assets 8,110.2 8,081.2
Total assets 11,119.5 10,983.4
Liabilities and Shareholders’ Equity    
Accounts payable 549.2 474.9
Payroll and related taxes 117.3 132.1
Accrued customer programs 379.6 442.4
Accrued liabilities 232.0 201.3
Accrued income taxes 85.9 96.5
Current indebtedness 467.9 190.2
Total current liabilities 1,831.9 1,537.4
Long-term debt, less current portion 2,749.9 3,052.2
Deferred income taxes 282.4 282.3
Other non-current liabilities 554.5 443.4
Total non-current liabilities 3,586.8 3,777.9
Total liabilities 5,418.7 5,315.3
Commitments and contingencies - Refer to Note 13
Controlling interests:    
Preferred shares, $0.0001 par value per share, 10 shares authorized 0.0 0.0
Ordinary shares, €0.001 par value per share, 10,000 shares authorized 7,409.4 7,421.7
Accumulated other comprehensive income 69.0 84.6
Retained earnings (accumulated deficit) (1,777.8) (1,838.3)
Total controlling interest 5,700.6 5,668.0
Noncontrolling interest 0.2 0.1
Total shareholders’ equity 5,700.8 5,668.1
Total liabilities and shareholders' equity $ 11,119.5 $ 10,983.4
Supplemental Disclosures of Balance Sheet Information    
Ordinary shares, issued and outstanding (in shares) 136.0 135.9
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (Parenthetical)
$ in Millions
Mar. 30, 2019
€ / shares
Mar. 30, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
€ / shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Statement of Financial Position [Abstract]        
Allowance for doubtful accounts | $   $ 6.8   $ 6.4
Stockholders' Equity:        
Preferred shares, par value (in dollars per share) | $ / shares   $ 0.0001   $ 0.0001
Preferred shares, authorized   10,000,000   10,000,000
Ordinary shares, par value (in EUR per share) | € / shares € 0.001   € 0.001  
Ordinary shares, authorized   10,000,000,000   10,000,000,000
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Shareholders' Equity Statement - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares Issued
Accumulated Other Comprehensive Income
Retained Earnings (Accumulated Deficit)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Adoption of new accounting standards | Adoption of new accounting standards $ 5.3   $ (1.0) $ 6.3
Beginning balance (shares) at Dec. 31, 2017   140.8    
Balance, beginning at Dec. 31, 2017 6,170.5 $ 7,892.9 253.1 (1,975.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 80.8      
Other comprehensive income (loss) 72.2   72.2  
Stock options exercised 0.2 $ 0.2    
Restricted stock plan (shares)   0.2    
Compensation for stock options 2.7 $ 2.7    
Compensation for restricted stock 10.0 10.0    
Cash dividends, $0.19 per share (26.7) (26.7)    
Shares withheld for payment of employees' withholding tax liability (1.5) $ (1.5)    
Repurchases of ordinary shares (shares)   (1.3)    
Repurchases of ordinary shares (108.1) $ (108.1)    
Ending balance (shares) at Mar. 31, 2018   139.7    
Balance, ending at Mar. 31, 2018 6,205.4 $ 7,769.5 324.3 (1,888.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Adoption of new accounting standards | Adoption of new accounting standards (3.4)     (3.4)
Beginning balance (shares) at Dec. 31, 2018   135.9    
Balance, beginning at Dec. 31, 2018 5,668.0 $ 7,421.7 84.6 (1,838.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 63.9      
Other comprehensive income (loss) (15.6)   (15.6)  
Restricted stock plan (shares)   0.2    
Compensation for stock options 1.8 $ 1.8    
Compensation for restricted stock 14.2 14.2    
Cash dividends, $0.19 per share (25.9) $ (25.9)    
Shares withheld for payment of employees' withholding tax liability (shares)   (0.1)    
Shares withheld for payment of employees' withholding tax liability $ (2.4) $ (2.4)    
Repurchases of ordinary shares (shares) 0.0      
Ending balance (shares) at Mar. 30, 2019   136.0    
Balance, ending at Mar. 30, 2019 $ 5,700.6 $ 7,409.4 $ 69.0 $ (1,777.8)
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]    
Dividends paid (in dollars per share) $ 0.19 $ 0.19
XML 29 R8.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Cash Flows From (For) Operating Activities    
Net income $ 63.9 $ 80.8
Adjustments to derive cash flows:    
Depreciation and amortization 96.6 109.5
Share-based compensation 12.4 12.7
Impairment charges 4.1 0.0
Change in financial assets (10.4) 9.6
Loss on extinguishment of debt 0.0 0.5
Restructuring charges 9.3 1.5
Deferred income taxes 3.9 (7.2)
Amortization of debt premium (1.9) (2.1)
Other non-cash adjustments, net 13.4 12.1
Subtotal 191.3 217.4
Increase (decrease) in cash due to:    
Accounts receivable (48.5) 2.6
Inventories (37.5) (43.7)
Accounts payable 75.4 57.5
Payroll and related taxes (19.9) (38.9)
Accrued customer programs (61.7) 17.3
Accrued liabilities (3.8) (24.0)
Accrued income taxes (10.0) 6.4
Other, net 9.2 (22.2)
Subtotal (96.8) (45.0)
Net cash from (for) operating activities 94.5 172.4
Cash Flows From (For) Investing Activities    
Proceeds from royalty rights 1.2 10.0
Royalty Pharma contingent milestone payment 250.0 0.0
Additions to property, plant and equipment (21.1) (13.4)
Net proceeds from sale of business and other assets 0.0 1.3
Net cash from (for) investing activities 230.1 (2.1)
Cash Flows From (For) Financing Activities    
Issuances of long-term debt 0.0 431.0
Payments on long-term debt (12.3) (444.5)
Borrowings (repayments) of revolving credit agreements and other financing, net (0.3) (6.2)
Deferred financing fees 0.0 (2.4)
Repurchase of ordinary shares 0.0 (108.1)
Cash dividends (25.9) (26.7)
Other financing, net (3.1) (5.7)
Net cash from (for) financing activities (41.6) (162.6)
Effect of exchange rate changes on cash and cash equivalents 3.8 0.9
Net increase (decrease) in cash and cash equivalents 286.8 8.6
Cash and cash equivalents, beginning of period 551.1 678.7
Cash and cash equivalents, end of period $ 837.9 $ 687.3
XML 30 R9.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 30, 2019
Accounting Policies [Abstract]  
Summary of significant accounting policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are dedicated to making lives better by bringing “Quality, Affordable Self-Care Products™” that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Segment Reporting Change

               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the Consumer Self-Care International segment to the Prescription Pharmaceuticals segment and we made certain adjustments to our allocations between segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Note 2 and Note 15.

Our new reporting and operating segments are as follows:

•
Consumer Self-Care Americas ("CSCA"), formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada.
•
Consumer Self-Care International ("CSCI"), formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.
•
Prescription Pharmaceuticals ("RX"), comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.

Recent Accounting Standard Pronouncements
    
Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract
 
This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement
 
This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.
 
January 1, 2020
 
We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606
 
This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans
 
This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.
 
December 31, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
XML 31 R10.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition
 3 Months Ended
Mar. 30, 2019
Revenue from Contract with Customer [Abstract]  
Revenue recognition REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
U.S.
$
768.8

 
$
786.4

Europe(2)
340.9

 
361.9

All other countries(3)
64.8

 
68.7

 
$
1,174.5

 
$
1,217.0


(1) Derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $5.2 million and $5.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively.
(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
CSCA(1)
 
 
 
Cough/cold/allergy/sinus
$
132.6

 
$
141.5

Gastrointestinal
100.3

 
92.2

Infant nutritionals
96.0

 
103.4

Analgesics
88.8

 
93.7

Smoking cessation
66.8

 
65.9

Animal health
19.6

 
26.3

Vitamins, minerals and dietary supplements
3.4

 
3.0

Other CSCA(2)
74.3

 
75.6

Total CSCA
581.8

 
601.6

CSCI
 
 
 
Cough/cold/allergy/sinus
95.7

 
98.7

Lifestyle
81.5

 
89.7

Personal care and derma-therapeutics
66.0

 
75.6

Natural health and vitamins, minerals and dietary supplements
29.8

 
33.2

Anti-parasites
26.7

 
28.1

Other CSCI(3)
51.1

 
52.5

Total CSCI
350.8

 
377.8

Total RX
241.9

 
237.6

Total net sales
$
1,174.5

 
$
1,217.0


(1)    Includes net sales from our OTC contract manufacturing business.
(2)
Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3)
Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $67.3 million and $69.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Short-term contract assets
Prepaid expenses and other current assets
 
$
18.1

 
$
25.5
XML 32 R11.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets
 3 Months Ended
Mar. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
 
 
December 31,
2018
 
Currency Translation Adjustments
 
March 30,
2019
CSCA(1)
 
$
1,713.7

 
$
1.2

 
$
1,714.9

CSCI(2)
 
1,151.3

 
(17.7
)
 
1,133.6

RX
 
1,114.8

 
2.9

 
1,117.7

Total goodwill
 
$
3,979.8

 
$
(13.6
)
 
$
3,966.2



(1)
We had accumulated impairments of $24.5 million and $161.2 million for the three months ended March 31, 2018 and March 30, 2019, respectively.
(2)
We had accumulated impairments of $868.4 million for the three months ended March 31, 2018 and March 30, 2019.

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):
 
March 30, 2019
 
December 31, 2018
 
Gross
 
Accumulated
Amortization
 
Gross
 
Accumulated
Amortization
Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
18.5

 
$
—

 
$
18.1

 
$
—

In-process research and development
14.3

 
—

 
31.2

 
—

Total indefinite-lived intangibles
$
32.8

 
$
—

 
$
49.3

 
$
—

Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements and supply agreements
$
180.4

 
$
101.9

 
$
178.6

 
$
99.0

Developed product technology, formulations, and product rights
1,333.1

 
686.0

 
1,318.8

 
654.6

Customer relationships and distribution networks
1,562.5

 
587.6

 
1,586.6

 
566.5

Trademarks, trade names, and brands
1,257.8

 
201.3

 
1,282.4

 
188.5

Non-compete agreements
12.6

 
11.7

 
12.9

 
11.8

Total definite-lived intangibles
$
4,346.4

 
$
1,588.5

 
$
4,379.3

 
$
1,520.4

Total intangible assets
$
4,379.2

 
$
1,588.5

 
$
4,428.6

 
$
1,520.4



We recorded amortization expense of $75.4 million and $87.2 million for the three months ended March 30, 2019 and March 31, 2018, respectively.     

We recorded an impairment charge of $4.1 million on a certain IPR&D asset during the three months ended March 30, 2019 due to changes in projected development and regulatory timelines.
XML 33 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories
 3 Months Ended
Mar. 30, 2019
Inventory Disclosure [Abstract]  
Inventories INVENTORIES

Major components of inventory were as follows (in millions):
 
 
March 30,
2019
 
December 31,
2018
Finished goods
$
474.0

 
$
444.9

Work in process
199.3

 
197.5

Raw materials
239.6

 
235.6

Total inventories
$
912.9

 
$
878.0
XML 34 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements
 3 Months Ended
Mar. 30, 2019
Fair Value Disclosures [Abstract]  
Fair value measurements FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
 
 
March 30, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
Measured at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Investment securities
 
$
3.7

 
$
—

 
$
—

 
$
9.4

 
$
—

 
$
—

Foreign currency forward contracts
 
—

 
3.2

 
—

 
—

 
3.8

 
—

Funds associated with Israeli severance liability
 
—

 
13.4

 
—

 
—

 
13.0

 
—

Royalty Pharma contingent milestone payments
 
—

 
—

 
83.6

 
—

 
—

 
323.2

Total assets
 
$
3.7

 
$
16.6

 
$
83.6

 
$
9.4

 
$
16.8

 
$
323.2

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
Foreign currency forward contracts
 
$
—

 
$
5.8

 
$
—

 
$
—

 
$
9.2

 
$
—

Contingent consideration
 
—

 
—

 
12.4

 
—

 
—

 
15.3

Total liabilities
 
$
—

 
$
5.8

 
$
12.4

 
$
—

 
$
9.2

 
$
15.3

 
 
 
 
 
 
 
 
 
 
 
 
 
Measured at fair value on a non-recurring basis:
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill(1)
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
42.2

Indefinite-lived intangible assets(2)
 
—

 
—

 
—

 
—

 
—

 
10.5

Definite-lived intangible assets(3)
 
—

 
—

 
—

 
—

 
—

 
22.4

Total assets
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
75.1



(1)
As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.
(2)
As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.
(3)
As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.

There were no transfers among Level 1, 2, and 3 during the three months ended March 30, 2019 or the year ended December 31, 2018.

Royalty Pharma Contingent Milestone Payments

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
323.2

 
$
134.5

Payments received
(250.0
)
 
—

Change in fair value
10.4

 
(9.6
)
Ending balance
$
83.6

 
$
124.9



We value our contingent milestone payments from Royalty Pharma using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma until the contingent milestones are resolved. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Volatility
30.0
%
 
30.0
%
Rate of return
8.02
%
 
8.08
%

During the three months ended March 30, 2019, the fair value of the Royalty Pharma contingent milestone payments increased $10.4 million driven by higher projected global net sales of Tysabri® and the estimated probability of achieving the earn-out. During the three months ended March 31, 2018, the fair value of the Royalty Pharma contingent milestone payments decreased $9.6 million due primarily to projected global net sales of Tysabri® temporarily falling below the threshold required for payment of the $250.0 million milestone payment for 2018.

In order for us to receive the 2020 milestone payment of $400.0 million, Royalty Pharma contingent payments for Tysabri® sales in 2020 must exceed $351.0 million. If Royalty Pharma contingent payments for Tysabri® sales do not meet the prescribed threshold in 2020, we will write off the $83.6 million asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to $400.0 million and recognize income of $316.4 million in Change in financial assets on the Condensed Consolidated Statements of Operations.

Contingent Consideration

The table below summarizes the change in fair value of contingent consideration (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
15.3

 
$
22.0

Changes in value
1.2

 
0.4

Currency translation adjustments
—

 
0.1

Settlements and other adjustments
(4.1
)
 
(4.4
)
Ending balance
$
12.4

 
$
18.1



Goodwill and Intangible Assets

Animal Health

When determining the fair value of our animal health reporting unit for the year ended December 31, 2018, we utilized a combination of comparable company market and discounted cash flow techniques. In our comparable company market approach, we considered observable market information and transactions for companies that we deemed to be of a comparable nature, scope, and size of animal health (Level 2 inputs). Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products, plus gross margin, advertising and promotion, and other operating expenses based on the growth plans (Level 3 inputs). In our discounted cash flow analysis, we utilized projected sales growth rate and discount rate assumptions of 2.5% and 9.8%, respectively. The discount rate correlates with the required investment return and risk that we believe market participants would apply to the projected growth rate. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows and applied the jurisdictional tax rate of 22.8%. We weighted indications of fair value resulting from the market approach and present value techniques, considering the
reasonableness of the range of measurements and the point within the range that we determined was most representative of fair market conditions.

When assessing our animal health indefinite-lived intangible asset for the year ended December 31, 2018, we utilized a multi-period excess earnings method ("MPEEM") to determine the fair value of the intangible asset. Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products. We utilized long-term growth rate and discount rate assumptions of (0.3)% and 9.8%, respectively, and we applied a jurisdictional tax rate of 22.8%.

When assessing our animal health definite-lived assets for impairment for the year ended December 31, 2018, we utilized a combination of MPEEM and relief from royalty methods to determine the fair values of definite-lived assets within the asset group. The projected financial information, inputs, and assumptions utilized were consistent with those utilized in the goodwill discounted cash flow analysis described above.

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):
 
March 30,
2019
 
December 31,
2018
 
Level 1
 
Level 2
 
Level 1
 
Level 2
Public Bonds
 
 
 
 
 
 
 
Carrying Value (excluding discount)
$
2,600.0

 
 
 
$
2,600.0

 
 
Fair value
$
2,472.0

 
 
 
$
2,316.6

 
 
 
 
 
 
 
 
 
 
Retail bond and private placement note
 
 
 
 
 
 
 
Carrying value (excluding premium)
 
 
$
286.1

 
 
 
$
292.5

Fair value
 
 
$
301.9

 
 
 
$
307.9



The fair values of our public bonds for all periods were based on quoted market prices. The fair values of our retail bond and private placement note for all periods were based on interest rates offered for borrowings of a similar nature and remaining maturities.

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.
XML 35 R14.htm IDEA: XBRL DOCUMENT v3.19.1
Investments
 3 Months Ended
Mar. 30, 2019
Investments [Abstract]  
Investments INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):
Measurement Category
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Fair value method
 
Prepaid expenses and other current assets
 
$
3.7

 
$
9.4

Fair value method(1)
 
Other non-current assets
 
$
3.7

 
$
4.4

Equity method
 
Other non-current assets
 
$
15.8

 
$
15.1


(1)
Measured at fair value using the Net Asset Value practical expedient.

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):
 
 
 
 
Three Months Ended
Measurement Category
 
Income Statement Location
 
March 30,
2019
 
March 31,
2018
Fair value method
 
Other (income) expense, net
 
$
6.1

 
$
4.4

Equity method
 
Other (income) expense, net
 
$
(0.7
)
 
$
0.2



On January 1, 2018, as a result of the adoption of ASU 2016-01 Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities ("ASU 2016-01"), we made a $1.0 million cumulative-effect adjustment to Retained earnings (accumulated deficit) net of tax that consisted of net unrealized losses on previously classified as available for sale securities from Other comprehensive income ("OCI").
XML 36 R15.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities
 3 Months Ended
Mar. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative instruments and hedging activities DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2018 and the year ended December 31, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.

Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in Other (income) expense, net on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of:

•
Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and

•
Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.

Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We recognized all changes in fair value of the excluded components in Other (income) expense, net, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and Retained earnings (accumulated deficit) from applying this policy on existing hedges at the date of adoption was immaterial.

We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to Note 5). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.

Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of March 30, 2019 and December 31, 2018.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is 18 months.

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.
    
All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

Interest Rate Swaps

Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. There were no active designated or non-designated interest rate swaps as of March 30, 2019 and December 31, 2018.

Foreign Currency Derivatives

Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):
 
 
Notional Amount
 
 
March 30,
2019
 
December 31,
2018
Israeli Shekel (ILS)
 
$
290.1

 
$
232.6

British Pound (GBP)
 
107.1

 
90.2

European Euro (EUR)
 
103.1

 
134.2

Swedish (SEK)
 
76.4

 
38.7

Danish Krone (DKK)
 
52.8

 
56.5

United States Dollar (USD)
 
42.0

 
39.3

Canadian Dollar (CAD)
 
35.4

 
31.7

Polish Zloty (PLZ)
 
28.7

 
18.2

Chinese Yuan (CNY)
 
16.8

 
—

Norwegian Krone (NOK)
 
14.9

 
6.2

Romanian New Leu (RON)
 
4.7

 
4.4

Mexican Peso (MPX)
 
2.6

 
25.9

Other
 
8.7

 
8.7

Total
 
$
783.3

 
$
686.6



Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):
 
 
 
Asset Derivatives
 
 
 
Fair Value
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Prepaid expenses and other current assets
 
$
0.6

 
$
2.0

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Prepaid expenses and other current assets
 
$
2.6

 
$
1.8

 
 
 
Liability Derivatives
 
 
 
Fair Value
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
4.2

 
$
6.4

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
1.6

 
$
2.8



The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):
 
 
Three months ended
 
 
March 30, 2019
Instrument
 
Amount of Gain/(Loss) Recorded in OCI(1)
 
Classification of Gain/(Loss) Reclassified from AOCI into Earnings
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
 
Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing
 
Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements
 
 
 
Interest expense, net
 
$
(0.4
)
 
Interest expense, net
 
$
—

Foreign currency forward contracts
 
$
(1.0
)
 
Net sales
 
0.2

 
Net sales
 
(0.1
)
 
 
 
 
Cost of sales
 
(1.3
)
 
Cost of sales
 
(1.1
)
 
 
 
 
 
 
$
(1.5
)
 
 
 
$
(1.2
)

(1) Net loss of $2.7 million is expected to be reclassified out of AOCI into earnings during the next 12 months.
 
 
Three months ended
 
 
March 31, 2018
 
 
Effective Portion
Instrument
 
Amount of Gain/(Loss) Recorded in OCI
 
Classification of Gain/(Loss) Reclassified from AOCI into Earnings
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements
 
 
 
Interest expense, net
 
$
(0.4
)
Foreign currency forward contracts
 
$
(0.2
)
 
Net sales
 
(0.1
)
 
 
 
 
Cost of sales
 
2.3

 
 
 
 
Interest expense, net
 
(1.0
)
 
 
 
 
Other (income) expense, net
 
(0.4
)
 
 
 
 
 
 
$
0.4



The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):
 
 
 
 
Three months ended
Non-Designated Derivatives
 
Income Statement
Location
 
March 30,
2019
 
March 31,
2018
Foreign currency forward contracts
 
Other (income) expense, net
 
$
(8.8
)
 
$
3.5

 
 
Interest expense, net
 
0.4

 
(0.9
)
Total
 
 
 
$
(8.4
)
 
$
2.6



The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Condensed Consolidated Statements of Operations in Other (income) expense, net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar-translated amounts of each Income Statement account in current and/or future periods.

The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):
 
 
Three months ended
 
 
March 30, 2019
 
 
Net Sales
 
Cost of Sales
 
Interest Expense, net
 
Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded
 
$
1,174.5

 
$
725.7

 
$
28.6

 
$
3.2

 
 
 
 
 
 
 
 
 
The effects of cash flow hedging:
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedging relationships
 
 
 
 
 
 
 
 
Foreign currency forward contracts
 
 
 
 
 
 
 
 
Amount of gain or (loss) reclassified from AOCI into earnings
 
$
0.2

 
$
(1.3
)
 
$
—

 
$
—

Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach
 
$
(0.1
)
 
$
(1.1
)
 
$
—

 
$
—

Interest rate swap agreements
 
 
 
 
 
 
 
 
Amount of gain or (loss) reclassified from AOCI into earnings
 
$
—

 
$
—

 
$
(0.4
)
 
$
—
XML 37 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Leases
 3 Months Ended
Mar. 30, 2019
Leases [Abstract]  
Leases LEASES

We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.
 
We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider
renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The balance sheet location of our lease assets and liabilities were as follows (in millions):
Assets
 
Balance Sheet Location
 
March 30,
2019
Operating
 
Operating lease assets
 
$
146.8

Finance
 
Other non-current assets
 
9.9

Total
 
 
 
$
156.7

Liabilities
 
Balance Sheet Location
 
March 30,
2019
Current
 
 
 
 
Operating
 
Accrued liabilities
 
$
34.8

Finance
 
Current indebtedness
 
1.9

Non-Current
 
 
 
 
Operating
 
Other non-current liabilities
 
116.4

Finance
 
Long-term debt, less current portion
 
4.7

Total
 
 
 
$
157.8

    
The below table shows our lease assets and liabilities by reporting segment (in millions):
 
 
Assets
 
Liabilities
 
 
Operating
 
Financing
 
Operating
 
Financing
 
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
CSCA
 
$
30.1

 
$
1.9

 
$
30.2

 
$
1.4

CSCI
 
43.5

 
6.1

 
44.4

 
3.3

RX
 
38.6

 
0.1

 
40.1

 
0.1

Unallocated
 
34.6

 
1.8

 
36.5

 
1.8

Total
 
$
146.8

 
$
9.9

 
$
151.2

 
$
6.6



Lease expense was as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Operating leases(a)
 
$
12.0

 
 
 
Finance leases
 
 
Amortization
 
$
0.7

Interest
 
0.1

Total
 
$
0.8


(a) Includes short-term leases and variable lease costs, which are immaterial.
    
Total operating lease expense for the three months ended March 31, 2018 was $11.9 million.

The annual future maturities of our leases as of March 30, 2019 are as follows (in millions):
 
 
Operating Leases
 
Finance Leases
 
Total
2019
 
$
31.0

 
$
1.7

 
$
32.7

2020
 
33.1

 
1.6

 
34.7

2021
 
24.0

 
2.9

 
26.9

2022
 
18.1

 
0.5

 
18.6

2023
 
15.0

 
0.3

 
15.3

After 2023
 
53.4

 
—

 
53.4

Total lease payments
 
174.6

 
7.0

 
181.6

Less: Interest
 
23.4

 
0.4

 
23.8

Present value of lease liabilities
 
$
151.2

 
$
6.6

 
$
157.8



Our weighted average lease terms and discount rates are as follows:
 
 
Three Months Ended
 
 
March 30,
2019
Weighted-average remaining lease term (in years)
 
 
Operating leases
 
6.81

Finance leases
 
2.59

Weighted-average discount rate
 
 
Operating leases
 
4.20
%
Finance leases
 
4.17
%


Our lease cash flow classifications are as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Cash paid for amounts included in the measurement of lease liabilities
 
 
Operating cash flows for operating leases
 
$
11.7

Operating cash flows for finance leases
 
$
0.1

Financing cash flows for finance leases
 
$
0.7

Leased assets obtained in exchange for new operating lease liabilities
 
$
4.7
Leases LEASES

We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.
 
We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider
renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The balance sheet location of our lease assets and liabilities were as follows (in millions):
Assets
 
Balance Sheet Location
 
March 30,
2019
Operating
 
Operating lease assets
 
$
146.8

Finance
 
Other non-current assets
 
9.9

Total
 
 
 
$
156.7

Liabilities
 
Balance Sheet Location
 
March 30,
2019
Current
 
 
 
 
Operating
 
Accrued liabilities
 
$
34.8

Finance
 
Current indebtedness
 
1.9

Non-Current
 
 
 
 
Operating
 
Other non-current liabilities
 
116.4

Finance
 
Long-term debt, less current portion
 
4.7

Total
 
 
 
$
157.8

    
The below table shows our lease assets and liabilities by reporting segment (in millions):
 
 
Assets
 
Liabilities
 
 
Operating
 
Financing
 
Operating
 
Financing
 
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
CSCA
 
$
30.1

 
$
1.9

 
$
30.2

 
$
1.4

CSCI
 
43.5

 
6.1

 
44.4

 
3.3

RX
 
38.6

 
0.1

 
40.1

 
0.1

Unallocated
 
34.6

 
1.8

 
36.5

 
1.8

Total
 
$
146.8

 
$
9.9

 
$
151.2

 
$
6.6



Lease expense was as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Operating leases(a)
 
$
12.0

 
 
 
Finance leases
 
 
Amortization
 
$
0.7

Interest
 
0.1

Total
 
$
0.8


(a) Includes short-term leases and variable lease costs, which are immaterial.
    
Total operating lease expense for the three months ended March 31, 2018 was $11.9 million.

The annual future maturities of our leases as of March 30, 2019 are as follows (in millions):
 
 
Operating Leases
 
Finance Leases
 
Total
2019
 
$
31.0

 
$
1.7

 
$
32.7

2020
 
33.1

 
1.6

 
34.7

2021
 
24.0

 
2.9

 
26.9

2022
 
18.1

 
0.5

 
18.6

2023
 
15.0

 
0.3

 
15.3

After 2023
 
53.4

 
—

 
53.4

Total lease payments
 
174.6

 
7.0

 
181.6

Less: Interest
 
23.4

 
0.4

 
23.8

Present value of lease liabilities
 
$
151.2

 
$
6.6

 
$
157.8



Our weighted average lease terms and discount rates are as follows:
 
 
Three Months Ended
 
 
March 30,
2019
Weighted-average remaining lease term (in years)
 
 
Operating leases
 
6.81

Finance leases
 
2.59

Weighted-average discount rate
 
 
Operating leases
 
4.20
%
Finance leases
 
4.17
%


Our lease cash flow classifications are as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Cash paid for amounts included in the measurement of lease liabilities
 
 
Operating cash flows for operating leases
 
$
11.7

Operating cash flows for finance leases
 
$
0.1

Financing cash flows for finance leases
 
$
0.7

Leased assets obtained in exchange for new operating lease liabilities
 
$
4.7
XML 38 R17.htm IDEA: XBRL DOCUMENT v3.19.1
Indebtedness
 3 Months Ended
Mar. 30, 2019
Debt Disclosure [Abstract]  
Indebtedness INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):
 
 
 
 
 
March 30,
2019
 
December 31,
2018
Term loans
 
 
 
 
 
 
2018 Term loan due March 8, 2020(1)
 
 
$
331.3

 
$
351.3

Notes and Bonds
 
 
 
 
 
 
Coupon
Due
 
 
 
 
 
 
5.000%
May 23, 2019(1)
 
 
134.6

 
137.6

 
3.500%
March 15, 2021
 
 
280.4

 
280.4

 
3.500%
December 15, 2021
 
 
309.6

 
309.6

 
5.105%
July 19, 2023(1)
 
 
151.5

 
154.9

 
4.000%
November 15, 2023
 
 
215.6

 
215.6

 
3.900%
December 15, 2024
 
 
700.0

 
700.0

 
4.375%
March 15, 2026
 
 
700.0

 
700.0

 
5.300%
November 15, 2043
 
 
90.5

 
90.5

 
4.900%
December 15, 2044
 
 
303.9

 
303.9

 
Total notes and bonds
 
 
2,886.1

 
2,892.5

Other financing
6.2

 
2.8

Unamortized premium (discount), net
9.8

 
12.2

Deferred financing fees
(15.6
)
 
(16.4
)
Total borrowings outstanding
3,217.8

 
3,242.4

 
Current indebtedness
(467.9
)
 
(190.2
)
Total long-term debt less current portion
$
2,749.9

 
$
3,052.2



(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
    
We are in compliance with all covenants under our debt agreements as of March 30, 2019.

Revolving Credit Agreements

On March 8, 2018, we terminated the revolving credit agreement entered into on December 5, 2014 and entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2014 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of March 30, 2019 or December 31, 2018.

Term Loans

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, maturing December 5, 2019. On March 8, 2018, we refinanced the €350.0 million outstanding under the term loan with the proceeds of a new €350.0 million ($431.0 million) term loan, maturing March 8, 2020 (the "2018 Term Loan"). In addition, as a result of the refinancing during the three months ended March 31, 2018, we recorded a loss of $0.5 million, consisting of the write-off of deferred financing fees in Loss on extinguishment of debt on the Condensed Consolidated Statements of Operations. During the three months ended March 30, 2019, we made $12.3 million in scheduled principal payments on the 2018 Term Loan.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no borrowings outstanding at March 30, 2019 or December 31, 2018.

We have financing leases that are reported in the above table under "Other financing" (refer to Note 8).
XML 39 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Earnings Per Share and Shareholders' Equity
 3 Months Ended
Mar. 30, 2019
Earnings Per Share [Abstract]  
Earnings per share and shareholders' equity EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Numerator:
 
 
 
Net income
$
63.9

 
$
80.8

 
 
 
 
Denominator:
 
 
 
Weighted average shares outstanding for basic EPS
135.9

 
140.8

Dilutive effect of share-based awards
0.3

 
0.6

Weighted average shares outstanding for diluted EPS
136.2

 
141.4

 
 
 
 
Anti-dilutive share-based awards excluded from computation of diluted EPS
2.1

 
0.7



Shareholders' Equity

Share Repurchases

Following the expiration of our 2015 share repurchase plan authorization, in October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. We did not repurchase any shares during the three months ended March 30, 2019. During the three months ended March 31, 2018, we repurchased 1.3 million ordinary shares at an average repurchase price of $81.92 per share, for a total of $108.1 million.
XML 40 R19.htm IDEA: XBRL DOCUMENT v3.19.1
Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 30, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated other comprehensive income (loss) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):
 
Fair Value of Derivative Financial Instruments, net of tax
 
Foreign Currency Translation Adjustments
 
Post-Retirement and Pension Liability Adjustments, net of tax
 
Total AOCI
Balance at December 31, 2018
$
(15.5
)
 
$
104.5

 
$
(4.4
)
 
$
84.6

OCI before reclassifications
(1.2
)
 
(16.8
)
 
(0.5
)
 
(18.5
)
Amounts reclassified from AOCI
2.9

 
—

 
—

 
2.9

Other comprehensive loss
$
1.7

 
$
(16.8
)
 
$
(0.5
)
 
$
(15.6
)
Balance at March 30, 2019
$
(13.8
)
 
$
87.7

 
$
(4.9
)
 
$
69.0
XML 41 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes
 3 Months Ended
Mar. 30, 2019
Income Tax Disclosure [Abstract]  
Income taxes INCOME TAXES

The effective tax rates were as follows:
Three Months Ended
March 30,
2019
 
March 31,
2018
21.1
%
 
26.9
%


The effective tax rate for the three months ended March 30, 2019 decreased compared to the prior year period due primarily to additional valuation allowances recorded against deferred tax assets in the prior year.

Our tax rate is subject to adjustment over the balance of the calendar year due to, among other things, the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments based on differing interpretations of the applicable transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, Internal Revenue Service ("IRS") proposed regulations related to tax reform); changes in U.S. GAAP; and expiration of or the inability to renew tax rulings or tax holiday incentives.

We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the United States, Israel, Belgium, France, and the United Kingdom.

On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the IRS, plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017. The cumulative deferred charge as recorded on the balance sheet is $29.7 million lower than the amounts reflected above due to overpayments credited to succeeding years, such that the actual refund the company is seeking to receive will be reduced by that amount. In addition, we recently conceded a royalty due to Perrigo U.S. on all omeprazole sales that equates to a 24% of our refund claims and any omeprazole adjustments that may be asserted by the IRS for future years.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

On July 11, 2017, we received a draft notice of proposed adjustment associated with transfer pricing positions for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December
31, 2013. Athena was the originator of the patents associated with Tysabri® prior to the acquisition of Athena by Elan in 1996. In response to the draft notice of proposed adjustment, we provided the IRS with substantial additional documentation supporting our position. The amount of adjustments that may be asserted by the IRS in the final notice of proposed adjustment cannot be quantified at this time; however, based on the draft notice received, the amount to be assessed may be material. We disagree with the IRS’s position as asserted in the draft notice of proposed adjustment and intend to contest it. For subsequent developments refer to Note 16.

On October 31, 2018, we received an audit finding letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the years ended December 31, 2012 and December 31, 2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri® intellectual property and other assets related to Tysabri® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Amended Assessment (“NoA”) on November 29, 2018 which assesses an Irish corporation tax liability against Elan Pharma in the amount of €1,636 million, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA by Irish Revenue. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. If we are ultimately successful in the judicial review proceedings the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made, which could take up to, or more than, a year.

We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Ireland and other jurisdictions in Europe. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015 (which covers the period of the Elan transaction). The Israel Tax Authority's audit of our fiscal years ended June 29, 2013 and June 28, 2014 concluded with no material impact to the financial statements and the Israel Tax Authority is now auditing our fiscal years ended June 27, 2015, December 31, 2015, December 31, 2016 and December 31, 2017.

Tax Law Changes

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (“U.S. Tax Act”). The U.S. Tax Act includes a number of significant changes to existing U.S. tax laws that impact us. These changes include a corporate income tax rate reduction from 35% to 21% and the elimination or reduction of certain U.S. deductions and credits including limitations on the U.S. deductibility of interest expense and executive compensation. The U.S. Tax Act also transitions the U.S. taxation of international earnings from a worldwide system to a modified territorial system. These changes were effective beginning in 2018. The U.S. Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated U.S. owned foreign corporations’ previously untaxed foreign earnings (“Transition Toll Tax”). We paid our full Transition Toll Tax liability as of December 31, 2018.

On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of the U.S. GAAP ASC 740 income tax accounting for tax law changes enacted in the U.S. during 2017, in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the U.S. Tax Act. In accordance with SAB 118, for the year ended December 31, 2017, we recorded an income tax benefit of $2.4 million in connection with the remeasurement of certain deferred tax assets and liabilities and also recorded a $17.5 million increase of current tax expense in connection with the Transition Toll Tax on cumulative U.S. owned foreign earnings of $1.2 billion. For the year ended December 31, 2018, we completed the accounting for the income tax effects of the U.S. Tax Act. Based on additional guidance issued by the IRS and updates to our calculations we recorded a benefit of $6.3 million related to the Transition Toll Tax. There were no other material changes to the amounts recorded at December 31, 2017. We also finalized the provisional estimate related to our assertion on unremitted earnings of foreign subsidiaries recording an additional deferred tax liability of $8.3 million for the state income tax impacts of repatriating undistributed foreign earnings.

The U.S. Tax Act subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We have elected an accounting policy to provide for the tax expense related to GILTI in the year the tax is incurred ("period cost method"). At December 31, 2018, we made a reasonable estimate of the tax effect of a GILTI inclusion for 2018 and recorded additional tax expense of $9.4 million, net of U.S. foreign tax credits. In 2018, we had no tax expense resulting from the base erosion anti-avoidance tax ("BEAT") in 2018 and recorded an immaterial tax benefit for deductions related to foreign-derived intangible income ("FDII").

On January 1, 2019, we adopted ASU 2018-02 Income Statement - Reporting Comprehensive Income. Upon adoption, we did not elect to reclassify the income tax effects of the U.S. Tax Cuts and Jobs Act from AOCI to Retained earnings (accumulated deficit).
XML 42 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Contingencies
 3 Months Ended
Mar. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Contingencies CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of March 30, 2019, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to, individually or in the aggregate, have a material adverse effect on our financial condition, results of operations, or cash flows. 

Price-Fixing Lawsuits

We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs and/or allocate customers starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The same class plaintiffs have filed complaints naming us as a co-defendant, along with 27 other manufacturers, alleging an overarching conspiracy to fix or raise the prices of 15 generic prescription pharmaceutical products starting in 2011. Perrigo manufactures only two of the products at issue, Nystatin cream and Nystatin ointment.

We have also been named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. The only allegations specific to us relate to Clobetasol, Desonide, Econazole, and Nystatin.

On August 3, 2018, a large managed care organization filed a complaint against us alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to us concern Clobetasol, Desonide, Econazole, and Nystatin cream/ointment.

Most recently, on January 16, 2019, a similar suit was brought by a health insurance carrier in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to us concern Clobetasol, Desonide, Econazole, and Nystatin cream/ointment.

Certain complaints listed above were amended in December 2017, January 2018, and April 2019. All of the above complaints have been consolidated for pretrial proceedings, along with complaints filed against other companies alleging price fixing with respect to more than two dozen other drugs, as part of a case captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 in the U.S. District Court for the Eastern District of Pennsylvania.

Pursuant to the court’s schedule staging various cases in phases, we moved to dismiss the complaints relating to Clobetasol and Econazole. The court issued a decision denying the motions in part in October 2018 and issued a second decision in February 2019 dismissing various state law claims, but allowing other state law claims to proceed. We filed answers to the Clobetasol complaints on December 31, 2018. We filed answers to the Desonide and Econazole complaints on March 15, 2019.

Motions to dismiss certain other complaints listed above were filed on February 21, 2019. Plaintiffs’ oppositions are due on May 2, 2019. Deposition discovery is currently stayed for all cases, but documentary discovery is proceeding. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.

Securities Litigation
 
In the United States (cases related to events in 2015-2017)

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders - shareholders who purchased shares during the period April 21, 2015 through May 3, 2017 on the U.S. exchanges; shareholders who purchased shares during the same period on the Tel Aviv exchange; and shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares.The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition and the alleged price fixing activities
with respect to six generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation has begun. We intend to defend the lawsuit vigorously.

On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Carmignac Gestion, S.A. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On January 16, 2018, Manning & Napier Advisors, LLC filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Manning & Napier Advisors, LLC v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5) and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On January 26, 2018, two different plaintiff groups (the Mason Capital group and the Pentwater group) each filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). The same law firm represents these two plaintiff groups, and the two complaints are substantially similar. These two cases are not securities class actions. One case is styled Mason Capital L.P., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The other case is styled Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al., and also was filed in the U.S. District Court for the District of New Jersey. Both cases are assigned to the same federal judge that is hearing the class action case and the other individual cases described above (Carmignac and Manning & Napier). Each complaint asserts claims under Securities Exchange Act sections 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the factual
allegations in these two cases overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the Carmignac case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to these cases conferred about how these cases should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in these cases. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuits vigorously.

On February 13, 2018, a group of plaintiff investors affiliated with Harel Insurance Investments & Financial Services, Ltd. filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). This lawsuit is not a securities class action. The new complaint is substantially similar to the amended complaint in the Roofers' Pension Fund case. The relevant period in the new complaint stretches from February 2014 to May 2, 2017. The complaint adds as defendants two individuals who served on our Board prior to 2016. The case is styled Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action cases and the four other individual cases described above (Carmignac, Manning & Napier, Mason Capital, and Pentwater). The Harel Insurance Company complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule 10b‑5) and section 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. The complaint also asserts claims based on Israeli securities laws. In general, the plaintiffs' allegations describe events during the period from February 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset from February 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the four opt out cases also described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On February 16, 2018, First Manhattan Company filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled First Manhattan Co. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the five other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. This lawsuit was filed by the same law firm that filed the Manning & Napier Advisors case and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier Advisors case. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. On April 20, 2018, the plaintiff filed an amended complaint that did not materially change the factual allegations of the original complaint. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On April 20, 2018, a group of plaintiff investors affiliated with TIAA-CREF filed a lawsuit against us and the same individuals who are the defendants in the Harel Insurance case complaint. This lawsuit is not a securities class action. The law firm representing the plaintiffs in the Harel Insurance case also represents the TIAA-CREF plaintiff entities in this case, and the new complaint is substantially similar to the Harel Insurance complaint. The relevant period in the new complaint is August 14, 2014 to May 2, 2017 inclusive. The case is styled TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action case and the six other individual cases described above (Carmignac, Manning & Napier, Mason Capital, Pentwater, Harel Insurance, and First Manhattan). The TIAA-CREF Investment Management complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule l0b-5), section 14(e) (related to tender offer disclosures) against all defendants as well as section 20(a) control person liability against the individual defendants. In general, plaintiffs' allegations describe events during the period from August 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset from August 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On October 29, 2018, Nationwide Mutual Funds and Nationwide Variable Insurance Trust (both on behalf of several fund series) filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the seven other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the First Manhattan case, the Manning & Napier Advisors case, and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. The defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Westchester Capital Funds filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P. case and the Pentwater Equity Opportunities Master Fund Ltd. case (described above) represents the affiliates of the Westchester Funds in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital and in the Pentwater cases described above. The case is styled WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The WCM case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the eight other individual cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5) and 14(e) against all defendants as well as 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 as well us up through May 3, 2017. Plaintiffs identify disclosures concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing
activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Hudson Bay Capital Management LP filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P., the Pentwater Equity Opportunities Master Fund Ltd., and the WCM cases (described above) represents the affiliates of Hudson Bay Capital Management in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital, in the Pentwater, and in the WCM cases described above. The case is styled Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The Hudson Bay Fund case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the nine other individual cases described above. The complaint asserts claims under Securities Exchange Act section 14(e) against all defendants and section 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On January 31, 2019, Schwab Capital Trust and a variety of other Schwab entities filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Schwab Capital Trust, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the ten other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, and the Nationwide Mutual Funds case described above and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending in the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual cases described above. We intend to defend the lawsuit vigorously.

On February 6, 2019, OZ Master Fund, Ltd. and a related entity filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the eleven other opt out cases described above. The complaint asserts claims under Securities Exchange Act
sections 10(b) (and SEC Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties have submitted an agreed stipulation to the court regarding a proposed schedule and are awaiting the court’s approval. We intend to defend the lawsuit vigorously.

On February 14, 2019, Highfields Capital I LP and related entities filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Highfields Capital I LP, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of Massachusetts. The complaint asserts claims under Securities Exchange Act sections 14(e) and 18 against all defendants, as well as 20(a) control person liability against the individual defendants. The complaint also asserts Massachusetts state law claims under Massachusetts Unfair Business Methods Law (chapter 93A § 11), and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged improper accounting for the Tysabri® asset. Some of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above and with allegations in one or more of the opt out cases described above. Plaintiffs do not provide a clear calculation of how they estimated damages and seek treble damages, punitive damages, and attorney's fees. On May 7, 2019, defendants filed a motion to transfer this case to the U.S. District Court for the District of New Jersey so that the proceedings in this case can be coordinated with the other cases (discussed above) pending in that court. We intend to defend the lawsuit vigorously.

On February 22, 2019, Aberdeen Canada Funds -- Global Equity Funds (and 30 other entities, some unrelated to Aberdeen) filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the twelve other opt-out cases pending in that Court. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5) against all defendants and 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged undisclosed pricing pressure for generic prescription pharmaceuticals, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, the Nationwide Mutual Funds case, and the Schwab Capital Trust case described above, and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual Funds cases described above. The plaintiff does not provide an estimate of damages. We intend to defend the lawsuit vigorously.

In Israel (cases related to events in 2015-2017)

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. Three cases were filed; one was voluntarily dismissed in each of 2017 and 2018 and one was stayed in 2018. We are consulting Israeli counsel about our response to these allegations and we intend to defend this case vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst & Young LLP ("EY") (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = 0.28 cents). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the Roofers’ Pension Fund case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.

In the United States (cases related to Irish Tax events)

On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (Masih v. Perrigo Company, et al.). Plaintiff purports to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contend that the Company, in its Form 10‑Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff does not provide an estimate of class damages. The Court has selected lead plaintiffs and changed the name of the case to In re Perrigo Company plc Sec. Litig. The lead plaintiffs filed an amended complaint on April 12, 2019, which names the same defendants, asserts the same class period, and invokes the same Exchange Act sections. The amended complaint generally repeats the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. We intend to defend the lawsuit vigorously.

In Israel (cases related to Irish Tax events)

On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our CFO Ronald Winowiecki in Tel Aviv District Court (Baton v. Perrigo Company plc, et. al.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the In re Perrigo Company plc Sec. Litig case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. We filed a request for a stay, the plaintiff agreed in part, and the court approved a stay and required the parties to update the court about the U.S. proceedings by September 1, 2019. We intend to defend the lawsuit vigorously.

Eltroxin

During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by our subsidiary, Perrigo Israel Agencies Ltd. The respondents included our subsidiaries, Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel.

One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.

Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd.

On June 16, 2015, we submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. We have filed our statement of defense to the underlying proceedings. The underlying proceedings have been stayed pending the outcome of the mediation process and, if necessary, a decision on the motion to appeal.

On November 14, 2017 the parties submitted an agreed settlement agreement to the approval of the Supreme Court, which referred the approval back to the District Court. During three hearings that took place on November 29, 2017, December 13, 2017 and January 11, 2018, the District Court opined that it would approve the settlement agreement subject to certain amendments to be proposed by the court (which would not impact the monetary settlement reached) and set a hearing for January 30, 2018 to discuss and finalize the proposed changes. Meanwhile, the Court ordered the settlement to be (1) provided to the Attorney General ("AG") for review (standard procedure); and (2) published in the written media (newspapers), to enable the class members to submit any objections or “opt-out” to  the proposed settlement by February 15, 2018.

On February 21, 2018, the District Court held a hearing to, among other things, review objections received from class members who had notified the District Court of their desire to opt out of the settlement. In addition, a representative of the AG's office notified the District Court that, based upon their preliminary examination of the settlement, they intend to object to the settlement in its current form. The District Court recommended that the parties continue to discuss and minimize objections to the settlement and scheduled another hearing for May 13, 2018.
    
The District Court Justice was appointed as a Supreme Court Justice and ordered to move the case to a different panel. In an effort to reach a decision before the appointment, an additional hearing was held on March 12, 2018 in which the court urged the parties to try and exhaust their negotiations to the fullest and provide an update by May 13, 2018. In addition, the Court ordered the AG to submit its opinion to the settlement agreement by May 30, 2018, which was extended until July 23, 2018.

On August 2, 2018, the AG submitted its objection to the settlement, noting, among other things, that it did not provide compensation for harm to autonomy. On August 12, 2018, we submitted our response to the Attorney General's objection together with an amended settlement which incorporated the court's comments.  Following the submission of the amended settlement agreement on August 23, 2018, the District Court rendered a decision that it will be willing to approve the amended settlement agreement providing that a few additional amendments will be made. Both parties agreed to carry out the requested amendments. On September 13, 2018, the AG filed a request to file a response to the amended settlement agreement and asked for an extension to file a response until
November 11, 2018, which was granted by the court. On November 11, 2018 the AG asked and was granted another ten days extension to file a response. On November 21, 2018 the AG filed its response in which he mainly repeated his previous objection to the settlement claiming that the settlement amount does not provide a suitable compensation for harm to the autonomy and that the mechanism payment is complex and will deter patients from receiving appropriate compensation for pain and suffering. The AG repeated his opinion that each member of the group should be compensated for harm to the autonomy while claiming a minimum amount of 250 NIS should be provided for each patient. In addition, the AG detailed an alternative mechanism and list of categories that he asserts would be a better and less complex solution to provide the compensation amount.

On November 29, 2018, the court approved the Eltroxin settlement agreement. In a lengthy decision, the court detailed the various aspects of the settlement as well as the objections submitted to the settlement, including the main objection submitted by the AG. The court added a number of comments ordering the parties to make minor changes to the agreement, mainly concerning the operation of the mechanism, however none of the agreement foundations are affected by these changes. The court found that the settlement is "worthwhile, reasonable and fair" and ordered its publication and approval.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV ("Holdco") (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo has recently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issue recently disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have a further basis for its counterclaim against Perrigo. The proposed additional counterclaim theory does not appear to increase any damages sought. The Tribunal has not decided whether to grant Alychlo permission to introduce the additional counterclaim. There can be no assurance that our Claim will be successful, and the Sellers deny liability for the Claim. We deny that Alychlo is entitled to any relief (including monetary relief) under either the existing counterclaim or the proposed additional counterclaim theory.
 The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.

Other Matters

Our Board of Directors received a shareholder demand letter dated October 30, 2018 relating to the allegations in the securities cases and price fixing lawsuits described above. The letter demands that the Board of Directors initiate an action against certain current and former executives and Board members to recover damages allegedly caused to the Company. In response, the Company reminded the shareholder that any derivative claim can only proceed in accordance with Irish law, the law that governs the Company’s internal affairs. The shareholder has responded that he intends to file a lawsuit asserting derivative claims but has not yet filed a lawsuit.
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Charges
 3 Months Ended
Mar. 30, 2019
Restructuring Charges [Abstract]  
Restructuring charges RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and asset impairments. The following reflects our restructuring activity (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
24.0

 
$
21.4

Additional charges
5.9

 
1.5

Payments
(9.0
)
 
(10.8
)
Non-cash adjustments
(0.4
)
 
0.3

Ending balance
$
20.5

 
$
12.4



The charges incurred during the three months ended March 30, 2019 were primarily associated with the reorganization of our executive management team. There were no other material restructuring programs that significantly impacted any individual segment for the three months ended March 30, 2019 or March 31, 2018. All charges are recorded in Restructuring expense on the Condensed Consolidated Financial Statements. The remaining $20.5 million liability for employee severance benefits and lease exit costs is expected to be paid within the next year.
XML 44 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Information
 3 Months Ended
Mar. 30, 2019
Segment Reporting [Abstract]  
Segment information SEGMENT INFORMATION
    
Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company.

The below tables show select financial measures by reporting segment (in millions):
 
 
Total Assets
 
 
March 30,
2019
 
December 31,
2018
CSCA
 
$
3,704.6

 
$
3,571.7

CSCI
 
4,597.8

 
4,613.0

RX
 
2,817.1

 
2,798.7

Total
 
$
11,119.5

 
$
10,983.4

 
Three Months Ended
 
March 30, 2019
 
March 31, 2018
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CSCA
$
581.8

 
$
94.2

 
$
10.1

 
$
601.6

 
$
118.6

 
$
15.2

CSCI
350.8

 
8.1

 
44.1

 
377.8

 
12.3

 
51.1

RX
241.9

 
60.6

 
21.2

 
237.6

 
61.2

 
20.9

Unallocated
—

 
(60.6
)
 
—

 
—

 
(35.8
)
 
—

Total
$
1,174.5

 
$
102.3

 
$
75.4

 
$
1,217.0

 
$
156.3

 
$
87.2
XML 45 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Subsequent Events
 3 Months Ended
Mar. 30, 2019
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS

Notice of Proposed Adjustment

On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of
Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on Perrigo’s liquidity and capital resources (refer to Note 12).

Animal Health Divestiture

On May 8, 2019, we signed a definitive agreement for the sale of our animal health business to PetIQ for $185.0 million in cash, plus a working capital adjustment. We expect to finalize the sale within the next six months. The divestiture of this business is not expected to have a material impact on our operations or financial results.

Ranir Global Holdings, LLC

On May 8, 2019, we reached a definitive agreement to purchase privately-held Ranir Global Holdings, LLC (“Ranir”) in a transaction valued at $750.0 million on a cash-free, debt-free basis. We intend to fund the transaction with approximately $450.0 million of cash on hand and the balance through short-term debt. Headquartered in Grand Rapids, Michigan, Ranir is a leading global supplier of private label and branded oral care products. The transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. The proposed transaction, which has been unanimously approved by both our and Ranier's boards of directors, is subject to the satisfaction of closing conditions, including customary regulatory approvals. The transaction is expected to close during the third quarter of calendar year 2019.
XML 46 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 30, 2019
Accounting Policies [Abstract]  
Basis of presentation Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Principles of consolidation all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Recently Issued Accounting Standards Recent Accounting Standard Pronouncements
    
Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract
 
This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement
 
This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.
 
January 1, 2020
 
We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606
 
This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans
 
This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.
 
December 31, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
Derivatives instruments and hedging On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2018 and the year ended December 31, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.

Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in Other (income) expense, net on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of:

•
Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and

•
Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.

Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We recognized all changes in fair value of the excluded components in Other (income) expense, net, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and Retained earnings (accumulated deficit) from applying this policy on existing hedges at the date of adoption was immaterial.

We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to Note 5). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.

Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of March 30, 2019 and December 31, 2018.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is 18 months.

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.
    
All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.
Leases We adopted ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.
 
We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider
renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven, or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
XML 47 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 30, 2019
Accounting Policies [Abstract]  
Schedule of New Accounting Pronouncements As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.
Recently Issued Accounting Standards Not Yet Adopted
Standard
 
Description
 
Effective Date
 
Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract
 
This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement
 
This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.
 
January 1, 2020
 
We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2017-04 Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
 
The objective of this update is to reduce the cost and complexity of subsequent goodwill accounting and simplify the impairment test by removing the Step 2 requirement to perform a hypothetical purchase price allocation when the carrying value of a reporting unit exceeds its fair value. If a reporting unit’s carrying value exceeds its fair value, an entity would record an impairment charge based on that difference, limited to the amount of goodwill attributed to that reporting unit. This will not change the guidance on completing Step 1 of the goodwill impairment test and would be applied prospectively. Early adoption is permitted.
 
January 1, 2020
 
We currently plan to adopt the standard prospectively on the effective date. Upon adoption, we will no longer be required to calculate the implied fair value of goodwill to measure a goodwill impairment. Rather, a Step 1 failure will result in an immediate impairment charge based on the carrying value of the reporting unit.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

ASU 2018-19 Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments
 
This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606
 
This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.
 
January 1, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans
 
This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.
 
December 31, 2020
 
We are currently evaluating the implications of adoption on our Consolidated Financial Statements.
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 30, 2019
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue We generated net sales in the following geographic locations(1) (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
U.S.
$
768.8

 
$
786.4

Europe(2)
340.9

 
361.9

All other countries(3)
64.8

 
68.7

 
$
1,174.5

 
$
1,217.0


(1) Derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $5.2 million and $5.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively.
(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
CSCA(1)
 
 
 
Cough/cold/allergy/sinus
$
132.6

 
$
141.5

Gastrointestinal
100.3

 
92.2

Infant nutritionals
96.0

 
103.4

Analgesics
88.8

 
93.7

Smoking cessation
66.8

 
65.9

Animal health
19.6

 
26.3

Vitamins, minerals and dietary supplements
3.4

 
3.0

Other CSCA(2)
74.3

 
75.6

Total CSCA
581.8

 
601.6

CSCI
 
 
 
Cough/cold/allergy/sinus
95.7

 
98.7

Lifestyle
81.5

 
89.7

Personal care and derma-therapeutics
66.0

 
75.6

Natural health and vitamins, minerals and dietary supplements
29.8

 
33.2

Anti-parasites
26.7

 
28.1

Other CSCI(3)
51.1

 
52.5

Total CSCI
350.8

 
377.8

Total RX
241.9

 
237.6

Total net sales
$
1,174.5

 
$
1,217.0


(1)    Includes net sales from our OTC contract manufacturing business.
(2)
Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3)
Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
Contract with Customer Balances The following table provides information about contract assets from contracts with customers (in millions):
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Short-term contract assets
Prepaid expenses and other current assets
 
$
18.1

 
$
25.5
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets (Tables)
 3 Months Ended
Mar. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
 
 
December 31,
2018
 
Currency Translation Adjustments
 
March 30,
2019
CSCA(1)
 
$
1,713.7

 
$
1.2

 
$
1,714.9

CSCI(2)
 
1,151.3

 
(17.7
)
 
1,133.6

RX
 
1,114.8

 
2.9

 
1,117.7

Total goodwill
 
$
3,979.8

 
$
(13.6
)
 
$
3,966.2



(1)
We had accumulated impairments of $24.5 million and $161.2 million for the three months ended March 31, 2018 and March 30, 2019, respectively.
(2)
We had accumulated impairments of $868.4 million for the three months ended March 31, 2018 and March 30, 2019.
Schedule of finite and indefinite-lived intangible assets Intangible assets and related accumulated amortization consisted of the following (in millions):
 
March 30, 2019
 
December 31, 2018
 
Gross
 
Accumulated
Amortization
 
Gross
 
Accumulated
Amortization
Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks, trade names, and brands
$
18.5

 
$
—

 
$
18.1

 
$
—

In-process research and development
14.3

 
—

 
31.2

 
—

Total indefinite-lived intangibles
$
32.8

 
$
—

 
$
49.3

 
$
—

Definite-lived intangibles:
 
 
 
 
 
 
 
Distribution and license agreements and supply agreements
$
180.4

 
$
101.9

 
$
178.6

 
$
99.0

Developed product technology, formulations, and product rights
1,333.1

 
686.0

 
1,318.8

 
654.6

Customer relationships and distribution networks
1,562.5

 
587.6

 
1,586.6

 
566.5

Trademarks, trade names, and brands
1,257.8

 
201.3

 
1,282.4

 
188.5

Non-compete agreements
12.6

 
11.7

 
12.9

 
11.8

Total definite-lived intangibles
$
4,346.4

 
$
1,588.5

 
$
4,379.3

 
$
1,520.4

Total intangible assets
$
4,379.2

 
$
1,588.5

 
$
4,428.6

 
$
1,520.4
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories (Tables)
 3 Months Ended
Mar. 30, 2019
Inventory Disclosure [Abstract]  
Schedule of inventory, current Major components of inventory were as follows (in millions): 
 
March 30,
2019
 
December 31,
2018
Finished goods
$
474.0

 
$
444.9

Work in process
199.3

 
197.5

Raw materials
239.6

 
235.6

Total inventories
$
912.9

 
$
878.0
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring and Nonrecurring Basis The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
 
 
March 30, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
Measured at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Investment securities
 
$
3.7

 
$
—

 
$
—

 
$
9.4

 
$
—

 
$
—

Foreign currency forward contracts
 
—

 
3.2

 
—

 
—

 
3.8

 
—

Funds associated with Israeli severance liability
 
—

 
13.4

 
—

 
—

 
13.0

 
—

Royalty Pharma contingent milestone payments
 
—

 
—

 
83.6

 
—

 
—

 
323.2

Total assets
 
$
3.7

 
$
16.6

 
$
83.6

 
$
9.4

 
$
16.8

 
$
323.2

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
Foreign currency forward contracts
 
$
—

 
$
5.8

 
$
—

 
$
—

 
$
9.2

 
$
—

Contingent consideration
 
—

 
—

 
12.4

 
—

 
—

 
15.3

Total liabilities
 
$
—

 
$
5.8

 
$
12.4

 
$
—

 
$
9.2

 
$
15.3

 
 
 
 
 
 
 
 
 
 
 
 
 
Measured at fair value on a non-recurring basis:
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill(1)
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
42.2

Indefinite-lived intangible assets(2)
 
—

 
—

 
—

 
—

 
—

 
10.5

Definite-lived intangible assets(3)
 
—

 
—

 
—

 
—

 
—

 
22.4

Total assets
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
75.1



(1)
As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.
(2)
As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.
(3)
As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
323.2

 
$
134.5

Payments received
(250.0
)
 
—

Change in fair value
10.4

 
(9.6
)
Ending balance
$
83.6

 
$
124.9
Reconciliation of Level 3 Liabilities The table below summarizes the change in fair value of contingent consideration (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
15.3

 
$
22.0

Changes in value
1.2

 
0.4

Currency translation adjustments
—

 
0.1

Settlements and other adjustments
(4.1
)
 
(4.4
)
Ending balance
$
12.4

 
$
18.1
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Our fixed rate long-term debt consisted of the following (in millions):
 
March 30,
2019
 
December 31,
2018
 
Level 1
 
Level 2
 
Level 1
 
Level 2
Public Bonds
 
 
 
 
 
 
 
Carrying Value (excluding discount)
$
2,600.0

 
 
 
$
2,600.0

 
 
Fair value
$
2,472.0

 
 
 
$
2,316.6

 
 
 
 
 
 
 
 
 
 
Retail bond and private placement note
 
 
 
 
 
 
 
Carrying value (excluding premium)
 
 
$
286.1

 
 
 
$
292.5

Fair value
 
 
$
301.9

 
 
 
$
307.9
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Investments (Tables)
 3 Months Ended
Mar. 30, 2019
Investments [Abstract]  
Equity securities The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):
Measurement Category
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Fair value method
 
Prepaid expenses and other current assets
 
$
3.7

 
$
9.4

Fair value method(1)
 
Other non-current assets
 
$
3.7

 
$
4.4

Equity method
 
Other non-current assets
 
$
15.8

 
$
15.1


(1)
Measured at fair value using the Net Asset Value practical expedient.
Equity security expense (income) The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):
 
 
 
 
Three Months Ended
Measurement Category
 
Income Statement Location
 
March 30,
2019
 
March 31,
2018
Fair value method
 
Other (income) expense, net
 
$
6.1

 
$
4.4

Equity method
 
Other (income) expense, net
 
$
(0.7
)
 
$
0.2
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities (Tables)
 3 Months Ended
Mar. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Foreign Currency Forward Contracts Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):
 
 
Notional Amount
 
 
March 30,
2019
 
December 31,
2018
Israeli Shekel (ILS)
 
$
290.1

 
$
232.6

British Pound (GBP)
 
107.1

 
90.2

European Euro (EUR)
 
103.1

 
134.2

Swedish (SEK)
 
76.4

 
38.7

Danish Krone (DKK)
 
52.8

 
56.5

United States Dollar (USD)
 
42.0

 
39.3

Canadian Dollar (CAD)
 
35.4

 
31.7

Polish Zloty (PLZ)
 
28.7

 
18.2

Chinese Yuan (CNY)
 
16.8

 
—

Norwegian Krone (NOK)
 
14.9

 
6.2

Romanian New Leu (RON)
 
4.7

 
4.4

Mexican Peso (MPX)
 
2.6

 
25.9

Other
 
8.7

 
8.7

Total
 
$
783.3

 
$
686.6
Schedule of derivative instruments in statement of financial position, fair value The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):
 
 
 
Asset Derivatives
 
 
 
Fair Value
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Prepaid expenses and other current assets
 
$
0.6

 
$
2.0

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Prepaid expenses and other current assets
 
$
2.6

 
$
1.8

 
 
 
Liability Derivatives
 
 
 
Fair Value
 
Balance Sheet Location
 
March 30,
2019
 
December 31,
2018
Designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
4.2

 
$
6.4

Non-designated derivatives:
 
 
 
 
 
Foreign currency forward contracts
Accrued liabilities
 
$
1.6

 
$
2.8
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):
 
 
Three months ended
 
 
March 30, 2019
Instrument
 
Amount of Gain/(Loss) Recorded in OCI(1)
 
Classification of Gain/(Loss) Reclassified from AOCI into Earnings
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
 
Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing
 
Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements
 
 
 
Interest expense, net
 
$
(0.4
)
 
Interest expense, net
 
$
—

Foreign currency forward contracts
 
$
(1.0
)
 
Net sales
 
0.2

 
Net sales
 
(0.1
)
 
 
 
 
Cost of sales
 
(1.3
)
 
Cost of sales
 
(1.1
)
 
 
 
 
 
 
$
(1.5
)
 
 
 
$
(1.2
)

(1) Net loss of $2.7 million is expected to be reclassified out of AOCI into earnings during the next 12 months.
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)
 
 
Three months ended
 
 
March 31, 2018
 
 
Effective Portion
Instrument
 
Amount of Gain/(Loss) Recorded in OCI
 
Classification of Gain/(Loss) Reclassified from AOCI into Earnings
 
Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements
 
 
 
Interest expense, net
 
$
(0.4
)
Foreign currency forward contracts
 
$
(0.2
)
 
Net sales
 
(0.1
)
 
 
 
 
Cost of sales
 
2.3

 
 
 
 
Interest expense, net
 
(1.0
)
 
 
 
 
Other (income) expense, net
 
(0.4
)
 
 
 
 
 
 
$
0.4
Amount of Gain/(Loss) Recognized against Earnings The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):
 
 
 
 
Three months ended
Non-Designated Derivatives
 
Income Statement
Location
 
March 30,
2019
 
March 31,
2018
Foreign currency forward contracts
 
Other (income) expense, net
 
$
(8.8
)
 
$
3.5

 
 
Interest expense, net
 
0.4

 
(0.9
)
Total
 
 
 
$
(8.4
)
 
$
2.6
Classification of Gain (Loss) Recognized in Earnings on Fair Value and Cash Flow Hedging Relationships The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):
 
 
Three months ended
 
 
March 30, 2019
 
 
Net Sales
 
Cost of Sales
 
Interest Expense, net
 
Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded
 
$
1,174.5

 
$
725.7

 
$
28.6

 
$
3.2

 
 
 
 
 
 
 
 
 
The effects of cash flow hedging:
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedging relationships
 
 
 
 
 
 
 
 
Foreign currency forward contracts
 
 
 
 
 
 
 
 
Amount of gain or (loss) reclassified from AOCI into earnings
 
$
0.2

 
$
(1.3
)
 
$
—

 
$
—

Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach
 
$
(0.1
)
 
$
(1.1
)
 
$
—

 
$
—

Interest rate swap agreements
 
 
 
 
 
 
 
 
Amount of gain or (loss) reclassified from AOCI into earnings
 
$
—

 
$
—

 
$
(0.4
)
 
$
—
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Leases (Tables)
 3 Months Ended
Mar. 30, 2019
Leases [Abstract]  
Balance Sheet Location of Lease Assets and Liabilities The balance sheet location of our lease assets and liabilities were as follows (in millions):
Assets
 
Balance Sheet Location
 
March 30,
2019
Operating
 
Operating lease assets
 
$
146.8

Finance
 
Other non-current assets
 
9.9

Total
 
 
 
$
156.7

Liabilities
 
Balance Sheet Location
 
March 30,
2019
Current
 
 
 
 
Operating
 
Accrued liabilities
 
$
34.8

Finance
 
Current indebtedness
 
1.9

Non-Current
 
 
 
 
Operating
 
Other non-current liabilities
 
116.4

Finance
 
Long-term debt, less current portion
 
4.7

Total
 
 
 
$
157.8

    
The below table shows our lease assets and liabilities by reporting segment (in millions):
 
 
Assets
 
Liabilities
 
 
Operating
 
Financing
 
Operating
 
Financing
 
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
 
March 30,
2019
CSCA
 
$
30.1

 
$
1.9

 
$
30.2

 
$
1.4

CSCI
 
43.5

 
6.1

 
44.4

 
3.3

RX
 
38.6

 
0.1

 
40.1

 
0.1

Unallocated
 
34.6

 
1.8

 
36.5

 
1.8

Total
 
$
146.8

 
$
9.9

 
$
151.2

 
$
6.6
Finance Lease Maturity The annual future maturities of our leases as of March 30, 2019 are as follows (in millions):
 
 
Operating Leases
 
Finance Leases
 
Total
2019
 
$
31.0

 
$
1.7

 
$
32.7

2020
 
33.1

 
1.6

 
34.7

2021
 
24.0

 
2.9

 
26.9

2022
 
18.1

 
0.5

 
18.6

2023
 
15.0

 
0.3

 
15.3

After 2023
 
53.4

 
—

 
53.4

Total lease payments
 
174.6

 
7.0

 
181.6

Less: Interest
 
23.4

 
0.4

 
23.8

Present value of lease liabilities
 
$
151.2

 
$
6.6

 
$
157.8
Operating Lease Liability Maturity The annual future maturities of our leases as of March 30, 2019 are as follows (in millions):
 
 
Operating Leases
 
Finance Leases
 
Total
2019
 
$
31.0

 
$
1.7

 
$
32.7

2020
 
33.1

 
1.6

 
34.7

2021
 
24.0

 
2.9

 
26.9

2022
 
18.1

 
0.5

 
18.6

2023
 
15.0

 
0.3

 
15.3

After 2023
 
53.4

 
—

 
53.4

Total lease payments
 
174.6

 
7.0

 
181.6

Less: Interest
 
23.4

 
0.4

 
23.8

Present value of lease liabilities
 
$
151.2

 
$
6.6

 
$
157.8
Lease Expense Lease expense was as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Operating leases(a)
 
$
12.0

 
 
 
Finance leases
 
 
Amortization
 
$
0.7

Interest
 
0.1

Total
 
$
0.8


(a) Includes short-term leases and variable lease costs, which are immaterial.
Weighted Average Lease Terms and Discount Rates Our weighted average lease terms and discount rates are as follows:
 
 
Three Months Ended
 
 
March 30,
2019
Weighted-average remaining lease term (in years)
 
 
Operating leases
 
6.81

Finance leases
 
2.59

Weighted-average discount rate
 
 
Operating leases
 
4.20
%
Finance leases
 
4.17
%
Leease Cash Flow Classifications Our lease cash flow classifications are as follows (in millions):
 
 
Three Months Ended
 
 
March 30,
2019
Cash paid for amounts included in the measurement of lease liabilities
 
 
Operating cash flows for operating leases
 
$
11.7

Operating cash flows for finance leases
 
$
0.1

Financing cash flows for finance leases
 
$
0.7

Leased assets obtained in exchange for new operating lease liabilities
 
$
4.7
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Indebtedness (Tables)
 3 Months Ended
Mar. 30, 2019
Debt Disclosure [Abstract]  
Schedule of debt Total borrowings outstanding are summarized as follows (in millions):
 
 
 
 
 
March 30,
2019
 
December 31,
2018
Term loans
 
 
 
 
 
 
2018 Term loan due March 8, 2020(1)
 
 
$
331.3

 
$
351.3

Notes and Bonds
 
 
 
 
 
 
Coupon
Due
 
 
 
 
 
 
5.000%
May 23, 2019(1)
 
 
134.6

 
137.6

 
3.500%
March 15, 2021
 
 
280.4

 
280.4

 
3.500%
December 15, 2021
 
 
309.6

 
309.6

 
5.105%
July 19, 2023(1)
 
 
151.5

 
154.9

 
4.000%
November 15, 2023
 
 
215.6

 
215.6

 
3.900%
December 15, 2024
 
 
700.0

 
700.0

 
4.375%
March 15, 2026
 
 
700.0

 
700.0

 
5.300%
November 15, 2043
 
 
90.5

 
90.5

 
4.900%
December 15, 2044
 
 
303.9

 
303.9

 
Total notes and bonds
 
 
2,886.1

 
2,892.5

Other financing
6.2

 
2.8

Unamortized premium (discount), net
9.8

 
12.2

Deferred financing fees
(15.6
)
 
(16.4
)
Total borrowings outstanding
3,217.8

 
3,242.4

 
Current indebtedness
(467.9
)
 
(190.2
)
Total long-term debt less current portion
$
2,749.9

 
$
3,052.2



(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.19.1
Earnings Per Share and Shareholders' Equity (Tables)
 3 Months Ended
Mar. 30, 2019
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Numerator:
 
 
 
Net income
$
63.9

 
$
80.8

 
 
 
 
Denominator:
 
 
 
Weighted average shares outstanding for basic EPS
135.9

 
140.8

Dilutive effect of share-based awards
0.3

 
0.6

Weighted average shares outstanding for diluted EPS
136.2

 
141.4

 
 
 
 
Anti-dilutive share-based awards excluded from computation of diluted EPS
2.1

 
0.7
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 30, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of accumulated other comprehensive income (loss) Changes in our AOCI balances, net of tax were as follows (in millions):
 
Fair Value of Derivative Financial Instruments, net of tax
 
Foreign Currency Translation Adjustments
 
Post-Retirement and Pension Liability Adjustments, net of tax
 
Total AOCI
Balance at December 31, 2018
$
(15.5
)
 
$
104.5

 
$
(4.4
)
 
$
84.6

OCI before reclassifications
(1.2
)
 
(16.8
)
 
(0.5
)
 
(18.5
)
Amounts reclassified from AOCI
2.9

 
—

 
—

 
2.9

Other comprehensive loss
$
1.7

 
$
(16.8
)
 
$
(0.5
)
 
$
(15.6
)
Balance at March 30, 2019
$
(13.8
)
 
$
87.7

 
$
(4.9
)
 
$
69.0
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes Income Taxes (Tables)
 3 Months Ended
Mar. 30, 2019
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation The effective tax rates were as follows:
Three Months Ended
March 30,
2019
 
March 31,
2018
21.1
%
 
26.9
%
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Charges (Tables)
 3 Months Ended
Mar. 30, 2019
Restructuring Charges [Abstract]  
Restructuring and related costs The following reflects our restructuring activity (in millions):
 
Three Months Ended
 
March 30,
2019
 
March 31,
2018
Beginning balance
$
24.0

 
$
21.4

Additional charges
5.9

 
1.5

Payments
(9.0
)
 
(10.8
)
Non-cash adjustments
(0.4
)
 
0.3

Ending balance
$
20.5

 
$
12.4
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Information (Tables)
 3 Months Ended
Mar. 30, 2019
Segment Reporting [Abstract]  
Schedule of segment reporting information, by segment The below tables show select financial measures by reporting segment (in millions):
 
 
Total Assets
 
 
March 30,
2019
 
December 31,
2018
CSCA
 
$
3,704.6

 
$
3,571.7

CSCI
 
4,597.8

 
4,613.0

RX
 
2,817.1

 
2,798.7

Total
 
$
11,119.5

 
$
10,983.4

 
Three Months Ended
 
March 30, 2019
 
March 31, 2018
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net
Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CSCA
$
581.8

 
$
94.2

 
$
10.1

 
$
601.6

 
$
118.6

 
$
15.2

CSCI
350.8

 
8.1

 
44.1

 
377.8

 
12.3

 
51.1

RX
241.9

 
60.6

 
21.2

 
237.6

 
61.2

 
20.9

Unallocated
—

 
(60.6
)
 
—

 
—

 
(35.8
)
 
—

Total
$
1,174.5

 
$
102.3

 
$
75.4

 
$
1,217.0

 
$
156.3

 
$
87.2
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Schedule of Revenue by Geographic Location (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Net sales [1] $ 1,174.5 $ 1,217.0
U.S.    
Disaggregation of Revenue [Line Items]    
Net sales [1] 768.8 786.4
Europe    
Disaggregation of Revenue [Line Items]    
Net sales [1],[2] 340.9 361.9
All other countries    
Disaggregation of Revenue [Line Items]    
Net sales [1],[3] 64.8 68.7
Ireland    
Disaggregation of Revenue [Line Items]    
Net sales $ 5.2 $ 5.4
[1] Derived from the location of the entity that sells to a third party.
[2] Includes Ireland net sales of $5.2 million and $5.4 million for the three months ended March 30, 2019 and March 31, 2018, respectively.
[3] Includes net sales generated primarily in Israel, Mexico, Australia and Canada.
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Net sales [1] $ 1,174.5 $ 1,217.0
CSCA    
Disaggregation of Revenue [Line Items]    
Net sales [2] 581.8 601.6
CSCA | Cough/Cold/Allergy/Sinus    
Disaggregation of Revenue [Line Items]    
Net sales [2] 132.6 141.5
CSCA | Gastrointestinal    
Disaggregation of Revenue [Line Items]    
Net sales [2] 100.3 92.2
CSCA | Infant nutritionals    
Disaggregation of Revenue [Line Items]    
Net sales [2] 96.0 103.4
CSCA | Analgesics    
Disaggregation of Revenue [Line Items]    
Net sales [2] 88.8 93.7
CSCA | Smoking cessation    
Disaggregation of Revenue [Line Items]    
Net sales [2] 66.8 65.9
CSCA | Animal health    
Disaggregation of Revenue [Line Items]    
Net sales [2] 19.6 26.3
CSCA | Vitamins, Minerals and Dietary Supplements    
Disaggregation of Revenue [Line Items]    
Net sales [2] 3.4 3.0
CSCA | Other CHCA    
Disaggregation of Revenue [Line Items]    
Net sales [2],[3] 74.3 75.6
CSCI    
Disaggregation of Revenue [Line Items]    
Net sales 350.8 377.8
CSCI | Cough, Cold, and Allergy    
Disaggregation of Revenue [Line Items]    
Net sales 95.7 98.7
CSCI | Lifestyle    
Disaggregation of Revenue [Line Items]    
Net sales 81.5 89.7
CSCI | Personal care and derma-therapeutics    
Disaggregation of Revenue [Line Items]    
Net sales 66.0 75.6
CSCI | Natural Health and Vitamins, Minerals and Dietary Supplements    
Disaggregation of Revenue [Line Items]    
Net sales 29.8 33.2
CSCI | Anti-Parasite    
Disaggregation of Revenue [Line Items]    
Net sales 26.7 28.1
CSCI | Other CHCI    
Disaggregation of Revenue [Line Items]    
Net sales [4] 51.1 52.5
RX    
Disaggregation of Revenue [Line Items]    
Net sales $ 241.9 $ 237.6
[1] Derived from the location of the entity that sells to a third party.
[2] Includes net sales from our OTC contract manufacturing business.
[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
[4] Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Net sales [1] $ 1,174.5 $ 1,217.0
Contract manufacturing    
Disaggregation of Revenue [Line Items]    
Net sales $ 67.3 $ 69.4
[1] Derived from the location of the entity that sells to a third party.
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Schedule of Contract Balances (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]    
Short-term contract assets $ 18.1 $ 25.5
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets - Goodwill (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Goodwill [Roll Forward]    
December 31, 2018 $ 3,979.8  
Currency Translation Adjustments (13.6)  
March 30, 2019 3,966.2  
CSCA    
Goodwill [Roll Forward]    
December 31, 2018 1,713.7  
Currency Translation Adjustments 1.2  
March 30, 2019 1,714.9  
Accumulated impairments (161.2) $ (24.5)
CSCI    
Goodwill [Roll Forward]    
December 31, 2018 1,151.3  
Currency Translation Adjustments (17.7)  
March 30, 2019 1,133.6  
Accumulated impairments (868.4) $ (868.4)
RX    
Goodwill [Roll Forward]    
December 31, 2018 1,114.8  
Currency Translation Adjustments 2.9  
March 30, 2019 $ 1,117.7  
XML 66 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets - Intangible categories (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Dec. 31, 2018
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Indefinite-lived intangibles: $ 32.8   $ 49.3
Gross 4,346.4   4,379.3
Accumulated Amortization 1,588.5   1,520.4
Total other intangible assets 4,379.2   4,428.6
Intangible assets amortization expense 75.4 $ 87.2  
Trademarks, trade names, and brands      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Indefinite-lived intangibles: 18.5   18.1
In-process research and development      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Indefinite-lived intangibles: 14.3   31.2
Impairment of indefinite lived intangible assets 4.1    
Distribution and license agreements and supply agreements      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Gross 180.4   178.6
Accumulated Amortization 101.9   99.0
Developed product technology, formulations, and product rights      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Gross 1,333.1   1,318.8
Accumulated Amortization 686.0   654.6
Customer relationships and distribution networks      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Gross 1,562.5   1,586.6
Accumulated Amortization 587.6   566.5
Trademarks and Trade Names [Member]      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Gross 1,257.8   1,282.4
Accumulated Amortization 201.3   188.5
Non-compete agreements      
Finite And Indefinite Lived Assets By Major Class [Line Items]      
Gross 12.6   12.9
Accumulated Amortization $ 11.7   $ 11.8
XML 67 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Dec. 31, 2018
Inventory Disclosure [Abstract]    
Finished goods $ 474.0 $ 444.9
Work in process 199.3 197.5
Raw materials 239.6 235.6
Total inventories $ 912.9 $ 878.0
XML 68 R47.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements - Financial Instruments at Fair Value (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Dec. 31, 2018
Measured at fair value on a non-recurring basis:    
Goodwill carrying amount $ 3,966.2 $ 3,979.8
Indefinite-lived intangible assets carrying value 32.8 49.3
Definite-lived intangible assets carrying value 2,757.9 2,858.9
Measured at fair value on a recurring basis | Level 1    
Assets:    
Investment securities 3.7 9.4
Foreign currency forward contracts 0.0 0.0
Funds associated with Israeli severance liability 0.0 0.0
Royalty Pharma contingent milestone payments 0.0 0.0
Total assets 3.7 9.4
Liabilities:    
Foreign currency forward contracts 0.0 0.0
Contingent consideration 0.0 0.0
Total liabilities 0.0 0.0
Measured at fair value on a recurring basis | Level 2    
Assets:    
Investment securities 0.0 0.0
Foreign currency forward contracts 3.2 3.8
Funds associated with Israeli severance liability 13.4 13.0
Royalty Pharma contingent milestone payments 0.0 0.0
Total assets 16.6 16.8
Liabilities:    
Foreign currency forward contracts 5.8 9.2
Contingent consideration 0.0 0.0
Total liabilities 5.8 9.2
Measured at fair value on a recurring basis | Level 3    
Assets:    
Investment securities 0.0 0.0
Foreign currency forward contracts 0.0 0.0
Funds associated with Israeli severance liability 0.0 0.0
Royalty Pharma contingent milestone payments 83.6 323.2
Total assets 83.6 323.2
Liabilities:    
Foreign currency forward contracts 0.0 0.0
Contingent consideration 12.4 15.3
Total liabilities 12.4 15.3
Measured at fair value on a non-recurring basis    
Measured at fair value on a non-recurring basis:    
Indefinite-lived intangible assets carrying value   46.9
Definite-lived intangible assets carrying value   72.0
Measured at fair value on a non-recurring basis | Level 1    
Assets:    
Total assets 0.0 0.0
Measured at fair value on a non-recurring basis:    
Goodwill 0.0 0.0
Indefinite-lived intangible assets 0.0 0.0
Definite-lived intangible assets 0.0 0.0
Measured at fair value on a non-recurring basis | Level 2    
Assets:    
Total assets 0.0 0.0
Measured at fair value on a non-recurring basis:    
Goodwill 0.0 0.0
Indefinite-lived intangible assets 0.0 0.0
Definite-lived intangible assets 0.0 0.0
Measured at fair value on a non-recurring basis | Level 3    
Assets:    
Total assets 0.0 75.1
Measured at fair value on a non-recurring basis:    
Goodwill 0.0 42.2 [1]
Indefinite-lived intangible assets 0.0 10.5 [2]
Definite-lived intangible assets 0.0 22.4 [3]
CSCA    
Measured at fair value on a non-recurring basis:    
Goodwill carrying amount $ 1,714.9 1,713.7
CSCA | Measured at fair value on a non-recurring basis    
Measured at fair value on a non-recurring basis:    
Goodwill carrying amount   $ 178.9
[1] (1)As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.
[2] (2)As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.
[3] (3)
As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.
XML 69 R48.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements - Additional Information (Details)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 30, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Transfers among level 1, 2, and 3 $ 0.0 $ 0.0      
Fair value adjustment   250.0      
Income recognized from change is asset 10.4 (9.6)      
Measured on a recurring basis | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Potential contingent milestone payments 83.6     $ 323.2  
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Increase (decrease) in fair value of milestone payment 10.4 (9.6)      
Estimated fair valued contingent milestone payment $ 83.6 $ 124.9   $ 323.2 $ 134.5
Royalty Pharma          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Rate of return 8.02% 8.08%      
Measurement Input, Price Volatility | Royalty Pharma          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Volatility rate assumed 0.300 0.300      
Measurement Input, Long-term Revenue Growth Rate | CSCA          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Reporting Unit, Discounted Cash Flow, Measurement Input       0.025  
Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input       (0.003)  
Measurement Input, Discount Rate | CSCA          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Reporting Unit, Discounted Cash Flow, Measurement Input       0.098  
Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input       0.098  
Measurement Input, Tax Rate | CSCA          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Reporting Unit, Discounted Cash Flow, Measurement Input       0.228  
Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input       0.228  
Scenario, Forecast          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Adjusted asset balance is prescribed threshold is exceeded     $ 400.0    
Scenario, Forecast | Royalty Pharma Contingent Milestone Payments          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Net sales threshold to trigger milestone payment     351.0    
Write-off of contingent milestone payment if sales threshold is not met     83.6    
Adjusted asset balance is prescribed threshold is exceeded     400.0    
Income recognized from change is asset     $ 316.4    
XML 70 R49.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Measured on a recurring basis - Level 3 - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Contingent consideration    
Contingent Consideration    
Beginning balance $ 15.3 $ 22.0
Changes in value 1.2 0.4
Foreign currency effect 0.0 0.1
Settlements and other adjustments (4.1) (4.4)
Ending balance 12.4 18.1
Royalty Pharma Contingent Milestone Payments    
Royalty Pharma Contingent Milestone Payments    
Beginning balance 323.2 134.5
Payments received (250.0) 0.0
Change in fair value 10.4 (9.6)
Ending balance $ 83.6 $ 124.9
XML 71 R50.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Public bonds $ 2,886.1 $ 2,892.5
Public bonds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Public bonds 2,472.0 2,316.6
Retail Bonds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Retail bond and private placement note 301.9 307.9
Reported Value Measurement | Public bonds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Public bonds 2,600.0 2,600.0
Reported Value Measurement | Retail Bonds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Retail bond and private placement note $ 286.1 $ 292.5
XML 72 R51.htm IDEA: XBRL DOCUMENT v3.19.1
Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Dec. 31, 2018
Jan. 01, 2018
Other (income) expense, net        
Schedule of Equity Method Investments [Line Items]        
Equity securities, fair value method, other expense (income) $ 6.1 $ 4.4    
Equity securities, equity method, other expense (income) (0.7) $ 0.2    
Prepaid expenses and other current assets        
Schedule of Equity Method Investments [Line Items]        
Equity securities, fair value method 3.7   $ 9.4  
Other non-current assets        
Schedule of Equity Method Investments [Line Items]        
Equity securities, fair value method [1] 3.7   4.4  
Equity securities, equity method, other non-current assets $ 15.8   $ 15.1  
Retained Earnings (Accumulated Deficit) | ASU 2016-01        
Schedule of Equity Method Investments [Line Items]        
Reclassification to retained earnings       $ 1.0
[1] (1) Measured at fair value using the Net Asset Value practical expedient.
XML 73 R52.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) - Foreign currency forward contracts - USD ($)
$ in Millions
Mar. 30, 2019
Dec. 31, 2018
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives $ 783.3 $ 686.6
Israeli Shekel (ILS)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 290.1 232.6
British Pound (GBP)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 107.1 90.2
European Euro (EUR)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 103.1 134.2
Swedish (SEK)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 76.4 38.7
Danish Krone (DKK)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 52.8 56.5
United States Dollar (USD)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 42.0 39.3
Canadian Dollar (CAD)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 35.4 31.7
Polish Zloty (PLZ)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 28.7 18.2
Chinese Yuan (CNY)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 16.8 0.0
Norwegian Krone (NOK)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 14.9 6.2
Romanian New Leu (RON)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 4.7 4.4
Mexican Peso (MPX)    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives 2.6 25.9
Other    
Foreign Currency Fair Value Hedge Derivative [Line Items]    
Notional amount of derivatives $ 8.7 $ 8.7
XML 74 R53.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) - Foreign currency forward contracts - USD ($)
$ in Millions
Mar. 30, 2019
Dec. 31, 2018
Designated derivatives: | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Asset Derivatives $ 0.6 $ 2.0
Designated derivatives: | Accrued liabilities    
Derivatives, Fair Value [Line Items]    
Liability Derivatives 4.2 6.4
Non-designated derivatives: | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 2.6 1.8
Non-designated derivatives: | Accrued liabilities    
Derivatives, Fair Value [Line Items]    
Liability Derivatives $ 1.6 $ 2.8
XML 75 R54.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2019
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings $ (1.5)
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net (1.2)
Net gain expected to be reclassified out of AOCI into earnings in the next 12 months (2.7)
Interest expense, net  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements (0.4)
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts 0.0
Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness 0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach 0.0
Net Sales  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements 0.0
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts 0.2
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach (0.1)
Cost of sales  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements 0.0
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts (1.3)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach (1.1)
Foreign currency forward contracts  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Amount of Gain/(Loss) Recorded in OCI $ (1.0)
XML 76 R55.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2018
USD ($)
Foreign currency forward contracts  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Recorded in OCI (Effective Portion) $ (0.2)
Designated derivatives:  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) 0.4
Designated derivatives: | Interest expense, net | Interest Rate Swap  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) (0.4)
Designated derivatives: | Interest expense, net | Foreign currency forward contracts  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) (1.0)
Designated derivatives: | Net sales | Foreign currency forward contracts  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) (0.1)
Designated derivatives: | Cost of sales | Foreign currency forward contracts  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) 2.3
Designated derivatives: | Other (income) expense, net | Foreign currency forward contracts  
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]  
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion) $ (0.4)
XML 77 R56.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) - Non-designated derivatives: - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain/(Loss) Recognized against Earnings $ (8.4) $ 2.6
Foreign currency forward contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain/(Loss) Recognized against Earnings (8.8) 3.5
Foreign currency forward contracts | Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain/(Loss) Recognized against Earnings $ 0.4 $ (0.9)
XML 78 R57.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]    
Net sales [1] $ 1,174.5 $ 1,217.0
Cost of sales 725.7 724.3
Interest expense, net 28.6 31.4
Other (income) expense, net 3.2 $ 4.3
Net Sales    
Foreign currency forward contracts    
Amount of gain or (loss) reclassified from AOCI into earnings 0.2  
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach (0.1)  
Interest rate swap agreements    
Amount of gain or (loss) reclassified from AOCI into earnings 0.0  
Cost of sales    
Foreign currency forward contracts    
Amount of gain or (loss) reclassified from AOCI into earnings (1.3)  
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach (1.1)  
Interest rate swap agreements    
Amount of gain or (loss) reclassified from AOCI into earnings 0.0  
Interest expense, net    
Foreign currency forward contracts    
Amount of gain or (loss) reclassified from AOCI into earnings 0.0  
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach 0.0  
Interest rate swap agreements    
Amount of gain or (loss) reclassified from AOCI into earnings (0.4)  
Other (income) expense, net    
Foreign currency forward contracts    
Amount of gain or (loss) reclassified from AOCI into earnings 0.0  
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach 0.0  
Interest rate swap agreements    
Amount of gain or (loss) reclassified from AOCI into earnings $ 0.0  
[1] Derived from the location of the entity that sells to a third party.
XML 79 R58.htm IDEA: XBRL DOCUMENT v3.19.1
Leases (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Jan. 01, 2019
Dec. 31, 2018
Leases [Abstract]      
Lease liabilities $ 151.2 $ 166.5  
Lease assets $ 146.8 $ 164.0 $ 0.0
XML 80 R59.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Balance Sheet Location of Assets and Liabilities (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Jan. 01, 2019
Dec. 31, 2018
Lessee, Lease, Description [Line Items]      
Operating lease assets $ 146.8 $ 164.0 $ 0.0
Finance leases 9.9    
Right-of-Use Asset 156.7    
Present value of lease liabilities 157.8    
Total operating lease liabilities 151.2 $ 166.5  
Total finance lease liabilities 6.6    
Operating lease assets      
Lessee, Lease, Description [Line Items]      
Operating lease assets 146.8    
Other non-current assets      
Lessee, Lease, Description [Line Items]      
Finance leases 9.9    
Accrued liabilities      
Lessee, Lease, Description [Line Items]      
Operating lease liability, current 34.8    
Current indebtedness      
Lessee, Lease, Description [Line Items]      
Finance lease liability, current 1.9    
Other noncurrent liabilities      
Lessee, Lease, Description [Line Items]      
Operating lease liability, noncurrent 116.4    
Long-term debt, less current portion      
Lessee, Lease, Description [Line Items]      
Finance lease liability, noncurrent 4.7    
CSCA      
Lessee, Lease, Description [Line Items]      
Operating lease assets 30.1    
Finance leases 1.9    
Total operating lease liabilities 30.2    
Total finance lease liabilities 1.4    
CSCI      
Lessee, Lease, Description [Line Items]      
Operating lease assets 43.5    
Finance leases 6.1    
Total operating lease liabilities 44.4    
Total finance lease liabilities 3.3    
RX      
Lessee, Lease, Description [Line Items]      
Operating lease assets 38.6    
Finance leases 0.1    
Total operating lease liabilities 40.1    
Total finance lease liabilities 0.1    
Unallocated      
Lessee, Lease, Description [Line Items]      
Operating lease assets 34.6    
Finance leases 1.8    
Total operating lease liabilities 36.5    
Total finance lease liabilities $ 1.8    
XML 81 R60.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Lease Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Leases [Abstract]    
Operating leases [1] $ 12.0  
Finance leases    
Amortization 0.7  
Interest 0.1  
Total $ 0.8  
Operating lease expense   $ 11.9
[1] (a) Includes short-term leases and variable lease costs, which are immaterial.
XML 82 R61.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Annual Future Maturities of Leases (Details) - USD ($)
$ in Millions
Mar. 30, 2019
Jan. 01, 2019
Operating Lease Liabilities, Payments Due [Abstract]    
2019 $ 31.0  
2020 33.1  
2021 24.0  
2022 18.1  
2023 15.0  
After 2023 53.4  
Total lease payments 174.6  
Less: Interest 23.4  
Present value of lease liabilities 151.2 $ 166.5
Finance Lease Liabilities, Payments, Due [Abstract]    
2019 1.7  
2020 1.6  
2021 2.9  
2022 0.5  
2023 0.3  
After 2023 0.0  
Total lease payments 7.0  
Less: Interest 0.4  
Present value of lease liabilities 6.6  
Lease Liabilities, Payments, Due [Abstract]    
2019 32.7  
2020 34.7  
2021 26.9  
2022 18.6  
2023 15.3  
After 2023 53.4  
Total lease payments 181.6  
Less: Interest 23.8  
Present value of lease liabilities $ 157.8  
XML 83 R62.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Weighted Average Lease Terms and Discount Rates (Details)
Mar. 30, 2019
Leases [Abstract]  
Weighted-average remaining lease term - Operating leases 6 years 9 months 21 days
Weighted-average lease term - Finance leases 2 years 7 months 2 days
Weighted-average discount rate - Operating lease (percent) 4.20%
Weighted-average discount rate - Finance lease (percent) 4.17%
XML 84 R63.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Lease Cash Flow Classifications (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2019
USD ($)
Leases [Abstract]  
Operating cash flows for operating leases $ 11.7
Operating cash flows for finance leases 0.1
Financing cash flows for finance leases 0.7
Leased assets obtained in exchange for new operating lease liabilities $ 4.7
XML 85 R64.htm IDEA: XBRL DOCUMENT v3.19.1
Indebtedness - Schedule of Borrowings Outstanding (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Outstanding balance $ 0.0 $ 0.0
Senior notes 2,886.1 2,892.5
Other financing 6.2 2.8
Unamortized premium (discount), net 9.8 12.2
Deferred financing fees (15.6) (16.4)
Total borrowings outstanding 3,217.8 3,242.4
Current indebtedness (467.9) (190.2)
Long-term debt, less current portion $ 2,749.9 3,052.2
2018 Euro-Denominated Term Loan due March 8, 2020    
Debt Instrument [Line Items]    
Series [1] 2018 Term loan due March 8, 2020  
Term loans $ 331.3 351.3
5.000% Unsecured Senior notes due May 23, 2019    
Debt Instrument [Line Items]    
Series [1] May 23, 2019  
Interest rate, stated percentage 5.00%  
Senior notes $ 134.6 137.6
3.500% Unsecured Senior notes due March 15, 2021    
Debt Instrument [Line Items]    
Series Mar. 15, 2021  
Interest rate, stated percentage 3.50%  
Senior notes $ 280.4 280.4
3.5% Senior note due December 15, 2021    
Debt Instrument [Line Items]    
Series Dec. 15, 2021  
Interest rate, stated percentage 3.50%  
Senior notes $ 309.6 309.6
5.105% Senior note due July 19, 2023    
Debt Instrument [Line Items]    
Series [1] July 19, 2023  
Interest rate, stated percentage 5.105%  
Senior notes $ 151.5 154.9
4.00% unsecured senior notes due November 15, 2023    
Debt Instrument [Line Items]    
Series Nov. 15, 2023  
Interest rate, stated percentage 4.00%  
Senior notes $ 215.6 215.6
3.9% senior note due December 15, 2024    
Debt Instrument [Line Items]    
Series Dec. 15, 2024  
Interest rate, stated percentage 3.90%  
Senior notes $ 700.0 700.0
4.375% senior note due March 15, 2026    
Debt Instrument [Line Items]    
Series Mar. 15, 2026  
Interest rate, stated percentage 4.375%  
Senior notes $ 700.0 700.0
5.30% unsecured senior notes due November 15, 2043    
Debt Instrument [Line Items]    
Series Nov. 15, 2043  
Interest rate, stated percentage 5.30%  
Senior notes $ 90.5 90.5
4.9% senior notes due December 15, 2044    
Debt Instrument [Line Items]    
Series Dec. 15, 2044  
Interest rate, stated percentage 4.90%  
Senior notes $ 303.9 $ 303.9
[1] Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
XML 86 R65.htm IDEA: XBRL DOCUMENT v3.19.1
Indebtedness - Additional Information (Details)
 3 Months Ended
Dec. 05, 2014
USD ($)
Mar. 30, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Mar. 08, 2018
USD ($)
Mar. 08, 2018
EUR (€)
Dec. 05, 2014
EUR (€)
Debt Instrument [Line Items]              
Debt instrument, issuance date Dec. 05, 2014            
Loss on extinguishment of debt   $ 0 $ 500,000        
Repayments of debt   12,300,000          
Outstanding balance   0   $ 0      
2014 Term loan due December 5, 2019              
Debt Instrument [Line Items]              
Face amount of debt $ 614,300,000         € 350,000,000.0 € 500,000,000.0
2018 Euro-Denominated Term Loan due March 8, 2020              
Debt Instrument [Line Items]              
Face amount of debt         $ 431,000,000.0 € 350,000,000.0  
2018 Revolver              
Debt Instrument [Line Items]              
Face amount of debt         $ 1,000,000,000.0    
Borrowings outstanding   $ 0   $ 0      
XML 87 R66.htm IDEA: XBRL DOCUMENT v3.19.1
Earnings Per Share and Shareholders' Equity (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Oct. 31, 2018
Numerator:      
Net income $ 63.9 $ 80.8  
Denominator:      
Weighted average shares outstanding for basic EPS 135.9 140.8  
Dilutive effect of share-based awards (in shares) 0.3 0.6  
Weighted average shares outstanding for diluted EPS 136.2 141.4  
Anti-dilutive share-based awards excluded from computation of diluted EPS (shares) 2.1 0.7  
Stock repurchase program, authorized amount     $ 1,000.0
Stock Repurchased During Period, Shares 0.0    
Share price (in dollars per share)   $ 81.92  
Repurchase of equity amount   $ 108.1  
Ordinary Shares Issued      
Denominator:      
Stock Repurchased During Period, Shares   1.3  
XML 88 R67.htm IDEA: XBRL DOCUMENT v3.19.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Accumulated Other Comprehensive Income [Roll Forward]    
Balance, beginning $ 5,668.0 $ 6,170.5
Other comprehensive income (loss), net of tax (15.6) 72.2
Balance, ending 5,700.6 6,205.4
Fair value of derivative financial instruments, net of tax    
Accumulated Other Comprehensive Income [Roll Forward]    
Balance, beginning (15.5)  
OCI before reclassifications (1.2)  
Amounts reclassified from AOCI 2.9  
Other comprehensive income (loss), net of tax 1.7  
Balance, ending (13.8)  
Foreign Currency Translation Adjustments    
Accumulated Other Comprehensive Income [Roll Forward]    
Balance, beginning 104.5  
OCI before reclassifications (16.8)  
Amounts reclassified from AOCI 0.0  
Other comprehensive income (loss), net of tax (16.8)  
Balance, ending 87.7  
Post-Retirement and Pension Liability Adjustments, net of tax    
Accumulated Other Comprehensive Income [Roll Forward]    
Balance, beginning (4.4)  
OCI before reclassifications (0.5)  
Amounts reclassified from AOCI 0.0  
Other comprehensive income (loss), net of tax (0.5)  
Balance, ending (4.9)  
Accumulated Other Comprehensive Income    
Accumulated Other Comprehensive Income [Roll Forward]    
Balance, beginning 84.6 253.1
OCI before reclassifications (18.5)  
Amounts reclassified from AOCI 2.9  
Other comprehensive income (loss), net of tax (15.6) 72.2
Balance, ending $ 69.0 $ 324.3
XML 89 R68.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes (Details)
€ in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Aug. 15, 2017
USD ($)
Mar. 30, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
Dec. 31, 2009
USD ($)
Nov. 29, 2018
EUR (€)
Income Tax Contingency [Line Items]                  
Effective income tax rate reconciliation, percent   21.10% 26.90%            
Income tax examination, penalties and interest expense $ 163.6       $ 24.7 $ 40.2 $ 61.5 $ 37.2  
Income tax overpayments applied to succeeding years   $ 29.7              
Royalty conceded on all omeprazole sales as a percent of refund claims (percent)   24.00%              
Income tax benefit     $ 2.4            
Tax expense in connection with Transition Toll Tax     $ 17.5            
Foreign earnings       $ 1,200.0          
Tax Cuts and Jobs Act of 2017, change in tax rate, provisional income tax expense (benefit)       6.3          
Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit)       8.3          
Global intangible low-taxed income, income tax expense (benefit)       $ 9.4          
Revenue Commissioners, Ireland                  
Income Tax Contingency [Line Items]                  
Unsettled audit assessment from income tax examination | €                 € 1,636
XML 90 R69.htm IDEA: XBRL DOCUMENT v3.19.1
Contingencies (Details)
$ in Millions
 2 Months Ended 12 Months Ended
Jan. 16, 2019
product
defendant
Nov. 21, 2018
ILS (₪)
Jun. 28, 2017
USD ($)
product
defendant
Jun. 28, 2017
ILS (₪)
product
defendant
Nov. 30, 2011
application
Dec. 31, 2018
case
Mar. 30, 2019
dozens
$ / ₪
Feb. 22, 2019
product
plaintiff
case
defendant
Feb. 14, 2019
defendant
Feb. 06, 2019
product
case
defendant
Jan. 31, 2019
product
case
defendant
Nov. 15, 2018
product
case
Oct. 29, 2018
product
case
defendant
Aug. 03, 2018
product
manufacturer
Apr. 20, 2018
product
case
Feb. 16, 2018
case
defendant
Feb. 13, 2018
product
case
defendant
Jan. 26, 2018
product
complaint
plaintiff
case
Jan. 16, 2018
product
defendant
Dec. 31, 2017
case
Nov. 01, 2017
defendant
Jun. 21, 2017
product
individual
Dec. 28, 2013
product
supermarket
manufacturer
Dec. 31, 2011
product
manufacturer
Loss Contingencies [Line Items]                                                
Number of manufacturers | manufacturer                                               27
Number of generic prescription pharmaceuticals | product                                   6       6   15
Number of products manufactured by the Company | product                                               2
Number of dozens of other drugs | dozens             2                                  
Number of individuals | individual                                           11    
Number of plaintiff groups | plaintiff                                   2            
Number of complaints | complaint                                   2            
Number of cases                                   2            
Number of overlapped cases                                   2            
Price-Fixing Lawsuit, Supermarket Chains                                                
Loss Contingencies [Line Items]                                                
Number of manufacturers | manufacturer                                             35  
Number of supermarket chains | supermarket                                             3  
Number of generic prescription pharmaceuticals | product                                             31  
Price-fixing Lawsuit, Managed Care Organization                                                
Loss Contingencies [Line Items]                                                
Number of manufacturers | manufacturer                           27                    
Number of generic prescription pharmaceuticals | product                           17                    
Price-fixing Lawsuit, Health Insurance Carrier                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product 30                                              
Number of defendants | defendant 30                                              
Carmignac Gestion, S.A. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of co-defendants | defendant                                         3      
Manning & Napier Advisors, LLC v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                                     6          
Number of co-defendants | defendant                                     3          
Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                                 6              
Number of co-defendants | defendant                                 2              
Number of opt out cases                                 4              
First Manhattan Co. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals                               6                
Number of co-defendants | defendant                               3                
Number of opt out cases                               5                
TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                             6                  
Number of opt out cases                             6                  
Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                         6                      
Number of co-defendants | defendant                         2                      
Number of opt out cases                         7                      
WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                       6                        
Number of opt out cases                       8                        
Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals                       6                        
Number of opt out cases                       9                        
Schwab Capital Trust, et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                     6                          
Number of co-defendants | defendant                     2                          
Number of opt out cases                     10                          
OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product                   6                            
Number of co-defendants | defendant                   2                            
Number of opt out cases                   11                            
Highfields Capital I LP, et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of co-defendants | defendant                 2                              
Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product               6                                
Number of co-defendants | defendant               2                                
Number of additional plaintiffs | plaintiff               30                                
Number of opt out cases               12                                
Cases Filed in Israel                                                
Loss Contingencies [Line Items]                                                
Number of cases                                       3        
Number of cases dismissed           1                                    
Number of cases stayed           1                                    
Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al.                                                
Loss Contingencies [Line Items]                                                
Number of generic prescription pharmaceuticals | product     6 6                                        
Number of current or former directors and officers | defendant     11 11                                        
Damages sought by plaintiff     $ 760.0 ₪ 2,700,000,000                                        
Foreign currency exchange rate, remeasurement | $ / ₪             0.28                                  
Eltroxin Class Action                                                
Loss Contingencies [Line Items]                                                
Number of applications filed | application         9                                      
Number of applications dismissed | application         1                                      
Number of applications consolidated | application         8                                      
Damages sought, value per patient | ₪   ₪ 250                                            
XML 91 R70.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Charges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Restructuring Reserve [Roll Forward]    
Beginning balance $ 24.0 $ 21.4
Additional charges 5.9 1.5
Payments (9.0) (10.8)
Non-cash adjustments (0.4) 0.3
Ending balance $ 20.5 $ 12.4
XML 92 R71.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Dec. 31, 2018
Segment Reporting Information [Line Items]      
Total Assets $ 11,119.5   $ 10,983.4
Net sales [1] 1,174.5 $ 1,217.0  
Operating Income (Loss) 102.3 156.3  
Intangible Asset Amortization 75.4 87.2  
CSCA      
Segment Reporting Information [Line Items]      
Total Assets 3,704.6   3,571.7
Net sales [2] 581.8 601.6  
Operating Income (Loss) 94.2 118.6  
Intangible Asset Amortization 10.1 15.2  
CSCI      
Segment Reporting Information [Line Items]      
Total Assets 4,597.8   4,613.0
Net sales 350.8 377.8  
Operating Income (Loss) 8.1 12.3  
Intangible Asset Amortization 44.1 51.1  
RX      
Segment Reporting Information [Line Items]      
Total Assets 2,817.1   $ 2,798.7
Net sales 241.9 237.6  
Operating Income (Loss) 60.6 61.2  
Intangible Asset Amortization 21.2 20.9  
Unallocated      
Segment Reporting Information [Line Items]      
Net sales 0.0 0.0  
Operating Income (Loss) (60.6) (35.8)  
Intangible Asset Amortization $ 0.0 $ 0.0  
[1] Derived from the location of the entity that sells to a third party.
[2] Includes net sales from our OTC contract manufacturing business.
XML 93 R72.htm IDEA: XBRL DOCUMENT v3.19.1
Subsequent Events (Details) - Subsequent Event - USD ($)
$ in Millions
May 08, 2019
Apr. 26, 2019
Subsequent Event [Line Items]    
IRS notice of proposed adjustment amount from 2011,2012 and 2013 audit of Athena, including penalty   $ 843.0
IRS notice of proposed adjustment, penalty (percent)   40.00%
Definitive agreement for sale of animal health business, amount $ 185.0  
Ranir Global Holdings, LLC    
Subsequent Event [Line Items]    
Definitive purchase agreement amount 750.0  
Cash on hand used to fund acquisition $ 450.0  
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 291 345 1 true 118 0 false 18 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.perrigo.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1004000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1004501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1005000 - Statement - Condensed Consolidated Statements of Shareholders' Equity Statement Sheet http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement Condensed Consolidated Statements of Shareholders' Equity Statement Statements 6 false false R7.htm 1005001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) Sheet http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityParenthetical Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) Statements 7 false false R8.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Revenue Recognition Sheet http://www.perrigo.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 2103100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.perrigo.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 11 false false R12.htm 2105100 - Disclosure - Inventories Sheet http://www.perrigo.com/role/Inventories Inventories Notes 12 false false R13.htm 2107100 - Disclosure - Fair Value Measurements Sheet http://www.perrigo.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2108100 - Disclosure - Investments Sheet http://www.perrigo.com/role/Investments Investments Notes 14 false false R15.htm 2109100 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivities Derivative Instruments and Hedging Activities Notes 15 false false R16.htm 2111100 - Disclosure - Leases Sheet http://www.perrigo.com/role/Leases Leases Notes 16 false false R17.htm 2112100 - Disclosure - Indebtedness Sheet http://www.perrigo.com/role/Indebtedness Indebtedness Notes 17 false false R18.htm 2113100 - Disclosure - Earnings Per Share and Shareholders' Equity Sheet http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquity Earnings Per Share and Shareholders' Equity Notes 18 false false R19.htm 2114100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 19 false false R20.htm 2115100 - Disclosure - Income Taxes Sheet http://www.perrigo.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2117100 - Disclosure - Contingencies Sheet http://www.perrigo.com/role/Contingencies Contingencies Notes 21 false false R22.htm 2118100 - Disclosure - Restructuring Charges Sheet http://www.perrigo.com/role/RestructuringCharges Restructuring Charges Notes 22 false false R23.htm 2119100 - Disclosure - Segment Information Sheet http://www.perrigo.com/role/SegmentInformation Segment Information Notes 23 false false R24.htm 2120100 - Disclosure - Subsequent Events Sheet http://www.perrigo.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 2302301 - Disclosure - Revenue Recognition (Tables) Sheet http://www.perrigo.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.perrigo.com/role/RevenueRecognition 27 false false R28.htm 2303301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.perrigo.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.perrigo.com/role/GoodwillAndIntangibleAssets 28 false false R29.htm 2305301 - Disclosure - Inventories (Tables) Sheet http://www.perrigo.com/role/InventoriesTables Inventories (Tables) Tables http://www.perrigo.com/role/Inventories 29 false false R30.htm 2307301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.perrigo.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.perrigo.com/role/FairValueMeasurements 30 false false R31.htm 2308301 - Disclosure - Investments (Tables) Sheet http://www.perrigo.com/role/InvestmentsTables Investments (Tables) Tables http://www.perrigo.com/role/Investments 31 false false R32.htm 2309301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivities 32 false false R33.htm 2311301 - Disclosure - Leases (Tables) Sheet http://www.perrigo.com/role/LeasesTables Leases (Tables) Tables http://www.perrigo.com/role/Leases 33 false false R34.htm 2312301 - Disclosure - Indebtedness (Tables) Sheet http://www.perrigo.com/role/IndebtednessTables Indebtedness (Tables) Tables http://www.perrigo.com/role/Indebtedness 34 false false R35.htm 2313301 - Disclosure - Earnings Per Share and Shareholders' Equity (Tables) Sheet http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityTables Earnings Per Share and Shareholders' Equity (Tables) Tables http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquity 35 false false R36.htm 2314301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLoss 36 false false R37.htm 2315301 - Disclosure - Income Taxes Income Taxes (Tables) Sheet http://www.perrigo.com/role/IncomeTaxesIncomeTaxesTables Income Taxes Income Taxes (Tables) Tables 37 false false R38.htm 2318301 - Disclosure - Restructuring Charges (Tables) Sheet http://www.perrigo.com/role/RestructuringChargesTables Restructuring Charges (Tables) Tables http://www.perrigo.com/role/RestructuringCharges 38 false false R39.htm 2319301 - Disclosure - Segment Information (Tables) Sheet http://www.perrigo.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.perrigo.com/role/SegmentInformation 39 false false R40.htm 2402402 - Disclosure - Revenue Recognition - Schedule of Revenue by Geographic Location (Details) Sheet http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails Revenue Recognition - Schedule of Revenue by Geographic Location (Details) Details 40 false false R41.htm 2402403 - Disclosure - Revenue Recognition - Schedule of Revenue by Product (Details) Sheet http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails Revenue Recognition - Schedule of Revenue by Product (Details) Details 41 false false R42.htm 2402404 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 42 false false R43.htm 2402405 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) Sheet http://www.perrigo.com/role/RevenueRecognitionScheduleOfContractBalancesDetails Revenue Recognition - Schedule of Contract Balances (Details) Details 43 false false R44.htm 2403402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) Sheet http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails Goodwill and Intangible Assets - Goodwill (Details) Details 44 false false R45.htm 2403403 - Disclosure - Goodwill and Intangible Assets - Intangible categories (Details) Sheet http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails Goodwill and Intangible Assets - Intangible categories (Details) Details 45 false false R46.htm 2405402 - Disclosure - Inventories (Details) Sheet http://www.perrigo.com/role/InventoriesDetails Inventories (Details) Details http://www.perrigo.com/role/InventoriesTables 46 false false R47.htm 2407402 - Disclosure - Fair Value Measurements - Financial Instruments at Fair Value (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails Fair Value Measurements - Financial Instruments at Fair Value (Details) Details 47 false false R48.htm 2407403 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 48 false false R49.htm 2407404 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) Details 49 false false R50.htm 2407405 - Disclosure - Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) Sheet http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) Details 50 false false R51.htm 2408402 - Disclosure - Investments (Details) Sheet http://www.perrigo.com/role/InvestmentsDetails Investments (Details) Details http://www.perrigo.com/role/InvestmentsTables 51 false false R52.htm 2409402 - Disclosure - Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) Details 52 false false R53.htm 2409403 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) Details 53 false false R54.htm 2409404 - Disclosure - Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details) Details 54 false false R55.htm 2409405 - Disclosure - Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) Details 55 false false R56.htm 2409406 - Disclosure - Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) Details 56 false false R57.htm 2409407 - Disclosure - Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) Sheet http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) Details 57 false false R58.htm 2411402 - Disclosure - Leases (Details) Sheet http://www.perrigo.com/role/LeasesDetails Leases (Details) Details http://www.perrigo.com/role/LeasesTables 58 false false R59.htm 2411403 - Disclosure - Leases - Balance Sheet Location of Assets and Liabilities (Details) Sheet http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails Leases - Balance Sheet Location of Assets and Liabilities (Details) Details 59 false false R60.htm 2411404 - Disclosure - Leases - Lease Expense (Details) Sheet http://www.perrigo.com/role/LeasesLeaseExpenseDetails Leases - Lease Expense (Details) Details 60 false false R61.htm 2411405 - Disclosure - Leases - Annual Future Maturities of Leases (Details) Sheet http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails Leases - Annual Future Maturities of Leases (Details) Details 61 false false R62.htm 2411406 - Disclosure - Leases - Weighted Average Lease Terms and Discount Rates (Details) Sheet http://www.perrigo.com/role/LeasesWeightedAverageLeaseTermsAndDiscountRatesDetails Leases - Weighted Average Lease Terms and Discount Rates (Details) Details 62 false false R63.htm 2411407 - Disclosure - Leases - Lease Cash Flow Classifications (Details) Sheet http://www.perrigo.com/role/LeasesLeaseCashFlowClassificationsDetails Leases - Lease Cash Flow Classifications (Details) Details 63 false false R64.htm 2412402 - Disclosure - Indebtedness - Schedule of Borrowings Outstanding (Details) Sheet http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails Indebtedness - Schedule of Borrowings Outstanding (Details) Details 64 false false R65.htm 2412403 - Disclosure - Indebtedness - Additional Information (Details) Sheet http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails Indebtedness - Additional Information (Details) Details 65 false false R66.htm 2413402 - Disclosure - Earnings Per Share and Shareholders' Equity (Details) Sheet http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails Earnings Per Share and Shareholders' Equity (Details) Details http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityTables 66 false false R67.htm 2414402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossTables 67 false false R68.htm 2415402 - Disclosure - Income Taxes (Details) Sheet http://www.perrigo.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.perrigo.com/role/IncomeTaxesIncomeTaxesTables 68 false false R69.htm 2417401 - Disclosure - Contingencies (Details) Sheet http://www.perrigo.com/role/ContingenciesDetails Contingencies (Details) Details http://www.perrigo.com/role/Contingencies 69 false false R70.htm 2418402 - Disclosure - Restructuring Charges (Details) Sheet http://www.perrigo.com/role/RestructuringChargesDetails Restructuring Charges (Details) Details http://www.perrigo.com/role/RestructuringChargesTables 70 false false R71.htm 2419402 - Disclosure - Segment Information (Details) Sheet http://www.perrigo.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.perrigo.com/role/SegmentInformationTables 71 false false R72.htm 2420401 - Disclosure - Subsequent Events (Details) Sheet http://www.perrigo.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.perrigo.com/role/SubsequentEvents 72 false false All Reports Book All Reports cy19q110q.htm cy19q110qex107.htm cy19q110qex109.htm cy19q110qex311.htm cy19q110qex312.htm cy19q110qex32.htm prgo-20190330.xsd prgo-20190330_cal.xml prgo-20190330_def.xml prgo-20190330_lab.xml prgo-20190330_pre.xml chart-039cc1c102fc583384a.jpg chart-263b0786b3f7a1559bc.jpg chart-5095151ccba65a95916.jpg chart-6681394ba8e6b7b6c0b.jpg chart-6741377481db3b5310c.jpg chart-c40ee33d0dfb9db21d0.jpg chart-ee2c5fc1da03539bb7f.jpg chart-f715b0ee48225a40866.jpg http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2018-01-31 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cy19q110q.htm": { "axisCustom": 0, "axisStandard": 25, "contextCount": 291, "dts": { "calculationLink": { "local": [ "prgo-20190330_cal.xml" ] }, "definitionLink": { "local": [ "prgo-20190330_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "cy19q110q.htm" ] }, "labelLink": { "local": [ "prgo-20190330_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "prgo-20190330_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "prgo-20190330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 609, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 16, "http://www.perrigo.com/20190330": 2, "http://xbrl.sec.gov/dei/2018-01-31": 10, "total": 28 }, "keyCustom": 64, "keyStandard": 281, "memberCustom": 60, "memberStandard": 58, "nsprefix": "prgo", "nsuri": "http://www.perrigo.com/20190330", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.perrigo.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Revenue Recognition", "role": "http://www.perrigo.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.perrigo.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Inventories", "role": "http://www.perrigo.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Fair Value Measurements", "role": "http://www.perrigo.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Investments", "role": "http://www.perrigo.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Derivative Instruments and Hedging Activities", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Leases", "role": "http://www.perrigo.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Indebtedness", "role": "http://www.perrigo.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Earnings Per Share and Shareholders' Equity", "role": "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquity", "shortName": "Earnings Per Share and Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Income Taxes", "role": "http://www.perrigo.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Contingencies", "role": "http://www.perrigo.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Restructuring Charges", "role": "http://www.perrigo.com/role/RestructuringCharges", "shortName": "Restructuring Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Segment Information", "role": "http://www.perrigo.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Subsequent Events", "role": "http://www.perrigo.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.perrigo.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Inventories (Tables)", "role": "http://www.perrigo.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.perrigo.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Investments (Tables)", "role": "http://www.perrigo.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "prgo:ScheduleofForeignCurrencyForwardContractsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "prgo:ScheduleofForeignCurrencyForwardContractsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "prgo:AssetsandLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Leases (Tables)", "role": "http://www.perrigo.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "prgo:AssetsandLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Indebtedness (Tables)", "role": "http://www.perrigo.com/role/IndebtednessTables", "shortName": "Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Earnings Per Share and Shareholders' Equity (Tables)", "role": "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityTables", "shortName": "Earnings Per Share and Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Income Taxes Income Taxes (Tables)", "role": "http://www.perrigo.com/role/IncomeTaxesIncomeTaxesTables", "shortName": "Income Taxes Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Restructuring Charges (Tables)", "role": "http://www.perrigo.com/role/RestructuringChargesTables", "shortName": "Restructuring Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Segment Information (Tables)", "role": "http://www.perrigo.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Revenue Recognition - Schedule of Revenue by Geographic Location (Details)", "role": "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails", "shortName": "Revenue Recognition - Schedule of Revenue by Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1QTD_srt_StatementGeographicalAxis_country_US", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Revenue Recognition - Schedule of Revenue by Product (Details)", "role": "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "shortName": "Revenue Recognition - Schedule of Revenue by Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1QTD_srt_ProductOrServiceAxis_prgo_CoughColdAllergyandSinusMember_us-gaap_StatementBusinessSegmentsAxis_prgo_ConsumerSelfCareAmericasMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Revenue Recognition - Additional Information (Details)", "role": "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1QTD_srt_ProductOrServiceAxis_prgo_ContractManufacturingMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)", "role": "http://www.perrigo.com/role/RevenueRecognitionScheduleOfContractBalancesDetails", "shortName": "Revenue Recognition - Schedule of Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)", "role": "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Goodwill and Intangible Assets - Intangible categories (Details)", "role": "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails", "shortName": "Goodwill and Intangible Assets - Intangible categories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Inventories (Details)", "role": "http://www.perrigo.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Fair Value Measurements - Financial Instruments at Fair Value (Details)", "role": "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "shortName": "Fair Value Measurements - Financial Instruments at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2018Q1QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2018Q1QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_ContingentConsiderationClassifiedAsEquityMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details)", "role": "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails", "shortName": "Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_ContingentConsiderationClassifiedAsEquityMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeniorNotes", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details)", "role": "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails", "shortName": "Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_DebtInstrumentAxis_prgo_PublicBondsandPrivatePlacementMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "-5", "lang": null, "name": "us-gaap:SeniorNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_prgo_OtherExpenseIncomeNetMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Investments (Details)", "role": "http://www.perrigo.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_prgo_OtherExpenseIncomeNetMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails", "shortName": "Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet Location (Details)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "shortName": "Derivative Instruments and Hedging Activities - Balance Sheet Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "prgo:CashFlowHedgeGainLossReclassifiedtoEarningsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "shortName": "Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "prgo:CashFlowHedgeGainLossReclassifiedtoEarningsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails", "shortName": "Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "shortName": "Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409407 - Disclosure - Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details)", "role": "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "shortName": "Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_prgo_OtherExpenseIncomeNetMember", "decimals": "-5", "lang": null, "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Leases (Details)", "role": "http://www.perrigo.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Leases - Balance Sheet Location of Assets and Liabilities (Details)", "role": "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "shortName": "Leases - Balance Sheet Location of Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Shareholders' Equity Statement", "role": "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "shortName": "Condensed Consolidated Statements of Shareholders' Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Leases - Lease Expense (Details)", "role": "http://www.perrigo.com/role/LeasesLeaseExpenseDetails", "shortName": "Leases - Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Leases - Annual Future Maturities of Leases (Details)", "role": "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails", "shortName": "Leases - Annual Future Maturities of Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Leases - Weighted Average Lease Terms and Discount Rates (Details)", "role": "http://www.perrigo.com/role/LeasesWeightedAverageLeaseTermsAndDiscountRatesDetails", "shortName": "Leases - Weighted Average Lease Terms and Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411407 - Disclosure - Leases - Lease Cash Flow Classifications (Details)", "role": "http://www.perrigo.com/role/LeasesLeaseCashFlowClassificationsDetails", "shortName": "Leases - Lease Cash Flow Classifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Indebtedness - Schedule of Borrowings Outstanding (Details)", "role": "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails", "shortName": "Indebtedness - Schedule of Borrowings Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:OtherLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "D2015Q2SD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Indebtedness - Additional Information (Details)", "role": "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "shortName": "Indebtedness - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "D2015Q2SD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Earnings Per Share and Shareholders' Equity (Details)", "role": "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails", "shortName": "Earnings Per Share and Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "decimals": "-5", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "ratio", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Income Taxes (Details)", "role": "http://www.perrigo.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "ratio", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2012Q2", "decimals": "INF", "first": true, "lang": null, "name": "prgo:LossContingencyNumberOfManufacturers", "reportCount": 1, "unique": true, "unitRef": "manufacturer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - Contingencies (Details)", "role": "http://www.perrigo.com/role/ContingenciesDetails", "shortName": "Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2012Q2", "decimals": "INF", "first": true, "lang": null, "name": "prgo:LossContingencyNumberOfManufacturers", "reportCount": 1, "unique": true, "unitRef": "manufacturer", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1005001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)", "role": "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Restructuring Charges (Details)", "role": "http://www.perrigo.com/role/RestructuringChargesDetails", "shortName": "Restructuring Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Segment Information (Details)", "role": "http://www.perrigo.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FI2019Q1_us-gaap_StatementBusinessSegmentsAxis_prgo_ConsumerSelfCareAmericasMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "I2019Q2Apr26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "prgo:IRSNoticeofProposedAuditAdjustmentAmountIncludingPenalty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420401 - Disclosure - Subsequent Events (Details)", "role": "http://www.perrigo.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "I2019Q2Apr26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "prgo:IRSNoticeofProposedAuditAdjustmentAmountIncludingPenalty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cy19q110q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 118, "tag": { "country_IE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian Dollar (CAD)" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "China, Yuan Renminbi", "terseLabel": "Chinese Yuan (CNY)" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_DKK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Denmark, Kroner", "terseLabel": "Danish Krone (DKK)" } } }, "localname": "DKK", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "European Euro (EUR)" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British Pound (GBP)" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_ILS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Israel, New Shekels", "terseLabel": "Israeli Shekel (ILS)" } } }, "localname": "ILS", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_MXN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Mexico, Pesos", "terseLabel": "Mexican Peso (MPX)" } } }, "localname": "MXN", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_NOK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Norway, Krone", "terseLabel": "Norwegian Krone (NOK)" } } }, "localname": "NOK", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_PLN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Poland, Zlotych", "terseLabel": "Polish Zloty (PLZ)" } } }, "localname": "PLN", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_RON": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Romania, New Lei", "terseLabel": "Romanian New Leu (RON)" } } }, "localname": "RON", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_SEK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sweden, Kronor", "terseLabel": "Swedish (SEK)" } } }, "localname": "SEK", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United States of America, Dollars", "terseLabel": "United States Dollar (USD)" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "currency_XXX": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "No currency", "terseLabel": "Other" } } }, "localname": "XXX", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current calendar year end date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document calendar period focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document calendar year focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document period end date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity central index key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity common stock, shares outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity emerging growth company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity filer category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity registrant name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity small business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of derivatives" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "prgo_A2014EuroDenominatedTermLoandueDecember52019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2014 Euro-Denominated Term Loan due December 5, 2019 [Member]", "label": "2014 Euro-Denominated Term Loan due December 5, 2019 [Member]", "terseLabel": "2014 Term loan due December 5, 2019" } } }, "localname": "A2014EuroDenominatedTermLoandueDecember52019Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_A2018EuroDenominatedTermLoandueMarch82020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Euro-Denominated Term Loan due March 8, 2020 [Member]", "label": "2018 Euro-Denominated Term Loan due March 8, 2020 [Member]", "terseLabel": "2018 Euro-Denominated Term Loan due March 8, 2020" } } }, "localname": "A2018EuroDenominatedTermLoandueMarch82020Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A2018RevolverMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Revolver [Member]", "label": "2018 Revolver [Member]", "terseLabel": "2018 Revolver" } } }, "localname": "A2018RevolverMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A3.500UnsecuredSeniornotesdueMarch152021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.500% Unsecured Senior notes due March 15, 2021 [Member]", "label": "3.500% Unsecured Senior notes due March 15, 2021 [Member]", "terseLabel": "3.500% Unsecured Senior notes due March 15, 2021" } } }, "localname": "A3.500UnsecuredSeniornotesdueMarch152021Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A3.5SeniornotedueDecember152021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.5% Senior note due 2021 [Member]", "label": "3.5% Senior note due December 15, 2021 [Member]", "terseLabel": "3.5% Senior note due December 15, 2021" } } }, "localname": "A3.5SeniornotedueDecember152021Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A3.9seniornotedue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.9% senior note due 2024 [Member]", "label": "3.9% senior note due 2024 [Member]", "terseLabel": "3.9% senior note due December 15, 2024" } } }, "localname": "A3.9seniornotedue2024Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A4.00UnsecuredSeniorNotesdueNovember152023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.00% Unsecured Senior Notes due November 15, 2023 [Member]", "label": "4.00% Unsecured Senior Notes due November 15, 2023 [Member]", "terseLabel": "4.00% unsecured senior notes due November 15, 2023" } } }, "localname": "A4.00UnsecuredSeniorNotesdueNovember152023Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A4.375seniornotedueMarch152026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.375% senior note due March 15, 2026 [Member]", "label": "4.375% senior note due March 15, 2026 [Member]", "terseLabel": "4.375% senior note due March 15, 2026" } } }, "localname": "A4.375seniornotedueMarch152026Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A4.9SeniorLoandue2044Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.9% Senior Loan due 2044 [Member]", "label": "4.9% Senior Loan due 2044 [Member]", "terseLabel": "4.9% senior notes due December 15, 2044" } } }, "localname": "A4.9SeniorLoandue2044Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A5.000UnsecuredSeniornotesdueMay232019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.000% Unsecured Senior notes due May 23, 2019 [Member]", "label": "5.000% Unsecured Senior notes due May 23, 2019 [Member]", "terseLabel": "5.000% Unsecured Senior notes due May 23, 2019" } } }, "localname": "A5.000UnsecuredSeniornotesdueMay232019Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A5.105SeniornotedueJuly192023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.105% Senior note due July 19, 2023 [Member]", "label": "5.105% Senior note due July 19, 2023 [Member]", "terseLabel": "5.105% Senior note due July 19, 2023" } } }, "localname": "A5.105SeniornotedueJuly192023Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_A5.30UnsecuredSeniorNotesdueNovember152043Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.30% Unsecured Senior Notes due November 15, 2043 [Member]", "label": "5.30% Unsecured Senior Notes due November 15, 2043 [Member]", "terseLabel": "5.30% unsecured senior notes due November 15, 2043" } } }, "localname": "A5.30UnsecuredSeniorNotesdueNovember152043Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "prgo_AberdeenCanadaFundsGlobalEquityFundetal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al. [Member]", "label": "Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al." } } }, "localname": "AberdeenCanadaFundsGlobalEquityFundetal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_AccruedCustomerPrograms": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of customer programs, which include customer chargebacks and rebates payable.", "label": "Accrued Customer Programs", "terseLabel": "Accrued customer programs" } } }, "localname": "AccruedCustomerPrograms", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "prgo_AccumulatedOtherComprehensiveIncomeRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income [Roll Forward]", "label": "Accumulated Other Comprehensive Income [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income [Roll Forward]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeRollForward", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "prgo_AnalgesicsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analgesics [Member]", "label": "Analgesics [Member]", "terseLabel": "Analgesics" } } }, "localname": "AnalgesicsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_AnimalHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Animal Health [Member]", "label": "Animal Health [Member]", "terseLabel": "Animal health" } } }, "localname": "AnimalHealthMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_AntiParasiteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Anti-Parasite [Member]", "label": "Anti-Parasite [Member]", "terseLabel": "Anti-Parasite" } } }, "localname": "AntiParasiteMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_AssetAdjustedFairValueifSalesThresholdMet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset, Adjusted Fair Value if Sales Threshold Met", "label": "Asset, Adjusted Fair Value if Sales Threshold Met", "terseLabel": "Adjusted asset balance is prescribed threshold is exceeded" } } }, "localname": "AssetAdjustedFairValueifSalesThresholdMet", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "prgo_AssetsandLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets and Liabilities, Lessee [Table Text Block]", "label": "Assets and Liabilities, Lessee [Table Text Block]", "terseLabel": "Balance Sheet Location of Lease Assets and Liabilities" } } }, "localname": "AssetsandLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "prgo_CarmignacGestionS.A.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Carmignac Gestion, S.A. v. Perrigo Company plc, et al. [Member]", "label": "Carmignac Gestion, S.A. v. Perrigo Company plc, et al. [Member]", "terseLabel": "Carmignac Gestion, S.A. v. Perrigo Company plc, et al." } } }, "localname": "CarmignacGestionS.A.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_CasesFiledinIsraelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cases Filed in Israel [Member]", "label": "Cases Filed in Israel [Member]", "terseLabel": "Cases Filed in Israel" } } }, "localname": "CasesFiledinIsraelMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_CashFlowHedgeGainLossReclassifiedtoEarningsNet": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "label": "Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "totalLabel": "Amount of Gain/(Loss) Reclassified from AOCI into Earnings" } } }, "localname": "CashFlowHedgeGainLossReclassifiedtoEarningsNet", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "prgo_ConcessionofRoyaltyDueonSalesasPercentofRefundClaimsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concession of Royalty Due on Sales as Percent of Refund Claims, Percent", "label": "Concession of Royalty Due on Sales as Percent of Refund Claims, Percent", "terseLabel": "Royalty conceded on all omeprazole sales as a percent of refund claims (percent)" } } }, "localname": "ConcessionofRoyaltyDueonSalesasPercentofRefundClaimsPercent", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "prgo_ConsumerSelfCareAmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consumer Self-Care Americas [Member]", "label": "Consumer Self-Care Americas [Member]", "terseLabel": "CSCA" } } }, "localname": "ConsumerSelfCareAmericasMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_ConsumerSelfCareInternationalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consumer Self-Care International [Member]", "label": "Consumer Self-Care International [Member]", "terseLabel": "CSCI" } } }, "localname": "ConsumerSelfCareInternationalMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_ContractManufacturingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Manufacturing [Member]", "label": "Contract Manufacturing [Member]", "terseLabel": "Contract manufacturing" } } }, "localname": "ContractManufacturingMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_ControllingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Controlling Interest [Abstract]", "label": "Controlling Interest [Abstract]", "terseLabel": "Controlling interests:" } } }, "localname": "ControllingInterestAbstract", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "prgo_CoughColdAllergyandSinusMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cough, Cold, Allergy and Sinus [Member]", "label": "Cough, Cold, Allergy and Sinus [Member]", "terseLabel": "Cough/Cold/Allergy/Sinus" } } }, "localname": "CoughColdAllergyandSinusMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_CoughColdandAllergyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cough, Cold, and Allergy [Member]", "label": "Cough, Cold, and Allergy [Member]", "terseLabel": "Cough, Cold, and Allergy" } } }, "localname": "CoughColdandAllergyMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_CurrentIndebtednessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Indebtedness [Member]", "label": "Current Indebtedness [Member]", "terseLabel": "Current indebtedness" } } }, "localname": "CurrentIndebtednessMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "prgo_DenominatorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Denominator [Abstract]", "label": "Denominator [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "prgo_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.perrigo.com/20190330", "xbrltype": "stringItemType" }, "prgo_EltroxinClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eltroxin Class Action [Member]", "label": "Eltroxin Class Action [Member]", "terseLabel": "Eltroxin Class Action" } } }, "localname": "EltroxinClassActionMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_FairValueAssetsLevel1Level2Level3TransfersAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount", "label": "Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount", "terseLabel": "Transfers among level 1, 2, and 3" } } }, "localname": "FairValueAssetsLevel1Level2Level3TransfersAmount", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "prgo_FairValueAssetsandLiabilitiesMeasuredonNonrecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Unobservable Input Reconciliation [Abstract]", "label": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Measured at fair value on a non-recurring basis:" } } }, "localname": "FairValueAssetsandLiabilitiesMeasuredonNonrecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "stringItemType" }, "prgo_FairValueAssumptionsRateofReturn": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Assumptions, Rate of Return", "label": "Fair Value Assumptions, Rate of Return", "terseLabel": "Rate of return" } } }, "localname": "FairValueAssumptionsRateofReturn", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "prgo_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyEffect": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Effect", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Effect", "terseLabel": "Foreign currency effect" } } }, "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyEffect", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "totalLabel": "Total" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "prgo_FiniteAndIndefiniteLivedAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finite and Indefinite-Lived Assets By Major Class [Line Items]", "label": "Finite And Indefinite Lived Assets By Major Class [Line Items]", "terseLabel": "Finite And Indefinite Lived Assets By Major Class [Line Items]" } } }, "localname": "FiniteAndIndefiniteLivedAssetsByMajorClassLineItems", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "stringItemType" }, "prgo_FirstManhattanCo.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Manhattan Co. v. Perrigo Company plc, et al. [Member]", "label": "First Manhattan Co. v. Perrigo Company plc, et al. [Member]", "terseLabel": "First Manhattan Co. v. Perrigo Company plc, et al." } } }, "localname": "FirstManhattanCo.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_FundsAssociatedWithIsraeliPostEmploymentBenefitsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Funds Associated With Israeli Post Employment Benefits Fair Value Disclosure", "label": "Funds Associated With Israeli Post Employment Benefits Fair Value Disclosure", "terseLabel": "Funds associated with Israeli severance liability" } } }, "localname": "FundsAssociatedWithIsraeliPostEmploymentBenefitsFairValueDisclosure", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "prgo_GastrointestinalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gastrointestinal [Member]", "label": "Gastrointestinal [Member]", "terseLabel": "Gastrointestinal" } } }, "localname": "GastrointestinalMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_GlobalIntangibleLowtaxedIncomeIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Global Intangible Low-taxed Income, Income Tax Expense (Benefit)", "label": "Global Intangible Low-taxed Income, Income Tax Expense (Benefit)", "terseLabel": "Global intangible low-taxed income, income tax expense (benefit)" } } }, "localname": "GlobalIntangibleLowtaxedIncomeIncomeTaxExpenseBenefit", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_GoodwillAndIndefiniteLivedIntangibles": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount, as of the balance sheet date, of goodwill and other indefinite-lived intangible assets. Goodwill represents the carrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of ASC Topic 350 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Indefinite-lived intangible assets represent the carrying amount of intangible assets which have a projected indefinite period of benefit (hence are not amortized), allocated to the reportable segment. These assets, acquired either individually or as part of a group of assets, in either an asset acquisition or business combination, are assessed at least annually for impairment. Examples may include trade secrets, contractual rights, trade names, and licensing agreements.", "label": "Goodwill And Indefinite Lived Intangibles", "terseLabel": "Goodwill and indefinite-lived intangible assets" } } }, "localname": "GoodwillAndIndefiniteLivedIntangibles", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "prgo_HarelInsuranceCompanyLTD.etal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al. [Member]", "label": "Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al." } } }, "localname": "HarelInsuranceCompanyLTD.etal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_HighfieldsCapitalILPetal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Highfields Capital I LP, et al. v. Perrigo Company plc, et al. [Member]", "label": "Highfields Capital I LP, et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "Highfields Capital I LP, et al. v. Perrigo Company plc, et al." } } }, "localname": "HighfieldsCapitalILPetal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_HudsonBayMasterFundLtd.etal.v.PerrigoCo.plcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al. [Member]", "label": "Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al. [Member]", "terseLabel": "Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al." } } }, "localname": "HudsonBayMasterFundLtd.etal.v.PerrigoCo.plcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_IRSNoticeofProposedAdjustmentPenaltyPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "IRS Notice of Proposed Adjustment, Penalty, Percent", "label": "IRS Notice of Proposed Adjustment, Penalty, Percent", "terseLabel": "IRS notice of proposed adjustment, penalty (percent)" } } }, "localname": "IRSNoticeofProposedAdjustmentPenaltyPercent", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "prgo_IRSNoticeofProposedAuditAdjustmentAmountIncludingPenalty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "IRS Notice of Proposed Audit Adjustment Amount, Including Penalty", "label": "IRS Notice of Proposed Audit Adjustment Amount, Including Penalty", "terseLabel": "IRS notice of proposed adjustment amount from 2011,2012 and 2013 audit of Athena, including penalty" } } }, "localname": "IRSNoticeofProposedAuditAdjustmentAmountIncludingPenalty", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "prgo_IncomeTaxExaminationUnsettledAssessedAuditLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income Tax Examination, Unsettled Assessed Audit Liability", "label": "Income Tax Examination, Unsettled Assessed Audit Liability", "terseLabel": "Unsettled audit assessment from income tax examination" } } }, "localname": "IncomeTaxExaminationUnsettledAssessedAuditLiability", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_IncomeTaxOverpaymentsAppliedtoSucceedingYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income Tax Overpayments Applied to Succeeding Years", "label": "Income Tax Overpayments Applied to Succeeding Years", "terseLabel": "Income tax overpayments applied to succeeding years" } } }, "localname": "IncomeTaxOverpaymentsAppliedtoSucceedingYears", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_IncreaseDecreaseInAccruedCustomerPrograms": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net change during the reporting period in the aggregate amount of accrued customer programs including chargebacks and rebate payables.", "label": "Increase Decrease In Accrued Customer Programs", "terseLabel": "Accrued customer programs" } } }, "localname": "IncreaseDecreaseInAccruedCustomerPrograms", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "prgo_IndefinitelivedIntangibleAssetsExcludingGoodwillMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input" } } }, "localname": "IndefinitelivedIntangibleAssetsExcludingGoodwillMeasurementInput", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "prgo_InfantNutritionalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Infant Nutritionals [Member]", "label": "Infant Nutritionals [Member]", "terseLabel": "Infant nutritionals" } } }, "localname": "InfantNutritionalsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al. [Member]", "label": "Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al. [Member]", "terseLabel": "Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al." } } }, "localname": "IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_LeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": 2.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease Liabilities", "label": "Lease Liabilities", "totalLabel": "Present value of lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Liabilities, Payments, Due [Abstract]", "label": "Lease Liabilities, Payments, Due [Abstract]", "terseLabel": "Lease Liabilities, Payments, Due [Abstract]" } } }, "localname": "LeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "stringItemType" }, "prgo_LeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Due", "label": "Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LeaseLiabilityPaymentsDue", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 5.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Due Year Five", "label": "Lease, Liability, Payments, Due Year Five", "totalLabel": "2023" } } }, "localname": "LeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 4.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Due Year Four", "label": "Lease, Liability, Payments, Due Year Four", "totalLabel": "2022" } } }, "localname": "LeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 3.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Due Year Three", "label": "Lease, Liability, Payments, Due Year Three", "totalLabel": "2021" } } }, "localname": "LeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 2.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Due Year Two", "label": "Lease, Liability, Payments, Due Year Two", "totalLabel": "2020" } } }, "localname": "LeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityPaymentsDueafterYearFive": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 6.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Due after Year Five", "label": "Lease, Liability, Payments, Due after Year Five", "totalLabel": "After 2023" } } }, "localname": "LeaseLiabilityPaymentsDueafterYearFive", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityPaymentsRemainderofFiscalYear": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 1.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Lease, Liability, Payments, Remainder of Fiscal Year", "totalLabel": "2019" } } }, "localname": "LeaseLiabilityPaymentsRemainderofFiscalYear", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": 1.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability, Undiscounted Excess Amount", "label": "Lease, Liability, Undiscounted Excess Amount", "totalLabel": "Less: Interest" } } }, "localname": "LeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LesseeCashFlowClassificationsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Cash Flow Classifications [Table Text Block]", "label": "Lessee, Cash Flow Classifications [Table Text Block]", "terseLabel": "Leease Cash Flow Classifications" } } }, "localname": "LesseeCashFlowClassificationsTableTextBlock", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "prgo_LesseeWeightedAverageLeaseTermsandDiscountRatesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Weighted Average Lease Terms and Discount Rates [Table Text Block]", "label": "Lessee, Weighted Average Lease Terms and Discount Rates [Table Text Block]", "terseLabel": "Weighted Average Lease Terms and Discount Rates" } } }, "localname": "LesseeWeightedAverageLeaseTermsandDiscountRatesTableTextBlock", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "prgo_LifestyleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lifestyle [Member]", "label": "Lifestyle [Member]", "terseLabel": "Lifestyle" } } }, "localname": "LifestyleMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_LongtermDebtLessCurrentPortionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Less Current Portion [Member]", "label": "Long-term Debt, Less Current Portion [Member]", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongtermDebtLessCurrentPortionMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "prgo_LossContingencyDamagesSoughtValueperPatient": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Damages Sought, Value per Patient", "label": "Loss Contingency, Damages Sought, Value per Patient", "terseLabel": "Damages sought, value per patient" } } }, "localname": "LossContingencyDamagesSoughtValueperPatient", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_LossContingencyNumberOfApplicationsConsolidated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Applications Consolidated", "label": "Loss Contingency, Number Of Applications Consolidated", "terseLabel": "Number of applications consolidated" } } }, "localname": "LossContingencyNumberOfApplicationsConsolidated", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfApplicationsDismissed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Applications Dismissed", "label": "Loss Contingency, Number Of Applications Dismissed", "terseLabel": "Number of applications dismissed" } } }, "localname": "LossContingencyNumberOfApplicationsDismissed", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfApplicationsFiled": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Applications Filed", "label": "Loss Contingency, Number Of Applications Filed", "terseLabel": "Number of applications filed" } } }, "localname": "LossContingencyNumberOfApplicationsFiled", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfCases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Cases", "label": "Loss Contingency, Number Of Cases", "terseLabel": "Number of cases" } } }, "localname": "LossContingencyNumberOfCases", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfCasesStayed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Cases Stayed", "label": "Loss Contingency, Number Of Cases Stayed", "terseLabel": "Number of cases stayed" } } }, "localname": "LossContingencyNumberOfCasesStayed", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfComplaints": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Complaints", "label": "Loss Contingency, Number Of Complaints", "terseLabel": "Number of complaints" } } }, "localname": "LossContingencyNumberOfComplaints", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfDozensOfOtherDrugs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Dozens Of Other Drugs", "label": "Loss Contingency, Number Of Dozens Of Other Drugs", "terseLabel": "Number of dozens of other drugs" } } }, "localname": "LossContingencyNumberOfDozensOfOtherDrugs", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfGenericPrescriptionPharmaceuticals": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Generic Prescription Pharmaceuticals", "label": "Loss Contingency, Number Of Generic Prescription Pharmaceuticals", "terseLabel": "Number of generic prescription pharmaceuticals" } } }, "localname": "LossContingencyNumberOfGenericPrescriptionPharmaceuticals", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfIndividuals": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Individuals", "label": "Loss Contingency, Number Of Individuals", "terseLabel": "Number of individuals" } } }, "localname": "LossContingencyNumberOfIndividuals", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfManufacturers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Manufacturers", "label": "Loss Contingency, Number Of Manufacturers", "terseLabel": "Number of manufacturers" } } }, "localname": "LossContingencyNumberOfManufacturers", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfOptOutCases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Opt Out Cases", "label": "Loss Contingency, Number Of Opt Out Cases", "terseLabel": "Number of opt out cases" } } }, "localname": "LossContingencyNumberOfOptOutCases", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfOverlappedCases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Overlapped Cases", "label": "Loss Contingency, Number Of Overlapped Cases", "terseLabel": "Number of overlapped cases" } } }, "localname": "LossContingencyNumberOfOverlappedCases", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfPlaintiffGroups": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Plaintiff Groups", "label": "Loss Contingency, Number Of Plaintiff Groups", "terseLabel": "Number of plaintiff groups" } } }, "localname": "LossContingencyNumberOfPlaintiffGroups", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfPrescriptionPharmaceuticals": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Prescription Pharmaceuticals", "label": "Loss Contingency, Number Of Prescription Pharmaceuticals", "terseLabel": "Number of products manufactured by the Company" } } }, "localname": "LossContingencyNumberOfPrescriptionPharmaceuticals", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberOfSupermarketChains": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Supermarket Chains", "label": "Loss Contingency, Number Of Supermarket Chains", "terseLabel": "Number of supermarket chains" } } }, "localname": "LossContingencyNumberOfSupermarketChains", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberofCodefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number of Co-defendants", "label": "Loss Contingency, Number of Co-defendants", "terseLabel": "Number of co-defendants" } } }, "localname": "LossContingencyNumberofCodefendants", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_LossContingencyNumberofCurrentOrFormerDirectorsAndOfficers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number of Current Or Former Directors And Officers", "label": "Loss Contingency, Number of Current Or Former Directors And Officers", "terseLabel": "Number of current or former directors and officers" } } }, "localname": "LossContingencyNumberofCurrentOrFormerDirectorsAndOfficers", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_ManningNapierAdvisorsLLCv.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manning & Napier Advisors, LLC v. Perrigo Company plc, et al. [Member]", "label": "Manning & Napier Advisors, LLC v. Perrigo Company plc, et al. [Member]", "terseLabel": "Manning & Napier Advisors, LLC v. Perrigo Company plc, et al." } } }, "localname": "ManningNapierAdvisorsLLCv.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_MeasurementInputTaxRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement Input, Tax Rate [Member]", "label": "Measurement Input, Tax Rate [Member]", "terseLabel": "Measurement Input, Tax Rate" } } }, "localname": "MeasurementInputTaxRateMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_NationwideMutualFundsetal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al. [Member]", "label": "Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al." } } }, "localname": "NationwideMutualFundsetal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_NaturalHealthandVMSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Natural Health and VMS [Member]", "label": "Natural Health and VMS [Member]", "terseLabel": "Natural Health and Vitamins, Minerals and Dietary Supplements" } } }, "localname": "NaturalHealthandVMSMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_NetSalesThresholdForMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Sales Threshold For Milestone Payment", "label": "Net Sales Threshold For Milestone Payment", "terseLabel": "Net sales threshold to trigger milestone payment" } } }, "localname": "NetSalesThresholdForMilestonePayment", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "prgo_NumberofAdditionalPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Additional Plaintiffs", "label": "Number of Additional Plaintiffs", "terseLabel": "Number of additional plaintiffs" } } }, "localname": "NumberofAdditionalPlaintiffs", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "prgo_NumeratorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Numerator: [Abstract]", "label": "Numerator [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "prgo_OZMasterFundLtd.etal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al. [Member]", "label": "OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al." } } }, "localname": "OZMasterFundLtd.etal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_OperatingLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Leases [Member]", "label": "Operating Leases [Member]", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeasesMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "prgo_OtherCHCAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other CHC [Member]", "label": "Other CHCA [Member]", "terseLabel": "Other CHCA" } } }, "localname": "OtherCHCAMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_OtherCHCIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other CHCI [Member]", "label": "Other CHCI [Member]", "terseLabel": "Other CHCI" } } }, "localname": "OtherCHCIMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_OtherExpenseIncomeNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Expense (Income), Net [Member]", "label": "Other Expense (Income), Net [Member]", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherExpenseIncomeNetMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "prgo_OtherGeographicalAreasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Geographical Areas [Member]", "label": "Other Geographical Areas [Member]", "terseLabel": "All other countries" } } }, "localname": "OtherGeographicalAreasMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "prgo_OtherOperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Operating Income (Loss)", "label": "Other Operating Income (Loss)", "negatedTerseLabel": "Other operating expense (income)" } } }, "localname": "OtherOperatingIncomeLoss", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "prgo_PersonalCareandDermaTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Personal Care and Derma-Therapeutics [Member]", "label": "Personal Care and Derma-Therapeutics [Member]", "terseLabel": "Personal care and derma-therapeutics" } } }, "localname": "PersonalCareandDermaTherapeuticsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_PotentialContingentMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Potential Contingent Milestone Payments", "label": "Potential Contingent Milestone Payments", "terseLabel": "Royalty Pharma contingent milestone payments", "verboseLabel": "Potential contingent milestone payments" } } }, "localname": "PotentialContingentMilestonePayments", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "prgo_PriceFixingLawsuitSupermarketChainsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price-Fixing Lawsuit, Supermarket Chains [Member]", "label": "Price-Fixing Lawsuit, Supermarket Chains [Member]", "terseLabel": "Price-Fixing Lawsuit, Supermarket Chains" } } }, "localname": "PriceFixingLawsuitSupermarketChainsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_PricefixingLawsuitHealthInsuranceCarrierMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price-fixing Lawsuit, Health Insurance Carrier [Member]", "label": "Price-fixing Lawsuit, Health Insurance Carrier [Member]", "terseLabel": "Price-fixing Lawsuit, Health Insurance Carrier" } } }, "localname": "PricefixingLawsuitHealthInsuranceCarrierMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_PricefixingLawsuitManagedCareOrganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price-fixing Lawsuit, Managed Care Organization [Member]", "label": "Price-fixing Lawsuit, Managed Care Organization [Member]", "terseLabel": "Price-fixing Lawsuit, Managed Care Organization" } } }, "localname": "PricefixingLawsuitManagedCareOrganizationMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_ProceedsfromContingentMilestonePayment": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Contingent Milestone Payment", "label": "Proceeds from Contingent Milestone Payment", "terseLabel": "Royalty Pharma contingent milestone payment" } } }, "localname": "ProceedsfromContingentMilestonePayment", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "prgo_PublicBondsandPrivatePlacementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Public Bonds and Private Placement", "label": "Public Bonds and Private Placement [Member]", "verboseLabel": "Public bonds" } } }, "localname": "PublicBondsandPrivatePlacementMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "prgo_RXPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RX Pharmaceuticals [Member]", "label": "RX Pharmaceuticals [Member]", "terseLabel": "RX" } } }, "localname": "RXPharmaceuticalsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_RanirGlobalHoldingsLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ranir Global Holdings, LLC [Member]", "label": "Ranir Global Holdings, LLC [Member]", "terseLabel": "Ranir Global Holdings, LLC" } } }, "localname": "RanirGlobalHoldingsLLCMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "prgo_ReportingUnitDiscountedCashFlowMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reporting Unit, Discounted Cash Flow, Measurement Input", "label": "Reporting Unit, Discounted Cash Flow, Measurement Input", "terseLabel": "Reporting Unit, Discounted Cash Flow, Measurement Input" } } }, "localname": "ReportingUnitDiscountedCashFlowMeasurementInput", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "prgo_RestructuringAdditionalCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring, Additional Charges", "label": "Restructuring, Additional Charges", "terseLabel": "Additional charges" } } }, "localname": "RestructuringAdditionalCharges", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_RetailBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Retail Bonds [Member]", "label": "Retail Bonds [Member]", "terseLabel": "Retail Bonds" } } }, "localname": "RetailBondsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "prgo_RightofUseAsset": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Right-of-Use Asset", "label": "Right-of-Use Asset", "totalLabel": "Right-of-Use Asset" } } }, "localname": "RightofUseAsset", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_RoyaltyPharmaContingentMilestonePaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Pharma Contingent Milestone Payments [Member]", "label": "Royalty Pharma Contingent Milestone Payments [Member]", "terseLabel": "Royalty Pharma Contingent Milestone Payments" } } }, "localname": "RoyaltyPharmaContingentMilestonePaymentsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "prgo_RoyaltyPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Pharma [Member]", "label": "Royalty Pharma [Member]", "terseLabel": "Royalty Pharma" } } }, "localname": "RoyaltyPharmaMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prgo_SalePriceofDivestiture": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sale Price of Divestiture", "label": "Sale Price of Divestiture", "terseLabel": "Definitive agreement for sale of animal health business, amount" } } }, "localname": "SalePriceofDivestiture", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "prgo_ScheduleOfDebtInstrumentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Debt Instruments [Table]", "label": "Schedule of Debt Instruments [Table]", "terseLabel": "Schedule of Debt Instruments [Table]" } } }, "localname": "ScheduleOfDebtInstrumentsTable", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "stringItemType" }, "prgo_ScheduleOfFiniteAndIndefiniteLivedAssetsByMajorClassTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Finite And Indefinite Lived Assets By Major Class [Table]", "label": "Schedule Of Finite And Indefinite Lived Assets By Major Class [Table]", "terseLabel": "Schedule Of Finite And Indefinite Lived Assets By Major Class [Table]" } } }, "localname": "ScheduleOfFiniteAndIndefiniteLivedAssetsByMajorClassTable", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "stringItemType" }, "prgo_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets [Table Text Block]", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite and indefinite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "prgo_ScheduleofForeignCurrencyForwardContractsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Foreign Currency Forward Contracts [Table Text Block]", "label": "Schedule of Foreign Currency Forward Contracts [Table Text Block]", "terseLabel": "Schedule of Foreign Currency Forward Contracts" } } }, "localname": "ScheduleofForeignCurrencyForwardContractsTableTextBlock", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "prgo_SchwabCapitalTrustetal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schwab Capital Trust, et al. v. Perrigo Company plc, et al. [Member]", "label": "Schwab Capital Trust, et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "Schwab Capital Trust, et al. v. Perrigo Company plc, et al." } } }, "localname": "SchwabCapitalTrustetal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_SmokingCessationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Smoking Cessation [Member]", "label": "Smoking Cessation [Member]", "terseLabel": "Smoking cessation" } } }, "localname": "SmokingCessationMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_TIAACREFInvestmentManagementLLC.etal.v.PerrigoCompanyplcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al. [Member]", "label": "TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al. [Member]", "terseLabel": "TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al." } } }, "localname": "TIAACREFInvestmentManagementLLC.etal.v.PerrigoCompanyplcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_TaxCutsandJobsActof2017ChangeinTaxRateProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Provisional Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActof2017ChangeinTaxRateProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit" } } }, "localname": "TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_TaxCutsandJobsActof2017IncompleteAccountingProvisionalUndistributedAccumulatedEarningsofForeignSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings of Foreign Subsidiary", "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings of Foreign Subsidiary", "terseLabel": "Foreign earnings" } } }, "localname": "TaxCutsandJobsActof2017IncompleteAccountingProvisionalUndistributedAccumulatedEarningsofForeignSubsidiary", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_TaxCutsandJobsActof2017IncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)", "terseLabel": "Tax expense in connection with Transition Toll Tax" } } }, "localname": "TaxCutsandJobsActof2017IncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_TaxCutsandJobsActof2017TransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act of 2017, change in tax rate, provisional income tax expense (benefit)" } } }, "localname": "TaxCutsandJobsActof2017TransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "prgo_TrademarksTradeNamesandBrandsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trademarks, Trade Names, and Brands [Member]", "label": "Trademarks, Trade Names, and Brands [Member]", "terseLabel": "Trademarks, trade names, and brands" } } }, "localname": "TrademarksTradeNamesandBrandsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "prgo_VitaminsMineralsAndDietarySupplementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vitamins, Minerals, and Dietary Supplements [Member]", "label": "Vitamins, Minerals, and Dietary Supplements [Member]", "terseLabel": "Vitamins, Minerals and Dietary Supplements" } } }, "localname": "VitaminsMineralsAndDietarySupplementsMember", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "prgo_WCMAlternativeEventDriveFundetal.v.PerrigoCo.plcetal.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al. [Member]", "label": "WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al. [Member]", "terseLabel": "WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al." } } }, "localname": "WCMAlternativeEventDriveFundetal.v.PerrigoCo.plcetal.Member", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "prgo_WriteoffofContingentMilestonePaymentifSalesThresholdNotMetAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Write-off of Contingent Milestone Payment if Sales Threshold Not Met, Amount", "label": "Write-off of Contingent Milestone Payment if Sales Threshold Not Met, Amount", "terseLabel": "Write-off of contingent milestone payment if sales threshold is not met" } } }, "localname": "WriteoffofContingentMilestonePaymentifSalesThresholdNotMetAmount", "nsuri": "http://www.perrigo.com/20190330", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r59", "r106" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r141", "r217", "r219", "r379" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r142", "r217", "r220", "r380", "r381" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.", "label": "Accelerated Share Repurchases, Final Price Paid Per Share", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "ASU 2016-01" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r25", "r218" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $6.8 and $6.4, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r19", "r353", "r368" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r63", "r68", "r69", "r224", "r261" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Post-Retirement and Pension Liability Adjustments, net of tax" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r62", "r68", "r69", "r260" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Fair value of derivative financial instruments, net of tax" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r66", "r67", "r68" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r65", "r68", "r69", "r261" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r61", "r68", "r69", "r261" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "terseLabel": "Subtotal" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to derive cash flows:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of adjustment to stockholders' equity associated with an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.", "label": "Adjustments Related to Tax Withholding for Share-based Compensation", "negatedTerseLabel": "Shares withheld for payment of employees' withholding tax liability" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) resulting from recognition of equity-based compensation for restricted stock units.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition", "terseLabel": "Compensation for restricted stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "terseLabel": "Compensation for stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r51", "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r83", "r99", "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt premium" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r99", "r160", "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Intangible assets amortization expense", "verboseLabel": "Intangible Asset Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive share-based awards excluded from computation of diluted EPS (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r99", "r172" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges", "verboseLabel": "Impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r136", "r351", "r367" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r56" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.", "label": "Assets, Fair Value Adjustment", "terseLabel": "Fair value adjustment" } } }, "localname": "AssetsFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r10", "r11", "r12", "r13", "r14", "r15", "r16", "r17" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/InvestmentsDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r270", "r276" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/InvestmentsDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Supplemental Disclosures of Balance Sheet Information" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r241", "r242" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r249", "r250", "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Definitive purchase agreement amount" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r248", "r251", "r254" ], "calculation": { "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Volatility rate assumed" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r314", "r315" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Reported Value Measurement" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r35", "r101" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r95", "r101", "r103" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r95", "r318" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r48", "r189", "r358", "r374" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies - Refer to Note 13" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r188", "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Dividends paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares Issued" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value (in EUR per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, issued and outstanding (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Ordinary shares, \u20ac0.001 par value per share, 10,000 shares authorized" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r72", "r74", "r75" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r104", "r259", "r263", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent consideration in a business combination that is classified in shareholders' equity.", "label": "Contingent Consideration Classified as Equity [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationClassifiedAsEquityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract with Customer Balances" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetGrossCurrent": { "auth_ref": [ "r212", "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Gross, Current", "terseLabel": "Short-term contract assets" } } }, "localname": "ContractWithCustomerAssetGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionScheduleOfContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for cost method and equity method investments included basis, impairment losses, recognized or unrecognized gains (losses).", "label": "Cost and Equity Method Investments Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "CostAndEquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Adoption of new accounting standards", "verboseLabel": "Reclassification to retained earnings" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Customer relationships and distribution networks" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "negatedLabel": "Current indebtedness" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r352", "r354", "r366" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails", "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r18", "r20", "r206", "r352", "r354", "r363", "r366" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt Instrument, Description", "terseLabel": "Series" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r321", "r324" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r45" ], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails": { "order": 5.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "negatedTerseLabel": "Deferred financing fees" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Date the debt instrument was issued, in CCYY-MM-DD format.", "label": "Debt Instrument, Issuance Date", "terseLabel": "Debt instrument, issuance date" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails", "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r46", "r107", "r206", "r207", "r208", "r209", "r320", "r321", "r324", "r364" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r320", "r321", "r322", "r323", "r324" ], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails": { "order": 4.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedTerseLabel": "Unamortized premium (discount), net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "totalLabel": "Total borrowings outstanding" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r235" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r105", "r236", "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r227", "r235" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r99", "r133" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r57", "r58", "r60", "r289" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral", "terseLabel": "Asset Derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r57", "r58", "r60", "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral", "terseLabel": "Liability Derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of Gain/(Loss) Recognized against Earnings" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r271", "r275", "r282", "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative instruments and hedging activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r268", "r271", "r282", "r286", "r287", "r290", "r292" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r279", "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r104", "r110", "r266", "r267", "r268", "r269", "r288" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives instruments and hedging" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated derivatives:" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed product technology, formulations, and product rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends, $0.19 per share" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r114", "r119", "r121", "r122", "r123", "r126", "r361", "r378" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r114", "r119", "r121", "r122", "r123", "r126", "r361", "r378" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per share and shareholders' equity" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfCashFlowHedgesOnResultsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Effect of Cash Flow Hedges on Results of Operations [Abstract]", "terseLabel": "The effects of cash flow hedging:" } } }, "localname": "EffectOfCashFlowHedgesOnResultsOfOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r318" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r109", "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate reconciliation, percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related taxes" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r36", "r137", "r147" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity securities, equity method, other non-current assets" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Equity security expense (income)" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity securities, fair value method" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedTerseLabel": "Equity securities, fair value method, other expense (income)" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r297", "r298", "r299", "r300", "r307", "r308" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Royalty Pharma Contingent Milestone Payments", "verboseLabel": "Measured at fair value on a recurring basis:" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r297", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r303", "r308" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r303", "r308" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r298", "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r222", "r223", "r225", "r299", "r346" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r306", "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r298", "r309" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "verboseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r222", "r223", "r225", "r299", "r347" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r222", "r223", "r225", "r299", "r348" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r222", "r223", "r225", "r299", "r349" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r303", "r308" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r303", "r308" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r303", "r308" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of Level 3 Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r297", "r306" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in the income statement for financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value", "verboseLabel": "Increase (decrease) in fair value of milestone payment" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r305" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "negatedTerseLabel": "Payments received" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Estimated fair valued contingent milestone payment" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Changes in value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Settlements and other adjustments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r297", "r306" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a nonrecurring basis generally include those items for which measurement inputs are not readily available and which are measured at fair value infrequently (for example, impaired assets).", "label": "Fair Value, Measurements, Nonrecurring [Member]", "terseLabel": "Measured at fair value on a non-recurring basis" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r297", "r306" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Measured on a recurring basis", "verboseLabel": "Measured at fair value on a recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/FairValueMeasurementsReconciliationOfLevel3AssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "auth_ref": [ "r316" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "negatedLabel": "Change in financial assets", "negatedTerseLabel": "Change in financial assets", "terseLabel": "Income recognized from change is asset" } } }, "localname": "FairValueOptionChangesInFairValueGainLoss1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r270", "r277", "r290" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Cost [Abstract]", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r327", "r334", "r342" ], "calculation": { "http://www.perrigo.com/role/LeasesLeaseExpenseDetails": { "order": 2.0, "parentTag": "prgo_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r330", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows for finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseCashFlowClassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Liabilities, Payments, Due [Abstract]", "terseLabel": "Finance Lease Liabilities, Payments, Due [Abstract]" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r326", "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 2.0, "parentTag": "prgo_LeaseLiabilities", "weight": 1.0 }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total finance lease liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "prgo_LeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liability, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Finance Lease Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "prgo_LeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liability, noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc3": { "order": 2.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "After 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 2.0, "parentTag": "prgo_LeaseLiabilityPaymentsDueYearTwo", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 2.0, "parentTag": "prgo_LeaseLiabilityPaymentsRemainderofFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 2.0, "parentTag": "prgo_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r329", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows for finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseCashFlowClassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r325" ], "calculation": { "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "prgo_RightofUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r327", "r334", "r342" ], "calculation": { "http://www.perrigo.com/role/LeasesLeaseExpenseDetails": { "order": 1.0, "parentTag": "prgo_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r339", "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - Finance lease (percent)" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesWeightedAverageLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r338", "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average lease term - Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesWeightedAverageLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r166" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r161", "r163", "r166", "r169", "r350" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets, Fair Value Disclosure", "terseLabel": "Definite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r166", "r350" ], "calculation": { "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r161", "r165" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r166" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Definite-lived intangible assets, net", "verboseLabel": "Definite-lived intangible assets carrying value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r279" ], "calculation": { "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails": { "order": 2.0, "parentTag": "prgo_CashFlowHedgeGainLossReclassifiedtoEarningsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of net gains or losses on foreign currency cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "terseLabel": "Amount of gain or (loss) reclassified from AOCI into earnings", "verboseLabel": "Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Net gain expected to be reclassified out of AOCI into earnings in the next 12 months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "auth_ref": [ "r275" ], "calculation": { "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Foreign Currency Cash Flow Hedges [Abstract]", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyExchangeRateRemeasurement1": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency.", "label": "Foreign Currency Exchange Rate, Remeasurement", "terseLabel": "Foreign currency exchange rate, remeasurement" } } }, "localname": "ForeignCurrencyExchangeRateRemeasurement1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyFairValueHedgeDerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Foreign Currency Fair Value Hedge Derivative [Line Items]", "terseLabel": "Foreign Currency Fair Value Hedge Derivative [Line Items]" } } }, "localname": "ForeignCurrencyFairValueHedgeDerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyFairValueHedgeDerivativeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivative instruments designated as foreign currency fair value hedging instruments.", "label": "Foreign Currency Fair Value Hedge Derivative [Table]", "terseLabel": "Foreign Currency Fair Value Hedge Derivative [Table]" } } }, "localname": "ForeignCurrencyFairValueHedgeDerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesForeignCurrencyForwardContractsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet": { "auth_ref": [ "r280" ], "calculation": { "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) relating to components of the gain (loss) on the cash flow hedging instrument excluded from the assessment of cash flow hedge effectiveness. Recognized in earnings.", "label": "Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net", "totalLabel": "Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net" } } }, "localname": "GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnComponentsExcludedFromAssessmentOfForeignCurrencyCashFlowHedgeEffectiveness": { "auth_ref": [ "r280" ], "calculation": { "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails": { "order": 2.0, "parentTag": "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) relating to components of the gain (loss) on foreign currency cash flow hedging instruments excluded from the assessment of hedge effectiveness. Recognized in earnings.", "label": "Gain (Loss) on Components Excluded from Assessment of Foreign Currency Cash Flow Hedge Effectiveness", "terseLabel": "Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach" } } }, "localname": "GainLossOnComponentsExcludedFromAssessmentOfForeignCurrencyCashFlowHedgeEffectiveness", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnComponentsExcludedFromAssessmentOfInterestRateCashFlowHedgeEffectiveness": { "auth_ref": [ "r280" ], "calculation": { "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails": { "order": 1.0, "parentTag": "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) included in earnings for the period relating to components of the gain (loss) on interest rate cash flow hedging instruments excluded from the assessment of fair value hedge effectiveness.", "label": "Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness", "terseLabel": "Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness" } } }, "localname": "GainLossOnComponentsExcludedFromAssessmentOfInterestRateCashFlowHedgeEffectiveness", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r99", "r202", "r203" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Administration" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r152", "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "March 30, 2019", "periodStartLabel": "December 31, 2018", "terseLabel": "Goodwill carrying amount" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillFairValueDisclosure": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Fair Value Disclosure", "terseLabel": "Goodwill" } } }, "localname": "GoodwillFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency Translation Adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r154", "r156" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Accumulated impairments" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r80" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r268", "r287" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r99", "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinite lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r108" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r77", "r99", "r134", "r147", "r359", "r376" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity securities, equity method, other expense (income)" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r232", "r233", "r234", "r237" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "terseLabel": "Income tax examination, penalties and interest expense" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r135", "r239" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Accrued income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Payroll and related taxes" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedTotalLabel": "Subtotal" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (decrease) in cash due to:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r98" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r120", "r125" ], "calculation": { "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of share-based awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r162", "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r168" ], "calculation": { "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangibles:", "verboseLabel": "Indefinite-lived intangible assets carrying value" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r162", "r168" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r159", "r164" ], "calculation": { "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Total other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r362" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedLabel": "Interest expense, net", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r279" ], "calculation": { "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails": { "order": 1.0, "parentTag": "prgo_CashFlowHedgeGainLossReclassifiedtoEarningsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "terseLabel": "Amount of gain or (loss) reclassified from AOCI into earnings", "verboseLabel": "Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements" } } }, "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Interest Rate Cash Flow Hedges [Abstract]", "terseLabel": "Interest rate swap agreements" } } }, "localname": "InterestRateCashFlowHedgesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "verboseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r52" ], "calculation": { "http://www.perrigo.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r55", "r150" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.perrigo.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "http://www.perrigo.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r54" ], "calculation": { "http://www.perrigo.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r53" ], "calculation": { "http://www.perrigo.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investment securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating Lease Liability Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc3": { "order": 1.0, "parentTag": "prgo_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "After 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r341" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 1.0, "parentTag": "prgo_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r356", "r372" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r298" ], "calculation": { "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r7", "r8", "r9", "r20", "r21" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "verboseLabel": "Distribution and license agreements and supply agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r20", "r354", "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "verboseLabel": "Borrowings outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Outstanding balance" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r20", "r354", "r365" ], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 }, "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetailsCalc2": { "order": 3.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable", "terseLabel": "Term loans" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r201", "r354", "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "verboseLabel": "Retail bond and private placement note" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current indebtedness" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r189", "r190", "r191", "r193", "r194", "r195", "r197", "r199", "r200" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Number of cases dismissed" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r189", "r192", "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought by plaintiff" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r139", "r140" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Unallocated" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue.", "label": "Measurement Input, Long-term Revenue Growth Rate [Member]", "terseLabel": "Measurement Input, Long-term Revenue Growth Rate" } } }, "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Measurement Input, Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r50", "r355", "r371" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r95" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash from (for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows From (For) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r95" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from (for) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows From (For) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r95", "r97", "r100" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash from (for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From (For) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r70", "r73", "r78", "r100", "r125", "r360", "r377" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adoption of new accounting standards" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Non-designated derivatives:" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r68", "r76" ], "calculation": { "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "OCI before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income", "verboseLabel": "Operating Income (Loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r335", "r342" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r328" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r326" ], "calculation": { "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails": { "order": 1.0, "parentTag": "prgo_LeaseLiabilities", "weight": 1.0 }, "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "netLabel": "Present value of lease liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesAnnualFutureMaturitiesOfLeasesDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "prgo_LeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "prgo_LeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r331", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseCashFlowClassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r325" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "prgo_RightofUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets", "verboseLabel": "Lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r339", "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - Operating lease (percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesWeightedAverageLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r338", "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesWeightedAverageLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r112", "r131", "r265" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r64", "r66", "r257", "r260" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Change in post-retirement and pension liability, net of tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r257", "r258", "r260" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss), attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent", "terseLabel": "Change in fair value of derivative financial instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r257", "r258", "r260" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r62", "r66", "r273", "r278", "r291" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of Gain/(Loss) Recorded in OCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r71", "r74", "r257", "r258", "r260" ], "calculation": { "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r62", "r66", "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Amount of Gain/(Loss) Recorded in OCI (Effective Portion)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r270", "r290" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "verboseLabel": "Accrued liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r20", "r354", "r369" ], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails": { "order": 3.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-term Debt", "terseLabel": "Other financing" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "verboseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesNonDesignatedDerivativesDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash adjustments, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of ordinary shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r94", "r177" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r91" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Cash dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r93" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Deferred financing fees" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r87", "r253" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash on hand used to fund acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r88" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred shares, $0.0001 par value per share, 10 shares authorized" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r33", "r34" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetLocationDetails", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r86" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Net proceeds from sale of business and other assets" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r89" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Issuances of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r90", "r93", "r111" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": { "auth_ref": [ "r89", "r92", "r102" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.", "label": "Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less", "terseLabel": "Borrowings (repayments) of revolving credit agreements and other financing, net" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepurchaseOfEquity": { "auth_ref": [ "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow resulting from the entity's share transaction.", "label": "Proceeds from (Repurchase of) Equity", "negatedTerseLabel": "Repurchase of equity amount" } } }, "localname": "ProceedsFromRepurchaseOfEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r96" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Proceeds from Royalties Received", "terseLabel": "Proceeds from royalty rights" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductionAndDistributionCosts": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to the production and distribution of goods or services to customers and clients.", "label": "Production and Distribution Costs", "terseLabel": "Distribution" } } }, "localname": "ProductionAndDistributionCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r173", "r373" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r68", "r76" ], "calculation": { "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified from AOCI" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r226", "r382" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RestructuringCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r99", "r176", "r181", "r185" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Charges [Abstract]" } } }, "localname": "RestructuringChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r177", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r176", "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "terseLabel": "Non-cash adjustments" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r210", "r370" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueCommissionersIrelandMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of Ireland.", "label": "Revenue Commissioners, Ireland [Member]", "terseLabel": "Revenue Commissioners, Ireland" } } }, "localname": "RevenueCommissionersIrelandMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r214", "r216", "r217" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByGeographicLocationDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r112", "r221" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r337", "r342" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/LeasesLeaseCashFlowClassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Goods, Net [Member]", "terseLabel": "Net sales" } } }, "localname": "SalesRevenueGoodsNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesOtherComprehensiveIncomeMovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Net Sales" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesClassificationOfGainLossOfCashFlowAndFairValueHedgingRelationshipsDetails", "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesEffectOfCashFlowHedgesIncludedInAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of derivative instruments in statement of financial position, fair value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Classification of Gain (Loss) Recognized in Earnings on Fair Value and Cash Flow Hedging Relationships" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/IncomeTaxesIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r157", "r158" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r157", "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r6", "r30", "r31", "r32" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory, current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r113", "r115", "r116", "r128", "r129", "r130" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r281", "r283" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Amount of Gain/(Loss) Recognized against Earnings" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r179", "r180", "r184" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and related costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/RestructuringChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r132", "r136", "r138", "r139", "r157" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r132", "r136", "r138", "r139", "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of segment reporting information, by segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Selling" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotes": { "auth_ref": [ "r357", "r375" ], "calculation": { "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes", "terseLabel": "Senior notes", "verboseLabel": "Public bonds" } } }, "localname": "SeniorNotes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsScheduleOfFixedRateLongTermDebtDetails", "http://www.perrigo.com/role/IndebtednessScheduleOfBorrowingsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Beginning balance (shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "negatedTerseLabel": "Shares withheld for payment of employees' withholding tax liability (shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r136", "r157", "r175", "r178", "r186", "r379" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.perrigo.com/role/FairValueMeasurementsFinancialInstrumentsAtFairValueDetails", "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://www.perrigo.com/role/LeasesBalanceSheetLocationOfAssetsAndLiabilitiesDetails", "http://www.perrigo.com/role/RevenueRecognitionScheduleOfRevenueByProductDetails", "http://www.perrigo.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r205" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r49", "r205" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r23", "r24", "r205", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r49", "r205", "r210" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r23", "r24", "r205", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchases of ordinary shares (shares)", "terseLabel": "Stock Repurchased During Period, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r23", "r24", "r205", "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchases of ordinary shares" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r27", "r28", "r145" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "totalLabel": "Total controlling interest" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets", "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r255", "r256", "r262" ], "calculation": { "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks and Trade Names [Member]" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/GoodwillAndIntangibleAssetsIntangibleCategoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]", "terseLabel": "Equity securities" } } }, "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfShareholdersEquityStatement", "http://www.perrigo.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r123" ], "calculation": { "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average shares outstanding for diluted EPS", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r117", "r123" ], "calculation": { "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding for basic EPS" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.perrigo.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.perrigo.com/role/EarningsPerShareAndShareholdersEquityDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 18 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3098-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75032774&loc=SL75039408-165497" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28567-108399" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r383": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r384": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 101 0001585364-19-000056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001585364-19-000056-xbrl.zip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�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end

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